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Introduction:  This thesis examines methods for updating searches for systematic 
reviews of healthcare interventions. Systematic reviews endeavour to find and synthesize 
all relevant research as a basis for the practice of evidence-based medicine. They are more 
useful if they are complete and up-to-date.  
Materials and Methods: The sample was 93 meta-analyses in allopathic medicine. 
Newer randomized controlled trials (RCTs) were sought through MEDLINE searches, 
and were assessed for relevance by physicians. Two Boolean searches, two similarity 
searches and one non-database search approach were tested. The Boolean searches were 
based on a simple subject search paired with a filter selecting only RCTs from Abridged 
Index Medicus journals or with the balanced Clinical Query. The two similarity searches 
were Support Vector Machine (SVM) and a Related Article search of PubMed based on 
the three newest and three largest studies from the original review.  
Main Results: Clinical Query provided good recall but with large retrievals. 
Abridged Index Medicus RCT had smaller retrieval sizes and lower recall, but did detect 
many large studies. The Related Article search showed the highest recall. Recall with 
SVM was lower, but retrievals were smaller. RCTs that cited the systematic review being 
updated were also tested but identified only a small proportion of new evidence.  
Relative performance of the test searches was consistent regardless of whether the 
intervention was a drug, device or procedure. All searches showed variability across 
clinical areas, but Related Articles RCT showed the most consistency. The pairing of 
Related Article RCT and Clinical Query gave excellent recall of new relevant material. 
Conclusions: Meta-analysts can identify new evidence through a simple structured 
Boolean search paired with a related articles protocol. By building on the evidence base 
formed in the original review, related article searching may replace time-consuming non-
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Chapter 1: Introduction 
1.0 OVERVIEW 
This thesis is about information retrieval issues in updating systematic reviews in 
healthcare. In this first chapter, I will introduce the problem, describe what a systematic 
review is, why they must be updated, and state the problems that this research attempts to 
address. I will present the goals of this thesis, the rationale, the research questions 
addressed and the potential contribution to the advancement of knowledge as well as its 
potential contribution to practical issues of updating systematic reviews.  
The main work of this thesis is to test the performance of several different search 
approaches in the search for new evidence for 100 systematic reviews. A sponsored 
project provided the opportunity to test these searches, so as part of the introduction, I 
will describe roles and responsibilities, to delineate what my contribution was, and what 
is the contribution of the research team was.  
In the second chapter, I will detail the historical aspects of the development of 
systematic reviews and the information retrieval methods used in them. The third chapter 
will provide a literature review of prior work in updating. It also serves as an example to 
the reader of an updated systematic review, as it was done using the methodology.  
The fourth and fifth chapter present the methods used in this research – the fourth 
chapter details the main experiment in which the experimental search methods are 
assessed. The fifth chapter covers a variety of topics that help put the main results in 
context. The discussion will cover the interpretation and application of these results, and 
demonstrate where advancements in knowledge have been achieved, as well as discussing 
the additional questions such research inevitably raises.  
1.1 STATEMENT OF THE PROBLEM 
A systematic review is a state-of-the art literature review designed to address the 
evidence in a narrowly defined topic, in a manner that is robust against epidemiological 
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bias. As time passes, a review becomes susceptible to bias as new information may exist 
that is different from the information synthesized in the review. Of course, until the 
evidence is actually examined, it is impossible to know if the conclusions of the review 
remain valid. Therefore, some mechanism is needed to ensure that reviews are up-to-date 
or at least that they have not been invalidated by newer information. 
1.2 RATIONALE 
Levine’s description of Cochrane Collaboration systematic reviews highlights the 
elements designed to prevent bias. “The Collaboration’s systematic reviews entail 
exhaustive literature searches and the selection and analysis of studies based on explicit, 
pre-specified criteria, sometimes, but not always, using meta-analyses, which are formal, 
mathematical combinations of numerical results.”1 A systematic review should provide 
the best evidence for clinicians, it should be the starting point for additional clinical trials, 
and should inform clinical practice guidelines. A systematic review is not able to do any 
of those things if it is not up to date. An out-of-date review is inherently biased if new 
studies differ in any systematic way from older studies. The scope note for the MeSH 
term bias is: 
“Any deviation of results or inferences from the truth, or processes leading 
to such deviation. Bias can result from several sources: one-sided or systematic 
variations in measurement from the true value (systematic error); flaws in study 
design; deviation of inferences, interpretations, or analyses based on flawed data 
or data collection; etc. There is no sense of prejudice or subjectivity implied in the 
assessment of bias under these conditions.”2 
A ruler with units marked as inches but which were all slightly shorter than an inch would 
produce biased measurements.  
The first wave of systematic reviews was created 30 years old, as will be 
described in Chapter 2. Even if the findings of those reviews were still valid, few people 
would have confidence in them unless new work demonstrated their ongoing validity. 
Thus, some efficient validation process is needed. Systematic reviews have grown 
substantially in numbers in recent years. There are an estimated 2500 new systematic 
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reviews published yearly.3 Few of those are explicit updates, so most may be a novel 
review that will need updating in the future.  
Most developed countries have Health Technology Assessment agencies and 
many of them face the problem of what to do with an aging fleet of reviews.4 Many of the 
issues surrounding maintaining a corpus of reviews relate to surveillance – how to 
efficiently detect signals that the integrity of the review is being challenged by the 
appearance of evidence in newly published studies? How to most effectively allocate 
updating resources across the fleet of reviews to be maintained? Electronic searching and 
expert opinion have been the principal techniques available for surveillance.4  
Several rationales for doing an update have been described; 1) increase precision 
around an effect estimate, 2) monitor changes in the magnitude and/or direction of an 
effect estimate, 3) minimize impact of time lag bias, 4) timely informing about new 
developments in a specific field, 5) minimize impact of publication bias, 6) missing or 
insufficiently detailed data, 7) broaden search comprehensiveness.5,6 Newly published 
studies that would be retrievable using the search strategies of the original review would 
be factors in the first three rationales.  
In systematic reviews, the role of the librarian is to develop the search strategies 
used to assemble the evidence base to be reviewed. They use systematic, reproducible and 
exhaustive methods to find as much of the research relevant to the topic of the review as 
possible. In constructing the search strategy, the searcher must attempt to protect the 
evidence base against publication bias (the preferential publication of positive results), 
reference bias (the preferential citation of results supporting one’s position), language 
bias (the increased likelihood of certain types of studies being published in English-
language sources), and bias from any additional source.7 
Most systematic reviews conducted today and in the past have relied upon 
Boolean searches of bibliometric databases to identify the majority of primary studies 
included in reviews.8 Expert searchers would normally approach the task by developing a 
highly sensitive search strategy, using one or more concepts of a carefully constructed 
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question, and using only limits that have been validated or are clearly relevant to the 
clinical question. This approach protects the review against missing relevant material, but 
retrieves a large quantity of irrelevant material that must be reviewed and excluded for 
cause by expert reviewers. A ratio of 1:9 included versus excluded bibliographic records 
would be a typical result of screening of a Boolean search result – this will be examined 
empirically in Chapter 5. 
A recent systematic review undertaken by our group shows that there has been 
some conceptual work on determining when to update, coming mostly from The 
Cochrane Collaboration and Agency for Health Care Research and Quality (AHRQ). 2 
There is one statistical technique that models how the need to update could be predicted 
by the amount of accumulating new evidence9 from our research group, a single piece 
looking at a practical technique in updating the search (updating by using the entry date 
of database records rather than the publication date), and a number of published 
techniques in the area of cumulative meta-analysis which help inform the issue of 
handling multiple testing. Finally, there has been some work looking at the growth of an 
area and identifying leveling off trends when the need to update may become less 
frequent.6 This work will be reviewed in detail in Chapter 3. While there is relatively little 
published research on updating methods and techniques, an informal listserv survey of a 
few years ago revealed that information specialists had a variety of techniques for 
updating the search during the course of the review, to detect evidence as it emerged or 
just prior to completion of the review.10 If information retrieval practices in this area are 
to be evidence-based, then research such as this thesis is needed. 
An Expert Working Group on Updating Systematic Review meet in Ottawa 
Canada in 2006, I was a participant.11 We developed a conceptual model for the updating 
of systematic review with three major components; a surveillance function that monitors 
for the emergence of new evidence, triggering conditions which include the detection of 
new evidence but also political influences and the gradual erosion of confidence in a 
review as it ages, and the update itself.12 This thesis will focus on detecting new evidence. 
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The ability to conduct electronic searches of bibliographic databases was an enabling 
technology for systematic reviews. Thirty years ago, the Cochrane Collaboration began 
publishing systematic reviews, and pledged to update them every year. That objective was 
unattainable, and was revised to every two years. Even that revised target is under review, 
as will be discussed in Chapter 3. In the past thirty years, few advances in searching have 
been made to support updating. While some technical tools such as Selective 
Dissemination of Information (SDI) exist, and many groups have unpublished working 
mechanisms for running update searches, this is largely uncharted territory. Anecdotally, 
the low precision of the searches done in systematic reviews is a barrier to monitoring the 
literature. 
In practice, there are few updated systematic reviews appearing except those 
undertaken by The Cochrane Collaboration. The literature is replete with systematic 
reviews on similar topics, although these are rarely explicitly positioned as updates of 
previous work.3 It is possible that journal editors are reluctant to publish updates of 
systematic reviews, and many non-Cochrane systematic reviews are indeed updates of 
earlier reviews but authors avoid drawing attention to that to enhance their chances of 
being published. 
1.3 RESEARCH QUESTIONS 
The major research objective of this thesis is to explore the performance 
characteristics for various approaches to surveillance, with the aim of identifying 
approaches that are more efficient for detecting emerging evidence than re-running the 
high recall search strategy used in reviews. 
Updating the evidence base of a systematic review is a different information 
retrieval problem than forming the original evidence base, and one that has been scarcely 
addressed. At the time of updating, most (ideally all) relevant studies and many irrelevant 
articles up to a certain point in timer are known. These studies would have been identified 
in the course of producing the original systematic review. The information contained in 
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these true positive (relevant) and true negative (irrelevant) examples has not been 
harnessed for updating. 
The first approach, the one I believe to be most exciting, is to use the results of the 
screened search for a systematic review to set up an efficient search for surveillance. 
Surveillance would be to detect the most influential evidence that would render a review 
in need of update (or at least trigger a consideration of whether an update should be 
done), based on the accumulation of new evidence. Using support vector machine (SVM), 
the included studies of this screened set would serve as true positive examples in a 
training set, and the remaining retrieved records, judged irrelevant, would serve as true 
negative examples. Updated Cochrane reviews can be used to test the performance of the 
SVM solution, based on retrievals during the updating period – with the newly included 
studies being the reference standard against which the performance characteristics, such 
are recall and precision, are assessed. This mechanism of using updated reviews 
overcomes the common objection that such machine learning approaches are over fitted 
to the data, being validated using a “leave one out” approach on the same sample used to 
develop them. This thesis will advance that aspect of information retrieval and inform 
more efficient updating. 
In the attempt to be exhaustive, systematic review searches have often had very 
low precision. This makes it challenging to update the literature, as many new irrelevant 
records will need to be examined, and it makes monitoring for definitive new studies 
challenging because of the low signal to noise ratio. Anecdotally, the volume of new 
studies to be assessed has been a barrier to updating. Thus, restricted Boolean searches 
were tested, to see if higher precision with adequate recall could be achieved. These 
narrower approaches to subject searching involve MEDLINE searches restricted to Core 
Clinical Journals (previously Abridged Index Medicus),13 or the Clinical Queries of the 
Hedges team.14 
Finally, electronic searches for systematic reviews are usually supplemented by a 
variety of techniques such as checking reference lists, contacting researchers active in the 
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field and reviewing conference abstracts. The value of these has not been empirically 
demonstrated, and their role in updating is not known. Therefore, the ability of 
complementary electronic search approaches, namely Boolean searches and similarity 
searches, to identify new relevant material is evaluated. 
Other approaches I evaluate are Related Articles searches in PubMed, citing 
references, and finally the convergence of multiple retrieval methods. Although many of 
these approaches have been studied in the past, an examination of their role in updating is 
novel. The only prior work I have been able to identify is a recent article by Cohen et al. 
2006,15 who used a neural network approach to build on the included studies of large 
systematic reviews. They achieved only modest increases in precision at the very high 
levels of recall desired for a full update. Yet even these small improvements in precision 
resulted in meaningful reductions in effort on the part of the review team.  
A strength of the research presented here is that the data collection was embedded 
in another large, well resourced, project. As a result, it was possible to test search 
performance on a large cohort of high quality and clinically important systematic reviews. 
The need for updating was determined based on various objective criteria such as the 
emergence of new studies, accumulation of new research participants in the studies, shift 
in the point estimate of effect, narrowing of the confidence interval, or emergence of 
studies either with more rigorous designs or objective clinical end-points instead of 
surrogate markers or subjective end-points. These criteria were developed by an expert 
group. The screening of new studies was not done by me, which could potentially have 
biased results, but by a medical team. Similarly, the decision about whether a systematic 
review needed to be updated or not was a team decision, made after rigorous examination 
that often involved intense discussion. Thus, that updating project provided a unique 




1.4 THE RESEARCH TEAM 
The project that formed the testing ground for these searches was commissioned 
and funded by Agency for Healthcare Research and Quality, a United States 
governmental organization. The project was granted to the University of Ottawa Evidence 
Based Practice Center in January 2006. I was the senior information specialist for that 
program at the time, and was the “internal leader” for the project. Dr. Kaveh Shojania was 
the clinical leader. Dr. David Moher, the director of the University of Ottawa Evidence 
Based Practice Center, was actively involved in guiding and overseeing all phases of the 
project. The findings of that project have been published as an Evidence Report,16 and 
several journal manuscripts derived from the project have been published,17-19 including 
one with preliminary results of the searches tested, on which I am the first author.18 
The protocol for the updating project was developed by this core group of 
investigators, with input from other team members, and under the guidance of a Technical 
Expert Panel. The Technical Expert Panel included representatives from several other 
Evidence Based Practice Centers, the Medical Director of the Agency for Healthcare 
Quality and Research, journal editors, senior statisticians and epidemiologists. Technical 
expert panel members and all other team members are formally acknowledged in 
Appendix 1. 
The information science team for the project was lead by myself, and included 
Jessie McGowan, Tamara Rader, both librarians, Alla Iansavichene, a co-op student with 
the University of Western Ontario Masters of Library and Information Science program, 
Raymond Daniel, a library technician, and Dr. Berry de Bruijn, a research scientist. I 
developed the approach to search strategy evaluation, selected the search approaches to 
be tested, and developed all procedures for the searches with one exception. I developed 
the system for tracking which results were found by which methods, and constructing the 
screening lists that blinded the reviewers to how the records had been identified. I 
undertook all data analysis related to search performance. Jessie McGowan developed the 
specific procedures for the Boolean searches and constructed the searches for a pilot of 
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the method. Jessie also peer reviewed all search strategies that I recreated based on the 
reports in the original systematic reviews, to ensure their accuracy. Tamara Rader created 
the Boolean searches for the remaining systematic reviews that were updated through 
searching. Raymond Daniel downloaded results of the Boolean searches and executed the 
citation and related article searches according the protocol I developed. He integrated all 
search results into a unified set for each review to be updated. As well, Raymond 
produced the spreadsheets and databases of bibliographic records that the reviewers used 
for screening and recording eligibility decisions. Alla Iansavichene assisted me with data 
cleaning and did initial coding and classification of the systematic reviews by disease 
area. She also created the year-by-year search strategies that charted the growth of the 
literature in these various areas – data that are reported in Evidence Report16 but not in 
this thesis.  
Dr. Berry de Bruijn ran the Support Vector Machine searches using data sets I 
prepared from replications of the searches in the original systematic reviews. He was 
principally responsible for making decision about the settings for the Support Vector 
Machine tests, but we worked collaboratively through various iterations, assessing 
performance and deciding on the next strategy. That work arose of discussion between his 
team at National Research Council and ours over a period of several years as we 
considered how Support Vector Machine could be harnessed for systematic reviews. 
These discussions were initiated by ‘Ba Pham, a statistician formerly with our group. 
Several pilot projects explored the utility of using such techniques to extract basic 
eligibility criteria from study abstracts, but this was the largest and most fruitful 
experiment with the technique to date, and the only one related to information retrieval.  
The review team consisted of two physicians with a background in research and 
clinical epidemiology, Dr. Mohamed Ansari and Dr. Jun Ji. They were responsible for 
screening new records, extracting data from relevant new reports, and integrating that into 
the systematic reviews being updated. They sought supporting evidence from other 
published sources and decided how to classify the impact of the new evidence, based on a 
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worksheet that handled calculations and provided guidance on the criteria for decisions. 
These were then discussed in a case conference involving the reviewers, Dr. Shojania and 
myself until consensus was reached on whether the review was in need of update, and 
what evidence triggered the need for update. 
Mary Ocampo extracted various milestone dates from the original and updated 
reviews, including the date the signaling evidence appeared. Those results are reported in 
the Evidence Report16 and one publication in Journal of Clinical Epidemiology19 but are 
not a part of this thesis Chantelle Garritty was administrative coordinator for the project 
and in that capacity handled contract issues, formal correspondence with the sponsoring 
agency, arranged conference calls with the Technical Expert Panel and undertook 
numerous other functions that enabled this research. She also completed a pilot survey of 
agencies that commission or undertake systematic reviews to learn about their updating 
practices and perceived needs. The results of the pilot were published in the Evidence 
Report16 and the results of the full survey are currently under peer review with a journal. 
That work informs this thesis. 
The main analysis from the updating project for the Agency for Healthcare 
Research and Quality was the survival analysis – how quickly systematic reviews go out 
of date. That analysis was planned and undertaken by Dr. Shojania. Steve Doucette did 
the statistical analysis for that part of the project. Those results are reported in the 
Evidence Report16 and in the Annals of Internal Medicine.17   
The analyses described in Chapter 3 – The Main Experiment arise out of the data 
collected as part of the Agency for Healthcare Research and Quality. In this thesis, I have 
expanded the analysis of considerably beyond what could be completed under a time-
limited research contract (the project report was submitted March 15, 2007). As well, the 
Support Vector Machine material was completed too late for inclusion in the report for 
that project or the initial journal article. That work described in Chapter 5 - Exploratory 
Analyses represents supplemental analyses that I conducted completely outside the scope 
of the updating project sponsored by the Agency for Healthcare Research and Quality.  
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In summary, I was co-investigator on larger project that provided the testing 
ground for the searches I developed. I planning the search approaches used and the 
experiment that tested them. I cleaned all search-related data, prepared all files for 
analysis, and undertook all analysis presented in this thesis, including figures and tables, 
unless explicitly noted. Of course, many other people assisted with the updating project 
and with this thesis. I acknowledge them as completely as I am able in Appendix 1. 
1.5 POTENTIAL CONTRIBUTIONS TO THE ADVANCEMENT OF KNOWLEDGE 
This thesis will contribute two major conceptual advances to the field of 
information retrieval for systematic reviews. First, it explores the structural relationship 
between different modes of information retrieval – traditional Boolean searches and 
similarity-based methods – in the context of updating. It will be shown that these methods 
are dimensionally distinct and complement each other to provide a level of recall that is 
difficult to achieve using either method alone. This is an important advance as systematic 
reviews strive for a very high level of recall. 
This thesis also introduces the idea of considering the information density of a 
document, here measured is the number of patients enrolled in studies that were identified 
by a search, rather then retrieval of studies, as the unit of measure in assessing the 
performance of searches in the systematic review context. Systematic reviews attempt to 
synthesis all available information, and in statistical synthesis, studies with the most 
patients are given more weight and so influence the results much more than smaller 
studies. The unit of information retrieval has been the articles that contain the 
information, not patients participating in studies. This focus may lead to disproportionate 
effort being expended to find studies that convey little information. Differences in 
efficiency of searches are more apparent when retrieval is evaluated based on the 
proportion of new research participants identified rather than the proportion of reports 
retrieved. Search methods that recall most relevant large studies while retrieving fewer 
irrelevant studies that need to be screened out permit more efficient surveillance. It then 
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becomes practical to update based on the appearance of new information, rather than the 
simple passage of time. 
1.6 POTENTIAL CONTRIBUTION TO PRACTICAL INFORMATION SCIENCE ISSUES 
This work provides a number of practical contributions to information science. It 
establishes norms for precision of systematic review searches, making it possible for 
librarians to bench mark their searches, and yields information for planning and 
budgeting systematic reviews for accurately.  
This thesis contributes a simple and useful procedure for using PubMed related 
articles to complement the traditional Boolean search strategy. Further, the utility of this 
simple technique is compared with the more complex Support Vector Machine. 
Although there has been a call to report how the search for a systematic review 
was validated, few reliable techniques exist.20 This thesis demonstrates a practical method 
to validate an electronic search by testing it against the included studies identified by any 
mechanism and indexed in a database. In addition, this work provides the first 




Chapter 2: Historical Context of Information Retrieval for Systematic 
Reviews 
2.0  INTRODUCTION 
This thesis is about information retrieval issues in updating systematic reviews. 
Systematic reviews have emerged in the past 30 years as part of the evidence movement 
within medicine. The history of this movement and of The Cochrane Collaboration have 
been written elsewhere (e.g,.1,22-24) and will be selectively reviewed here. The history of 
information retrieval is important to the context of this thesis. Again, this will be 
reviewed only briefly, but the rise of online information retrieval was an important 
enabling technology for systematic reviews, and it will be shown that the growth of 
systematic reviews followed the growth of MEDLINE searching closely. Finally, the 
history of information retrieval in systematic reviews will be examined, looking at 
milestones and major contributors through the lens of the Cochrane Methods Groups 
Newsletters, which places them in the context of other developments in systematic review 
methodology. 
This review will also introduce the reader to some of the tools that will be 
examined later, such as the Cochrane Central Register of Controlled Trials (CENTRAL) 
and the Randomized Controlled Trial publication type tag available in the MEDLINE 
database, produced by the US National Library of Medicine.  
2.1 THE EVIDENCE MOVEMENT 
Archie Cochrane was a physician, born in Scotland in 1909, whose views on the 
practice of medicine were influenced by his experiences serving in the International 
Brigade during the Spanish Civil War.25 Iain Chalmers identified Archie Cochrane’s 1972 
text “Effectiveness and Efficiency”26 as a seminal work in the evidence movement in 
medicine.27 Cochrane argued that, “because resources would always be limited, they 
should be used to provide equitably those forms of health care which had been shown in 
properly designed evaluations to be effective.”28 David Sackett and other leaders in the 
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field, including Sir Muir Gray and Brian Haynes, published an influential editorial in the 
journal BMJ in 1996 in which they defined: 
Evidenced Based Medicine: the conscientious, explicit, judicious use of current 
best evidence in making decisions about the care of individual patients.29 
Systematic reviews are one tool of evidence-based medicine. Land’s Dictionary of 
Epidemiology30 defines a systematic review as: 
The application of strategies that limit bias in the assembly, critical appraisal, and 
synthesis of all relevant studies on a specific topic. Meta-analysis may be, but is 
not necessarily, used as part of this process. 
It describes meta-analysis as: 
The statistical synthesis of the data from separate but similar, i.e. comparable 
studies, leading to a quantitative summary of the pooled results. 
The term systematic review was adopted by those wishing to distinguish such 
evidence-based reviews from the traditional narrative review. In 1987, Cindy Mulrow 
published an important empirical study of the quality of 50 review articles published in 
four prominent medical journals. She assessed them on the basis of eight previously 
proposed criteria and found that, while most had clearly specified objectives and 
conclusions, only one had clearly specified methods of identifying, selecting, and 
validating included information.31 Huth, the editor of Annals of Internal Medicine who 
initially rejected but ultimately published the piece, provides a commentary on Mulrow’s 
article, written many years later. He argues that, although review articles were absolutely 
essential for practitioners, Mulrow demonstrated that these narrative reviews did not meet 
the standards required of scientific papers.32  
The first systematic review is thought to be an examination of the literature on 
scurvy, conducted by James Lind in 1753.33 The full title of the work is “A treatise of the 
scurvy. In three parts. Containing an inquiry into the nature, causes and cure, of that 
disease. Together with a critical and chronological view of what has been published on 
the subject”. Ian Chalmers traces other early examples of systematic reviews scattered 
through the next 200 years.22 The first use of the term “meta-analysis” is credited to Gene 
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Glass in 1976.22 Articles titled as systematic reviews began appearing in MEDLINE in 
1954, but most of the early literature reviews in the PubMed systematic review subset are 
described as “critical review of the literature,” following Lind’s early lead (Table 1, based 
on MEDLINE results of March 2009). 
  
Table 1. Change in Terminology of Reports in the MEDLINE Systematic Review 
Subset 
Term 1975 1985 1995 2005 
Critical review 25 51 111 206 
Meta-analysis 0 16 541 2520 
Systematic review 0 1 40 1471 
Integrative or qualitative review 0 0 8 42 
Estimated number of systematic reviews in 
MEDLINE 
25 69 725 3331 
Columns do not total to the estimated number of reviews as each review could have used any, all or none of 
these term in the bibliographic record. 
Chalmers traces the roots of the statistical analyses for combining studies back as 
far as 1860, but he credits Glass with pulling the techniques together.22 At that time, it 
was recognized that meta-analysis could provide statistical precision. To ensure validity, 
it was necessary to set some standard so that the studies included in the meta-analysis 
were as free from bias as possible. Archie Cochrane set the bar at randomized controlled 
trials (RCTs). Altman explains that randomized controlled trials have a number of 
features which, when properly implemented, avoid bias in design or analysis. These are 
random allocation of participants to the treatment of interest or the comparison treatment, 
blinding as to which treatment is being given, intention-to-treat analysis in which 
participants are analyzed even if they failed to complete the treatment to which they were 
assigned, and a sample size sufficient to reduce the effects of the ‘play of chance’.34  
2.11 EVIDENCE HIERARCHY 
Evidence-based medicine is a method in which practice is informed by the best 
available evidence. Various hierarchies of research designs have been developed, with the 
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stronger evidence, that is, designs that have more robust protection against bias built into 
them, placed above weaker designs. The metaphor of a pyramid is used because there 
tends to be fewer publications for designs higher in the hierarchy. Restricting searches to 
studies designs with robust designs (those that are at the top of the evidence pyramid) 
helps narrow down the amount of literature to be appraised. The combination of stronger 
designs and reduced volume of material to consider is a great benefit for busy clinicians. 
Systematic reviews and meta-analyses, particularly those restricted to randomized 
controlled trials, are generally regarded as the highest level of evidence (Figure 1). 
ScHARR describes a similar hierarchy.35 
 
The original hierarchy of strength of evidence for treatment decisions was 
presented by Guyatt et al. in their influential “Users’ Guide to the Medical Literature” 
series in JAMA. This group placed N-of-1 randomized trials above systematic 
reviews.36,37 Other hierarchies exist, such as the 5S model developed by Brian Haynes.38 
The five S’s are studies, syntheses, synopses, summaries, and systems, recognizing that in 
many modern healthcare environments, highly formalized point of care systems, called 
                                                
* SUNY Downstate Medical Center.Medical Research Library of Brooklyn. Guide to 
Research Methods: The Evidence Pyramid. Available at: Evidence-based Medicine 
Tutorial (http://library.downstate.edu/EBM2/2100.htm). 2006. Accessed: 3-7-2009. 
Used with permission. 




Clinical Decision Support Systems (CDSS), guide practice. These too should be 
evidence-based. 
2.12 Progress in Systematic Review Methodology 
Methodology advanced quickly for systematic reviews and meta-analyses. Editors 
of the James Lind Library point out that the first edition of a landmark text titled 
Systematic Reviews39 was published in 1996 and was less than 100 pages long while the 
second edition40 published six years later was nearly 500 pages in length.24 Of the 26 
chapters in the second edition, only one41 deals with searching. 
As methodological complexity has increased, reporting standards have become 
more stringent, requiring more detailed reporting of the methods used in the systematic 
review. In 1996, David Moher led a 30-member international study group in the 
development of the QUOROM statement.42 QUOROM consolidated the evidence of the 
day on methodological issues in the conduct of systematic reviews. The group’s 
deliverable was a checklist of 18 items to be reported so that the quality of the review 
could be assessed. In addition, it called for the use of a flow chart to account for the 
disposition of all articles identified in the searches used to locate evidence for the review. 
QUOROM has already had an impact - a recent study found a linear improvement in the 
number of checklist items reported from 2000 to 2005. For instance, in 2000-2001, 38% 
of the sample reported adequate details of the search. This rose to 47% in 2002-2003, and 
49% in 2004-2005.43 A revision to the QUORUM statement is in preparation. Called 
PRISMA, the new version contains a checklist of 27 items, up from 18 in the original 
version.44 There were no librarians represented in the original study group, whereas two 
participated in the updating process. 
In summary, the evidence movement is both a philosophy and a set of processes 
and products. The processes are designed so that both the researcher and the practitioner 
avoid biased information as much as possible. The products therefore, should be free of 
bias, and methods have evolved rapidly to help ensure that goal. The evidence pyramid 
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places research above opinion, synthesized evidence above single studies, and systematic 
reviews or meta-analyses of randomized controlled trials at or near the pinnacle.  
2.2 THE COCHRANE LIBRARY 
The Cochrane Collaboration was named in honour of Archie Cochrane, who 
challenged that, “… a great criticism of our profession that we have not organised a 
critical summary, by specialty or subspecialty, adapted periodically, of all relevant 
randomised controlled trials.”28 The Cochrane Library was to be the answer to that 
challenge, developed by the international team who make up The Cochrane 
Collaboration.  
Mark Starr and Ian Chalmers traced the development of The Cochrane Library, 
which saw its first issue in 1996, and has used an electronic platform from the onset. It 
had a number of predecessors, the first of which was The Oxford Database of Perinatal 
Trials (ODPT), which was developed as a source for systematic reviewers. The database 
was published twice yearly as a complement to several print publications summarizing 
the evidence. The original medium was 5 1/4 inch computer diskettes. Starr describes the 
print publications derived from the ODPT as a time slice of the state of the research 
evidence at the time of publication.  
The benefits of this “database plus print” approach were: 
 “Unlike more traditional printed articles, the ODPT database system 
allowed the raw data used in the meta-analyses to be stored with the article, 
which in turn meant that statistics could be calculated and figures drawn in 
‘real time’, that is, when the figure was displayed. As new studies were 
added to the database, and new data became available, they were 
automatically incorporated in the analyses.  
 
One interesting feature when displaying meta-analyses in ODPT was 
that you could watch the pooled effect estimate and confidence interval 
change as each trial was added into the analysis, the ordering being based on 
the assessed quality of each study, its statistical power, or its year of 
publication.”23 
 
The format was highly innovative but did not prove to be commercially viable 
Oxford University Press ceased publishing it in 1992. Update Software redesigned the 
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product with an emphasis on the systematic reviews. They also enhanced the ease-of-use 
for the average desktop computer user (a new breed of computer user at the time). The 
product was re-launched in 1992 as The Cochrane Pregnancy and Childbirth Database 
(CCPC) – the abbreviation reflects the original name, Cochrane Collaboration Pregnancy 
and Childbirth database. At the same time, government funding was secured to open the 
UK Cochrane Centre, with the goal of expanding the work in perinatal medicine to other 
areas of healthcare. The Centre has employed a librarian from the beginning. The Centre 
was renamed the UK Cochrane Centre in 1993 with the launch of the international 
Cochrane Collaboration. 
Notable technical features of the reviews at this time were that they were highly 
structured, enabling users to search and retrieve by population, by intervention or by 
outcome. There was also a graph generated directly from the stored data, which 
summarized the outcome data for each review. In 1993, review-authoring software called 
Review Manager (RevMan) was made available. This enabled authors to develop the 
review in a structured template that could support varied output formats based on ASCII 
text, SGML, XML, and various proprietary formats.  
In 1994, Update Software demonstrated a prototype of a new CD-ROM 
publication, The Cochrane Database of Systematic Reviews (CDSR) and it included 615 
systematic reviews in the database. By 1996, the Cochrane Controlled Trials Register was 
added, to help identify primary studies, as was a commenting system that allowed readers 
to add comments to protocols or finished reviews. The database and register became the 
Cochrane Library, to which other databases were added as they were developed. 
Thus, from the beginning, Cochrane reviews have been designed for an electronic 
platform, with the ability to incorporate new data as it became available, and to 
summarize the data in real time. Starr points out that the electronic format is not 
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constrained by space, allowing more transparent and detailed reporting (including text, 
graphics and tables) than would generally be possible in print documents.23 Space was 
becoming a real issue, given the QUOROM standard’s demand for detailed reporting of 
ever-more complex methods. 
2.3 INFORMATION RETRIEVAL 
Kagalovsky and Moehr attribute the rise of information retrieval research in the 
1950’s to two factors. First, there was an influx of documents released after World War II 
and it was necessary to be able to locate them.45 Second, the rise of computer technology 
provided useful tools to organize, index, and retrieve documents.45  
The United States’ National Library of Medicine was a leader, not only in health 
information retrieval, but generally. It was operating the MEDLARS system (an acronym 
for Medical Literature Analysis and Retrieval System) and offering on-demand batch 
searches by 1964.46 Cheryl Rae Dee has written a recent and comprehensive history of the 
development of MEDLARS, and explains that the system grew out of efforts to 
modernize and expedite preparation of the print Index Medicus and other products such 
as recurring bibliographies.47 In 1971, MEDLINE (MEDLARS Online) went into 
operation, allowing off-site, online searches, instead of batch searches. The National 
Library of Medicine eliminated the in-house batch service in 1973.46 Other major online 
databases were developed in this period, often with U.S. government funding and 
associated with either the National Institutes of Health or the United States Department of 
Defense. In the case of Chemical Abstract Services (CAS) both were involved.46 
2.31 Growth of Online Searching 
MEDLARS was developed to overcome the limitations of a “card-bound” Index 
Medicus system. As Adams described in the 1975 Annual Report of the National Library 
of Medicine, “The fastest card sorter then available could handle 1,000 cards per minute. 
To search 750,000 cards would take twelve and one-half hours.”48 Adams goes on to 
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describe the early history of online searching through the National Library of Medicine. 
An initial development grant was awarded to General Electric in 1960 and the 
MEDLARS system was operational in 1964.  
This system was initially used to develop Index Medicus, but experiments in 
online information retrieval began soon after, and the 100 journals of Abridged Index 
Medicus were available to 90 institutional subscribers for online searching in 1970† 
MEDLINE became available in 55 cities in 1972, with 66 hours of on-line services a 
week.48 Searchers were required to undergo two weeks of training, and end-user 
searching was largely unheard of.49  
Starr considers the beginning of the perinatal registry, in 1974, to be one of the 
milestones of The Cochrane Collaboration. This was an effort to identify and index all 
randomized controlled trials in perinatal medicine.1 By 1985, 3,500 trials had been 
identified.1 Technologies for the registry were a card file of references to perinatal trials, 
and the development of a MEDLINE search strategy which was run monthly.23 Today, it 
is difficult to imagine what it might have been like to try to identify all trials on a topic 
without access to electronically searchable databases. Indeed, the rise of electronically 
searchable biomedical databases was an essential enabling technology for systematic 
reviews. 
 
                                                
†Here is a description of the previous off-line or batch search process. “Beginning in 
1965, searches could be submitted to the National Library of Medicine or to one of the 
decentralized processing centers that were established in the United States and overseas. 
Specially trained librarians, who had attended courses that lasted as long as 3 months, 
then formulated each search and submitted it to a MEDLARS Search Center, where punched 
cards were fed into a computer, and the resulting printout was shipped back by parcel 
post. In the United States, turnaround time averaged 4 to 6 weeks.” From Coletti 2001,49 
citing Pizer 1969.50 
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Indicators of the growth of both electronic biomedical database searches and of 
the publication of systematic reviews and meta-analysis are readily accessible. Annual 
reports of the National Library of Medicine report the number of MEDLARS and later 
MEDLINE searches conducted through National Library of Medicine,51-57 and searching 
MEDLINE itself for the number of records retrieved using the PubMed systematic review 
subset58 yield approximations‡ of the number of reviews. These are presented in Figure 2. 
The years from 1973, the first full year that MEDLARS could be searched online, to 1996 
are presented.  
As can be seen in Figure 2, 140,000 online MEDLARS searches were being 
conducted in 1973. By the time the first meta-analysis of perinatal trials was published in 
1979, there were half a million MEDLARS searches annually. Meta-analyses and 
                                                
‡ All records retrieved were examined for 1970-1974 to determine which might be systematic reviews. As 
the volume rose, numbers retrieved using the subset are divided by 3 to estimate the number that might be 
assessed as systematic reviews if examined individually. Shojania reported precision of around 50% for the 
systematic review subset when initially created, but that was with a subject search as well, which would 
increase precision.58 Examining a 2004 cohort, we found that 30% of articles retrieved with a modified 
systematic review search were finally classified as a systematic review.3 The consistency of these filters 
across time has not been investigated, although terminology has changed (Table 1). 
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systematic reviews were not common in the journal literature at the dawn of online 
searching. Taking the PubMed sys revs subset as a ‘surrogate’ for the number of sys revs 
in MEDLINE, the years 1970-1974 yielded only 35 systematic reviews, commonly called 
critical reviews of the literature. The years 1975–1982, indexed between 25 and 50 
publications likely to be systematic reviews. The year 1983 saw 53 such publications. The 
count of indexed systematic reviews surpassed 100 by 1987, approached 300 by 1990, 
and 600 by 1992, 700 by 1994, and 874 by 1996. In 1996, there were 7,329,947 online 
searches of MEDLINE. These figures reflect only those searches done through the 
National Library of Medicine. By 1982, National Library of Medicine was leasing 
MEDLARS to private sector provider, of which Bibliographic Retrieval Services (BRS) 
and DIALOG Information Services Inc. (DIALOG) were the first.59 
In 1997, PubMed was introduced and anyone could search it through the World 
Wide Web without any training, any special account, and without any direct cost. The 
introduction of PubMed resulted in a drastic change in the number of MEDLINE 
searches.60 There were 13 million MEDLINE searches during the first ten years shown in 
Figure 2. Today, there are three million PubMed searches, and approximately 400,000 
referrals from Google, every day.61 Writing in 2001, Donald A. B. Lindberg, Director of 
the National Library of Medicine explained, “In three years the Library has seen the 
number of searches on its MEDLINE database rise from seven million searches a year to 
250 million. The Library estimates that 30 percent are done by the members of the public 
for themselves and their families.”62 This may have been the point where ready access to 
current, synthesized evidence became essential to the practicing clinician. 
2.4 INFORMATION RETRIEVAL IN SYSTEMATIC REVIEWS 
The original perinatal reviews were supported by a trial registry that was based on 
index cards. There have been major advances in information retrieval since then. 
Landmarks were the hiring of an information specialist with the opening of the UK 
Cochrane Centre in 1992, the development of the CENTRAL,63 a joint project of The 
Cochrane Collaboration and National Library of Medicine to identify all controlled trials 
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in MEDLINE and re-index them with the Randomized Controlled Trial or Controlled 
Clinical Trial publication type tags,41 the publication of the Cochrane Highly Sensitive 
Search Strategy  (HSSS) for identifying randomized controlled trials in MEDLINE in 
1994,64 and its revision in 2006.21 These major milestones all involve The Cochrane 
Collaboration, and so the searching-related news from the Cochrane Methods Groups 
Newsletter, an annual publication beginning in 1997, will be reviewed.  
The Cochrane Information Retrieval Methods Group was active by 1997, 
disbanded in 2001, and resumed operation and was registered as a Cochrane Entity in 
2004 with an expanded mandate. 
Kay Dickersin and Jean-Pierre Boissel initiated The Trials Registers Development 
Group (TRDG) at the request of The Cochrane Collaboration steering group (March 
1996). The objective of the TRDG was to develop a central register of trials, to support 
those preparing, maintaining and disseminating systematic reviews within The Cochrane 
Collaboration.65 Proposed design elements included fields for design and operational 
characteristics and results, in addition to the bibliographic record.  
At this stage, Cochrane methodological advice through Methods Working Groups 
was thought necessary for “methods used to prepare and maintain reviews (e.g., statistical 
methods) and decisions about the methods that are used by the Collaboration to meet its 
aims (e.g., informatics).” (Mike Clarke, Andy Oxman, Lesley Stewart in a column called 
“Methods Working Groups: Are They Working?”65) There was no mention of literature 
searching as an essential aspect of review methods.§ There was however, an Informatics 
Group convened by David Badger and a Coding and Classification Methods Group, 
convened by William Hersh. The Coding and Classification group was focused on the 
indexing of material produced by The Cochrane Collaboration, and on preparing for 
Cochrane reviews to be indexed in MEDLINE by the National Library of Medicine. The 
Informatics Group was focused on harnessing new technologies to advance the goals of 
                                                
§ I am a co-author on a Cochrane Methodological Review protocol titled “Checking reference lists to find 
additional studies for systematic reviews” which was published in The Cochrane Library in Issue 1, 2009. 
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the Collaboration.65 Original research in searching was being done, regardless of the lack 
of importance placed on it. In the 1997 Methods Groups Newsletter, the paper by Kay 
Dickersin, Roberta Scherer and Carol Lefebvre titled “Identifying relevant studies for 
systematic reviews”64 was cited as an example of a systematic review of a methodological 
questin by Andy Oxman in his column “Empirical Methodological Studies”.65 This paper 
established that conventional search methods might identify only half of the relevant 
controlled trials from MEDLINE, and introduced the Highly Sensitive Search Strategy.64 
In the 1998 newsletter, the Dickersin, Scherer and Lefebvre paper was featured in 
detail. In a commentary on that paper, William Hersh mentions the effort spearheaded by 
The Cochrane Collaboration to re-index RCTs with the publication type tags.66 There is 
no detail of the project in the Methods Groups Newsletters but a full description of the 
project is found elsewhere.41 An examination of indexing of studies in MEDLINE had 
shown that many studies that used the controlled designs were not indexed that way.41 In 
1994, the UK Cochrane Centre and the New England Cochrane Centre began examining 
records retrieved by the Highly Sensitive Search Strategy to identify additional trials, and 
the National Library of Medicine re-indexed them as either Controlled Clinical Trials or 
Randomized Controlled Trials, as appropriate according to the design used. These records 
were also added to the CENTRAL. Review of studies published from 1965 to 1979 
resulted in the indexing of 70,000 additional records as controlled trials in MEDLINE.41 
Although there are numerous references to the practice of handsearching of 
journals to identify controlled trials, there is no description of the considerable efforts of 
the Collaboration to methodically search over 1,700 journals cover-to-cover, as this effort 
fell under the jurisdiction of the various Cochrane Centres, Fields and Review Groups and 
Cochrane Fields, rather than to any of the Cochrane Methods Groups.66 This 
handsearching effort complemented the electronic re-tagging effort and identified over 
17,000 reports of trials not in MEDLINE. These were also added to the trials register.66 
Also from the 1998 Newsletter, we learn that the Informatics Group was 
developing an integrated website for the Collaboration. The Coding and Classification 
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group was considering how to index trials identified from sources other than MEDLINE 
and how to identify conference abstracts for the trials register.66  
By 1999, the Coding and Classification Group had become the Information 
Retrieval Methods Group, convened by William Hersh and Phillipa Middleton. The focus 
of the group was on improving information retrieval from The Cochrane Library. 
Initiatives included improving documentation, developing an inventory of search engine 
capabilities, and promoting The Cochrane Library by having a contest for informatics and 
library students. Students would use the Library in some project that they would present 
at the following Cochrane Colloquium, with their expenses paid.  
Elsewhere in the Methods Groups Newsletter, a report by Barbara Rapp described 
PubMed and its capabilities. The Related Articles search feature, with relevance-ranked 
results, was presented, with a concise explanation of how document similarity was 
determined.67 As well, in 1999, RevMan software underwent an update to convert it to a 
32-bit architecture and some features were added, including a section to describe 
contributions of each reviewer, and a new format to store references in a structured 
format.67 
In 2000, the Information Retrieval Methods Group discussed how to involve more 
librarians with The Cochrane Collaboration, and how to improve dissemination of 
methods research, often presented at the Cochrane Colloquium, by including this in the 
Cochrane Methodology Register. The bulk of the attention, though, was focused on the 
extensive problems with the searchability of The Cochrane Library, which were 
documented by a smaller working group drawn from within the Information Retrieval 
Methods Group. The working group, led by Phillipa Middleton, developed a strategy to 
communicate issues to the Collaboration and to Update Software, the developers of The 
Cochrane Library software.68 
In 2001, the Informatics Group disbanded, as it had been quite inactive and had 
not fulfilled the key functions of the Methods Groups. This decision was taken by the 
group when it met at the 2000 Cochrane Colloquium. The Information Retrieval Methods 
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Group also disbanded, apparently based on a decision by the conveners, who were still 
William Hersh and Phillipa Middleton. They stated, “We believe there is no longer need 
for the Group in the Collaboration, and the functions we could perform are actually being 
performed by others in the Collaboration. Active members of the Group feel we do little 
more than meet each year at the Colloquium and do not provide any substantive support 
for the Collaboration. The main functions that the Collaboration needs in terms of 
information retrieval are; (1) assisting Collaborative Review Group's with searching in 
the production of systematic reviews, and (2) managing feedback and identifying 
problems with The Cochrane Library. … Because these functions are maintained by 
others, and many in the Group are actually interested in methodology research anyway, it 
is felt that the Group does not serve much purpose for the Collaboration.” Members 
agreed to stay in touch.69 
In other Cochrane developments, the 2001 newsletter revealed a policy change, 
communicated through The Cochrane Reviewers’ Handbook, that it was now 
recommended that reviews be updated at least every two years, rather than at least each 
year. There were plans for major revisions to the part of the Handbook concerned with 
locating and selecting studies. The International Standard Randomized Controlled Trial 
Number (ISRCTN) was described, along with the hope that it would simplify 
identification of multiple reports of a single randomized controlled trial.69  
Research in progress highlighted two research projects relevant to information 
retrieval: a study by Sally Hopewell, Mike Clarke, Carol Lefebvre, and Roberta Scherer 
called “A comparison of handsearching with electronic searching to identify reports of 
randomized trials”70 and a 1988 study by Steve McDonald titled “Assessment of the 
precision of search terms in phases 1 and 2 of the MEDLINE Highly Sensitive Search 
Strategy for 1994-1997” [which appears not to have been published other than in the 
Methods newsletter.]69 
 Although the Information Retrieval Methods Group had disbanded, there was 
some attention to issues of searching in the 2002 Methods Groups Newsletter. Karen 
 
28 
Robinson reminded those planning to do methodological reviews of the importance of 
identifying unpublished methodological studies, noting that 9% of the records in the 
Cochrane Methodology Register were abstracts from meetings.71 Sally Hopewell and 
others had begun a systematic review of research studies examining the effect of grey 
(semi-published or unpublished) literature on meta-analyses of randomized controlled 
trials.71 
In 2003, Carol Lefebvre reported that information science journals were being 
hand searched to identify relevant methodological research to add to the Cochrane 
Methodology Register. She also provided examples of evidence-based information 
science research underway within The Cochrane Collaboration: 
• Assessing which bibliographic databases to search by recording and comparing 
reports of randomized trials identified in each database and analyzing the 
overlap.72  
• Evaluating whether searching MEDLINE is as effective as handsearching 
MEDLINE-indexed journals to retrieve randomized trials for possible inclusion in 
systematic reviews.70  
• Evaluating the comparative effectiveness of handsearching versus electronic 
searching of a variety of biomedical databases to identify reports of randomized 
trials for possible inclusion in systematic reviews.73 
• Comparing cover-to-cover searching of journals by hand with searching the full-
text of journal articles electronically on screen and with keyword searching of the 
full-text of journal articles electronically. (Weir, unpublished)  
• Designing objectively-derived highly sensitive search strategies for identifying 
reports of randomized trials in MEDLINE and EMBASE and reports of 
systematic reviews / meta-analyses in MEDLINE by identifying terms which 
occur frequently in ‘gold-standards’ of known reports but which do not occur 
frequently in other records in the databases.74  
Other work relevant to searching was also featured in the newsletter; Egger et al.’s 
work on “How important are comprehensive literature searches and the assessment of 
trial quality in systematic reviews?”75 This work reported a complex picture of effect size 
varying by publication status (published or grey literature), language of publication, trial 
size and susceptibility to bias. The 2002 Thomas C. Chalmers award went to Pamela 




The Information Retrieval Methods Group was attempting to stage a comeback, 
under the leadership of Carol Lefebvre, Steve Pritchard and Alison Weightman. The draft 
module was published in the Methods Group Newsletter.78 The proposed scope was much 
broader than that of the original group; “The Group will seek to provide advice and 
support, to conduct research and to facilitate information exchange regarding methods to 
support the information retrieval activities of The Cochrane Collaboration.” Some of the 
areas identified for empirical research were: “conducting and maintaining systematic 
reviews of information retrieval methods” and “developing and evaluating retrieval 
strategies for research evidence to support the systematic review process (systematic 
reviews, randomized controlled trials and other types of research evidence) for use by The 
Cochrane Collaboration.” The proposed mandate included training searchers in effective 
information retrieval, the appraisal and evaluation of search strategies, carrying out, 
supporting and encouraging research, offering policy advice to the Steering Group and 
other parts of the Collaboration, updating of the searching section of the Cochrane 
Reviewers' Handbook,79 advising on good practice in reporting search methods, and 
formalizing a method for monitoring the quality of searching techniques employed in 
Cochrane reviews. It was suggested that the Group would complement the work of other 
Groups, notably the Cochrane Reporting Bias Methods Group, as Egger et al.’s work had 
demonstrated how intertwined the issues of study identification and reporting bias were.75 
The proposed Information Retrieval Methods Group had identified 100 potential 
members or supporters by the time the 2004 Methods Group Newsletter was published in 
June,80 but the group was not formally registered as a Cochrane entity until November 
2004.81 
By 2005, the group had 150 members and had had a very successful initial 
meeting, attended by 50 people.81 Early work of the group was described, and included 
contributing to the InterTASC web resource of published search filters, and a project in 
which I was a co-principal investigator, along with Jessie McGowan, to develop a 
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checklist for assessing the quality of search strategies in Cochrane reviews (Peer Review 
of Electronic Search Strategies - PRESS).82,83 
The 2005 Newsletter also featured work by Su Golder et al. titled “Developing 
efficient search strategies to identify papers on adverse events using precision and 
sensitivity analysis and using statistical analysis”, which had been presented at the 
Colloquium and was published the following year.84 There was growing interest in harms 
reflected in other reports in the newsletter. 
By the 2006 report to the Methods Groups Newsletter, Jessie McGowan had been 
recruited to take Steve Pritchard’s place as co-convener on his retirement. Major 
initiatives included the publication of a revision of the Highly Sensitive Search Strategy,21 
revision of the searching chapter of the Cochrane Handbook,79 and initiatives to address 
the issue of the descriptions of the searches used in Cochrane reviews, undertaken in 
collaboration with Health Technology Assessment groups.85 
Other search-related research that was presented involved the challenges of 
finding diagnostic studies86,87 and a new filter for detecting clinically sound treatment 
studies in EMBASE from the McMaster University group.88 Meanwhile, work by Lasse 
Schmidt and Peter Gøtzsche suggested that traditional review articles may not have 
improved decisively since Mulrow’s work in 1987, in the sense that work cited in these 
non-systematic reviews was biased in favour of studies with positive outcomes.89 
 If harms were a theme of the 2005 newsletter, then updating was the theme in 
2006. Rob Scholten described the Updating Working Group and announced a pilot 
project to set priorities for updating, given that the objectives of updating every two years 
was not proving to be feasible either for review authors or review groups that needed to 
edit and approve the reviews.85 Work by Simon French et al. on “How do conclusions 
change when Cochrane reviews are updated?” was also reviewed.90  
The 2007 Methods Groups Newsletter featured the completed work by Wong88 
and Golder.84 The Thomas C. Chalmers Award for the best presentation at the Cochrane 
Colloquium was again awarded to a paper on searching; “Comparison of two different 
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search strategies in identifying literature for a diagnostic test accuracy review of Down’s 
syndrome screening” by Alldred et al. unpublished]  
News from the Information Retrieval Methods Group included details of 
representation of information retrieval methods to various Cochrane advisory groups, 
workshop activity, work on the Handbook revisions, and progress of the PRESS project. 
In other Methods Group activity, there was a proposal to form an Adverse Events 
Methods Group, with 30 interested members, but there was no report from the Updating 
Working Group.91 
The 2008 Information Retrieval Methods Group column in the newsletter updated 
the status of projects ongoing from the previous year, and reported on a new initiative to 
develop a framework and methodology for locating evaluation studies that have 
previously been identified as hard to access, particularly originating from low- and 
middle-income countries. The project had been funded by the Cochrane Opportunities 
Fund and was to be led by one of the co-conveners, Alison Weightman, with participation 
from three other Cochrane entities.92,93 
A featured study was Pamela Whiting's report “Systematic reviews of test 
accuracy should search a range of databases to identify primary studies.”92 Its 
methodological strengths will be noted below. Relevant to this thesis, a Cochrane 
methodology review titled: “When and How to Update Systematic Reviews”94 was 
reported. The next chapter will be an update of that review. 
In summary, the most common topics of research in the Methods Groups 
Newsletters relevant to systematic review searching were search filter development and 
testing and studies of the contribution of databases. Searching-related studies focused on 
Boolean database searching, hand searching of journals, or a comparison of the two. 
There were no evaluation studies of the contribution of checking reference lists,** 
although the technique is often recommended. There is only one mention and no 
                                                
** I am a co-author on a Cochrane Methodological Review protocol titled “Checking reference lists to find 
additional studies for systematic reviews” which was published in The Cochrane Library in Issue 1, 2009. 
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empirical research on similarity searching techniques such as the PubMed Related 
Articles feature.  
The methodological sophistication of the reported information retrieval research 
has increased over the first 12 volumes of Methods Groups Newsletters. As will be shown 
later, work on empirical methods for search filter development74 resulted in the improved 
recall of the 2006 revision of the Highly Sensitive Search Strategy21 compared to the 
original.64 Progress is also evident in studies of the contribution of databases. The most 
recent92 showed much more sophisticated methods for developing the “gold standard”. It 
distinguished whether a study was indexed in a database (coverage) or whether it was 
retrieved through searching, and finally recognized that the impact of missed studies from 
a source depends, in part, on whether those missed studies report results that differ 
consistently from the studies that are identified.  
As well as the Cochrane Information Retrieval Methods Group, several groups 
outside of The Cochrane Collaboration should be mentioned for their contribution to 
information retrieval in systematic reviews. Health Technology Assessment international 
Special Interest Group for Information Resources (HTAi SPIG-IR) maintains an active 
listserv for those interested in information retrieval in the closely allied field of health 
technology assessment and holds a one-day workshop on information retrieval each year 
at the HTAi annual meeting. The InterTASC Information Specialists’ Sub-Group 
(InterTASC ISSG) of UK-based HTA information specialists maintains a web site of 
methodological search filters along with a critical appraisal tool for such filters.  
Moving to the broader field of evidence-based librarianship, significant entities 
include a conference called International Evidence Based Library & Information Practice 
Conference that has been held every two years, under the leadership of Andrew Booth as 
International Program Committee Chair. The first conference was held in Sheffield in 
2001 and the fifth will be held in Stockholm in July 2009. The Evidence Based 
Librarianship Interest Group (EBLIG) of the Canadian Library Association sponsors the 
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open source journal Evidence Based Library and Information Practice, now in its fourth 
year of publication.  
2.4 SUMMARY 
Systematic reviews of randomized controlled trials are the highest level of 
evidence to inform medical decisions. The Cochrane Collaboration is the dominant entity 
creating systematic reviews, with most significant contributors in the field participating. 
The Cochrane Library was initially designed around a dynamic electronic platform, where 
updating could occur in real time. Although this real time updating was not feasible in the 
end, this original goal may have shaped research in statistical techniques of updating, to 
be seen in the next chapter. 
Electronically searchable databases were an important enabling technology 
preceding the routine production of systematic reviews. Despite this, the proper focus of 
the Information Retrieval Methods Group was initially framed as supporting the 
searchability of the Library itself, without a role to play in conducting original research 
on information retrieval methods for systematic reviews. The Group disbanded. However, 
original research had been going on from the inception of the Collaboration, with the 
landmark work being the development of the HSSS. The handsearching and electronic 
retagging projects were major and highly successful initiatives and they helped develop 
MEDLINE and the Cochrane Central Register of Controlled Trials (CENTRAL) into vital 
sources for systematic review work. Strengths of The Cochrane Collaboration include the 
early development of a trials register, and having a librarian on staff from the founding of 
the UK Cochrane Centre. These strengths are embodied in the renewed and active 
Information Retrieval Methods Group. 
Much of the subsequent searching research has involved developing filters for 
additional databases besides MEDLINE, and developing filters for other study designs 
besides randomized controlled trials. Other ongoing streams of research within the 
Collaboration (not detailed to any extent here) are work on statistical methods and 
epidemiological bias. Emphasis on systematic reviews of diagnostic studies and how best 
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to address harms have emerged as themes within the Collaboration in recent years. These 
themes have been reflected in information retrieval research. Updating systematic reviews 
is a most recent theme, and the research on that is reviewed extensively in the next 
chapter. It will be seen that very little research has been published on how best to update 
searches for systematic reviews. 
Finally, this review has not be a systematic review and is probably subject to all 
the deficiencies noted by Mulrow.31 The highlights of the evidence movement, the 
Cochrane Library and the infrastructure for searching were selected and reported 
subjectively. The coverage of search-related research and innovations relevant for 
systematic reviews is restricted to literature featured in The Cochrane Collaboration 
Methods Groups Newsletter, and the selection process for material featured in the 
newsletter is bound to have had some biases. However, the intent is only to set the stage, 
and illustrate the development of the fields and to document for history the evidence 
presented in these newsletters. In the next chapter, the literature on updating systematic 




Chapter 3: A Systematic Review of Prior Work on Updating Systematic 
Reviews 
3.0 INTRODUCTION 
Prior to undertaking the University of Ottawa Evidence-based Practice Center 
study on updating systematic reviews, from which much of the data in this thesis are 
drawn,16 the Ottawa group undertook a methodological systematic review of updating 
methods. This was published both as a journal article6 and as a Cochrane methodology 
review.94 Although published fairly recently, the search date for the review is 2005, and 
there has been a great deal of interest and activity related to the issues of updating 
systematic reviews since that time. Therefore, I updated the search and screened the 
results for additional relevant material.  
3.1 REVIEW METHODS 
3.1.1 Search Methods 
The following methods were used to identify potentially eligible reports. The 
electronic search strategy from the original review covered the period from 1966-
December 2005 and was re-run in MEDLINE (1950 to January Week 4 2009) using the 
Ovid interface, and restricted to records entering MEDLINE since the date of the last 
search (December 2005). The search was also re-run in the Cochrane Methodology 
Register (Issue 1 2009) using the Wiley interface. In addition, LISTA, a library science 
database, was searched using the strategy (update or updating or updated) and 
(systematic review* or meta-analys*)in any field, with a publication year of 2005 or 
later. The other search strategies are available in the appendix to the journal article.6 The 
first five PubMed Related Articles were checked for each record from the MEDLINE 
search that was retained after initial screening, and for all MEDLINE-indexed articles 
included in the original systematic review.  
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Citing references were sought for 11 articles of interest6,17,18,95-102 and for the ten 
journal-published articles included in the original review, although only citing references 
published since the search date of the original review were retained for screening. Scopus 
was used as the source of citing references due to its greater currency.  
Abstracts from an international Health Technology Assessment conference called 
HTAi, held July 6-9. 2008, Montréal, Canada were examined, based on a suggestion of 
one author contacted (available at http://www.htai2008.org/en_ebook.phtml). Finally, any 
relevant material already known to me was added to the database.  
Full publications of relevant new conference abstracts were sought, and where full 
publication was not identified, the first or corresponding author was contacted by email 
with a request to provide the full presentation, or any subsequent publications or other 
relevant material. Most of those approached responded and either provided material that 
is more complete or confirmed that there was no additional material available. 
3.1.2 Screening and Selection of Relevant Articles 
For the original review, a report was eligible if it described the development or 
use of one or more method, technique, or strategy either for updating or for determining 
the need to update systematic reviews in health care. Empirical studies, editorial reports 
or descriptions of such methods that appeared in an updated systematic review were all 
eligible.6  
Ideally, selection of articles for a systematic review is based on the consensus of 
two or more readers that the article meets all inclusion criteria. This helps protect the 
review against unintended bias or simple misinterpretation on the part of a single reader. 
This review update was undertaken with only one person (myself) screening and making 
eligibility decisions, therefore screening was liberal and all records that appeared 
informative to issues of updating systematic reviews were included. 
Only 15 reports, representing seven studies, were eligible for the original review. 
The evidence base proved to be quite limited, with a small body of literature on 
cumulative meta-analysis103-106 and the volume of new evidence needed to overturn 
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previous meta-analytic results,9,101 one evaluation of the shelf-life of clinical practice 
guidelines produced for the Agency for Healthcare Research and Quality,107 and some 
suggested approaches to updating from The Cochrane Collaboration.27,108,109 These 
findings will be integrated with the new material. 
3.2  RESULTS 
For this update, 1,411 new records were identified. Of these, 1,188 were from the 
Boolean database searches, 208 were uniquely from citing references, 13 additional 
articles were found through Related Articles follow-up searches, and two new articles 
were provided by authors. All relevant material that I had known of prior to the search 
was also detected by the search. The title and abstract of these records were examined, 
and 94 appeared potentially relevant to the systematic review. For these potentially 
relevant studies, the full article was obtained and examined, and 30 of these were 
retained.  
As well as being more plentiful, the new material was richer in content, reflecting 
a rapidly developing field. The evidence is summarized below, grouped under the themes 
of searching developments, developments in meta-analytic methods, fading of treatment 
efficacy, stability of observed effects, step-by-step updating procedures, determining 
when to update, establishing priorities for updating, hurdles in updating, and 
harmonization of updating efforts between agencies.  
3.2.1 Searching Developments in Updating 
The original systematic review included only one study related to searching, a 
conference abstract that concluded update searches should be restricted to any record 
entering the database since the last research, rather than being restricted by publication 
date.110 
Turning to the new studies, Cohen has published three papers on document triage. 
In the 2006 paper, Cohen used a voting perceptron, a type of artificial neural network, to 
triage documents to be screened for eligibility for systematic reviews. The screened 
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records for 15 systematic reviews of drug intervention were used as the as training sets.15 
That paper was excluded from the original review, however two new papers111,112 
continue that work and have explicit application to updating. In the second paper,111 
Support Vector Machine is tested, and area under the curve is the evaluation criteria. A 
significant area under the curve would indicate that the relevance ranking of documents 
by Support Vector Machine was better than chance. The screened records of the original 
reviews served as both the training and test sets using split samples. These records had 
been identified through Boolean searching. The goal was to rank a particular set so that 
relevant articles would be seen first, and that there would be very high recall, that is, 95% 
or more of relevant articles would be ranked. This group did not test the ability to detect 
subsequent publications; instead, they tested the ability of the final algorithm to rank 
articles from the Boolean searches for the original reviews. Nevertheless, if effective, the 
methods could be used to find and rank newer articles in order to update the review. 
An investigator can control what features of a document are considered by 
Support Vector Machine to determine relevance. Cohen’s group looked both at features 
that would be specific to a particular review as well as non-topic-specific training. 
Effective non-topic-specific training has been independently demonstrated by 
Aphinyanaphongs113,114 and more recently by they McMaster University group.115 Non-
specific features would be, for example, randomized controlled trials from major medical 
journals. In these results, Cohen found topic-focused training out-performed non-specific 
training. Non-specific training still had merit and could be useful in updating where there 
were very few studies included in the review that could be used as positive training 
examples, or in contexts other than updating when no topic-specific training set was 
available.  
In terms of document feature sets, Cohen tested title and abstract units, MeSH 
term variants (MeSH) and UMLS terms identified for each phrase (MMTX) alone and in 
combinations. MeSH terms are subject headings from the MEDLINE thesaurus. Variants 
examined were MeSH headings designated as major terms for that article, terms and 
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subheadings separately, and terms and subheadings together as complete MeSH terms. 
UMLS terms are terms from the Unified Medical Language System, described by the 
National Library of Medicine as a meta-thesaurus useful in investigating knowledge 
representation and retrieval questions.116 MeSH and text-based features used together 
provided the best performance. There was no performance advantage to including UMLS 
features. It has been thought that using UMLS might help compensate for records where 
MeSH terms were missing, such as new in-process records. However, text-based features 
performed adequately when MeSH terms were not available, and using UMLS was 
computationally intensive.  
Working backwards, Cohen’s initial presentation of this line of inquiry117 showed 
that training on a set of relevant documents produced good performance (i.e. high recall) 
in cross validation using that same set of documents but had much lower performance 
when applied to subsequently published documents. They noted that, “by its very nature, 
the field of science changes over time, as does the language used to describe it.” Although 
they undertook some analysis in an attempt to explain the decline in performance, they 
were unable to do so completely, but concluded that document triage systems may need 
frequent re-training or even need continuous training. In subsequent papers, they do not 
bring this out, but train and test on the same sample. This may be methodologically 
important. MeSH, as any thesaurus, is intended to draw together vartions in terminology 
to a single concept. This should mitigate regional and temporal variations in usage. MeSH 
features did not appear to figure prominently in successful ranking.  
In a related paper, with Yang as the lead author, this group reports on a system to 
automatically identify and harvest MEDLINE records for the screening sets used in 
systematic reviews.112 The system, called SYRIAC (for the Systemic Review Information 
Automated Collection system), takes an export of an EndNote screening database, 
performs some record clean up, submits the records to PubMed, and then adds the 
EndNote fields and PubMed fields for matched records to a data warehouse, along with 
reviewer’s decisions on the relevance of each item. Eighty-two percent of records from 
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the screening database were successfully matched with a PubMed record, an 
improvement from the 30%-50% match rate this group achieved with similar data using 
PubMed’s Batch Citation Matcher. Many of the unmatched records could have been from 
sources not indexed in MEDLINE, including grey literature.  
The point of forming the data warehouse was that records from this system would 
be used as the true positive and true negative training set for a classifier. The system 
could automatically update the data at intervals as additional records are screened and 
classified. Such as system is important as infrastructure for a surveillance system for new 
material; it would replace many of the manual tasks involved in the preparation of data 
for this thesis. 
The Cochrane Collaboration Updating Steering Group has prepared a draft report 
which includes a decision tree to determine if a review needs to be updated, and a 
checklist to determine what changes are needed to the Cochrane Review, section by 
section.118 Most of those recommendations will be discussed in Section 3.2.2, but the 
guidance for monitoring for new studies through searches is as follows: 
• Auto Alerts to monitor bibliographic databases (i.e., automatic rerun of full 
search strategy every time new studies are entered into a bibliographic database, with any 
new hits sent by e-mail) 
• Auto Alerts to monitor tables of contents of journals 
• PubMed ‘Related Articles’ feature (citing Sampson 200818) 
• Citation tracking (via Citation Indexes e.g., Science Citation Index); and 
• Checking Cochrane Review Group Specialised Register. 
The terms in the search strategy are to be checked periodically for changes and the 
strategy and associated auto alerts are to be kept up to date. If the search is revised, the 
details of search strategy are to be reported in the body of the review or in an appendix.  
They also advocate reporting the complete date of search, not just month and year, 
but unfortunately are not clear that the salient information is the date of last update of the 
database, not the calendar date when the search was run. 
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3.2.2 Step-By-Step Updating Procedures  
The original review identified an early paper by Chalmers et al. on preparing and 
maintaining meta-analyses, which describes the processes used in maintaining the 
original Oxford Database of Perinatal Reviews described in the previous chapter.27 The 
position taken by The Cochrane Collaboration in 1995, on maintaining and updating 
Cochrane Collaboration Reviews was also reported in the original updating review. 
Essentially, this involved repeating the search at least every two years, and determining if 
there were relevant new studies. If none were found, that was noted in the review when it 
was re-published in the next issue of The Cochrane Library, otherwise, reviewers were to 
integrate the new material and publish an updated version of the review.108,109 
The Cochrane Pain, Palliative and Supportive Care Group has a checklist for 
updating.119 Designed to ensure standards are met so that the review is as complete as 
possible prior to submission for editorial and peer review, it covers all aspects of the 
review. It is equally applicable to an original review as to an update, however for many 
sections there is guidance on how new material should be integrated and flagged (for 
instance, changes in some sections warrant mention in the “What’s New” section and 
these are flagged). The Pain, Palliative and Supportive Care Group checklist informed the 
Cochrane Updating Steering Group’s work.118 
The Cochrane Collaboration Updating Steering Group has considered the 
Collaboration’s updating strategy in some detail. Their report provides section by section 
guidance on how a Cochrane review should be updated.118 For some sections, the 
instructions are as simple as “Contact details: Are they correct? If no: update as 
necessary.” Guidance for other sections, such as the results section, is much more 
complex, covering the cases of meta-analysis, narrative synthesis in absence of meta-
analysis and quantitative analysis other than meta-analysis. Under quantitative analysis 




Clinical Evidence is a medical reference source, published in both print and 
electronic format, which is promoted as both evidence-based and up-to-date. The editorial 
team reviews all topics annually.120 Their search protocol includes an initial search for 
high quality systematic reviews. If a systematic review exists, further searches are done 
only for randomized controlled trials published after the search date of the review, using 
MEDLINE, Embase, and The Cochrane Library as default sources. Auto Alerts to 
monitor bibliographic databases are set up and results collated annually. The editorial 
team now develops a topic plan before each update, allowing them to tailor the approach 
to the update based on the topic, so some topics will be updated simply based on a 
repetition of the search, others may have a component added, such as searches for harms 
data or new treatements.121 
 The Clinical Evidence team appraises any new material using recognized criteria, 
and good quality evidence is combined into structured summaries by 
clinicians/specialists. The updated topic is peer reviewed before publication. New studies 
are highlighted whether they change the conclusion or not. Substantive changes in the 
evidence are highlighted in the topic summaries. Substantive changes may arise from re-
interpretation of existing evidence, appearance of new studies, emergence of harms, either 
from new studies, clinical experience, or restructuring, such as how the intervention 
works in different sub-populations, or at different dose levels.121  
3.2.3 Establishing Priorities for Updating 
French examined a cohort of Cochrane Collaboration Reviews that had been 
published by 1998 and updated by 2002 to see if and how conclusions changed for those 
reviews that had new studies added in the updated versions.90 Two reviewers 
independently classified the conclusions of the pairs of reviews as either unchanged, 
having minor changes, or having changes that alter the substance or interpretation of the 
conclusions. The ratio of old and new confidence intervals around the point estimate for 
the primary outcome was calculated, and any change in significance was noted. 
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 There were 119 eligible reviews. In almost all cases, the width of the confidence 
interval stayed the same or narrowed. The odds of a change in conclusion increased by 
3.3% for every 1% change in the width of the confidence interval. In five cases, statistical 
significance changed from significant to non-significant, and six reviews with a 
previously non-significant result for the primary meta-analysis became significant in the 
update. Conclusions showed substantive change in only 14 of the 119 reviews, and only 
four of these were accompanied by changes in statistical significance of the primary 
outcome. In eight of the 14 cases, changes in conclusions concerned outcomes other than 
the primary outcome. The only factors associated with changed conclusions were change 
in significance and change in the width of the confidence interval. The authors point out 
that these are not useful for predicting the need to update.  
French et al. note that in a number of reviews that had to be excluded because the 
research question had changed and these new reviews were quite likely to have different 
conclusions than those of the originals. Although French et al. did not find predictors of 
the need to update, they concluded that the evidence did not support routine time-bound 
updating, and that the search for indicators of the need to update should continue.90 
Sutton et al.102 used statistical power as a basis for predicting the amount of new 
information that is likely to be needed to change the statistical significance of a meta-
analysis. The unit of information considered is the number of participants randomized in 
new trials. Sutton’s team has developed software that will calculate the number needed 
for both random and fixed effects meta-analysis and with relative risk and other 
measures.101 The methods were tested on a set of 12 meta-analyses, with studies being 
removed until the analysis became non-significant. The number of new participants 
needed was calculated using Sutton’s formula and simulations of new studies were 
developed to test the method’s performance.  
Sutton also calculated the New Participant Ratio according to the method first 
proposed in a project in which Barrowman and I were co-principal investigators.9 This 
method, which uses the New Participant Ratio, was included in the original review. 
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Briefly, it focuses on meta-analyses that are not statistically significant. It follows the 
logic of the “File Drawer” technique for estimating publication bias.122 That technique 
asks how many statistically non-significant studies would have to be lingering, 
unpublished, in a file drawer before they could undermine the statistical significance of a 
result. The New Participant Ratio instead looks at how many participants would have to 
emerge in new studies before the non-significant result could become significant, 
necessitating the update of the review.9  
Comparing Sutton’s estimate of the amount of new information with the New 
Participant Ratio showed good concordance between the two predicted numbers. Both 
methods correctly ranked 10 of 12 systematic reviews in terms of likelihood of change. 
Rankings were the same for both methods for positions 1 through 7 of the 12 positions. 
Two of the remaining five systematic reviews were ranked in a different sequence by the 
two methods. Sutton et al.’s method produced two anomalies. The 5th ranked study result 
did not change significantly when the real new studies were re-introduced, and the study 
ranked least likely to need updating did change significantly. The exceptions were 
explored to help understand the operation of the method. 
Sutton proposes that this method can be used to monitor a suite of reviews. 
Number of new participants needed for likely change in effect significance would be 
established for all reviews in a group, such as all reviews by a particular Cochrane 
Review Group, or all Evidence Reports sponsored by the Agency for Healthcare Research 
and Quality. Editors would than track the number of new participants from new eligible 
trials and updating resources would be allocated to those reviews most likely to change. 
They note that their method could be adapted to clinical limits, to track a certain change 
in effect size, instead of statistical limits. The software has also implemented the 
quantitative signals used in the survival analysis of our updating project.16,17 They suggest 
that composite signals are a useful avenue for further exploration. 
Sutton’s method is flexible. Various outcome measures can be included, either 
fixed or random effects meta-analytic approaches can be accommodated, and signals can 
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be based on statistical or clinical criteria. Although all 12 meta-analyses tested by Sutton 
had significant findings that were rolled back to non-significant, the method can be used 
to predict change from non-significant to significant. While presented as a method to set 
updating priorities, it could equally be applied to set a priori criteria for updating a given 
meta-analysis.  
Sutton et al. argues that a strategic approach to updating will reduce the number of 
updates and reduce the problem of multiple testing (which will be discussed at length in 
Section 3.2.6). They further suggest that review authors build estimates of the amount of 
new information needed to warrant updating into the original review.  
Both French90 and Sutton’s102 research found that adding additional information 
will narrow the confidence interval of a meta-analysis and may result in a change of 
significance. Both studies also identify cases where the change came in ways that could 
not be captured in the meta-analysis. Both papers conclude that reviews can require 
update for reasons other than changes in the primary outcome, and that these may be less 
predictable. Ultimately, both argue that a system for establishing updating priorities is 
preferable to updating all reviews on a fixed schedule. 
3.2.4 When to Update 
The original version of the systematic review of updating cited The Cochrane 
Collaboration’s policy that reviews should be updated every two years. It has become 
clear that this target is not practical.95,96,100,123 The Cochrane Collaboration Updating 
Steering Group started a project to look at updating in September 2007, with support from 
the Cochrane Opportunities Fund (Kirsty Loudon, personal communication, February 21, 
2008). Their draft report titled Methods to guide decisions of whether, and when, to 
update Cochrane reviews takes a new approach, with updating occurring as needed, 
recognizing that “it is not possible to give a predetermined definitive answer to decide 
when a Cochrane review should be updated.”  
Continual monitoring of the literature is recommended to ascertain if the field is 
moving quickly or slowly, and monitoring strategies are described below. A decision tree 
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is provided to help authors decide if an update is needed, and the decision to update is the 
responsibility of the review team. The most likely triggers are the findings of a new study, 
but other possible triggers, or combination of triggers, might include; new evidence (e.g., 
information about new treatment regimes, harms, economic data, or outcome measures), 
new methodology (e.g., new statistical techniques, or changes in the Cochrane Handbook 
for Systematic Reviews of Interventions or RevMan), or factors such as age of the review, 
imminent use of the review in policy or guidelines, and response to feedback from users 
of the review.118 
The Drug Effectiveness Review Project (DERP) of the Agency for Healthcare 
Quality and Research produces systematic reviews examining classes of drugs, such as 
newer antihistamines, Alzheimer’s drugs and drugs to treat attention deficit hyperactivity 
disorder. The DERP team have presented a system for deciding when a review done as 
part of the program needs to be updated.124,125 
In their 2007 presentation at the Cochrane Colloquium, they outlined a 
surveillance process for identifying reviews in need of updating. This involves annual 
literature reviews in MEDLINE and searches of the web sites of the American and 
Canadian regulatory agencies for prescription drugs. Identified material is screened by the 
author of the original review according to the inclusion criteria of the original review. 
New information is presented to a decision making panel with representatives of those 
who fund, commission and use the reviews. Applying the approach resulted in a decision 
to update in 43% of 23 topics in the first report124 and 53% of 30 topics a year later.125 
Decisions were analyzed in terms of the number of new trials, new drugs, new indications 
for the drugs and new safety alerts, resulting in nine decision rules. All reviews with more 
than 26 new controlled clinical trials had been chosen for update (n=5). Beyond that, the 
decision rules were much more complex and anomalies occurred. For example, when the 
decision tree was pruned to force fewer rules, the result was that all reviews with more 
than 26 new trials or fewer than 11 new trials would be updated, but if the number of new 
trials fell between 11 and 26, no update would take place.124  
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Survival analyses showed median survival times of 9 to 23 months, with all 
psychiatric topics going out of date within 12 months. However, none of the parameters 
considered were predictive of the need to update.124 The team concluded that surveillance 
did work well for setting updating priorities but that no simple formula could codify the 
judgments of the decision making teams.124 The DERP team is also involved with the 
work of Cohen et al.15 
3.2.5 Hurdles in Updating 
Several authors describe logistical and motivational challenges involved in 
updating systematic reviews. Linde describes the situation of several Cochrane 
Collaboration Reviews in complementary and alternative medicine for which he is an 
author.96 He notes that complementary and alternative medicine has seen a growth of 
higher quality and larger trials. These are positive developments, however, they increase 
the work involved in updating a systematic review. In some cases, inclusion criteria 
needed to be changed to reflect the availability of trials with stronger study designs that 
therefore were less susceptible to bias. In these cases, the review has to be re-worked 
extensively. In another review, the early trials were mostly placebo controlled and did not 
use standard diagnostic criteria. Newer trials used a variety of controls and the 
standardized diagnostic criteria, meaning that they cannot simply be combined with the 
trials in the original review – differences in results have to be interpreted in light of the 
difference in how the trials were conducted. This means that the review needs 
considerable restructuring. Because of the extent of changes, the revision has to undergo 
complete peer review, adding time and complexity to the process.  
In another case, Linde reported that there was little new material, but the review 
had been done in the early days of The Cochrane Collaboration and it would take a great 
deal of work, including re-doing much of the data extraction and analysis, to meet current 
reporting standards.96 In this same case, the topic of the review was no longer a research 
focus for the review authors. In another example, a safety review was undertaken as well 
as an efficacy review but only the efficacy review was submitted as a Cochrane review 
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since the prospective of updating the safety review on a regular basis was too daunting. 
Linde concludes that successful updating is critical to the long-term survival of The 
Cochrane Collaboration but that regular updates cannot be done without dedicated 
financial support. 
Ervin95 cites previous reports of limited success in meeting updating targets.90,126 
Henderson127 and Koch123 provide similar results. Ervin notes that authors’ motivations 
for undertaking an original review vary, and may influence their motivation to update. 
For instance, a review may be done as part of a course requirement or as a necessity to 
obtain funding for primary research, such as a randomized controlled trial. The necessary 
motivation may not be there to maintain the review through future updates. Ervin reviews 
the theory of planned behaviour and suggests how it could be applied to assessing 
motivation for updating. Further, such work sheds light on the practical assistance needed 
to overcome identified barriers, such as financial support and access to librarians and 
methodologists.  
Jacquerioz et al. report on discussions in March 2007 to develop strategies to 
increase the impact of systematic reviews on maternal and childbirth health issues.128 The 
meeting was sponsored by the Agency for Healthcare Research and Quality but had a 
strong Cochrane influence and looked at creating, updating and disseminating systematic 
reviews. In terms of updating, participants considered it more appropriate to have the 
frequency of updates depend upon the topic, as well as the number and quality of new 
data, rather than at a fixed time, with some rapidly moving disciplines requiring more 
frequent updating than other slower moving fields. Streamlining of information flow 
through centralized searching and notification when a certain quantity of new information 
had accumulated was thought to be helpful. The New Participant Ratio9 was suggested as 
a potentially fruitful approach to identifying the need to update null reviews. Identifying 
willing workers for updating was a second theme. Some suggestions were a matching 
system to pair interested volunteers and authors seeking assistance as well as promoting 
updates as ‘training’ for learning how to prepare a review de novo.  
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French et al. hypothesize that the existence of new evidence could be a barrier to 
updating - i.e. that reviews with little new evidence may be preferentially updated due to 
workload issues.90 They do not provide any evidence to support or refute the existence of 
such a phenomenon, they merely point out that studying only reviews that have been 
updated may give a biased picture of the true number of reviews in which conclusions 
would change with updating. 
Garritty et al. conducted a survey of updating issues and practices of agencies that 
conduct or sponsor systematic reviews.4 The survey asked about barriers to updating and 
the leading barriers, and the percent of respondents who endorsed them somewhat or 
strongly were: limited funding and resources (72%), reviewer motivation (55%), lack of 
academic recognition for updating (49%), the need to re-do data extraction (45%), and 
need to re-assess study quality (38%). 
3.2.6 Developments in Meta-analysis Methods Relevant to Updating 
The original review on updating included a number of studies involving 
cumulative meta-analysis. Cumulative meta-analysis is a statistical procedure in which 
the effect estimate based on all studies combined is sequentially updated by incorporating 
each newly available study. It should be capable of identifying the earliest time that a 
definitive conclusion can be reached. A significant limitation is that the chance of falsely 
rejecting the null hypothesis (making a type 1 error) increases due to repeated hypothesis 
testing. The original review examined the work of Pogue and Yusuf on sequential 
monitoring boundaries.104 They adapt a system that was initially developed for use in 
clinical trials where the significance level of each testing of the null hypothesis is made 
more stringent. 
Turning to the new research, a number of recent closely related papers present and 
explore the concept of trial sequential analysis based on information size.129-132 This is the 
sample size that would be needed to detect a certain effect size with statistically 
acceptable risks of falsely accepting or rejecting the null hypothesis.130 Information size is 
analogous to sample size calculations for clinical trials. However, unlike the situation of 
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repeat testing within a single clinical trial, sample size for meta-analysis must take into 
account heterogeneity between studies.131  
Trial sequential analysis establishes boundaries where the effect size needed to 
achieve statistical significance is adjusted upward when the optimal information size has 
not yet been achieved.131 In one study, a quarter of meta-analyses that had statistically 
significant findings and had achieved the necessary heterogeneity-adjusted information 
size would have had false positive results in earlier versions, had the meta-analysis been 
updated as each new trial appeared.131 
Thorlund’s paper examines meta-analyses with both the required information size 
and with significant findings.131 Meta-analysis was done retrospectively with uncorrected 
cumulative meta-analysis and with monitoring boundaries established using trial 
sequential analysis. They claim that in the sample studies, trial sequential analysis 
eliminated false positive results, which would have been common in cumulative meta-
analysis. 
Borm and Donders argue that trial sequential analysis can only partially adjust for 
repeated updating of meta-analyses because of the many unknown factors and unplanned 
pattern of studies and few, if any, meta-analyses have stopping rules.133 They suggest that 
the assumptions underlying the notion of “optimum information size” that would produce 
a convincing result are often violated as new trials continue to be conducted, even after 
the optimum information size is attained. These authors propose a “failsafe k”, which they 
describe as comparable to the “failsafe N” approach for evaluating the impact of 
publication bias. Publication bias is the tendency to preferentially publish studies that 
support a particular point of view – usually preference is given to publishing studies or 
outcomes with studies that show positive result. Failsafe N represents the number of 
missing studies with null effects that could be added to a meta-analysis without 
undermining the statistical significance of the results. Borm and Donders’ new measure, 
failsafe k, is the “maximum number of times a meta-analysis can be updated before the 
type I error exceeds the threshold of statistical significance.” Through simulations, they 
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evaluate how periodic updates alter the type 1 error rate. The experimental variables they 
used were publication bias, frequency of updates, the stopping rule for drop in p, the 
power of the trials, and heterogeneity.  
Hu et al. also look at controlling type 1 error in cumulative meta-analysis, using a 
method they call LIL, for law of iterated logarithm.134 Their 2003 paper103 demonstrated a 
method for use with meta-analyses of continuous outcomes (such as amount of weight 
loss), while the 2007 paper looks at binary outcomes (such as mortality). Like Borm and 
Donders’ failsafe k method, the LIL method does not require pre-specification of the 
maximum information, that is, it is not necessary to assume that new research will stop 
once a definitive result has been achieved through meta-analysis.  
Hu et al. re-examine Lau’s famous example of 33 trials comparing intravenous 
streptokinase with placebo.135 Lau demonstrated that by 1973, it would have been 
apparent, through cumulative meta-analysis, that more patients hospitalized for acute 
myocardial infarction were alive after 30 days if treated with streptokinase than with 
placebo. In fact, the full benefit of this life-saving therapy was not recognized until 1988. 
This paper has been highly influential and has been cited over 500 times.†† Re-analyzing 
Lau’s data and applying the LIL correction for repeat testing, Hu argues that compelling 
evidence of the superiority of this treatment was only available in 1988, or, using slightly 
less conservative methods, by 1977.  
In this research, the investigators only update the meta-analyses once each year, 
rather than with the publication of each new study. Annual updating was the frequency 
originally intended by The Cochrane Collaboration. Hu et al. argue that the decision to 
update a meta-analysis should be based on increments of new information, where 
information is the sample size, or number of participants in studies. Updating should not 
be done after each study or after a certain amount of time – even with statistical 
correction, it is best to minimize the number of inspections. 
                                                
†† As of March 21, 2009, Web of Science recorded 535 citing articles. 
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While much of the attention has focused on inflated type 1 error due to repeat 
testing in cumulative meta-analysis, Bender et al. point out that multiplicity exists in 
many forms in meta-analysis; multiple outcomes, multiple groups, multiple time points, 
multiple effect measures, subgroup analyses, and multiple looks at accumulating data.136 
They suggest that there is no completely satisfactory solution now, and they advise 
consumers of systematic reviews to be aware of the problem when evaluating the 
evidence. In terms of multiplicity due to multiple looks at accumulating data in updating 
of meta-analysis, they summarize the work of Pogue and Yusuf,104 Wetterslev et al.,132 
and Hu et al.134 in monitoring boundaries and other corrections. Bender et al. point out 
that if the accumulating trials are interpreted within a Bayesian framework, there is no 
need to adjust for multiplicity. They introduce an important distinction between 
cumulative meta-analysis completed retrospectively, such Lau et al.’s demonstration that 
evidence supported intravenous streptokinase as thrombolytic therapy for acute 
myocardial infarction years before that effect was widely recognized,135 and cumulative 
meta-analysis prepared as the evidence accumulates and for the purpose of supporting 
decisions. Bender et al. argue that the former does not need to address multiple testing, 
but the latter does. In summary, Bender recommends that reviewers, “incorporate sample 
size considerations and the expected degree of heterogeneity for the primary effect 
measure(s) in prospectively planned cumulative meta-analyses, and that they adjust the 
threshold for statistical significance or the inflation of the test statistic to account for 
future multiple looks as data accumulates, if the required sample size has not yet been 
reached and if future review updates are planned.”136  
Although there are a number of papers focusing on controlling type 1 error rate in 
cumulative meta-analysis, in practice, most systematic reviews appear to be updated in 
batch mode, rather than as each new study appears. A search for “update” and 
“cumulative”, limited to systematic review or meta-analysis in PubMed, yielded only 14 
records, two of which were the updating systematic review being updated here.6,94 Many 
were irrelevant due to the use of “cumulative” in other contexts, such as cumulative 
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toxicity, cumulative indices, cumulative incidence, lifetime cumulative and average 
exposures, and Cumulative Index to the Nursing and Allied Health Literature - the 
CINAHL database. On examination, four of the remaining records did not appear to refer 
to an updated systematic review, and two were updated guidelines but were not based on 
cumulative meta-analysis. Finally, only three readily discernible examples of updated 
systematic reviews using cumulative meta-analysis could be identified as of February 28, 
2009.137-139  
3.2.7 Fading of Treatment Efficacy  
Ioannidis studied highly cited treatment studies and found that they generally 
presented positive results and often showed large effects of treatment.140 While many of 
these findings were supported by the results of subsequent studies, 16% were refuted and 
another 16% had stronger effects than subsequent studies – significantly more than a 
control sample of less frequently cited trials. Ioannidis points out numerous influences 
could account for this finding. Since then, an number of interesting results have 
appeared.140 
Gehr et al. discussed the fading of reported effectiveness.141 They state that the 
real effect of a medical therapy should be constant over time, but many factors may 
influence reports of effectiveness. They studied four drugs; Pravastatin and Atorvastatin 
to lower cholesterol and the anti-glaucoma drugs Timolol and Latanoprost. They looked 
at randomized controlled trials that either tested these drugs or used them as a control to 
test another newer therapy. Three of these drugs showed statistically significant decreases 
in reported efficacy over time, the other drug (Atorvastatin) showed constant effects. 
They tested a number of potential explanatory variables, including publication bias, and 
found that the only consistent factor was that sicker patients were treated in the early 
studies. Study size, and whether the drug of interest was the test or control for the trial, 
made little or no difference. They speculate that other factors may be that positive trials 
are published more quickly than negative trials (a form of publication bias), and that 
improvements in the conduct of studies over the years make exaggerated positive results 
 
54 
less likely – in this case the apparent fading would be an artifact. They caution systematic 
reviewers that such time effects may need to be considered when interpreting results.  
McAlister and Mohamed looks at the evolution of evidence142 and described 
“regression toward the truth”. Much of the McAlister and Mohamed paper is a 
commentary on Vaitkus and Brar,143 who studied a series of 27 randomized trials and 17 
meta-analyses examining N-acetylcysteine for the prevention of contrast induced 
nephropathy. They described Vaitkus & Brar’s findings that earlier studies reported larger 
treatment effects than later studies as “regression to the truth effect”. Vaitkus and Brar 
restricted their observations to randomized controlled trials, thus allowing them to make 
this observation with confounding publication date with study design.143 McAlister 
attempted to replicate this finding using meta-analysis included in a comparison of paired 
Cochrane Collaboration Reviews and industry-supported meta-analysis on the same topic. 
They found that the majority of the meta-analyses showed smaller treatment effects than 
the first trial, and smaller treatment effects than the largest trial. They argued that this 
demonstrates the strength of meta-analysis, that meta-analysis is inherently conservative, 
and that all relevant studies should be included, rather then than excluding small or early 
studies as unreliable.142 
The editorial team of Clinical Evidence reviewed all substantive changes in two 
print issues (December 2005 and June 206). In that period, covering about one year of 
updates, 1,807 treatment topics were updated, 23% had substantive changes and 17% of 
those entailed changes in the characterization of how effective the treatment was. Results 
were evenly split, with 51% the treatments reclassified as more beneficial, and 49% 
reclassified as less beneficial based on the updated evidence or revised interpretation.121 
In subsequent data from the August 2007 edition144 and from the February 2008 
edition,145 52% and 55% of topics with substantive changes were reclassified as less 
beneficial or more harmful than previously categorized. 
 
55 
3.2.8 Stability of Observed Effects 
Stability of observed effects is related to the ideas of optimum information size. It 
may be possible to look at a body of research results and declare them stable and unlikely 
to change in the future. Presumably, further updating would be unproductive unless there 
was some abrupt shift in how the illness was manifested or a new treatment or prevention 
strategy emerged.  
In the original updating review, the work of Mullen, Muellerleile and Bryant was 
presented.106 They used cumulative meta-analytic techniques and gauged the “cumulative 
slope” or rate of change in effect size with the addition of each new study. The smaller 
the magnitude of the slope of the regression line, the greater the confidence that the 
pooled effect size was becoming stable. When the rate of change slows sufficiently, it 
may be appropriate to stop updating a meta-analysis.  
In this update, Muellerleile and Mullen used simulation to develop the indicators 
of sufficiency and stability in cumulative meta-analysis used in updating public health 
interventions, and then applied them to existing, published datasets.146 Stability refers to 
the leveling of the slope described above. Sufficiency is a new element in their work and 
refers to statistical significance – whether there is sufficient evidence that the 
phenomenon exists. This is examined through another variant of the failsafe number used 
by Barrowman et al.9 and by Borm and Donders133 – the number of unpublished, 
irretrievable studies with null effects that would need to exist to undermine the statistical 
significance of a finding.122 Muellerleile and Mullen created a failsafe ratio that is 
calculated based on the failsafe number of studies and the number of studies already in 
the collection. From the point in time when that ratio exceeds 1.0, they argued that there 
would be no need for additional research to establish that the phenomenon under study 
did exist.  
Applying this work to two examples, they found that cumulative meta-analysis of 
evaluations of heart-healthy eating programs reached sufficiency and stability quickly, 
and subsequent evaluations have represented excessive time and effort. On the other 
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hand, a similar analysis of drug abuse prevention programs showed that the meta-analysis 
achieved stability some time ago – the size of the treatment effect has remained more or 
less constant, but sufficiency has never been established, implying that future evaluations 
of such programs are not worthwhile.146 
3.2.9 Harmonization of Updating Efforts 
Harmonization refers to common standards and coordination of efforts between 
agencies. The idea of harmonizing updating efforts between agencies arose during a 
consensus development workshop with the international Expert Working Group on 
Updating Systematic Reviews that pre-dated the Ottawa Evidence-Based Practice 
Center’s primary research on updating.11 Harmonization was included as a theme by 
Garritty et al.4 in a survey of agencies that sponsor systematic reviews and Health 
Technology Assessments. Seventy percent of respondents somewhat or strongly agreed 
that centralizing efforts across institutions or agencies that produce systematic reviews 
would be a worthwhile efficiency, although numerous barriers to such inter-agency 
cooperation were perceived. Several articles address this, if somewhat peripherally.  
Whitlock’s group147 outlined a series of steps that can help reviewers reach 
reasoned decisions about the incorporation of existing systematic reviews into a new 
systematic review and enumerate potential hazards to consider in doing so. They 
discussed the challenges and suggest that a reporting standard be developed for review of 
reviews. They suggested using previous reviews at least to serve as a crosscheck on the 
completeness of the search for primary studies and as a source for primary studies. They 
suggested updating the searches even for very recent reviews. They noted exceptions, 
particularly when the systematic review being undertaken links several bodies of 
knowledge, one or more of which may be firmly established, such as the health benefits 
of smoking cessation. In these cases, no update of the search was warranted. Other than as 
a means of identifying primary studies, they urged caution in the re-use of reviews, 
suggesting that only high quality reviews be retained, and that some verification of the 
accuracy of screening decisions and data extraction be done. Whether or not previous 
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reviews are incorporated, Whitlock et al. recommended that reviewers address any 
inconsistencies between previous reviews and the current review. Methods used to locate, 
screen, and appraise reviews and to resolve discrepancies should be reported in a 
reproducible and transparent manner. They noted that reporting of the handling of 
previous reviews is not now a part of the QUOROM guidelines.42 
McAlister142 does not suggest a method for harmonizing, but addresses the issue 
of redundancy in the literature, with particular reference to the large number of reviews 
on N-acetylcysteine. In terms of research priorities, “17 meta-analyses examining a 
narrow clinical question which contributes relatively little to the global burden of disease 
represents a disappointing duplication of effort, particularly in light of the fact that the 
therapeutic options for many diseases which cause substantial disability adjusted life 
years lost worldwide have not been systematically examined at all.” This is a sobering 
observation in light of Chalmers’ initial challenge that, “… a great criticism of our 
profession that we have not organised a critical summary, by specialty or subspecialty, 
adapted periodically, of all relevant randomised controlled trials."28  
The Cochrane Collaboration recently conducted a strategic review of its 
structures, processes and governance. Members of the Collaboration ranked the 
recommendations, and the recommendation, “to develop a partnership strategy to engage 
other systematic review producers and knowledge packagers” was ranked sixth out of 26 
recommendations.148 
3.3 SUMMARY 
The systematic review updating work reported in this thesis began in 2005, and 
coincided with an upsurge of interest in the topic. While The Cochrane Collaboration’s 
initial objective of updating all reviews annually was discarded in favour of bi-annual 
updating, even that target now appears neither achievable nor necessary. Most work has 
focused on updating on an “as needed” basis; however, it is not at all clear how the need 
can best be ascertained. The work on controlling type 1 error in cumulative meta-analysis 
that was reviewed in the initial systematic review on updating continues, although there 
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are relatively few examples of cumulative meta-analysis being used in actual updates of 
systematic reviews. Still, the work on controlling type 1 error is relevant to the extent that 
concepts such as optimum information size can inform when to update.  
Apparent changes in efficacy between an original and updated meta-analysis need 
to be interpreted in light of a small body of work that suggests that the true, and often 
lower, level of effectiveness of medical treatments may only be apparent over time. Some 
research explores how best to determine when the stability of observed effects has 
occurred. 
The Cochrane Collaboration and Drug Effectiveness Review Program (DERP) 
have both outlined protocols for deciding when to update, and they are generally based on 
expert opinion informed to some extent by new evidence. The Cochrane Collaboration, 
DERP, and Clinical Evidence have drafted search protocols to use for monitoring, but 
none of these has been evaluated, and the Cochrane protocol is cumbersome.  
Sutton proposes prospective determination of the number of new participants in 
trials that will be needed to change a significance level of a meta-analysis, and using the 
accumulation of new studies to inform priorities for updating. The issue remains how best 
to identify those new participants. Sutton and Cohen’s groups have both developed 
information systems for automating some of the tasks of surveillance. Sutton has 
developed a system to assess power and determine the number of new participants to be 
watched for. Cohen’s group has automated the process of building training sets to use 
with classifiers. 
Inter-agency cooperation in the refining and in the practical application of 
methods such as those developed by Sutton and Cohen’s groups, could help overcome 
some of the perceived barriers to harmonization of updating efforts across the corpus of 
systematic reviews.  
Themes run through several of these topics. Some findings are stable, and need no 
further examination, such as the effects of smoking cessation or heart-healthy eating 
programs. Updating should be based on the appearance of new information, rather than 
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the passage of time. New information may either take the form of 1) the number of new 
study participants (rather than the number of new studies) or 2) the emergence of non-
linear information. Examples of non-linear information include the emergence of 
previously unrecognized harms, introductions of new competing treatments, or some new 
understanding of sub-populations whose disease condition or response to treatment may 




Chapter 4: Methods for the Main Experiment 
4.0  INTRODUCTION 
The main experiment tests several search strategies to determine their 
performance in the task of identifying important new evidence to updating systematic 
reviews. These searches are tested in three cohorts of clinically important systematic 
reviews of reasonable quality. The test searches were used to identify new evidence to see 
if those reviews became out of date during the observation period. Accuracy of the 
conclusions based on the new evidence found was verified against confirmatory sources. 
The performances of the test searches were determined using recall as the primary 
outcome and, in some cases, precision as a secondary outcome.  
This chapter presents the methods used to select the cohort, construct the searches, 
and prepare the search results for screening, the screening procedures themselves, and the 
confirmation of findings. In addition, methods and procedures for the creation of the 
dataset used for analysis, the outcome measures chosen, along with the rationale for 
selection, and the statistical procedures for analyzing the data for the main experiment are 
presented.  
4.1 CREATING THE COHORTS 
A cohort of 109 systematic reviews served as the basis for evaluating the 
performance of test searches, and for examining the nature of changes in evidence over 
time. The methods used to identify, select and describe this cohort are reported in this 
section. These methods are those of the Agency for Healthcare Research and Quality 
(AHRQ) updating project, published as an AHRQ Technical Report.16 The investigators, 
principally Dr. Kaveh Shojania, determined the eligibility criteria, a signal for the need to 
update a systematic review, and definitions of major and invalidating new evidence. A 
Technical Expert Panel advised on and approved the protocol.  
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4.1.1 Study Identification 
Systematic reviews were used as the sampling frame. They were identifed from 
commentaries in ACP Journal Club, a bimonthly publication of the American College of 
Physicians that aims “to select from the biomedical literature articles that report original 
studies and systematic reviews that warrant immediate attention by physicians attempting 
to keep pace with important advances in internal medicine.”149 The process used for ACP 
Journal Club selection involves “reliable application of explicit criteria for scientific 
merit, followed by assessment of relevance to medical practice by clinical specialists.” 
Moreover, systematic reviews indexed in ACP Journal Club must meet specific standards. 
They must report the search methods used and the inclusion and exclusion criteria. 
Eligible systematic reviews must include at least one study that would, on its own, meet 
the criteria for write-up in ACP Journal club, according to the standards set for the 
relevant study type. Therefore, a systematic review of a treatment would need to include 
as least one study with random allocation of participants to comparison groups, endpoint 
assessment of at least 80% of those entering the investigation, and an outcome measure of 
known or probable clinical importance.149 Thus, choosing this sampling frame allowed us 
to identify systematic reviews of reasonable quality that are directly relevant to clinical 
practice.16 
4.1.2 Eligibility Criteria 
4.1.2.1 Main Cohort 
In addition to selection by ACP Journal Club, the following eligibility criteria 
were imposed. Eligible systematic reviews must have evaluated the clinical benefit or 
harm of a specific drug, device, or procedure (or of a class of drugs, devices or 
procedures). There must have been a quantitative synthesis (meta-analysis) that included 
a point estimate and 95% confidence interval for at least one clinical outcome (e.g. 
disease endpoint, functional status or mortality) or established intermediate outcome (e.g., 
blood pressure, glycemic control, standard instrument for measuring disease activity, such 
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as a depression scale). Evaluations of alternative and complementary medicines, as well 
as educational and behavioural interventions were not eligible.  
Furthermore, the systematic review must have been published between 1995 and 
2005, but with the date of the final search conducted no later than December 31 2004. 
This was to ensure at least one full year for new evidence to appear.  
 At least one conventional meta-analytic estimate of treatment benefit or harm 
must have been reported in the form of a relative risk, odds ratio, or absolute risk 
difference for binary outcomes and weighted mean differences for continuous outcomes. 
Up to four eligible benefits and up to two eligible harms were studied. We excluded 
individual patient data meta-analyses, meta-regressions, and indirect meta-analyses 
because of the difficulty of determining whether or not data from new trials would alter 
previous quantitative results. Studies reporting standardized effect sizes were excluded to 
avoid the complexity of assessing new data reported using various different outcome 
scales, because it would be problematic to determine which, if any, outcome would have 
been one that would have been incorporated into the standardized effect measure.  
The systematic review must have included at least one randomized controlled 
trial, in keeping with ACP Journal Club criteria, but other included studies in the 
qualifying meta-analyses were restricted to quasi-randomized or controlled clinical trials.  
The cohort was limited to no more than 30 Cochrane Collaboration Reviews, as 
these have been found to differ in many ways from other systematic reviews in the peer 
reviewed literature on the basis of style and possibly on topic coverage.3,126 A sample size 
of 100 systematic reviews was established for the survival analysis of systematic review. 
This was thought to be large enough to evaluate up to five predictors of survival, but also 
reflect the practical resource limitation. A subset of the explicit updates was established to 
test the experimental search methods against the search conducted for the review. This 
subset and the AHRQ cohort described below were used to test the performance of 
Support Vector Machine (SVM). Several additional inclusion criteria were imposed for 
 
63 
that purpose, and the reviews with explicit updates were screened against those additional 
criteria.  
4.1.2.2 Updated Cochrane Cohort 
All Cochrane Collaboration Reviews found eligible for the main cohort (n=27) 
were assessed for eligibility against the following additional criteria. 1) The text of a 
review and an updated version was available. 2) The search for the original review was 
comprehensive (defined, following the Oxman and Guyatt quality assessment scale for 
meta-analyses, as a search of MEDLINE and at least one other electronic bibliographic 
database, and one or more non-database method such as hand searching or checking 
reference lists150) and therefore likely to identify most relevant studies. This was 
important for three reasons. First, if the updated systematic review missed important new 
evidence, than the denominator for recall would be underestimated and this could inflate 
the apparent recall of the test searches. Second, precision estimates for the new searches 
could be deflated because the numerator would be underestimated if the test searches 
identified relevant new material that was missed by the original reviewers. Both recall 
and precision inaccuracies might differentially disadvantage the test search methods least 
like those used by the systematic reviewers in performing The Cochrane Collaboration 
updates or the AHRQ searches. Third, SVM requires a training set of true positive 
examples, and a more complete search should provide a better training set. 3) The 
MEDLINE search of the original review and the update were reported in enough detail 
that an information specialist experienced in systematic review searching could replicate 
it. This permitted re-creation of the true negative set, and determination of the retrieval 
size of the author’s search. 4) The search dates for MEDLINE were reported so the 
update interval covered by the review could be established. 5) A list of included studies 
was presented in the original review and the update so that true positives could be 
identified. 6) At least ten RCTs or quasi-RCTs must have been included in the original 
review. This requirement was to give an adequate true positive training set for SVM. 
Finally, 7) at least 67% of papers included in the original review had to be retained in the 
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update. It was also designed to exclude reviews where the inclusion criteria had changed 
substantially between the original and the update. Cochrane Collaboration Reviews were 
selected as they were the majority of reviews that had updates, and they were most likely 
to report all necessary information. 
4.1.2.3 AHRQ Cohort 
A cohort of ten Evidence Reviews published by the AHRQ was selected. AHRQ 
sponsored the updating research, and agency officials were interested to see how well the 
methods developed for determining need of update for journal and Cochrane 
Collaboration Reviews would work when applied to the type of systematic review 
published by the AHRQ. Based on an examination of characteristics of AHRQ Evidence 
Reports prepared for a previous proposal for methodological research,151 AHRQ reports 
more closely resemble health technology assessment reports than conventional systematic 
reviews of treatment interventions in that they tend to be multi-faceted, including issues 
of diagnosis and prognosis, not just treatment issues. The same eligibility criteria were 
applied to the selection of AHRQ reports that were used to select the main cohort except 
that coverage in ACP Journal Club was not required. We also applied the additional 
eligibility criteria associated with the updated Cochrane cohort except that the AHRQ 
reports did not require an update. 
4.1.3 Search Strategy 
Reviews were identified through a search of the ACP Journal Club database on 
Ovid,152 undertaken January 31, 2006. The database contained articles from ACP Journal 
Club and Evidence Based Medicine published from 1991 to November/December 2005. 
We sought systematic review and meta-analyses using a search targeted at the 
standardized titles and abstracts used by ACP Journal Club.153 The search to identify 
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4. (search$ or medline).ab. 
5. or/1-4 
6. limit 5 to articles with commentary 
4.1.4 Cohort Selection Process 
Records retrieved by the search were downloaded into Reference Manager citation 
management software,154 then uploaded to SRS™155 a web-based platform for systematic 
reviews. Eligibility assessments were conducted by physicians with experience in clinical 
epidemiology. Records were screened in alphabetical order by first author until 100 
eligible reviews (with a maximum of 30 Cochrane Collaboration Reviews) were 
identified.  
Two reviewers screened each record for eligibility based on title, abstract and 
indexing terms. Records with consensus in favour of eligibility were promoted and a 
second assessment was made based on the full report, to confirm eligibility. Once 
screening was completed, a review of the cohort was made to ensure that only one 
systematic review of a particular topic was included, to avoid double counting the same 
changes in evidence (or lack thereof). Reviews were considered to overlap when they had 
a common population and intervention. When an eligible review was identified as an 
explicit update of an earlier review (e.g., in the case of Cochrane Collaboration Reviews, 
which are updated and reissued periodically as a matter of policy), we used the earliest 
version in the time frame of 1995-2005, even if this was not the version reviewed by ACP 
Journal Club. We used the version of that review in The Cochrane Library, Issue 1 2006 
as the most current version. If the review had been withdrawn, we used the final version 
prior to withdrawal. The Effective Practice and Organization of Care review group kindly 
provided access to previous issues of The Cochrane Library.  
When more than one review on the same topic was identified among journal 
published reviews, only the earliest was included. Subsequent reviews on the same topic 
were retained as an aid to identifying newer evidence, but were excluded from the cohort.  
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4.2 TEST SEARCHES: IDENTIFICATION OF NEW EVIDENCE 
A necessary part of the process of determining if a cohort review was out of date 
was to find new relevant evidence. It was determined a priori that this would be used as 
an opportunity to evaluate a number of alternate approaches to searching. This section 
describes the test searches which from the core of this research.  
Three broad approaches to information retrieval are Boolean searches, similarity 
searches and citation searches. Boolean searches are typically used in systematic reviews. 
These are searches constructed of search strings and use operators (i.e., AND, OR, NOT) 
to express the search logic. I have recently reported on several variants of this 
approach.(3) The second type is a similarity search which works from known examples to 
find new relevant material. Citation-based methods identify material citing or cited by 
relevant examples. Checking reference lists is an example of citation searching used in 
systematic reviews.156 
Currently, the approach to searching when updating systematic reviews has been 
to repeat the search methods of the original review. This using includes electronic 
Boolean searches of multiple bibliographic databases plus measures such as contacting 
experts and checking reference lists. Monitoring has largely been a matter of re-running 
electronic searches or considering nominations or studies found incidentally by reviewers. 
Similarity searches have not been described frequently in systematic review 
methods. When updating a systematic review, unlike the case when performing a de novo 
review, a comprehensive collection of relevant studies is available as a basis for similarity 
searching. Here, I develop and test two variants of similarity searching, PubMed Related 




4.2.1 Boolean Searches 
4.2.1.1 Clinical Query 
The first subject search variant involves the Clinical Query, for high quality 
clinical studies. This query was developed by the Hedges team, based at McMaster 
University, Hamilton, Canada, who have developed and validated a number of search 
strategies to find high quality studies to answer clinical questions related to treatment, 
prognosis, harms and aetiology and numerous other topics for MEDLINE and other 
databases.157  This was chosen because it is developed specifically to identify high quality 
studies, and these may represent the best evidence for inclusion in systematic reviews. 
The filters are designed to find methodologically sound primary studies quickly,14 
although one recent case report found it had the same recall but lower precision than the 
original Highly Sensitive Search Strategy.158 This study included only systematic reviews 
of treatment interventions, but filters created and validated using the same methodology 
exist for other studies types, such as diagnostic studies159 and health services research,160 
thus making the methods adaptable for types of systematic reviews other than 
intervention effectiveness.  
4.2.1.2 AIM RCT 
The second subject search focused on randomized controlled trials published in 
journals included in MEDLINE’s Core Clinical Journals subset.13 This journal subset was 
formerly known as Abridged Index Medicus, and this approach will be referred to as AIM 
RCT. Tsay and Yang examined the bibliometric characteristics of randomized controlled 
trials and found that of the 42 journals comprising the first zone of the Bradford 
distribution (i.e. the small number of journals in which contain the nucleus of the 
literature) 25 of these were NLM “core clinical journals”161 Searching this journal subset 
potentially provides an efficient way to find the papers most influential in overturning the 




The final subject searching approach was to use the Cochrane Central Register of 
Controlled Trials (CENTRAL) to identify new studies of potential relevance. CENTRAL 
was created and is maintained with the object of being as complete a source for 
identifying new trials as possible.41  
4.2.2 Citation Searches 
The above Boolean approaches based on subject searches require expertise to 
create the search strategy for each review. Knowledge of searching techniques is required, 
and the person undertaking the search must form a good understanding of the topic of the 
review. The additional methods tested here are algorithmic and not dependent on 
knowledge of the field or interpretation of the question, an observation made by Pao and 
Lee in regards to citation searching.162 
4.2.2.1 Citing RCTs 
Citing reference searching, where papers citing the systematic review itself are 
retrieved, could be used it identify relevant new material. Patsopoulos et al.163,163 have 
recently demonstrated that meta-analyses received more citations than any other study 
design both in the first two years and in the longer term. Using citing references to 
identify related material may have greater utility in monitoring for newly emerging 
relevant literature related to a particular meta-analysis given the propensity to cite them. It 
remains to be seen whether it is a useful mechanism to identify subsequent RCTs. 
Citation of systematic reviews may become more common as journals and some granting 
agencies introduce formal requirements that prior literature be systematically 
considered.164 If citations of systematic reviews follow the same citation patterns as 
RCTs,140 highly cited systematic reviews may be more likely to be refuted through 
subsequent research, thus more likely to be in need of update than less highly cited 
systematic reviews. Thus, even if the performance metrics of citation tracking indicate 
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poor performance as a surveillance tool, a high citation rate may indicate that closer 
surveillance through other methods is warranted. 
Bernstram et al., in experimental work, found citation-based algorithms useful in 
improving MEDLINE recall, finding them superior to non-citation-based methods.165 An 
advantage over Clinical Queries remained, even after citation lag was introduced 
experimentally. The authors noted however, that this is not the optimal approach for those 
seeking the most recent information available, as is the case in systematic reviews. They 
also note that not all important relevant items are cited by related works, so such an 
approach is necessarily incomplete.165  
In other work, Pao and Lee found that recent seed articles will not have had time 
to be cited often, while those published more than 12 years prior seemed to produce little, 
so there may be a window of ten years or so where the method is productive.162 
Algorithmic approaches may also be useful in areas that are difficult to search, such as 
cross-disciplinary or emerging topics.166 
 
4.2.3 Similarity Searches 
4.2.3.1 Related Article RCT 
PubMed’s Related Articles feature provides an avenue to identify potentially 
relevant material through query-by-example. It may be possible to identify the core 
literature by starting with known relevant items and searching for related items (query 
expansion). Some advantages of such a method include that it is relatively quick, can be 
replicated, is not dependent on searcher skill, and relies only on access to the published 
review and PubMed. Some disadvantages are that its performance characteristics 
(precision and recall) have not been formally demonstrated and it may not be possible to 
re-run the searches automatically at intervals, a characteristic that is desirable in a 
surveillance method.  
The PubMed Related Article function retrieves pre-computed nearest neighbours. 
Terms, including weighted free text and index terms, are given a local weight based on 
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frequency in the document, adjusted for document length, and a global weight based on 
frequency in the corpus. Near neighbours are bibliographic records with high scores when 
all the terms common to both records are considered.167 Lin et al. have described the 
inner workings of the related article algorithm, PMRA, describing it as a topic-based 
content similarity model.168,169 They found that the related article search was a well-used 
feature of PubMed. Based on query logs gathered during a one-week period in June 2007 
roughly a fifth of all non-trivial PubMed user sessions contain at least one related article 
search.168 
In previous work, Lui and Altman used the Related Articles feature to 
incrementally update a bibliography, achieving recall of 75%, a strict precision of 32% 
and a partial precision of 42%.170 Bernstram show preliminary evidence that better results 
can be obtained by using multiple seed articles and using a combination of nearest 
neighbour sets.165  
The approach used here, which will be to select a few of the included studies as 
seed articles for Related Articles searching, has an analogue counterpart in pearl-growing 
where the indexing of relevant articles informs the search strategy. White explored taking 
a number of citations to a relevant article that jointly express the topic of interest, and 
using these as seed to generate descriptor terms for searching.171 Schlosser et al.172 
describe the use of pearl-growing in developing a Boolean search strategy for systematic 
reviews. They advocate a comprehensive approach where a set of relevant articles is 
assembled, and these are searched in each database under consideration to determining 
relevant indexing terms. 
4.2.3.2 Support Vector Machine 
The final approach used here and potentially useful for surveillance of emerging 
evidence is support vector machine (SVM), a machine learning technique or classifier 
that operates by finding an algorithm that defines a “vector space” distinguishing True 
Positives from True Negatives in a training set. That algorithm was applied to classify 
new examples.173 Here, I used the search result from the original review as the training 
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set, with True Positives being the studies included in the review (the relevant retrievals) 
and True Negatives being the studies found by the authors’ search but excluded from the 
review (irrelevant retrievals). The new examples to be classified are articles published 
since the first search. Those classified as Positives by the SVM are retrieved. 
Pavlidis and Wapinski argued that the strength and widespread applicability of the 
SVM are due to a number of advantages it holds compared to other machine learning 
techniques. These include a strong theoretical foundation, scalability, making it suitable 
for use with large databases (such as MEDLINE), flexibility, including the ability to 
incorporate prior knowledge, and finally its accuracy.174  
Machine learning approaches have been explored in systematic reviews. Cohen 
tried to explain variations in performance across the topics by reference to the number of 
features without great success. They may have overlooked one important correlation 
present in their results; the correlation between precision of the initial query and the 
precision of the neural network was 0.911. That is, the searches that were easier for the 
librarian were also easier for the neural network. They do acknowledge that there would 
have to be something non-obvious about the retrieval task for the classifier to work from 
in order for it to out-perform the human query builder. SVM may have an advantage over 
the neural network approach used by Cohen in that it can incorporate a much larger 
number of features. Cohen also used a very high threshold for recall. Performance may be 
better in a context where the objective is literature surveillance to detect a signal to 
update, rather than when the objective is exhaustive identification of evidence. Still, at the 
high recall threshold used, they concluded that machine learning did bring efficiencies to 
the updating process. It may be that using machine learning for surveillance can introduce 
efficiencies by focusing updating efforts on those reviews most likely to be out of date, a 
fundamentally different approach.  
O’Blenis et al.175 reported exploratory work using Naïve Bayes Classifier 
algorithm to take over the classification of results once reviewers have screened enough 
records to provide a training set. This classifier also returns a ranked result set that allows 
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the documents to be considered in order of likely relevance. Considering documents in 
order of relevance is the most efficient way to monitor emerging literature for an 
accumulation of new evidence that would render a SR in need of update. Cohen identified 
that in the actual update, such relevance ranking is not of great interest.15 They considered 
the possibility of using “Really Simple Syndication” (RSS) feeds to notify investigators 
of new material, stating “these notifications would be useful both for focusing the 
reviewer’s time on the most likely articles to include high quality topic-specific evidence, 
as well as to alert the review team when a sufficient amount of new evidence had 
accumulated to warrant an update of a given drug class review.”15 
4.2.4 Methods for Executing Each Search 
4.2.4.1 Clinical Query, AIM RCT, and MA Searches 
The Boolean approaches require knowledge of search techniques. A structured 
approach was taken to developing these queries in order to reduce operator dependence 
and maximize the generalizability of results. Jessie McGowan, a senior librarian with 
extensive experience in systematic review searches completed the first ten systematic 
reviews needing update searches. Then, working with Tamara Rader who executed the 
remaining searches, the following step-by-step instructions for developing and executing 
these searches in the Ovid MEDLINE interface were developed. Part one involves 
analyzing the topic and searching the subject area (Figure 3).  
Part 1 
1. Select article to be updated and read the abstract 
2. Identify key words for the condition, population (if it’s children or elderly for 
example) and for the intervention 
3. Read the methods section to determine when the search was performed. If no date 
is given, search from the year before the date of publication. 
4. Open OVID MEDLINE 
5. Enter key words for the condition and determine the most appropriate MeSH 
heading. If a suitable MeSH heading is found, then there is no need to combine 
with natural language keywords. 
6. Enter key words for the intervention and determine the most appropriate MeSH 
heading. If a suitable MeSH heading is found, there is no need to combine 
keywords. 
7. If necessary combine using “OR” the keywords & MeSH headings you have 
selected for the intervention & condition. 
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Part 2 involves limiting the Subject Search to type of study design using pre-
determined OVID “limits” – here is where the differences for CQ, AIM RCT and MA 
searches are specified. Naming conventions and download instructions specified in Part 2 
reflect the record keeping steps needed for this project. 
9. Limit the search to the year you noted earlier. Either the year the search was done, 
or the year before the paper was published. 
10. To limit your results to RCT-AIM results, click “More Limits” 
11. Select the line of your subject search limited by year 
12. Check the box marked AIM Abridged Index Medicus 
13. Scroll down until you get to Publication Types 
14. Select Randomized Controlled Trials 
15. Click “Limit Search”  
16. Save the search results by selecting options at the bottom of the screen called 
Results Manager.  
17. In the first column, select the option: “All in this set” 
18. In the second column, click the red box “Select Fields” 
19. DE-select all the fields EXCEPT for UI – unique identifier 
20. In the third column select: Brief (Titles) Display and Include Search History 
21. In the Sort Keys section for Primary, choose “year of publication” and 
“descending” and in Secondary, choose “Entry Date” and “descending” 
22. Click Save 
23. The file name should reflect the cohort number, the method of search and the 
number of results for example: 151 RCT AIM (25).txt  
24. Return to Main Search Page 
25. To limit your results to CQ, click “More Limits” 
 
74 
26. Select the line of your subject search limited by year 
27. Scroll down until you get to Clinical Queries 
28. Select Therapy (Optimized) 
29. Click “Limit Search” 
30. Perform steps 16-22 
31. Again, the file name should reflect the cohort number, the method of search and 
the number of results for example: 151 CQ (143).txt  
32. Return to Main Search Page 
33. To limit your results to MA (Meta-analysis), click “More Limits” 
34. Select the line of your subject search limited by year 
35. Scroll down until you get to Publication Types 
36. Select Meta-analysis 
37. Click “Limit Search” 
38. Perform steps 16-22 
39. Again, the file name should reflect the cohort number, the method of search and 
the number of results for example: 151 MA (10).txt 
40. Return to the main search page 
41. Now you are done the subject searching. TO SAVE the search click “Save 
Search/alert” 
42. You will be prompted for your user name: “epcupdating” and password “xxxxxx” 
43. Name the search SS 151 and select “permanent” 
44. Select save 
45. Return to main page and delete the set to begin a new search. 
 
4.2.4.2 Subject Search CENTRAL, inCENTRAL 
The CENTRAL database (The Cochrane Library, Issue 3, 2006) was searched 
through the Ovid interface. The subject search developed for each review was used 
(Figure 3), with the following adjustments to compensate for difference in operation of 
MeSH term searches between Ovid MEDLINE and Ovid CENTRAL, which were 
apparent from the pilot. Starred MeSH headings (the MeSH headings representing the 
major focus of the article) were converted to unstarred terms, as starring provided 
inconsistent results particularly for exploded subject headings. ‘‘Exp Antibacterial 
agents/’’ was replaced with ‘‘exp Antibiotics/.’’ CENTRAL is a secondary database, 
where trials are identified from other databases or from handsearch (as examples) thus 
there could be a lag of years between publication and identification and indexing in 
CENTRAL. CENTRAL does not allow limiting by record entry date. Not all records have 
MEDLINE indexing terms. Therefore, we tested CENTRAL only for cohort reviews 
where a signal for updating occurred to provide as basis for comparison of retrieval size 
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when search methods are held constant, and to get an indication of how complete the 
indexing of the newer relevant studies was, without correcting for indexing lag. 
CENTRAL records were not added to the screening pool, but were merged into the big 
database so that extent of coverage of the relevant material could be determined.  
4.2.4.3 Citing RCT Searches 
Several sources index citing references, including ISI Science Citation Index, 
Scopus and Ovid. Scopus and Ovid are relatively new providers of this service. ISI 
Science Citation Index is well established. One research report indicated that Scopus 
yielded more citing references than ISI in health science,176 our experience matched this. 
We piloted the search for citing references in Scopus by using the first 50 systematic 
reviews that were found eligible for the cohort and then selected four for testing in the 
other databases, selecting two highly cited systematic reviews and two cited less often. In 
most cases, Scopus provided more cited references than ISI for journal published 
systematic reviews (Table 2). Ovid’s indexing of citing references appeared quite 
incomplete. Scopus was therefore used as the citing reference source for journal-
published systematic reviews. 
 
Table 2. Citations of Journal-Published Reviews by Indexing Source 
      
 Scopus 
 Ovid  ISI 
 CohortID  Y  Year N  Year  N  Year  N 
 6  2000  2000  7  2000  11     
     2005  1  2005  11  2005  0 
 13  1999  2000  31  2000  26  Not found 
     2001  1  2001  26     
     2002  1  2002  26     
 120  2001  2000  9  2000  23  Not found 
     2001  5  2001  23     
     2004  3  2004  23     
 264  1999  2000  1  -  -  Not found 
     2001  9  2001  11     
     2002  1  2002  11     




The pilot identified an issue with the indexing of citations in Scopus for Cochrane 
Collaboration Reviews. Cochrane Collaboration Reviews are re-issued with each 
quarterly issue of The Cochrane Library. Scopus appeared to count citations to issues 
from different years as though they were distinct systematic reviews, with the number 
cumulating only annually, but not across years. Subsequent testing showed that Ovid 
indexes cumulatively. ISI did not routinely index Cochrane reviews at the time this work 
was undertaken (Table 2). Since the reason for identifying citing references was to 
identify subsequent randomized controlled trials and systematic reviews on the same 
topic, a citation to any issue of the review was of interest. The Ovid interface was 
therefore selected as the citing source for Cochrane Collaboration Reviews, as it gave 
more integrated coverage. 
 
Having selected the interface for Cochrane and Journal-published reviews, the 
actual identification of citing references was done by looking up the index review in the 
citation database (Scopus or Ovid) and then searching the citing references in PubMed to 
determine which of the citing reference was an RCT. I undertook the pilot searches and 
Raymond Daniel, a library technician, completed the remaining citing RCT searches. The 
PubMed IDs for all citing RCTs for that review were downloaded and later integrated into 
the corresponding All.xls file.  
4.2.4.4 Related Articles RCT and Related Articles MA Searches 
Originally, I intended that the seed articles should be those identified by one of the 
systematic reviewers knowledgeable about field as the “pivotal studies” from the review 
to be updated. As the method was otherwise quite mechanical, requiring no specialized 
knowledge, I decided instead to select seed articles using quantitative criteria that could 
be easily applied. The following criteria were standardized during a pilot with ten 
systematic reviews. The three largest and three newest included studies were selected. 
Where these overlapped, they were not replaced. So if two of the three newest studies 
were also among the largest, only four studies would be used. Where multiple reports of 
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the same study were included in a systematic review, only one was used, and the one that 
appeared to be the main report was selected as the seed. The selected seed articles were 
identified in PubMed. If one of the seed articles was not indexed in PubMed, it was 
dropped and not replaced. Relevance was not assessed in the pilot, only the viability of 
the method, in the sense that the seeds could be readily identified, and that the number of 
seeds generated a reasonable number of results (Table 3). As the method did appear 
viable, it was adopted for this project. I undertook the ten Related Article pilot searches. 
Raymond Daniel, a library technician, completed the remaining Related Article searches 
using an established protocol, initially under supervision and then independently. 
 




 Search start date 
  





N of MAs 
 31  1997/01/01  5  177 10 
 38  1995/01/01  6  200  10 
 40  1998/01/01  5  183  7 
 43  1998/02/01  3  26  8 
 50  2003/02/01  4  84  10 
 56  1998/01/01  3  86  7 
 70  1996/10/01  5  222  3 
 94  2004/01/01  5  47  1 
 96  1999/12/01  4  48  7 
 104  1994/01/01  5  132  8 
Seed items were identified from the screening worksheet (Figure 3). In the 
example shown, the three newest studies are PubMed IDs 9857355, 10782589 and 
11427285. The three largest studies are 6755247, 6233921 and 9651632. The PubMed 
IDs for seeds were entered into the PubMed search box, and retrieved. The Related 





The 1156 related articles are returned, sorted by relevance, with the seed articles 
appearing highest in the list. A null search is set up for records with a publication type of 
Randomized Controlled Trial and a PubMed entry date after the search date of the 
original review, which is December 15, 1994 in this case. A null search consisting only of 
limits, with no entry in the search box, is needed as a related article search cannot be 
limited directly. In the History tab, the related article search and limit are combined 
(Figure 6). The number of hits was noted and the records were downloaded. The limits 
were then change to the search date used plus one year, and publication type of Meta-
Analysis. The number of hits was noted and the PubMed IDs were copied from the UI 
List display, and saved to a text file for later integration into the All.xls files. 
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As this method did not provide access to the relevance scores, the searches were 
repeated later in the project using the eLink utility, a different search interface than that 
provided at the main PubMed search screen. Elink is one of a number of Entrez 
programming utilities that are designed to retrieve search results for use in subsequent 
applications. The PubMed eLink utility allows searching of nearest neighbours to 






Search Parameters, many of which are optional, include Database (db), Record 
Identifier (id, here PubMed ID), Relative Date or Date Range, Date Type (edat=database 
entry date, mdat=date of last modification or pdat=publication date) and one Search Limit 
(term). A single search limit can be applied, in this case Randomized Controlled 
Trial[ptyp] was applied to restrict the retrieval to nearest neighbours that were RCTs. As 
MHDA was not available as a date type in eLink, no date limit was used. The results are 







The XML was pasted into a Microsoft Word document where the global search-
and-replace function was used to convert field separators to tabs. The tab-separated result 
was then pasted into a spreadsheet, which resulted in each field becoming a spreadsheet 
column. Irrelevant fields were removed by deleting those columns, until only the PubMed 
ID and similarity score remained. A column representing the CohortID was added. These 
were then pasted into an SPSS file, and the SPSS function Merge Files / Add Variables 
was used to add the similarity scores to the big database. Because MHDA was not 
available through the eLink interface, records from this related article query that did not 
match the PubMed ID of an existing Related Article RCT retrieval were ignored.  
4.2.4.5 Support Vector Machine 
For each systematic review in the set of six updated Cochrane Collaboration 
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Reviews and ten AHRQ Evidence Reports selected for study, I replicated the reviewer’s 
original MEDLINE search strategy if it was in Ovid, or translated it to Ovid in order to 
derive the true positive and true negative training sets (Figure 8). Jessie McGowan 
verified the replications. True positives were those MEDLINE indexed records that 
represented the included studies of the original review, regardless of whether they were 
found by the authors’ search of MEDLINE. The true negative training set included those 
MEDLINE records that would have been retrieved by the authors’ search at the time they 
executed it, but which were not included in the reviews. These were records that would 
have been screened and found ineligible by the reviewers. For the updated Cochrane 
Collaboration Reviews, targets were predetermined to be those studies included in the 
updated review that were not in the original, and which entered MEDLINE after the 
search for the original review. The full retrieval set, at least to the point where the review 
was found to be in need of update was reviewed for the AHRQ cohort. 
I prepared all material for the SVM searches, which were executed by Berry de 
Bruijn, a Research Officer with the Interactive Information program of the Canada 
Institute for Information Technology (CISTI), part of the National Research Council. 
 
1. exp Pharyngitis/ 
2. pharyngit$.mp. 
3. exp Tonsillitis/ 
4. tonsillit$.mp. 
5. (Sore adj throat$).mp. 
6. or/1-5 




11. RANDOMIZED CONTROLLED TRIAL.pt. 
12. CONTROLLED CLINICAL TRIAL.pt. 
13. RANDOMIZED CONTROLLED TRIALS.sh. 
14. RANDOM ALLOCATION.sh. 
15. DOUBLE BLIND METHOD.sh. 
16. SINGLE-BLIND METHOD.sh. 
17. or/11-16 
18. (ANIMALS not HUMAN).sh. 
19. 17 not 18 
20. CLINICAL TRIAL.pt. 
21. exp CLINICAL TRIALS/ 
22. (clin$ adj25 trial$).ti,ab. 






27. RESEARCH DESIGN.sh. 
28. or/20-27 
29. 28 not 18 
30. 29 not 19 
31. 19 or 30 
32. 10 and 31 
33. remove duplicates from 32 
34. ("3057159" or "1905799" or "8945796" or "9219402" or "9270458" or "9116551" or 
"9051558" or "10634735").an. 
35. 34 not 33 
36. (1996$ or 1997$ or 1998$ or 1999$ or 200$ or 2001$ or 2002$ or 200301$ or 200302$ or 
200303$ or 200304$ or 2003050$).ed. 
37. 36 and 33 
38. 37 not 34 
 
Figure 8. Replicated Search Strategy.  
Lines 1-32 is the replicated search. Line 34 gathers the MEDLINE-indexed included studies and is the true 
positive set. Line 35 identified MEDLINE misses. Line 37 limits replication of the authors’ search to the 
dates covered by the authors’ search. Line 38 isolates the material the authors’ would have screened and 
excluded – it is the true negative set. The study is Del Mar 1997.177  
 SVM was run on MEDLINE hosted locally at the National Research Council 
NRC. MEDLINE was refreshed prior to running the searches. The approach was piloted 
with one AHRQ report, CohortID 91 and various configurations were tried, observing the 
placement of targets within the retrieval. In initial testing, a fine-grained filter consisting 
of TP vs. TN was then applied, both with and within MeSH headings. This reduced the 
set size, resulting in a few targets being missed, but targets appeared to rank well within 
the larger set. Including MeSH at that stage influenced rankings only, rankings presented 
here were performed without MeSH. Partial output from AHRQ CohortID 91 is shown in 































Figure 9. Partial SVM Output For CohortID 91. 
A target shown in bold in position 24 of 54449 ranked records 
First, the MEDLINE set was filtered with the revised HSSS,21 yielding 105,951 
records. Preliminary testing indicated that this filter would retrieve 99.1% of MEDLINE 
indexed relevant new evidence from the cohort of 100. This filter was added primarily to 
improve processing speed, relative to running the classifier against all of MEDLINE. 
With the filter, processing for one systematic review took about ten minutes. Next, a 
coarse grained filter was applied; TP and TN were combined in a single set labeled POS. 
Adjacent PubMed IDs (the next higher PubMed ID to each member of POS, as long as 
that higher number was not itself a member of POS) were combined in a set to represent 
WORLD. The model was trained on POS vs. WORLD, using words and phrases from 
title, abstract, author names, and journal name. This model was run against the records 
passing the HSSS filter (n=105,951). PubMed ID and relevance scores were recorded.  
4.2.5 Ranking 
I have previously reported ranking of large Boolean search results with statistical 
search engines that work from document similarity ratings.178 Any successful ranking 
approach has application in screening the update set as reviewers could screen a small set 
of likely candidates. O’Blenis et al. also report efforts at using machine learning to 
relevance rank large sets interactively so reviewers can screen those records most likely 
to be relevant first.175 
 The similarity searches, Related Article and SVM, return relevance scores. This 
provides searchers with the option of establishing thresholds for retrieval (e.g. a pre-
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determined retrieval size, or a minimum relevance score). The utility of these rankings 
were analyzed two ways. First, the proportion of targets placed above certain cut-points 
was tested against the proportion expected if ranking was random. Simple Interactive 
Statistical Analysis (available at: 
http://www.quantitativeskills.com/sisa/distributions/binomial.htm) was used for this 
analysis after testing it by replicating the results of previous research.178 Second, for RI 
RCT and SVM searches, the ROC curve of recall at various cut points was constructed. 
 
4.3 PREPARATION OF MATERIAL FOR SCREENING 
4.3.1 Building the Updating Spreadsheet 
An updating spreadsheet was created for each systematic review in the cohort. It 
contained a worksheet showing studies included in the original review and new candidate 
studies and new meta-analyses. Meta-analytic calculator worksheets enabled the 
reviewers to enter meta-analytic results from the original review and add data from newer 
studies. Two summary sheets allowed reviewers to summarize major findings and classify 
results in terms of need to update, type of new evidence, and survival times. 
4.3.1.1 Screening Worksheet 
The worksheet of the spreadsheet that showed the included studies and candidate 
studies was prepared by the IS team. This worksheet was used by reviewers to record 
their relevance assessment of the candidate studies here, and for eligible studies, recorded 
the number of participants included in the trial.  
Once a cohort review was confirmed to be eligible, all included studies were 
identified, each was looked up in Ovid MEDLINE, and if it was found, the bibliographic 
record was downloaded into a Reference Manager database created for that systematic 
review. Place holding records were added to the database for studies included in the 
review but not found in MEDLINE. Two bibliographies were created using specially 
created Reference Manager output formats.  
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The first bibliography was a tab-delimited file which was used as the basis of the 
screening worksheet used to track existing and new evidence. The file contained the 
unique Reference ID assigned by Reference Manager, the surname of the first author, 
year of publication, PubMed ID and date of MEDLINE indexing (MHDA). Columns 
were added to the spreadsheet to record variables not available as MEDLINE fields. The 
number of participants included in each study was extracted from the abstract, or if 
necessary, the systematic review, or if necessary, from the original article and these data 
were added to the spreadsheet. Additional columns in the spreadsheet were added for the 
CohortID number used to identify the systematic review within the project, the type of 
record (Original, except when an explicit update of the systematic review subsequently 
excluded the record, in which case the type was coded as Original Only), whether the 
record was on topic, whether it was eligible (both were coded as “Y” for all studies 
included in the original review), and a column in which the reviewers could add notes.  
The second bibliography was a simple list of the PubMed IDs. These were saved 
as a text file which was edited to create an Ovid search string in the form: 
 (18788016 or 17348209 or 17209469 or 17201639 or 17195692 or 17194559 or 
17187296 or 17185740).ui.  
This string was used in two ways. First, I used it in the procedure that established 
which of the included and MEDLINE-indexed studies would have been found by the 
author’s MEDLINE search, for those cohort reviews where that was tested. Second, I 
used it as the true positive set of records for SVM searches, for those systematic reviews 
where SVM was used.  
4.3.1.2 Candidate List 
New meta-analyses and primary studies were listed after the Original and 
Original Only studies on the screening worksheet. The construction of these lists is as 
follows. 
Each test search was run and results were downloaded and saved. PubMed ID 
numbers were isolated from the retrievals. The procedure for this varied – in PubMed, the 
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PubMed IDs can be displayed as a simple list. In Ovid and SVM retrievals, download 
included some extraneous material which had to be edited out to isolate the PubMed IDs. 
Once isolated, the PMIDs retrieved by each search were pasted into a spreadsheet called 
the All.xls file. Columns were added for the CohortID, the unique identifier for the 
systematic review used in the project, and a code indicating the search method that found 
that item.  
An integration search was used to resolve PubMed IDs into a set with no 
duplicates. An Ovid search string was prepared from the PubMed IDs in the All.xls file, 
with not attempt to remove duplicates. This string was run in Ovid MEDLINE, and the 
search strategy was saved in the project account. The retrieval set was first limited to 
records with the publication type “meta-analysis”, and these were downloaded in reverse 
chronological order. The remaining records were then downloaded, in chronological 
order.  
A separate candidates database was created for each systematic review in the 
cohort and the records downloaded from the integration search were imported into it, first 
the newer meta-analyses, followed by the primary studies which were the candidates. 
From this file, a tab delimited text file was created using a custom bibliographic output 
style, and this file was imported into the spreadsheet that contained the basic information 
for the studies included in the original. Type was coded as either MA (meaning meta-
analyses) or Candidate for these new records. 
Neither the Reference Manager database of candidates nor the candidate list 
generated from it contained any information about which search methods had retrieved 
the record, effectively blinding the reviewers who assessed the candidates for eligibility. 




Studies included in the original review are presented first, arranged oldest to newest and 
are assessed as eligible and on topic. The number of study participants (N) is extracted. 
For the second and subsequent report of the same study, no new N is attributed. Study 
refids 14, 24 and 26 are examples of this. Next, newer meta-analyses (MAs) are shown, in 
reverse chronological order. Finally, newer primary studies (Candidates) are shown. 
These are assessed for eligibility by the review, so have no initial value. N is extracted 
and recoded by the reviewer for the first instance of candidate studies assessed as eligible. 
 
4.3.1.3 Meta-analytic Calculator 
Once the Include Studies panel of the updating spreadsheet was prepared by the IS 
team, the meta-analytic worksheet was given to the reviewer. The reviewer also received 
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the Reference Manager database containing the bibliographic record with abstract for the 
newer MAs and the Candidates found by the test searches.  
A spreadsheet template was created by Alison Jennings that allowed the reviewer 
to enter a meta-analytic value from a systematic review, and add new data sequentially. 
Separate template worksheets were designed for each of the eligible meta-analytic 
measures: odds ratio, relative risk, risk difference and weighted mean difference. The 
reviewer assigned to the systematic review selected between one and six eligible 
outcomes (up to four benefits and up to two harms) for assessment, and duplicated the 
worksheet for the appropriate summary measure as needed. The reviewer then transcribed 
the basic meta-analytic result for each selected outcome from the systematic review to the 
appropriate calculator worksheet. Data from eligible candidate studies were added, and 
the meta-analysis was updated after each entry. Conditional formatting alerted the 
reviewer when a stopping rule was met. Once the stopping rule was met for an outcome, 
the reviewer transcribed data to the summary page of the spreadsheet, and classified the 
type of new evidence and calculated the survival time. A more detailed example of the 
function and use of the meta-analytic calculator is provided below (Section 3.5.1). 
4.4 OUTCOME MEASURES 
Following Tague-Sutcliffe’s pragmatics of information retrieval experiments,179 
the experimental units of this experiment are the searches of the query, where the query is 
the topic of the systematic review, and the different strategies for the same query are 
assessed on the basis of recall and precision. Recall is the proportion of relevant 
documents correctly retrieved, and precision is the proportion of retrieved records that are 
correctly retrieved. Recall and precision are used as the principle basis for evaluation of 
search performance in these experiments. Saracevic attributes the introduction of these 
measures to Kent, Berry, Leuhrs, & Perry, 1955 (180 Citing Kent, Berry, Leuhrs, & Perry, 
1955). Two persistent problems in information retrieval evaluation research are 
establishing relevance and establishing the denominator for calculating recall. A third 
issue, one that has received less discussion, is the statistical measure used to summarize 
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outcomes. Assessment of relevance and establishment of the denominator will be 
discussed here. Summary measure will be discussed with the description of statistical 
analysis. Finally, alternative outcome measures will be considered briefly in this section. 
4.4.1 Assessment of Relevance 
The main criteria that will be used to assess search performance are recall and 
precision. Both of these are relevance-based measures,181 and indeed “relevance is a, if 
not even the, key notion in information science in general and information retrieval in 
particular”180 and so the definition of relevance used in these studies needs to be 
discussed.  
Borlund argues that relevance in multifaceted, with the consequence that there is 
poor consensus among information scientists as to its meaning.182 Blair argues that it is 
utility that matters, and that utility can be assessed only by the originator of the query.183 
Borlund argues that situational relevance many be the most realistic type of relevance to 
users in most applications.182 Situational relevance is defined by Saracevic as “usefulness 
in decision making” and so is nearly synonymous with utility.180  
Topicality or “aboutness” is distinguished from relevance by utility (see Tague 
Sutcliffe 179). Aboutness can be expressed through indexing and is independent from the 
need of any user.180,184 Overall, there seems to be some consensus that relevance from a 
user perspective, rather than from a system perspective, (or what Kemp calls 
pertinence185) is subjective, is in the eye of the beholder, and is the more important 
outcome in information retrieval. The theory of relevance should inform system and 
interface design.186  
However relevance is operationalized, it should measure what is important in the 
search, and the relevance judgments should be made consistently.183 A challenge to this is 
the observation that, “real-life IR experiments demonstrate that a user’s relevance 
judgment can change during a search through interacting with a search engine, viewing 
retrieved documents, and so forth.”187 An example in the systematic review context would 
be a second report, even a covert double publication188 of the same randomized controlled 
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trial. The first and second report may be equally eligible, but having found the first report, 
the utility of the second report is low. van der Weide and van Bommel explore this 
through the concept of the incremental information value of documents, which declines 
when previous similar documents have be obtained.184 This topicality can be absolute, but 
relevance is not. This leads to Ellis’ assertion of a paradox of relevance‡‡ “The more one 
uses the "real" relevance, the less one can measure it.”185  
4.4.1.1 Partial and Full Relevance 
We assessed both topicality and utility. Topicality was the assessment by the 
reviewer that the retrieval was “On Topic” – that is, should probably have been retrieved 
by a search for that systematic review. On Topic is more of a system-side measure, the 
extent to which records that were retrieved ought to have been retrieved and are not “false 
drops” even thought they may not be fully relevant. Utility was operationalised as 
“Eligible” – the retrieved item was both On Topic and could be included in the analysis of 
one of the six chosen outcomes. Eligible was a narrower standard than On Topic, and all 
Eligible records were assumed to also be On Topic. Eligible also reflects a more user-side 
approach. This relevance standard of Eligible could also be narrower than the inclusion 
criteria for the original systematic review. A report on an outcome not eligible or not 
chosen for the updating exercise or presenting data in a form that could not be included in 
the meta-analysis of one of the selected outcomes could be fully Eligible for the review 
yet rated as On Topic but not Eligible in this study. Finally, to address the issue of second 
and subsequent reports of the same trial where the later reports are relevance but not 
useful, reviewers assessed such reports as On Topic, and if they reported on the same 
selected outcomes, as Eligible, but no new participants were attributed to them.  
A still narrower definition of relevance would be Hersh’s outcome-oriented 
approach where only the material that ultimately has an impact on outcomes is 
                                                
‡‡ Also attributed to Saracevic 1975 by Hersh189 
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relevant.189 In this research, this would be operationalized as those new studies that 
actually rendered the systematic review in need of update.  
The designation of On Topic corresponds well to aboutness, at least conceptually. 
The designation of Eligible is a subset of the useful articles; they are useful in a particular 
sense of bringing new information to the meta-analysis. The variable “N” quantifies the 
new information, and could be zero where that new information is not novel.  
There can be articles within the candidate list that are useful but not Eligible. 
These articles could provide important background information, inform on methods or 
attune the reviewer to controversies or doubts about the treatment under study, or as 
Kagolovsky describes it, provide important prompts to the user.45 Saracevic notes that 
“people may and do derive relevance from ideas and clues in articles that no system could 
readily recognize, at least as yet. But, that depends also on domain expertise.”180 White 
reviews the sorts of hidden associations that document users perceive that make 
seemingly disparate works relevant and lead to knowledge discovery, and suggests that 
co-citation is more apt than indexing terms to capture this sort of relevance.186  
4.4.2 Establishing the Denominator for Recall 
Relevance is a challenge for both precision and recall, but recall faces the 
additional challenge of establishing the denominator. The denominator for the calculation 
of recall is the total number of relevant studies in the dataset. Tague-Sutcliffe179 suggests 
five possible approaches to this task; 1) predetermine the relevant set in some way, 2) use 
a small test set, 3) assess a random sample of unretrieved items, 4) use relative recall, 5) 
use a very broad search. Each of these will be considered in slightly more detail and from 
the perspective of systematic review work. 
1. The relevant set is predetermined in some way. Tague-Sutcliffe gives the 
example of using the title of a paper as the basis for a query, and the cited 
documents as the relevant set. This is very similar to the approach used with 
updated Cochrane reviews in this experiment – it was assumed that the 
reviewers found and included (and so cited) the newer relevant documents. 
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Tague-Sutcliffe notes that this approach is arbitrary, and there may be other 
documents in the database that are also relevant. To guard against this, 
additional inclusion criteria were imposed to – the searches must have been 
comprehensive and a reproducible MEDLINE search strategy must have been 
presented. In addition, the possibility that additional relevant documents went 
undetected will be explored with the updated Cochrane Collaboration Rreviews 
through capture-recapture methods described later.  
2. A small test set is used, and all documents are assessed for relevance. Tague-
Sutcliffe notes that this may not be a reliable guide to results with a larger file. 
This approach is not relevant for these investigations. 
3. A random sample is taken of non-retrieved set and all documents in the sample 
are assessed. Tague-Sutcliffe notes that the low base rate of relevant documents 
in most databases renders the necessary sample size impractical. An approach 
used to overcome this problem in the epidemiological literature, sequential 
screening, could be applied to an information retrieval problem, and has 
parallels with systematic review screening process.190 In sequential screening, a 
preliminary screening instrument with high sensitivity but low specificity 
identifies a high-risk subgroup, which is evaluated more rigorously. By raising 
the base rate of the second sample, screening efficiency is enhanced. This is 
similar to the two stage screening common in systematic reviews, where the 
retrieval is biased toward recall (sensitivity), with low precision (positive 
predictive value), and a rapid screening is done using readily available titles and 
abstracts. In the second phase, the complete document is assessed, a more 
expensive test, but precision of this second phase is greatly enhanced by 
increasing the base rate in the second sample. Derogatis provides a clear and 
concise description of the rationale for sequential testing.190 An informative 
example can be seen in Benn’s simulations of various sequential testing 
strategies for prenatal Down syndrome screening, where the false positive and 
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false negative consequences are marked, the base rate is low, and tests vary in 
their performance characteristics, risks and invasiveness.191 While this approach 
has some parallels with the systematic review process and is potentially useful 
in establishing a denominator, it was not used in this research. 
4. In comparative tests, relative recall is calculated, where the denominator 
includes all relevant documents found by any method. Tague-Sutcliffe notes 
that this method work well in comparative tests, but results may not generalize 
to other databases or other query sets. It has previously been argued that this 
method is a useful solution in the case of systematic reviews with 
comprehensive searches, and approximates the recall seen with a gold standard 
based on hand searching.192 It is the main method used with the 77 systematic 
reviews that were updated with additional searching. The recall of each test 
search has as the denominator the relevant records identified by any of the test 
searches or included in newer systematic reviews on the same or similar topics. 
5. Finally, in a large database, use a very broad search, or carry out a complete 
review of subsets known to be rich in relevant items, and use the total number 
of relevant items found as the denominator. This is the approach used in much 
search validation work, where the results of a hand search are used as the “gold 
standard’ and to form the denominator.193  
In summary, the main approaches used in these experiments to ensuring a 
complete denominator for recall is the predetermined relevant set, used for the updated 
Cochrane reviews, and relative recall for those reviews updated by screening newer 
systematic reviews and candidates identified by the test searches. Achieving perfect recall 
is a trivial task, achieved by simply retrieving every record in the database. Useful recall 




4.4.3 Recall of New Studies and Recall of New N  
As well as assessing recall of new studies, recall of new N was examined. In 
meta-analysis, larger studies can carry more weight and thus may be more likely to render 
a review in need of update.  
4.4.4 Complements to Recall 
Some measure of efficiency of retrieval is often used as a complement to recall. 
Here precision, specificity and fallout will be described. These measures, as well as 
recall, can be derived from a 2x2 table (Table 4). 
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A+C B+D A+B+C+D 
   
       
Recall is calculated as 
Recall = A/(A+C) 
4.4.4.1 Precision 
Precision is the proportion of relevant documents retrieved by the search and is 
the equivalent of the positive predictive value of a diagnostic test.181 It is calculated as  
Precision = A/(A+B)    (Table 4) 
Number needed to read (NNR) is the reciprocal of precision and represents screening 
efficiency or screening burden for the user. Lendgrebe suggests that when class 
imbalance is present (a very small proportion of the database is relevant), precision is the 
better measure than accuracy or sensitivity. Both precision and sensitivity are influenced 
by such a skewed distribution of relevant and irrelevant items, but precision remains 
much more sensitive to performance in retrieval of the small number of relevant items.194 
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Precision is a classic indicator of search quality, and there are no particular challenges to 
its use. There is a trade-off between recall and precision, however it is less marked than 
the trade-off between recall and specificity.181 
4.4.4.2 Specificity  
Specificity is used in diagnostic tests, thus is a familiar measure within the 
epidemiological community. It is the proportion of irrelevant records that are not 
retrieved by the search and is calculated as  
Specificity = D/(B+D)    (Table 4) 
Specificity has been used extensively in filter development, in particular, it is part of the 
standard methodology of the Hedges team.157 Values for specificity are almost always 
very large in information retrieval when a very large database is used, as most references 
are not retrieved.181 It is used by the Hedges group to compare the relative efficiency of 
candidate search terms within the same database.157 
4.4.4.3 Fallout or False Positive Rate  
Fallout is the proportion of non-relevant documents that are retrieved (false 
positives) out of all non-relevant documents (true negatives plus false positives).195 It is 
calculated as 
Fallout = B / (B+D)     (Table 4) 
As with recall, all relevant documents need to be identified in order to establish the 
denominator, which is in this case one minus the number of relevant documents. As with 
specificity, fallout deals only with the non-relevant items. Van Rijsbergen (p. 149) argues 
that there is a functional relationship between recall, precision and fallout determined by 
the proportion (density) of relevant documents in the collection which he calls G or 
generality, calculated as  
G = Number of relevant documents/ Total number of documents.  




Precision = (Recall * G) / ((Recall * G) + Fallout * (1-G)) 
Precision = (A/(A+C)) * G  / ( (A/(A+C) * G) + ((B/(B+D) * 1-G)) ) 
4.4.5 Summary Measures 
The appeal of summary measures is that they provide a single indicator of search 
performance, but the disadvantage is that the interpretation of the measure is not obvious. 
Here three summary measures are briefly considered as alternatives to examining both 
precision and recall as the primary and secondary outcome measures.  
4.4.5.1 Accuracy 
Accuracy looks at the overall percent of correct classification across the whole 
database, it is; 1-(false positives + false negatives) or 1-(A+D). It is highly influenced by 
class priors, or the distribution of true negatives and true positives,194 and so is of little 
use in searching where most records are not relevant. More formally by Lendgrebe et 
al.,194 citing Weiss196;”In an imbalanced setting, where the prior probability of the 
positive class is significantly less than the negative class (the ratio of these being defined 
as the skew or ), accuracy is inadequate as a performance measure since it becomes 
biased towards the majority class.” 
4.4.5.2 E   
E was proposed by van Rijsbergen as a general measure of effectiveness 195 (p. 
174) which can be weighted toward recall or precision depending on which of those 
attributes is more important in the situation being considered by altering the value of , 
where  is the relative value of recall.181 
4.4.5.3 F  
F measure195 is a combined measure used in the precision-recall case. It is the 
geometric mean of precision and recall, in which the two measures are weighted equally, 
defined as 




Posfrac = (TP+FP)/N  or   (A + B) / A+B+C+D 
. “This measure is useful in applications requiring second-stage manual processing of the 
positive outcomes of the classifier (such as medical screening tests), and estimates the 
reduction in manual effort provided by the classification model.”194 While this is 
potentially interesting given the sequential screening approach used in systematic 
reviews, it has not previously been used in that context, and there seems no compelling 
reason to adopt it here. 
4.4.6 Receiver Operator Characteristic (ROC) Analysis 
Receiver Operator Characteristic (ROC) analysis is commonly used to evaluate 
classifiers where subjects are classified into two categories197 and can be used for SVM 
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and Related Article RCTs, where threshold of retrieval can be varied according to 
relevance score and records are classified as relevant or irrelevant. Area under the ROC 
(AUC) can be viewed as a performance measure that is integrated over a region of 
possible operating points (decision thresholds). Curves close to the rising diagonal are 
indicative of poor performance, while larger areas under the curve, which occur when the 
line rises sharply, are indicative of good performance .198 Figure 11 illustrates the ROC 
curve for an effective screening test, of endovaginal ultrasonography for detecting 
endometrial cancer, originally published by Deeks.198  
Receiver Operator Characteristic (ROC) analysis is commonly used to evaluate 
classifiers where subjects are classified into two categories197 and can be used for SVM 
and Related Article RCTs, where threshold of retrieval can be varied according to 
relevance score and records are classified as relevant or irrelevant. Area under the ROC 
(AUC) can be viewed as a performance measure that is integrated over a region of 
possible operating points (decision thresholds). Curves close to the rising diagonal are 
indicative of poor performance, while larger areas under the curve, which occur when the 
line rises sharply, are indicative of good performance.198 The figure below illustrates the 
ROC curve for an effective screening test, of endovaginal ultrasonography for detecting 
endometrial cancer, originally published by Deeks.198  
Search methods with dichotomous relevance values of 0 or 1 do not permit altered 
retrieval thresholds and so ROC analysis is not possible – this is the case with the 
Boolean searches and citing reference method.194 
 
4.4.7 Summary of Outcome Measures 
“Precision and recall remain standard measures of effectiveness to this day, with 
some variations on the theme. They measure the probability of agreement between what 
the system retrieved or constructed as relevant (systems relevance), and what a user or 
user surrogate assessed or derived as relevant (user relevance).”180 Sampson et al. have 
previously defended the use of these parameters in the context of systematic review 
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searches; “the information retrieval paradigm used in systematic reviews is classically 
suited to evaluation using the measures of recall and precision. Retrieval occurs in batch 
mode, although preliminary work may be exploratory and interactive. High recall and 
high precision are sought, with large retrieval sets being the norm. Retrieved documents 
are classified into a binary relevance scheme as eligible or ineligible for inclusion in the 
review. Finally, measures are taken to minimize the subjectivity or idiosyncrasy of the 
relevance assessment: the search result is evaluated against explicit criteria, often by two 
reviewers who must reach consensus, so that the work could be independently 
replicated.”192  
4.5 PROCEDURES FOR IDENTIFYING NEW RELEVANT STUDIES 
After eligibility was confirmed and the screening spreadsheet was developed, the 
reviewer received a package with a copy of the original systematic review (and the 
update, if one was available), the spreadsheet with the included studies, newer meta-
analyses, and candidates as well as the template for all data extraction and calculation, 
and the Reference Manager database containing the bibliographic record for the newer 
MAs and the candidates. 
Each reviewer read the systematic review, and then stated the question of the 
review in PICO format, recording this on the updating spreadsheet, also noting major 
inclusion criteria. PICO is a structured approach to posing questions commonly used in 
evidence-based medicine, where P is the population of interest (often the disease), I is the 
intervention of interest, C is the comparator, and O is the outcome.199 Relevant new 
evidence would have to match all elements, as well as be a suitable study design.  
 The reviewer then selected up to four efficacy outcomes and two harms following 
the eligibility criteria of a clinical outcome (e.g. disease endpoint, functional status or 
mortality) or established intermediate outcome (e.g., blood pressure, glycemic control, 
standard instrument for measuring disease activity, such as a depression scale) with a 
meta-analysis with point estimate and 95% confidence interval.  
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The selected outcomes were recorded on the updating spreadsheet. For each 
outcome, the meta-analytic measure used (such as odds ratio or weighted mean 
difference), the number of trials in the original, the number of participants in total and 
number of participants in the largest included trial was recorded. For each selected 
outcome, the reviewer added a new worksheet using the template associated with the 
particular meta-analytic measure. The reviewer next recorded the pooled estimate and 
upper and lower 95 percentile confidence intervals. As new studies were identified, the 
data from the new trial was added. The spreadsheet calculator computed a new pooled 
estimate and confidence interval using a fixed effects model that included the additional 
evidence.  
4.5.1 Example of Process for Assessing the Need to Update  
An example may add clarity to the screening and updating assessment. A meta-
analysis published in 2002 examined angiotensin receptor blockers in heart failure.200 The 
population was patients with symptomatic heart failure and the intervention was 
angiotensin receptor blockade (ARB). The comparison was either placebo or angiotensin-
converting enzyme (ACE) inhibitors. The primary outcome of the original review was all 
cause mortality and the secondary outcome was hospitalization for heart failure. 
Important inclusion criteria were random allocation, parallel group design, blinded and 
treatment of at least four weeks duration. Sixteen randomized controlled trials published 
between 1995 and 2001 were included in the original review. Study size ranged from 33 
patients in a 1999 study to 5014 patients in a 2001 study.  
Three meta-analyses from that review were selected as outcomes for updating and 
were transcribed to the updating spreadsheet. The three were mortality in trials comparing 
ARB versus eitherplacebo or ACE inhibitors, hospitalizations in trials of ARB versus 
either placebo or ACE inhibitors and mortality in studies of ARB versus placebo. All 
three meta-analyses had used odds ratios, none were significant in the original systematic 
review. In all cases the confidence interval spanned the line of effect. If the line of effect 
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was crossed, it indicates that the odds of outcome occurring did not differ statistically 
between groups.  
Three new trials were found for the first outcome. The event rate (number of 
deaths in the course of the study), was recorded for the intervention and control group, as 
was the number of patients studied. As each of the three new studies was added, the 
spreadsheet calculated the odds of the event occurring in each group, and the odds ratio 
between groups for that study. The pooled odds ratio and upper and lower bounds of the 
95% confidence interval were also computed. The pooled result was tested to see if it had 
become significant, indicated by a Z score of 1.96 or greater, corresponding to a p value 
of 0.05 or less. The robustness of this finding was tested, since a change from just non-
significant to just significant (or vice versa) could easily be overturned with the addition 
of the next new study and so was not a compelling reason to perform an update. Marginal 
significance was operationalized as a Z score between 1.881 and 2.054. Next, the old and 
new upper and lower confidence interval were compared to see if there had been a change 
in the width of 95% confidence interval by at least 50% (i.e., CI new / CI old  0.5 or CI 
new / CI old  1.5). Robustness of this change was also examined.  
Figures pertaining to size criteria, namely number of new studies, number of new 
participants, ratio of number of new to old studies and ratio of number of new and old N 
were computed. An increase in number of patients by 50% or more (either overall for a 
specific outcome) or an increase in number of trials by 50% or more (either overall for a 
specific outcome) or a new study more than three times the size of the largest study in the 
original systematic review were all flagged.  
In our example, the first three new eligible studies all compared ARB with 
placebo and examined mortality, one of the selected outcomes. All three trials were 
published in 2003. The odds ratio in the original review was 0.68 with a 95% confidence 
interval from 0.38 to 1.22, so there was no clear advantage to either the treatment or the 
control. After the first study was added, the odds ratio was virtually unchanged at 0.673 
(0.388 - 1.168). The addition of the second and third new studies changed the pooled 
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estimate to 0.837 (0.697 - 1.006) and 0.835 (0.696 - 1.003) respectively. This brings the 
odds ratio to borderline significance, which would have been an issue if the question were 
whether the crossing of the line was robust, but indeed the line of effect was not crossed, 
so this result is ignored. The width of the confidence interval was reduced by more than 
50%, and this is noted, but this finding is not in itself sufficient to signal that the review 
needs updating, as nothing about this would be likely to change clinical practice. For this 
outcome, we do see that there has been a greater than 50% change in the number of 
patients studied. The largest trial in the original review comparing ARB and placebo and 
reporting on mortality involved 844 participants. These three new studies had 218, 2028 
and 292 new participants respectively. Had the largest new study been more than three 
times the size of the largest study in the original, this would have been flagged.  
In summary, considering the material published between May 15, 2001, and the 
end of 2003, there is a large body of new evidence on mortality, which increased the 
precision of the point estimate, but which did not shift the point estimate much and did 
not change it from being non-significant to significant. Since the conclusions and 
treatment implications would remain unchanged, the update can wait. 
For the outcome of hospitalization for heart failure, the original pooled odds ratio 
was 0.86 with a 95% confidence interval of 0.69 - 1.06, close to significant. A meta-
analysis by Lee, published in 2004, reported on this outcome. One large new study 
included in the Lee meta-analysis was added to the original estimate. The odds ratio of 
the new study was 0.640 with a confidence interval from 0.530 - 0.780, indicating fewer 
hospitalization in the intervention group (ARB) than in the control group (placebo). 
Pooling this new result with the previous results, the updated odds ratio became 0.730 
with a 95% confidence interval of 0.633 - 0.843. Because 1.00 (equality) is outside the 
confidence interval, we can say that the pooled estimate of the effect now supports that 
ARB is superior to placebo. Based on this outcome, this therapy, which was previously 
characterized as promising or likely beneficial, is now more clearly favourable and 
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uncertainty has been reduced. A signal for updating has occurred; as this finding should 
be communicate so that clinicians can change their practice.  
The reviewer would now transcribe the flagged evidence and the stopping criteria 
to summary page of the updating spreadsheet and seek an expert opinion source that 
would affirm or challenge the conclusion that the intervention significantly reduces 
hospitalizations for heart failure relative to placebo, and should be adopted in practice. As 
this updating project was retrospective, it had the benefit of hindsight, and could examine 
current sources of expert opinion such as Clinical Evidence (BMJ Publishing Group) or 
even more recent meta-analyses to confirm the findings of the updating exercise. 
The reviewer’s work in this is to assess the new studies for eligibility, extract the 
relevant data (here the number of events and number of participants in each group), and 
enter these in the spreadsheet, which computes the new variables and flags changes that 
exceed the thresholds set. Confirmatory sources were then consulted, and the case 
presented and discussed at a case conference where the classification could be accepted, 
or the evidence re-interpreted. On some occasions, if expert sources indicated that the 
finding of the original meta-analysis was no longer considered best practice, additional 
searching could be requested or spot searching could be done to identify the trials or 
meta-analysis that appeared pivotal in informing current best practice. Any new evidence 
found this way would be added to the updating spreadsheet as Reviewer Nominated to 
capture that the search had missed important evidence. 
In this example, a total of eight eligible new studies were identified, all by 
examining a single new systematic review published in 2004 (Lee) The original review 
was considered current as of May 15, 2001, the last search date reported. The first eligible 
new evidence appeared in February 6, 2002, and the threshold for updating was crossed 
October 27, 2003. The survival time of the original systematic review was calculated by 
subtracting the original publication date from the indexing date of the new evidence 
resulting in the signal. It was 623 days (about one year and eight months). In the 
systematic reviews where no signal for updating occurred, the survival was calculated as 
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the number of days between the original publication data and the end date of our update 
searches. 
As in this example, reviewers first assessed newer meta-analyses, starting with the 
newest. The logic of this screening order was the newest review would be most likely to 
include all the relevant evidence. If the newer systematic review was On Topic, the 
primary studies included in it were assessed for relevance (both On Topic of the 
systematic review and Eligible for the outcomes selected for updating). These primary 
studies were then sought in the candidate list, and their relevance recorded. If assessed as 
Eligible, the total number of study participants (N), both in the intervention and control 
arms, was recorded, not the number included in the specific meta-analyses used in the 
updating. If a previous report of an eligible study had been assessed as eligible, than no N 
was attributed to subsequent instances. If a primary study was not present in the candidate 
list, but was assessed as Eligible, it was added to the end of the list, and N recorded. 
These were treated as false negatives and were included in the denominator for recall for 
each systematic review.  
If all newer systematic reviews were examined without any stopping rules being 
met, the reviewer would then begin screening the candidate list, from oldest to newest. 
The logic for this screening order was that we wanted to identify the earliest point where 
the review was in need of update, and for efficiency, we wanted to stop screening just 
beyond this point. A margin was included so that if a statistical threshold was met with 
one study, but the estimate reverted back to its original state with the inclusion of the next 
eligible study, than the review was not considered in need of update. The same 
assessment and recording procedure was used with the candidates as was used with the 
primary studies in newer meta-analyses. 
4.5.2 Determination of Need to Update 
The need to update was determined by the appearance of major or potentially 
invalidating new evidence. Quoting from the survival analysis, potentially invalidating 
new evidence “would make one no longer want clinicians or policymakers to base 
 
105 
decisions on the original findings (such as a pivotal trial that characterized treatment 
effectiveness in terms opposite of those in the original systematic review).” Major 
changes in evidence “would affect clinical decision making in important ways without 
invalidating the previous results (such as the identification of patient populations for 
whom treatment is more or less beneficial).”17 
4.5.2.1 Conceptualization 
Prior to this project, an international workshop was held in Ottawa, Canada in 
March 2006 to consider various aspects of updating systematic reviews.11 One goal of the 
workshop was to create a framework. An issue explored in the workshop was the notion 
of triggers for updating. Triggers could arise from the evidence, or from external factors 
including the passage of time (as uncertainty builds with the passage of time), but in 
general, a trigger occurs when a state of uncertainty exists about the continued validity of 
the review and the resolution of that uncertainty is sufficiently important from a policy or 
scientific standpoint that resources are committed and an update is initiated. 
Alternatively, if update is not practical, a review could be withdrawn.  
The Updating project attempted to operationalize triggers arising from new 
evidence. In this phase, the new evidence is screened and added to the meta-analysis. 
Certain rules determined whether the result has changed in important ways, or otherwise 
the weight of new evidence would indicate that the review should be updated. The 
“stopping rules” or “signals for updating” were probably the most difficult aspect of the 
protocol to develop and were mainly the work of Kaveh Shojania and David Moher. 
Ideally, stopping rules would operate in such a way that could be independently replicated 
by others and would produce meaningful results – that is, in cases where the update was 
triggered, the finding of the updated review would be different in some important way 
from the findings of the original review. Ultimately, as the systematic review is a tool for 
evidence-base medicine, the differences should be great enough to warrant a change in 
practice.189 Both qualitative and a quantitative signals were explored through length 
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debate within the AHRQ updating project team and between the team and the Technical 
Expert Panel.  
4.5.2.2 Classification 
In the end, the triggers, or definitions of signals that a review needed to be 
updated, where chosen to be consistent with previous work comparing whether two sets 
of results relating to the same question were concordant or discordant.17 A number of 
these were presented in the example of the actual assessment of the original meta-analytic 
result in the face of new evidence. The complete set is presented in Table 5. 
 
Table 5. Summary of Classification of New Evidence. 
 Reviewers first assessed amount of new evidence (C criteria) and statistical impact (B 
criteria), then sought expert opinion that would support or refute the change or lack of 
change in outcome (A criteria). The direction of change implied by the evidence 
(increased or decreased certainty in efficacy, and direction of change (increased or 
decreased) in therapeutic use implied by the findings, were then evaluated. Final 
classification was then made.  
Expert Criteria: type in the source of expert opinions below, and quote the expert 
opinion 
A1 Pivotal trial*, new meta-analysis, practice guideline (from major 
specialty organization or published in peer-reviewed journal), or 
recent textbook (e.g., UpToDate) characterizes the treatment in 
opposite terms to those in the cohort review: definitely or probably 
effective  definitely or probably ineffective or vice versa (i.e., 
ineffective  effective).  
A2 Pivotal trial, new meta-analysis, practice guideline, or recent textbook 
calls into question the use of the treatment on the basis of harm (i.e., 
the treatment would no longer be recommended because risks 
outweigh benefits). A new result for harm that does not undermine 
use, but has clear potential to affect treatment decisions would count 
as a notable change (specifically, A4).  
A3 Pivotal trial, new meta-analysis, practice guideline, or recent textbook 
characterized another treatment as significantly superior to the one 
evaluated in the cohort review (based on efficacy or harm).  
A4 Pivotal trial, new meta-analysis, “discordant” meta-analysis, trial 
indexed in ACP J Club, more recent practice guideline, or recent 
textbook does not contradict the previous review, but adds an 
important caveat, about the patient populations who benefit, way in 
which treatment has to be delivered in order to derive benefit, 
increases in harm that are not sufficient to undermine use altogether, 
but would clearly temper affect clinical decision making.  
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A5 Instead of a caveat, there has been expansion of the role of the 
treatment (e.g., the treatment has now been shown to be of benefit in 
primary prevention, not just secondary; or now shown to be of benefit 
in children or aged population etc). 
A6 Therapy previously characterized as “promising”, “likely beneficial” 
or similar description and now characterized as definitely beneficial. 
Conversely, if original review characterized therapy as “probably not 
effective” and now characterized as "definitely not effective". This 
criterion can be summarized as a movement of one category on the 5-
point scale in Direction of Change.  
A7 Discordant meta-analysis or trial indexed in ACP Journal Club 
characterized the treatment in sufficiently different terms to the cohort 
review that disagreement would have met criteria for ‘Major change’ 
(A1) except the source was not a pivotal trial, new-meta-analysis, or 
more recent practice guideline, or recent textbook.  
Statistical Criteria  
B1 Line of no effect crossed. 
B2 The new result indicates a relative change in effect size of at least 50% 
(e.g., RRnew / RRold <=0.5 or RRnew / RRold >=1.5 – same applies 
for OR, RD, WMD).  
B3 New and old point estimates differ significantly 
Size Criteria  
C1 Increase in number of patients  50% (either overall for a specific 
outcome) † 
C2 Increase in number of trials 50% (either overall for a specific 
outcome)  
C3 The biggest New Study  3 times larger than the previous largest trial 
C4 Width of 95% confidence interval changed by at least 50%  
(i.e., CI new / CI old <=0.5 or CI new / CI old >=1.5) 
Direction of change: Certainty 
  
Consider the five position scale in which a study conclusion (‘X is 
beneficial’ or ‘Y is harmful’) is characterized as: 
Definitely true | Possibly true | Unclear | Possibly not true | Definitely 
not true 
Change in certainty is defined in terms of the absolute distance from 
the center position ("unclear"). When the new result lies further from 
the center than the result in the cohort review, then certainty has 
increased; if the new result is closer to the center, then certainty has 
decreased. And, if the distance is the same to the center (even if on 
opposite sides) then certainty has not changed. 
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Direction of change: Therapeutic Use 
 Effective to ineffective (A1, A6, or A7) = Decreased utility 
 Harm (A2 or A4) = Decreased utility 
 A new treatment is superior (A3) = Decreased utility 
 Caveat (A4) = Decreased utility 
 Ineffective à Effective (A1, A6, or A7) = Increased utility 
 Expansion (A5) = Increased utility 
Final Classification  
  ‡ Potentially invalidating 
 
§ Major (indicate though if based on expert or stats by itself involving 
primary or harder outcome) 
  Minor (at least one size criteria without any of the other criteria)  
  
None of the above (meaning at least one eligible new study found, but 
not meeting any of the criteria) 
  No new studies found 
Source: Summary page, updating spreadsheet template 
*A pivotal trials was defined as one having a sample size of at least 3 times the largest 
previous trial, published in one the top 5 medical journals (New England Journal of 
Medicine, The Lancet, JAMA, Annals of Internal Medicine or BMJ) based on journal 
impact factor. 
†In other words, either the total number of patients in all of the included trials has 
increased by at least 50% or the number of patients who contributed to the analysis of one 
of the included outcomes has increased by at least 50%.  
‡ Assign potentially invalidating if expert criteria A1-A3 are met. 
§ Assign major if expert criteria A4-A7 are met, regardless of statistical criteria; or ii) 
statistical criteria on the primary outcome or a harder outcome. Harder outcome is defined 
as either a harder outcome than any of the outcomes in the cohort meta-analysis or an 
outcome harder than the ones that had statistically significant results in the cohort meta-
analysis. E.g., if the cohort review showed significant reduction in myocardial infarctions 
and then a significant result for mortality would count if the cohort review’s result for 
mortality was not significant or if mortality had not been analyzed at all.  
4.5.3 Quality Control Measures 
A number of quality control measures were taken to ensure objective and 
repeatable assessment of eligibility of cohort systematic review and new evidence. Initial 
reviewer calibration was undertaken to ensure reviewers assessing material consistently, 
and double screening was used for selecting the systematic reviews making up the cohort, 
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with discrepancies discussed and resolved by consensus. When assessing the need to 
update each review, reviewers were first to achieve consensus on the PICO elements. The 
PICO elements informed eligibility of newer material. Resources did not permit dual 
screening of candidates. 
One challenge in information retrieval experiments is that assessment of relevance 
may be influenced by material previously found and thus shift over time.187 Tague-
Sutcliffe identifies sequence effects due to either learning or fatigue as a challenge in 
repeated measures designs where the results of various search approaches are assessed.179 
Here, integrating all query results for an update into a single candidate list eliminated the 
need for multiple passes and blinded the reviewers to which search identified the 
candidates. Focusing first on the results of newer meta-analyses and assessing only to the 
point where a signal occurred limited the screening burden and hopefully also screening 
fatigue. Providing an explicit method to record second and subsequent publications of the 
same date was intended to minimize sequence effects.187 Automating the calculation of all 
quantitative signals minimized human error in assessments. 
Case conference (KS, JJ, MA, MS) was used to review and finalize the 
determination of updating status and final classification of the new evidence as potentially 
invalidating, major, minor, new studies only, or no new evidence. This was an 
opportunity to assess the expert opinion, and explore reasons for discordance. Additional 
searching was requested if results seemed incomplete, based on current opinion or the 
knowledge of any members of the review team. 
One member of the review team (JJ) performed quality checks when extracting 
data from the updating spreadsheets to transcribe into the main survival data set. I 
reviewed all screening worksheets when extracting data for the main search performance 
data set. In either case, incomplete or incongruent data were referred back to the reviewer 
for completion or clarification. 
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4.5.4 Limitations of the Screening Method 
This screening approach has a number of implications for the recall and precision 
estimates. First, it will be apparent that not all candidates were assessed. Second, there are 
systematic differences between the amount of evidence assessed for reviews that did go 
out of date and those that did not go out of date. For those systematic reviews where the 
results were overturned with new meta-analyses, it was possible that only a few 
candidates were assessed, and only relevant candidates were classified – all these would 
be On Topic and most would be Eligible. On the other hand, for systematic reviews that 
were not in need of update, the entire candidate list would be evaluated, including 
retrieved records that were not eligible. Recall of signaling evidence can be calculated but 
precision cannot be accurately established from these data. Precision of the searches 
requires that the whole retrieval, or at least a systematic portion of it, be assessed. 
Complete screening of the AHRQ cohort was done to permit precision estimates.  
An additional, but less problematic, situation is that some evidence that was not 
added into the calculator could be assessed as relevant. This occurs when new meta-
analysis includes studies published subsequent to the study that the signal resulted from. 
In our ARB example, there was one smaller study that appeared several months after the 
signal date, and it is recorded as On Topic and Eligible, with N attributed. Thus, recall is 
recall of evidence identified by our methods as relevant – it may not correspond exactly 
with recall of evidence included in one or more of the updated outcomes prior to the 
stopping rule. The assessment process is presented graphically in Figure 12. 
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4.6 REVIEW-LEVEL DATA EXTRACTION 
Characteristics of reviews that were extracted included first author, journal, 
journal impact factor, PubMed ID, type (Cochrane Collaboration Review, journal 
published review or health technology assessment report), date of publication, MHDA, 
date of the most recent search, clinical area, whether updated by searches or by a newer 
systematic review, the number of studies included in the original review, the total number 
of participants represented in the original review, the intervention type (drug, device or 
procedure), control type (standard care, placebo, alternative drug/ device/ procedure or 
multiple controls) and study designs included (RCT only or RCTs plus quasi-RCTs or 
controlled clinical trials (CCTs)). 
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Where possible, these variables were extracted from the MEDLINE record. 
Otherwise, they were extracted by a member of the team – mostly by the IS team, but the 
intervention type, control type, and study design were determined by the review team. 
All systematic reviews in the cohort were classified according to clinical area. 
This variable was used to describe the sample, and forms the basis for the analysis of 
growth of the literature. Several factors were considered in the classification: ISI journal 
classification, the Cochrane CollaborationReview Group where the topic might be placed, 
the high level MEDLINE subject heading (MeSH) that the population (condition) would 
be indexed under and finally, which heading on the AHRQ Evidence Report web page 
might best suit the review. Where a review seemed to fit two or more categories, we 
recorded all applicable. We then sought to reduce the number of classifications to around 
ten, with most reviews falling into one of the ten categories. I undertook review with 
another reviewer (AI) and our consensus was reviewed and confirmed by a medically 
trained reviewer (MA). We arrived at 13 categories and adopted the ISI journal 
classification to name them.  
4.7 DATA SET CREATION 
Creation of the master dataset containing all studies included in the original 
reviews, in the updates, the newer meta-analysis, candidates, and reviewer nominated 
records, was a major undertaking. 
The procudures I developed and used were: 
1. All.xls files were pasted into an SPSS197 file and pivoted 
2. The screening worksheets of the updating spreadsheets were cleaned and pasted into 
another SPSS file 
3. The two SPSS files were merged 
4. Another SPSS file had characteristics of the reviews, survival, and final classification. 
This was created for the survival analysis.17 
5. Necessary review-level data was added to the main dataset by a series of recodes. 
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The all.xls files recorded which searches had retrieved each PubMed ID. These were 
organized so that eachretrieval was a case with three variables; PubMed ID, CohortID for 
which it had been retrieved, and the search method that had retrieved it (Figure 13).  
 Highlighting in Figure 13 shows that 3 search methods retrieved PubMed ID 10667492.  
It was necessary to arrange the data so that each PubMed ID was a case, and each search 
approach was a dichotomous variable where 1 signified that the search had retrieved that 
PMID and where 0 signified that it had not retrieved it. The SPSS Restructure facility was 
used to restructure cases into variables (Figure 14).  
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After restructuring, I integrated the retrieval data with relevance data using the SPSS 
merge files procedure. A primary key of CohortID and PubMed ID was used to match 
cases from the two datasets. The compound primary key was necessary as some PubMed 
IDs had been retrieved for more than one systematic review in the cohort. After the two 
datasets were merged, the review-level data was added to the dataset using a series of 
recode commands (Figure 14).  
4.8 DATA ANALYSIS 
Description of the Searches 
Boolean searches, both those used in the test searches and those used by the 
original review authors in the AHRQ and Updated Cochrane cohorts, were characterized 
on a number of dimension. The number of the following features employed was 
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considered; free text, explode MeSH terms, use of starring or major MeSH terms, 
subheading (either attached or floating), and filters. Filters were any query statements 
designed to include or exclude specific study designs or publication types. This included 
the clinical queries, AIM RCT, highly sensitive search strategy, but others as well, 
including the query “(prevention or preventive or therapy or therapeutic or 
treatment).ti,sh.”201 and, in another Evidence Report,202 the construction:  
16. 15 or 14 
17. 16 not letter.pt. 
18. 17 not editorial.pt. 
19. 18 not case report/ 
20. case report/ and clinical trial.pt. 
21. 18 and 20 
22. 19 or 21 
Language limits and manoeuvres to limit to human studies or exclude animal-only 
studies were counted. 
 The number of search terms was determined by making a copy of the search in 
Word and deleting any lines that contained limits, filters or were Boolean combinations of 
other line such as “(1 or 2) and 3”. Boolean ORs, ANDs and adjacency operators were 
replaced with carriage returns to isolate each term on a separate line. The lines were then 
numbered, and the number of lines was taken as the number of search terms.  
4.9 SEARCH PERFORMANCE BY INTERVENTION TYPE 
Day et al.203 found that simplified search strategies achieved 100% recall in 
pharmacological interventions but as low as 40% recall in non-pharmacological 
interventions in musculoskeletal and pain systematic reviews. Recall of the searches will 
be examined in a subgroup analysis of systematic reviews in which the intervention 
studies was classed as a drug (n=89, 86%), compared with those where the intervention 
was a device or a procedure (N=16, 14%). 
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4.10 STATISTICAL ANALYSIS 
Data were analyzed quantitatively through SPSS version 16.197 For the main 
analyses, the independent variable is search method. Recall was the primary outcome 
measure (dependent variable), and precision and its variant, number needed to read, were 
secondary outcome measures. Most analysis was descriptive rather than inferential, and 
visual presentation was used where practical. Recall and precision, which are ratios 
(proportions), are interval level data. Recall and precision were aggregated across queries, 
both with overall mean (macro-averaging) and average of measures for individual 
systematic reviews (micro-averaging). The former gives more weight to the document 
and the later gives more weight to the query in the averaging process179 (see p. 483). 
Classifications, as nominal level descriptive data, were summarized as counts. Rankings 
and relevance scores, as ordinal data, were summarized using median and inter-quartile 
range. 
Most graphical presentations were prepared using Plot for Mac OS X.204 Survival 
plots and ROC curves were prepared using SPSS.197 Growth of the literature plots were 
prepared using CurveExpert 1.3.205 Venn diagrams were prepared using Adobe Photoshop 
Elements.206 
Calculation of recall was performed in SPSS. Each search method was coded as 
either 1 (retrieved) or 0 (not retrieved) for each record considered. Recall could be 
calculated directly by selecting records that were assessed as eligible, and taking the mean 
for each search type for those records. For instance, if the review with CohortID of 109 
had 10 new records assessed as Eligible by the reviewers, if 9 of those 10 records had 
SVM coded as 1 and the remaining record has SVM coded as 0, the mean of SVM would 
be 0.90, and this, as the proportion retrieved, equalled recall.  
Precision could not be calculated directly in SPSS. For each search type, all 
records retrieved by those searches were retrieved in SPSS, and a cross tabulation was 
made of Target by Set. Target was 1 if the record had been assessed as eligible. The 
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number retrieved and number eligible were transcribed to Excel, where the proportion of 
retrieved that were eligible was calculated. 
ROC was used for those test searches that provide relevance scores and so permit 
adjustment to the threshold for retrieval – the SVM and Related Article searches. Area 
under the curve was calculated with the SPSS ROC procedure which plots an ROC curve, 
and computes the area under the ROC curve with confidence intervals.197  
4.11 SUMMARY OF THE MAIN EXPERIMENT 
The design and methods can be summarized following Tague-Sutcliffe’s 
“Pragmatics of Information Retrieval Revisited” 179  
Decision 1. To test or not to test?  
Test – there is a need and the work is novel (see Chapters 2 and 3). 
Decision 2. What kind of test?  
A laboratory test with standardized users (reviewers see Section 4.5), a single 
database, standardized searchers, and specified search constraints (see Section 4.2). 
Decision 3. How to operationalise the variables?  
The independent variables are the test searches; a broader Boolean search (Clinical 
Query) and narrower version (AIM RCT), two similarity searches – RI RCT and 
SVM, and finally a citation search – citing RCTs (see Section 4.2). Dependent 
measures are principally recall and, where possible, precision (see Section 4.4.7). 
Decision 4. What database to use?  
All search approaches were tested in MEDLINE, although CENTRAL was examined 
for comparison (see Section 4.2.4.2).  
Decision 5. Where to get queries?  
The queries are the populations and interventions of systematic reviews of drugs, 
devices or procedures in allopathic medicine from ACP Journal Club (See 4.1.2). 
Decision 6. How to process the queries?  
Queries were processed through publicly available interfaces (Ovid MEDLINE or 
PubMed) for all but SVM where NRC’s SVM interface was used (see Section 4.2). 
 
118 
Retrievals were assembled into single sets and presented to reviewers in spreadsheets 
(see Section 4.3). Assessed retrievals were restructured in SPSS into repeated 
measures formats (see Section 4.7).  
Decision 7. How will factors under investigation be assigned to experimental units? 
The factors under investigation are the search strategies and the experimental unit 
corresponds to the systematic review to be updated. For example, each systematic 
review to be updated could have been randomly assigned to one search approach. 
Instead, all searches were used for all systematic reviews in a repeated measures or 
within subject design, maximizing data use and reducing inter-query variation. The 
exception of support vector machine which was not assigned to all systematic reviews 
in the cohort but to two subsets – AHRQ reviews and updated Cochrane reviews that 
met certain objective criteria (see Section 4.8). 
Decision 8. How to collect the data?  
Data collected to describe the sample and the retrieved records was derived whenever 
possible from bibliographic records, or where that was not possible, was abstracted by 
one or more members of the research team (see Section 4.6). Data on relevance of 
retrievals was determined by the decision of authors of updated reviews, where 
available, but otherwise was collected by reviewers who assessed records, blind to 
retrieval method, for topicality and relevance to the systematic review to be updated 
(see Section 4.3.1.3). Classification of the impact of the new material was based on 
group discussion and consultation with published sources of expert opinion (see 
Section 4.5.2). 
Decision 9. How to analyze the data?  
Data were analyzed quantitatively, using recall as the primary outcome measure, and 
precision and its variant, number needed to read, as the secondary outcome measures 
(see Section 4.4.7). Most analysis was descriptive rather than inferential, and visual 
presentation was used where practical. Recall and precision were aggregated across 
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queries, both with overall and average means. Rankings and relevance scores were 
also considered (see Section 4.8).
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Chapter 5: Methods - Exploratory Analyses 
5.0 INTRODUCTION 
The previous chapter laid out the methods for identifying a cohort of clinically 
important systematic review of reasonably quality, identifying new evidence using test 
searches to see if those reviews became out of date during the observation period, and 
determining the performance of those searches. This chapter explores other information 
retrieval issues in updating systematic reviews. Aspects of both the searches and of the 
resulting evidence will be explored. First, the structural relationship between searches 
will be examined to explore why those searches perform as they do. Understanding the 
performance of the original searches informs updating practices and helps place the 
performance of the tested searches in context. Thus, precision of the searches in a cross-
sectional sample of systematic reviews from 2004 is examined, and recall of the 
systematic review searches for the updated Cochrane cohort and the AHRQ cohort is 
examined.  
Characteristics of the new evidence will be examined, as will the question of 
whether the survival of the review depends on how old the evidence in it is. Not all 
evidence is necessarily retained in an updated systematic review. Comparison of the 
nature of material retained and not retained may provide insights into how evidence shifts 
over time, which may have implications for updating systematic reviews.  
5.1 STRUCTURAL RELATIONSHIP BETWEEN SEARCHES 
5.1.1 Unique Contribution and Overlap 
Unique retrievals are those records retrieved by only one of the searches tested. 
Frequencies of unique retrievals, unique On Topic retrievals, unique Eligible retrievals, 
unique Eligible studies with N attributed were calculated for the various test searches for 
all three cohorts. Unique retrievals were identified through a series of SPSS Select 
statements that selected records retrieved by the test search and not by any of the others. 
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New variables were created to represent the unique component, named in the manner; 
RI_RCT_Only, CQ_Only et cetera. Crosstabs then identified the components of those 
variable that were On Topic, Eligible, and had New N Attributed. Searches examined were 
Related Article RCT, Citing RCT, SVM95, SVM200point5, Clinical Query, and Subject 
Search in CENTRAL. Abridged Index Medicus RCT was not tested since it is a narrower 
version of Clinical Query, and so yields no unique material. The records found by the 
reviewer authors Actual searches but not by any of the test searches was also identified 
and reported, but since the authors’ searches were highly variable in recall, unique 
retrievals where examined for the test searches relative to each other, regardless of 
whether the review authors’ actual search would or did also find the record.  
Overlap was also calculated between all pairs in the set Related Article RCT, 
Citing RCT, SVM95, SVM200point5, Clinical Query, Subject Search in CENTRAL and 
Abridged Index Medicus RCT. The size of the unique component of each search and the 
degree of overlap between searches was presented as a proportional Venn diagram, were 
the diameter of the circle representing each search retrieval was calculated as: 
 
 
And n is the size of the retrieval. 
5.1.5 Convergence of Multiple Retrieval Methods 
Prior research in contexts other than systematic review searches suggests that 
retrieval of the same citation by multiple methods signals its relevance. Saracevic and 
Kantor found a striking increase in precision when items were retrieved by more than one 
searcher, and they reviewed previous work looking at overlapping retrieval in a variety of 
contexts, concluding that the degree of agreement in representation of concepts in search 
terms was consistently low, but the overlapping area was of great interest. They proposed 
a “super-strategy” in which searches of a question independently by several searchers, 
and the overlap in the retrieved sets is examined.166,170 It has also been shown that articles 




relevant.207 More directly relevant to the current question, Pao and Lee found a 5% 
overlap between MEDLINE subject searching and citation searching, but 86% of those 
identified by both methods were judged at least partially relevant and 68% were judged 
relevant.208 Wu and McClean reviewed the prior work in data fusion, a technique derived 
from multisensor processing and applied to multiple document lists for the same 
information need, results from different information retrieval systems, or as in this thesis, 
different retrieval strategies in the same system. They tested three fusion techniques in 
four datasets and found, in the univariate analyses, that the effectiveness of combining 
strategies (fusion) was associated with low overlap between queries and high precision 
for the individual queries. In multivariate analysis, high precision became the least 
important factor, while a high standard deviation of mean average precision across the 
query methods was predictive of good performance of the fused results. They explained 
their results; “if some results are better than some others, then these good results are more 
likely to share some common opinion, and their common opinion will dominate the whole 
group; while those poor results share less common opinion, and their eect on fusion is 
limited. On the other hand, if all the results are close in performance, then no one result or 
several results can dominate the whole group, and less improvement can be made by data 
fusion.” They also note that overlap is most informative when the systems are relatively 
different, and that the number of quite different systems cannot be very large.209 Beitzel 
also found that improvements were only seen when the different query methods produced 
a fairly large number of unique relevant results.210  
Lee explored the phenomenon using TREC data and concluded that different 
query methods retrieve similar sets of relevant documents but retrieve different sets of 
non-relevant documents. He found that ranking the combined results based on rank within 
the retrieved sets was more effective than weighting based on similarities scores.211  
The association between the relevance of records and the number of methods 
retrieving the record was examined to see whether the association would hold true in 
systematic review searches. This analysis is an extension of the work to find sufficient 
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search strategies in the cohort of systematic reviews updated through searching. In the 
main cohort, the records found through the test searches and assessed for eligibility were 
selected. The number of different search methods that retrieved each was calculated by 
summing the scores for Related Article RCT, Clinical Query, Abridged Index Medicus 
RCT and Citing RCT. Each search was scored as 1 if it retrieved a given record and 0 if it 
did not retrieve that record. Thus, the sum of the scores for these variables indicated how 
many of the searches retrieved the record in question. SVM was not included in this 
analysis as results were not available for the entire cohort. The number of searches 
identifying each of the Eligible (n=423) and ineligible records (n=8410) was assessed. 
Differences between the number of methods retrieving ineligible records and the number 
of methods retrieving eligible records were calculated and tested using 2. A significant 
difference, in favour of relevant records being retrieved by more of the searches, would 
suggest that convergence was signalling relevance, or maybe more likely, that many of 
those records picked up by a minority of searches are being found by those searches for 
some idiosyncratic reason other than relevance. 
The subject searches are not independent – for example, Abridged Index Medicus 
RCT is narrower to Clinical Query – so the three subject search methods were collapsed 
and retrieval convergence of Boolean, similarity and citing searches were examined – 
using fewer systems that are less alike, following Wu and McLean.209 The number of 
types retrieving each record was computed, and 2 calculated between the number of 
search types retrieving (1-3) and eligibly. Finally, as so few records were identified by the 
citing reference search, the eligibility of records found by both Clinical Query and 
Related Article RCT was tested against retrieval by only one or the other of these 
searches, representing the subject search and similarity search approaches.  
5.1.3 Related Article Seed Refinement 
The performance of the Related Articles was explored in detail in the cohort of 
updated Cochrane reviews. The three newest and three largest studies included in the 
original review were selected as seeds for the related article searches. There was no 
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empirical basis for chosing this criteria. The rationale was simply that large studies would 
carry the most weight in a meta-analysis and the new studies would represent any secular 
trend. It is possible that other seed selection criteria could provide a better proformance. 
To explore this possibility, seeds are classified based on qualifications as seeds 
(independent variable) and performance (dependent variable). The strength of the 
association between these variables was assessed. The objective was to determine 
whether only one or the other type of seed (large or new) is needed. Reducing the number 
of unproductive seeds could improve precision. In the updated systematic reviews, each 
new included study was tested to determine which seed it was related to. Seed yielding 
one or more new included studies were considered productive. Seeds not yielding any 
new studies were considered unproductive. Seeds that were related to all new included 
studies were considered super seeds. The number of productive seeds and the number of 
articles related to each productive seed was reported. Productivity of MEDLINE Misses 
used as seeds was compared to non-misses used as seeds.  
The feasibility of improving precision of the Related Article searches by limiting 
the retrieval size was explored. Rankings were examined for the two cohorts where 
support vector machine was also tested, the six updated Cochrane reviews and the ten 
AHRQ Evidence Reports. Position of eligible record in the ranking of related article 
retrieval was recorded, and recall and precision of the truncated searches was computed.  
5.1.4 Sufficient Strategies 
Given some overlap exists between searches, and that more overlap is expected in 
relevant than irrelevant articles, each additional search method beyond the minimum set 
needed to identify all or nearly all eligible records would reduce precision without 
improving recall. Sufficient search strategies are combinations of searches that would 
retrieve all relevant studies. These were determined for the 72 systematic reviews in the 
main cohort where one or more new relevant studies were identified. In a spreadsheet, 
each Eligible record is listed, along with its type, and the searches that retrieved the 
record (Figure 15). The combination of search methods needed to retrieve all candidate 
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studies assessed as Eligible was determined by inspection. This combination was 
considered a sufficient strategy for that systematic review. Where two or more 
combinations would retrieval all new Eligible records, the retrieval size of the different 
combinations was calculate to identify which combination had the highest precision.  
 
 
5.1.5 Capture – Recapture 
The Capture-Recapture technique is used by biologists to estimate the size of 
animal populations. A sample is captured, tagged and released. A subsequent sample is 
captured, and the proportion of previously captured animals is noted.212 Total population 
size is estimated from the numbers of new animals, recaptured animals, and animals not 
appearing in the subsequent sample. This technique has also been called “Comparison of 
multiple methods of ascertainment” (COMMA).213 
Capture-recapture has been used in epidemiology to estimate ascertainment rates 
for diseases.214 Capture-recapture has been used to detect missing studies from systematic 
reviews213 and to detect publication bias.215 Most recently, the technique has been applied 
 
126 
to the task of deciding when a search is finished by estimating the total number of on 
topic and eligible studies likely to be in the literature and determining if additional 
sources might yield a worthwhile harvest.216 Qualitative research, and qualitative 
systematic reviews also may use the idea of ‘saturation’ – that sufficient data have been 
collected.217  
The technique is used here to test the hypothesis that there were missing studies in 
the updated Cochrane reviews. As will be elaborated below, positive dependence of 
sources will tend to produce an underestimate of the true population size, and negative 
dependence will tend to produce an over-estimate.218 Therefore, the behaviour of capture-
recapture estimates based on pairs of searches can also help illustrate the relationship 
between searches when compared to the total number of relevant studies found by any of 
the searches.  
Capture-recapture analysis requires data in a format that permits calculation of the 
intersection of data from different sources. In this case, the PubMed unique identifier 
provides an ideal mechanism. Diagnostic quality of the data is important.218 This thesis 
uses two different methods to assess relevance, equivalent to the diagnostic methods in 
epidemiological studies. In two of the samples, a reviewer from our team assessed 
relevance. In the third sample, relevance was determined by the decision of the original 
author to include a study in the update of a systematic review.  
Source dependence is a main limitation of the capture-recapture method when the 
objective is to estimate the population size. “Any two sources A and B are dependent if 
the overall, i.e., average, probability of members of a population who appear in their 
intersection or ‘overlap’ is equal to the product of the average probabilities of appearing 
in A, and B.”218 If, as is the case with AIM RCT, one is a nested set of the other, the 
probability of being in the smaller source (say 0.20) will be larger than the product of the 
individual probabilities (say 0.20 * 0.30 or 0.06), and the population will be 
overestimated. Where there is no overlap, the dependence will be negative as the 
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probably of being in either is larger than the probability of being in both, which is 0.00, 
and so the population size will be underestimated. 
The situation is more complex when more than two sources exist but in the 
examples of extreme overlap and no overlap, the same errors of estimation will occur. In 
fact, Bennett et al. argue, usually there is variation in overlap with some pairs of sources 
being more dependent than others are, making the overall dependence difficult to 
quantify.215 Hook and Regal note that even when not independent, if the investigator can 
ascertain the likely direction of dependence (positive or negative) than the capture-
recapture method is still useful as it can be used to set plausible upper and lower 
boundaries on the true population size.4 Multiple pairs, with different directions of 
dependence could conceivably by employed to make such estimates.  
An assumption of the method is that each with a source, each member of the 
population has the same “ascertainability” or probability of capture.218 Superficially, this 
seems unlikely to occur in the case of searching. It is the variability in indexing and in the 
text the authors use in the title and abstract that makes searching difficult. Still, within 
this sample, some restrictions have been imposed that reduce variability between studies. 
These include that the intervention must be a single or class of drug, medical device or 
procedure, and not a CAM therapy. In fact most (87% in the main cohort - see Section 
6.9) were drug interventions. Further, the study designs must have been randomized 
controlled trials or controlled clinical trials. Searching and indexing is well developed for 
these intervention types and studies designs and reporting guidelines have been in place 
for the duration of the update interval that should ease indexing and retrieval.219 
The final assumption, as outlined by Hook and Regal, is “that the population 
under study is ‘closed,’ i.e., that there are no entries or losses during the study period.”218 
This assumption is met in the case of the test searches, in that all samples were drawn 
very nearly simultaneously, and limited by entry date into the database. 
Hook and Regal outline the computational aspects. Conceptually, it is a case of 
multiple 2x2 tables, where the cell containing population members missed by both 
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ascertainment methods are being estimated. These estimates can be solved using Bayesian 
or non-Bayesian models.218  
Funnel plot methods (described below) are another approach to estimating missing 
studies. It is assumed that the non-identification results from some bias. These biases, 
such as those described by Song220 and Tricco,7 influence identification and selection and 
so violate the assumption of equal ascertainability.215 Bennett et al. used the Capture-
Recapture method to estimate publication bias, or the number of studies missing 
altogether from the literature.215 Ascertainment methods were electronic database 
searching, contacting experts, and hand searching of journals. Bennett et al. compared 
estimates from capture-recapture methods to funnel plots in a case study involving 
resistance training for older adults. The objective of the exercise was to estimate the 
robustness of the conclusions of the review in the face of a potentially incomplete 
evidence base. Eight databases were searched, reference lists of identified trials and 
relevant reviews were examined, conference proceedings were searched by hand and the 
first author of each relevant study was contacted in an effort to identify additional studies.  
The funnel plot indicated that studies were missing, and using the most plausible 
model of dependencies between sources, Capture-Recapture resulted in an estimate that 
that two studies were missed overall (95% CI 0, 8).215 The capture-recapture model that 
seemed most plausible showed a positive dependency (interaction) between databases and 
experts as well as experts and hand searching.215  
Spoor et al. applied the capture-recapture technique to evaluate the completeness 
of a systematic review search in randomized controlled trials published in the journal 
Diabetic Medicine. They compared a MEDLINE search using the original Highly 
Sensitive Search Strategy (HSSS) for detecting randomized clinical trials64 to the results 
of hand searching, and estimated that the population of trials was 160 (95% confidence 
interval 158-164) and the number of studies still unidentified after the two searches at 2 
(0-6).3 They obtained identical results with maximum likelihood estimator and with 











Capture-Recapture will be used here to compare the estimates of various 
combinations of searches against the number found through all test searches. 
Dependencies between methods, which should be positive in the case of searches of the 
same type (i.e., between similarity methods) while less dependency is expected between 
different type of searches (i.e., dependency between similarity searches will be more that 
between a similarity search and a Boolean search). The expectation is that using two 
methods of ascertainment that are relatively independent will provide more complete 
retrieval than using two methods of ascertainment that have greater dependency. 
5.1.5.1 Data analysis for Capture-Recapture 
Spoor et al. estimated the total number of randomized controlled trials using the 
maximum likelihood estimator N=M(n/m) where:  
M = number of publications identified in MEDLINE 
n = number identified by hand searching 
m = number identified by both 
The estimate of the total population size is: 
N=(M+1) (n+1)/(m+1) -1, rounded to the nearest whole number.213 
Their results were easily reproduced using this equation, however Spoor et al. provide no 
information on the calculation of the confidence interval around this estimate, so other 
measures were sought. 
Jensen reviewed unbiased estimators and presented a method for calculated 
confidence intervals for Bailey's nearly unbiased estimator for sampling with 
replacement.221  
Under Bailey’s method, the derivation of the point estimate for the total 














Using these methods on Spoor’s data, the resulting estimate of the total number of 
RCTs and the 95% confidence interval are 160 (157, 164), very similar to Spoor’s result 
of 160 (158-164). 
This method was extended to the current data. Since the best estimate should be 
obtained by the two methods with highest recall and most likely to be independent, 
Related Article RCT and Clinical Query were used. Targets retrieved by either Related 
Article RCT or Clinical Query were selected from all sets and a cross tabulation of 
Related Article RCT and Clinical Query was performed to determine 
M = number of publications identified in Related Article RCT  
n = number identified by Clinical Query 
m = number identified by both. 
 
While this approach, of selecting the two methods that appear independent and 
have the highest recall, may be reasonable, no precedents were identified in the literature. 
Another approach is to collapse methods. Bennett et al. used this approach in comparing 
sources searched for evidence that Progressive Resistance Training reduces disability in 
the elderly. In this analysis all ascertainment methods were collapsed into three 
approaches; 1) databases, 2) hand searching of conference abstracts or reference lists and 
3) nomination by experts. Bennett does not fully explain the rationale for collapsing 
methods, but presumably, this was done to reduce the complexity of the model and deals 
with positive dependencies between sources within an approach. 
In our sample, the true number of relevant articles is most closely approximated in 
the AHRQ Evidence Report set. In that set, all records retrieved by the searches were 
assessed directly. In the updated Cochrane cohort, new material was identified by the 
author searches for the updated systematic reviews. In the main cohort, newer systematic 
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reviews on the same or similar topics were first examined, and in many cases is was not 
necessary to examine all candidates to determine that the review was out of date. 
Therefore, in the Cochrane and Main cohorts, it is possible or even likely that there were 
additional records in the retrievals that were relevant. 
In this experiment, the test searches can be grouped into subject searches 
(represented by Clinical Queries and Abridged Index Medicus RCTs although Abridged 
Index Medicus RCTs is redundant) and similarity searches (represented by Related 
Article RCT and SVM200point5). Citing References was a third method, but it is not 
included as its yield was poor and computing a maximum likelihood estimator based on 
three samples exceeds my computational abilities.  
In order to determine the yield by approach, a variable named RI 
RCTorSVM200point5 was computed as the maximum of Related Article RCT and 
SVM200point5, and so equals 1 if a target had been retrieved by either of these search 
methods. Then all targets that were detected by either Clinical Query or Related Article 
RCT or SVM200point5 were retrieved, and a cross tabulation of Clinical Query and 
RI_RCTorSVM200point5 was performed. The total number of targets identified by each 
approach and their intersection was derived from the tables. This was entered into the 
equation for a two-source capture-recapture analysis, again using Bailey’s estimate and 
Jensen’s method for confidence intervals. 
The above analysis provides an estimate of the total number of studies that might 
exist, some of which might not have been found. However, this and other analyses also 
provide an opportunity to explore the behaviour of the Capture-Recapture method when 
searches with demonstrated poorer recall are used to estimate the population size. The 
tendency to over- and under-estimate can be exploited to explore the dependencies 
between searches by comparing estimated with actual number, where underestimates 
indicate dependence between searches. In particular, the estimate obtained by using the 
Authors’ MEDLINE search (Actual) and the Update search in CENTRAL, and Clinical 
Queries and the subject search in CENTRAL, and Clinical Queries and the subject search 
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in CENTRAL, will be tested to see if these can be considered as independent approaches 
to trial identification.  
5.1.6 Multidimensional Scaling 
Multidimensional scaling (MDS) is an exploratory technique used to visualize 
proximities. As few assumptions need to be made about data distributions, it is less 
restrictive than Factor Analysis. Factor analysis works from correlations and requires that 
the underlying data are distributed as multivariate normal, and that the relationships are 
linear, therefore it is easily distorted with small samples.[222 p. 603] MDS works from 
similarity measures.223  Thus, multidimensional scaling can situate the searches in two or 
more dimensions. Examining where different search methods lie on the dimensions may 
be useful for interpreting factors that influence the overlapping and unique components of 
the various searches. That understanding may inform optimum combinations of searches. 
The Jaccard coefficient is a similarity measure that has been used in information 
science for co-citation analysis224 and to examine the overlap between databases,225 
between retrieval methods, and between library collections,226,227 so will be used as an 
example of the computational method used. The Jaccard coefficient (Sj) measures 
similarity of sets by dividing the size of the intersection by the size of the union of the 
sets. What is being measured is the similarity of the retrieved sets. In this case, the sets 
are the retrieved records of the searches under study.  
Sj = a/(a+b+c), where 
a = number of retrievals common to both searches 
b=number of retrievals unique to first search method 
c=number of retrievals unique to second search method. (Adapted from 225) 
The Jaccard coefficient varies between 0 and 1 with larger values indicating 
greater similarity. The Jaccard coefficient has two features appropriate for describing 
overlap: it is self-normalizing and as it considers only records retrieved by one or the 




ownership or joint absences is not a basis for similarity227) bias is avoided in small sample 
sizes.224,228 Equal weight is given to matches and nonmatches.197 
The proximity matrix is a similarity matrix created in SPSS using the variables 
(called stimuli) and then analyzed using the SPSS procedure ALSCAL (for alternating 
least squares scaling). The proximity matrix used as input for the MDS procedure was 
required to have at least five variables or stimuli, which were the searches. As the main 
cohort had only four searches for primary studies (Related Article RCT, Clinical Query, 
Abridged Index Medicus RCT, and Citing RCT), the two searches used to identify newer 
meta-analyses were added to the modelling. The first search used the subject search 
developed for Clinical Query but had the MEDLINE Meta-analysis publication type 
added as a limit. The second search to find newer meta-analyses was the Related Articles 
search result, limited to publication type meta-analysis. In both meta-analyses searches, 
the earliest date for the search was one year after the search data for the systematic review 
being updated. A separate multidimensional scaling analysis was run combining the two 
cohorts in which SVM was tested (the AHRQ Evidence Reports and the six updated 
Cochrane reviews), adding the SVM200point5 search. The searches for newer meta-
analyses were not run for these cohorts, so were not included in the modelling. 
The default two-dimensional Euclidean distance model was used for the 
analysis.197 Euclidean distance is the ‘ordinary’ distance between two points.229 In this 
model, input is assumed to be square symmetric matrices with data elements that are at 
the ordinal level of measurement (which is suitable for binary outcome data). The default 
output includes the improvement in Young’s S-stress for successive iterations, two 
measures of fit for each input matrix (Kruskal’s stress and the squared correlation, RSQ), 
and the derived configurations for each of the dimensions.197  
Goodness of fit was assessed by examining the stress values. High stress values 
reflect that the input proximities cannot be well represented with a small number of 
dimensions. While MDS, as its name implies, can scale on multiple dimension, with so 
few input variables two or, at most, three meaningful dimensions would be expected. 
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Resulting dimensions of the derived stimulus configuration plots were visually inspected 
for interpretability and clustering.230 If necessary, correlations between the scores of the 
searches on the resulting dimensions and aspects such as retrieval size or recall will be 
examined post hoc.231  
5.1.7 Correlations 
In work by Cohen et al. studying the potential for reducing workload in systematic 
review preparation using automated citation classification,15 there was a very high 
correlation (0.91) between precision of the original query developed by the librarian for 
use in performing the systematic review, and the precision of the classifier tested. This 
result is not reported directly, but can be derived from Table 7 of the paper. This raises 
the concern that some topics are simply easier to search than others – when the librarian 
who constructed the search used in the review was able to achieve good precision, the 
classifier was also able to achieve good precision. The utility of a similarity search or 
ranking scheme is limited if it works well only in those cases where human searchers can 
achieve relatively high precision. Therefore, the correlation between precision of the 
Actual search and the precision of SVM and Related Article RCT will be examined in the 
updated Cochrane reviews  
5.2 PRECISION OF SEARCHES IN A CROSS-SECTIONAL SAMPLE  
There are no published norms for recall and precision of systematic review 
searches against which the performance of the test search can be compared (although 
most sources state that searches should be of high recall and so will usually sacrifice 
precision.79,232 In 1999, the QUORUM standard for reporting systematic reviews was 
published, mandating an accounting of the flow of bibliographic references through the 
screening process.42 Precision can be calculated from these data.  
A cross sectional sample of systematic reviews first indexed in MEDLINE in 
December of 2004 provides a recent cohort for such an examination.3 Three hundred 
systematic reviews were included, of which 125 (41.7%) were Cochrane reviews. 
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Investigators recorded whether the published review had a description of review flow in 
text, tables or in a QUOROM flow diagram. Of 300 included studies, 109 reported on this 
aspect, and 20 of these provided a flow diagram.  
In new work, I examined the full text of these 109 systematic reviews to 
determine, where possible, the total retrieval of all searches, the number of unique 
references retrieved from all searches (whether electronic or manual), the number of 
records screened after duplicates were removed, the number of passing initial screening 
on the basis of the bibliographic record and obtained in full-text version for more detailed 
evaluation by reviewers and finally, the number of studies included in the systematic 
review. Data were taken from the QUOROM flow diagram, where available, or were 
extracted from the text of the review or determined by counting references to included 
studies.  
There were many ambiguities in the authors’ descriptions. Where it was unclear 
whether the number being reported reflected that total number of unique records retrieved 
or the number examined in full text, efforts were made to roughly replicate the 
MEDLINE search to determine which was more probable. Wherever possible, the N 
eligible was taken as the number of papers found eligible, but sometimes only the number 
of eligible studies were reported, and this number was used. Often it was not clear if 
papers or studies were reported (the revised PRISMA encourages more precise reporting 
in this regard44). The descriptions of article flow and the way these were coded for the 
final four systematic reviews examined is shown in Table 6.  
 
Table 6. Examples of Authors’ Descriptions of Study Flow 
Text 
"The search of the Cochrane Library … failed to yield any studies related to the subject of 
the review. The final search in MEDLINE produced 1889 papers. The abstracts were assessed and 
the relevant papers were narrowed down to 85. … Copies of the papers were obtained.… Before 
reading the papers, their references were screened for relevant non-retrieved papers. These search 
produced another 50 papers. Their abstracts were read and it was decided to retrieve only 31 of 
them.… The handsearch of … did not produce any studies that were not already identified as 
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relevant or not relevant by the electronic search. Out of total of 116 papers, 23…”233  
N retrieved before 
duplicate removal 
N of records screened N articles retrieved 
and screened 
N eligible 
n/a 1946 116 23 
"Results: The literature search revealed 1,984 abstracts. Included were 244, 42, and 12 
articles in the first, second and third selections steps, respectively.”234  Steps 1, 2 and 4 
corresponded to the abstract, full text and final inclusion. 
N retrieved before 
duplicate removal 




1984 244 12 
"Thirty-six relevant randomized controlled trials have been presently identified, from an 
original pool of 1365 studies generated by the search (which identified 27 trials) and from updates 
to the search conducted over 2000 to August 2002 for the CCDAN Controlled Trials Register.”235 
The exact total screened is not known but 1365 would be the minimum, and this figure is used. 
Trials, not eligible publications are reported but the number of eligible articles was determined by 
counting references in the Included Study list. 
N retrieved before 
duplicate removal 
N of records screened N articles retrieved 
and screened 
N eligible 
n/a 1365 n/a 54 
"We screened 645 abstracts and articles from which…. The results of this literature 
review are summarized in tables 1-5.”236 The number of references in those tables was counted to 
determine the number of included studies. 
N retrieved before 
duplicate removal 
N of records screened N articles retrieved 
and screened 
N eligible 
n/a 645 n/a 14 
"We identified over 3900 papers using the keyword and reference list search. From 
perusal of the abstracts, over 70 papers were retrieved and of these 19 papers met the study 
inclusion criteria."237  
 
Precision was calculated when the number of included studies and the number of 
unique retrievals could both be determined, and was simply the ratio of these two 
numbers. Overall and median precision were calculated and data are presented 
graphically. 
N retrieved before 
duplicate removal 
N of records 
screened 
N articles retrieved 
and screened 
N eligible 
n/a 3900 70 19 
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Each systematic review in the epidemiology study was classified as to primary 
focus; treatment or prevention, diagnosis, epidemiology or other. Other included 
systematic reviews focusing on harms, education, associational studies, instrumentation 
and research methods. Median precision was calculated for the reviews of each type. 
5.3 RECALL OF THE SEARCHES IN THE ORIGINAL REVIEWS 
Relative recall is the recall of one component of a multifaceted search compared 
to the recall of all methods.192,238 Relative recall of the MEDLINE search can be 
calculated for the two cohorts were the searches used by the authors of the original 
reviews were replicated, the updated Cochrane reviews and the AHRQ cohort. For these 
two cohorts, the MEDLINE indexing status of all included studies was determined as part 
of the identification of the SVM true positive training set (Figure 6, Chapter 3). As has 
been previously described, the MEDLINE search result of the authors’ search, less the 
records for the included studies, formed the true negative training set. Those included 
studies indexed in MEDLINE but not retrieved by the authors’ search were identified by 
taking the true positives set NOT the true negative set.  
The recall of the authors’ searches was calculated as follows: 
 







5.4 RELATED ARTICLE SEARCHING AS AN ADJUNCT SEARCH IN THE ORIGINAL 
REVIEW 
 The utility of Related Article searching as an adjunct to the Boolean search in 
original systematic review was explored. Once an original review is at the stage where 
screening has been complete, the searcher is in a position to identify the three largest and 
three newest eligible trials. It would be possible to run the Related Article search at that 
stage, and identify material not already captured by the other searches. Kastner et al. 
provide an example of such as search for missed material, although studies found through 
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the database searches that has passed initial screening and were retrieved in full text were 
used as seeds, and the procedure was run before the non-database searches (cited 
references, grey literature sources, trial registries and contacting experts) were 
undertaken. They note that all of the relevant new studies found were published after the 
date of the database searches, i.e., no trials missed by the Boolean database searches were 
found by the related article searches.216 
In the updated Cochrane reviews, the Related Article RCT procedure was run and 
date limited to the period covered by the searches of the original review. Retrieval size, 
recall of included studies, recall of MEDLINE misses from the original and position of 
MEDLINE misses within the retrieved set was calculated to determine if the technique 
could identify MEDLINE-indexed material not found by the authors’ MEDLINE search. 
5.5 PERFORMANCE OF THE HSSS REVISED 
The 2006 revision of Cochrane Collaboration’s revised Highly Sensitive Search 
Strategy (HSSS2006) was used as a pre-filter for the SVM tests, however, at the time there 
had been no independent validation of that revised filter. In addition, although analyzing 
the reason for retrieval failure in all MEDLINE misses is beyond the scope of this thesis, 
these data do provide an opportunity to see how often the methodological filter would 
have been a cause of retrieval failure. It is possible that the subject search would also 
have failed to identify the record; however, that would not be possible to test without 
replicating all of the searches. 
The filter tested was derived from the paper and erratum21 that presented the 
various strategies for identifying randomized controlled trials from MEDLINE. The 
strategy with the highest recall was assessed as the HSSS2006. In Glanville et al.’s sample, 
the highest recall was achieved with Strategy A (recall of 0.993 and precision of 0.213) 
and this strategy was tested. 
Glanville et al. presented the strategy in PubMed format. For the purposes of this 
work, the search was translated into OVID MEDLINE syntax. This was done in as a four-
stage process. First, the string, as presented in the erratum, was submitted to PubMed, and 
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the search was limited to retrieve MEDLINE records only. The number of retrieved 
records was noted. Second, the “Details” box of PubMed was examined. PubMed 
translates the users’ input, and the actual search run is presented in the Details box. That 
search string was submitted to PubMed as a series of single search commands (Table 7), 
which were then re-combined using Boolean expressions to verify that the single 
statements produced the same number of records as the original submission. The number 
of record retrieved by each search command was noted, so that they could be compared 
with the OVID counts. Third, these single term queries were combined, and the total was 
verified as being the same as the original PubMed search. Finally, each single term was 
submitted to OVID MEDLINE and counts were verified against the PubMed counts to 
confirm that the translation was accurate. 
 
Table 7. HSSS2006 Counts for Each Element in PubMed and Ovid 
Query* PubMed PubMed limited 
to MEDLINE 
Query Ovid 
 N N  N 
 #21 not #24 1941487 1882219 9 not 12 1859937 
 #22 not #23 3142301 3129042 10 not 11 3077794 
 humans [mh] 9624337 9624336 humans.sh. 9694282 
 animals [mh] 12766638 12753378 animals.sh.† 4055990 
 #14 or #15 or #16 or 
#17 or #18 or #19 or 
#20 
2268708 2209409 or/1-8 2188346  
 Groups [tiab] 834178 790190 groups.ti,ab. 789810 
 trial [tiab] 199739 190416 Trial.ti,ab. 190850 
 Randomly [tiab] 116285 108677 randomly.ti,ab. 109125 
 dt [sh] 1155260 1155260 dt.fs.‡ 1163190 
 placebo [tiab] 103776 100300 placebo.ti,ab.  100919 
 randomized [tiab] 164877 157307 Randomized.ti,ab.  158443  
 clinical trial [pt] 494988 494359 clinical trial.pt. 434900 
*Search strings are presented in the reverse order of entry. 
†exp Animals/ yields 12865972 hits and the final number when exp animals/ is used is 
1859169. 
‡dt.sh. results in zero hits in Ovid, so dt.fs. was used. 
Two anomalies were noted in the translation. First, PubMed explodes all subject 
headings unless a no-explode command is specified. In Ovid, exploding the animal term 
results in a very large retrieval. It was determined that searching Animal.sh. yielded the 
same final numbers, once all search terms were combined, as were obtained by searching 
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animal[mh] in PubMed, although the counts for the single query statement are quite 
different in the two interfaces. The second adjustment needed was the subheading DT (for 
drug therapy) is searched as a subject heading in PubMed (dt[sh]). A literal translation of 
this to dt.sh. yielded no hits in Ovid, but searching DT as a floating subheading (dt.fs.) 
yielded a comparable result to the PubMed search string.  
Searches were conducted April 30, 2007. At that time, the Ovid database coverage 
dates were 1950 to April Week 3 2007. The retrieval size of the PubMed version of the 
HSSS was 1882219 when limited to MEDLINE, and the OVID translation yielded 
1859937 (a ratio of 1.012).  
The final OVID version of the filter was: 
(clinical trial.pt. or randomized.ti,ab. or placebo.ti,ab. or dt.fs. or randomly.ti,ab. 
or trial.ti,ab. or groups.ti,ab.) not (animals/ not humans/) 
The translated search was tested against relevant evidence from three sources; the 
MEDLINE-indexed signalling evidence (n=58), targets from Cochrane SVM collection 
(originally n=27, before “old” studies added to the review were excluded), and all 
Eligible records from the screened material (n=687). After overlap was removed, 695 
pieces of MEDLINE-indexed relevant evidence remained. 
PubMed IDs for these 695 records were submitted as a query, the HSSS2006 was 
run, and the PubMed IDs missed by the HSSS2006 were determined through a NOT 





call 20006Re =  
A similar procedure was used to test the original version of the highly sensitive 
search strategy. Retrieval size of the two versions of the HSSS was compared, without 
duplicate removal as set size exceeded the limit for duplicate removal in OVID 





5.6 CHARACTERISTICS OF THE EVIDENCE IN UPDATED SYSTEMATIC REVIEWS 
5.6.1 Where Does the New Evidence Come From? 
The PubMed IDs for all Eligible new evidence were extracted from the big dataset 
and were submitted to PubMed. Records were downloaded and imported into Reference 
Manager where duplicates between cohorts were removed. After duplicate removal, the 
Reference Manager indexes were purged, and frequencies of authors and journals were 
prepared using the Reference Manager feature of “print to file, include reference count”. 
Numbers of authors and journals were determined by examining the database properties.  
The distribution of journals was examined according to Bradford’s law which 
states that journals in a single field can be divided into three parts, each containing the 
same number of articles: 1) a core of journals on the subject, relatively few in number, 
that produces approximately one-third of all the articles, 2) a second zone, containing the 
same number of articles as the first, but a greater number of journals, and 3) a third zone, 
where the ratios of journals in the three zones are 1:n:n!, where n is some constant.239 In 
Bradford’s study of physics journals, 9 journals contributed one-third of the articles, 5 
times 9 (45), produced the next third, and 5 times 5 times 9 journals (225), produced the 
final third.240  
Journal impact factor of the journals contributing new evidence were examined, 
based on the 2007 Journal Citation Report.241 The proportion of evidence from Abridged 
Index Medicus journals was calculated. The Abridged Index Medicus title list of February 
2008 was used.13  
5.6.2 Does Old Evidence Persist? 
The phenomenon of trials included in the original review but excluded from 
updates was noticed. These are the trials coded as Original Only. Two possible 
explanations for such exclusions from subsequent updates are, first, that the inclusion 
criteria of the systematic reviews changed in subsequent versions. For instance, in the 
update, only placebo controlled trials are eligible, whereas trials using placebo or active 
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controls were included in the original. A second reason for subsequent exclusion would 
be that an error had been made and a trial considered eligible in the original could be 
found to be ineligible later on.  
Frequency and characteristics of Original Only evidence, including publication 
date relative to other studies included in the review, indexing status (indexed in 
MEDLINE or not), and sample size are examined. Cochrane reviews list study exclusion 
reasons, and these were recorded for each of the Original Only studies. Finally, the 
distribution of signals for updating was compared for those updated Cochrane reviews 
with and without Original Only studies, through cross tabulation and 2. 
5.7 IS MATURITY OF THE LITERATURE A PREDICTOR OF SURVIVAL? 
The need for update is a function of the stability of the evidence. If little or no new 
evidence is emerging, or the evidence is largely confirmatory, representing more of the 
same, than updating a review is unlikely to result in treatment implications. For the main 
survival analysis,17 all aspects of survival were studied relative to either the date of the 
search or the date of publication of the systematic reviews in the cohort. The maturity of 
the evidence base in the original review may also warrant consideration as a factor in the 
survival of the findings of the review. Reviews done very close to the first evidence may 
be less stable (likely to go out of date more quickly or more easily) than those done long 
after the first evidence emerged. 
Expecting that factors may not change in linear fashion as the time since the first 
studies increases, age of the oldest evidence was examined categorically, with the 
observed range divided into quintiles. Those reviews used in the survival analysis were 
studied (n=100). A variable representing the span between the year of publication of the 
earliest evidence included in the review and the year of the search used in the review was 
computed in two steps. First, in the study-level dataset, all included studies that were 
either Original or Original Only were selected and cases summaries were created that 
reported the minimum publication year for these studies for each CohortID. This output 
was transcribed to the database containing the review-level data and age of the oldest trial 
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was computed as the year of the oldest trial minus the year of the search done for the 
systematic review, in whole years. These were sorted from shortest to longest time span 
and the rank of each observation was calculated. The array was divided into fifths, as 
close to the 20th, 40th, 60th, 80th and 100th percentiles of this distribution as possible. As 
whole years were used there were many tied values, consequently the number of 
systematic reviews in each quintile varies (Table 8). The first quintile includes the 
youngest evidence – those reviews where all included studies were published within the 
six years prior to the search. The fifth quintile contains the oldest evidence – the oldest 
trials included in these reviews were published at least 23 years prior to the search. For 
the review with the longest evidence base, the oldest trial preceded the search by 47 
years.  
 
Table 8. Distribution of Systematic Reviews by Age of First Evidence 
  Maximum Age of First Evidence at Search 
 Quintile  Years N of Systematic Reviews 
 in the Quintile 
Youngest 1 6 25 
  2 10 17 
  3 16.4 18 
  4 22 23 
 Oldest 5 47 17 
 
Characteristics of these quintiles in terms of the mean and standard deviation of 
the number of studies included in the review and of the number of patients in the reviews 
were calculated. Survival analysis was conducted using years from the final search date to 
primary survival by quintile of oldest evidence. If there is a major or potentially 
invalidating signal, primary survival is calculated as the publication date of the original 
systematic review to the earliest of the date of new evidence resulting in final 
classification, the date of the qualitative signal, or the date of the quantitative signal 
involving the primary outcome. Otherwise, survival is the time from the final search date 
of the original systematic review to September 1, 2006  
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Distribution of signals (reviews with potentially invalidating or major new 
evidence (n=59)) across the cohorts was examined and tested using 2. The nature of new 
evidence emerging in the different quintiles was examined. The three qualitative signals 
that could occur in reviews with potentially invalidating new evidence were; opposing 
findings; substantial harm; or a superior new treatment. The four qualitative signals for 
major changes in evidence were; important changes in effectiveness short of ‘opposing 
findings’; clinically important expansion of treatment; clinically important caveat and 
finally; opposing findings from discordant meta-analysis or non-pivotal trial. This is 
presented graphically. 
Heterogeneity and publication bias are two issues that could be present in the 
evidence in the original review. Both introduce challenges in the interpretation of 
evidence. Heterogeneity is simply variation seen among the results of different trials in 
the meta-analysis. Some variation is expected due to chance, but additional variation may 
be introduced through differences in patient selection, aspects of study design, or other 
factors that complicate interpretation of a pooled result.198 The Cochrane Handbook now 
distinguishes between clinical diversity, methodological diversity and statistical 
heterogeneity.242 Diversity can contribute to statistical heterogeneity, and the main 
question is whether that diversity provides meaningful clinical information, or whether it 
obscures the true result.242 For example, DerSimonian and Levine showed how 
differences in patient groups and in the way studies were conducted accounted for the 
strong positive effect of calcium supplementation for prevention of preeclampsia seen in a 
meta-analysis which was not substantiated in a subsequent large trial that controlled for 
clinical and methodological diversity.243 
Statistical heterogeneity is a question of whether the estimates of intervention 
effectiveness from different sources vary more than would be expected by chance.244 It 
can be tested multiple ways, but one method that is easily interpreted is a 2 value. If the 
2 value is equal to the number of studies less one (the degrees of freedom of the test) 
than there is no measurable heterogeneity present. Larger values of 2indicate that more 
 
145 
heterogeneity is present.244 Although some measures exist for managing heterogeneity 
statistically, namely, random-effects meta-analysis, it is also necessary to consider if 
studies should be combined.242,243 Moher et al. found that heterogeneity was investigated 
in 68% of the 2004 cohort of systematic reviews but this figure rose to 91% in those 
systematic reviews where a meta-analysis was performed.3 
 Heterogeneity was assessed in 93% of the systematic reviews in the sample used 
here for the survival analysis. Presence or suspicion of heterogeneity was a factor in 61% 
of the reviews, and was a significant predictor of survival in the multivariate analysis.17  
Publication bias is the greater likelihood that trials with certain characteristics 
(usually positive findings) will be published than trials without those 
characteristics.7,220,245-247 Publication bias can also be seen in the delayed publication of 
trials with negative or ambiguous findings, relative to those with positive results.248 
Published trials are more easily located for inclusion in systematic reviews, so when signs 
of publication bias are observable, it may be that the results of meta-analysis do not 
represent the underlying truth, making these meta-analyses more susceptible to being 
overturned as subsequent results emerge.  
Publication bias is usually assessed graphically, through funnel plots in which 
sample size or standard error (or some other measure of study precision) is plotted against 
treatment effect size. More scatter is expected by chance in smaller studies than in larger 
studies however, chance would scatter the estimates symmetrically.75 Lack of symmetry 
in the lower part of the plot can indicate publication bias, or overestimation of effect in 
small studies due to methodological weakness (Figure 16).249 Copas and Shi characterize 
this lack of symmetry as non-ignorable non-random missing data.250 [Kjaerdard explains 
the statistical analysis of funnel plot asymmetry nicely251] Moher et al. found that 31% of 





Publication bias was assessed as an explanatory variable in the survival analysis. 
The text of the systematic reviews in the main cohort was examined for any mention that 
the authors’ assessed publication bias, and whether publication bias was described as 
present or suspected. Some assert that publication bias is present in almost all research, 
and can be suspected even if the funnel plot is symmetrical.252 Sixty percent of the main 
cohort used in the survival analysis reported on publication bias, and it was present or 
suspected in 18% of the sample. Publication bias was not found to be associated with 
survival,17 however as it is likely to be indicative of missing studies, it is relevant as an 
information retrieval issue.  
Finally, the nature of systematic reviews surviving and those with signals for 
updating was examined. Conclusions from the abstract of the original reviews were 
presented alongside the qualitative signal for those systematic reviews with major or 
potentially invalidating new evidence. The nature of that evidence was taken from 
summaries prepared for each systematic review in the course of the updating process. The 
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summaries were written by a member of our project team, Jun Ji or Mohammed Ansari, 
and were scrutinized and finalized in case conference.  
5.8 TECHNICAL NOTE - OPERATIONALIZATION OF DATES 
Two aspects of dates are important for this thesis, as updating involves moving 
forward from a particular point of time. Calculating survival and quantifying the amount 
of new information both depend on a starting date and it is important that the starting 
dates be calculated consistently across reviews in the cohort. Secondly, this research took 
place over a span of time, and is retrospective. Therefore, it is necessary to determine 
what material would have been present in a database and would have been retrievable 
contemporaneously with the reviewers’ search. 
Date variables extracted from the systematic reviews include most recent search 
date, date of submission for publication, date of acceptance for publication, date of 
publication and date of indexing, date of first new evidence and final survival date. Some 
of these variables were used only for a study of time lags in the preparation and 
publication of systematic reviews.19 Priority for date sources was the MEDLINE record, 
the publication itself, or an estimate. If partial dates were reported, the missing 
components were imputed as follows: if month is missing, the 6th month was assumed, if 
day of month was missing, the 15th was assumed. Dates were extracted and then verified 
by a second person. Data cleaning runs were undertaken in SPSS to test for improbable 
values such as an acceptance date earlier than the submission date. All such cases were 
due to date imputation and the imputed value was changed to the earliest logical value.  
Search date was taken as the date reported in the methods section of the 
systematic review - the most recent date was used if more than one was given. Cochrane 
reviews have a number of date fields as part of the review template and the most recent 
among these three dates was recorded; the date reported in search strategy section in the 
body of the report or the “Date new studies sought but none found”, or the “Date new 
studies found and included/excluded”. The field “Date new studies found but not yet 
included/excluded” was ignored. For database dates, the end date reported for MEDLINE 
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searching was used (i.e., 1966-June Week 4, 2003) if available. If the MEDLINE date 
was not reported, any other database end date was used. If no end date was reported, the 
variable was treated as missing.  
Submission date was the submission date or the date the manuscript was received 
as stated in the article. These data were available only for journal published reviews - 
AHRQ and Cochrane reviews had no equivalent. Acceptance date was the date stated in 
the article. 
For all types of reviews, the publication date was taken from the Ovid MEDLINE 
records, for indexing date, the MHDA from the Ovid MEDLINE record was used. The 
publication date for original Cochrane reviews that no longer appeared in MEDLINE was 
taken as the date of most recent amendment. When no "most recent search date" could be 
determined, we used publication date minus one year. In the survival analysis, survival 
was calculated with publication date as the start date.17 
For dating records of new material, it was necessary to determine not when the 
material was published, but rather when it was in the database, and when it was fully 
indexed. Several of the searches rely on the publication type Randomized Controlled 
Trial, which is assigned during indexing, and is not available for PubMed in process 
records. Related Article nearest neighbour scores are pre-computed for fast processing167 
however, even records as supplied by the publisher have related articles, and are retrieved 
as related articles. Still, we were interested in Related Articles that were also randomized 
controlled trials, so relevant related articles not yet fully indexed might be missed. Thus, 
for MEDLINE retrievals, MHDA was used instead of publication date or database entry 
date to establish the sequence and age of records.
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Chapter 6: Results 
6.1 THE COHORTS 
6.1.1 Main Cohort 
The search of ACP Journal Club yielded 651 records for potentially eligible 
systematic reviews. Records were downloaded sorted by author surname, to provide a 
quasi-random screening order. Three hundred and twenty five reviews were screened to 
achieving the target sample size of 100 reviews. 165 records were excluded on the basis 
of the ACP Journal Club record, and 160 articles were excluded after assessment of the 
full-text article. Exclusion reasons are shown in (Figure 17).  
Seventy-two of the systematic reviews were journal-published reviews. Twenty-
seven were Cochrane Collaboration Reviews, one was a health technology assessment 
published by the Canadian Agency for Drugs and Technologies in Health.  
Survival data for this cohort have been published.17 Fifty-seven (57%, 95% 
confidence interval, 47% to 67%) of the reviews had a signal for updating during the 
observation period, and median survival of these was 5.5 years (CI, 4.6 to 7.6 years) from 
publication. For the 57 reviews with signals for updating, median time to event was 3.0 
years (inter-quartile range, 0.9 to 5.1 years) from publication. 
Seventy-four of the systematic reviews were assessed entirely against new 
evidence found through four test searches; Clinical Query, Abridged Index Medicus 
RCTs, Citing RCTs, and Related Article RCTs. Three systematic reviews were first 
assessed through a known update, but then further update searching was done using the 
test searches to bridge from the end of the update to September 2006, the end of our 
search period.  
These 77 systematic reviews are the basis for the main evaluation of these four 
test searches. Each of the 77 systematic reviews included a median of 13 studies (inter-
quartile range, 8 to 21) and 2666 participants (inter-quartile range, 1284 to 8345) (Table 
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9). Most reviews evaluated drug therapies; the most common clinical content areas were 
cardiovascular medicine, gastroenterology and neurology. We were able to identify at 
least one new eligible trial for 70 systematic reviews, with a median of 5 new trials (inter-
quartile range, 1 to 6) and 1,185 patients (inter-quartile range, 173 to 5,054) per review. 
These findings are very similar to the findings for the cohort of 100. 
Table 9. Characteristics of the Cohort of 77 Systematic Reviews Updated by 
Searching 








Publication type   
Peer-reviewed journal article  64 72 
Cochrane review  12 27 
Health technology assessment*  1 1 
Therapy evaluated   
Medications  67 85 
Medical devices 3 8 
Procedures 7 7 
Clinical topic area   
Cardiovascular 19 20 
Gastroenterology 11 13 
Neurology 10 11 
Other 10 categories  <8 each <10 each 
Publication period   
January 1995–February 1997 13 16 
March 1997–April 1999 15 22 
May 1999–June 2001 18 25 












IQR is inter-quartile range 
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Twenty three systematic reviews were assessed exclusively against an updated 
systematic review, most of these were Cochrane reviews. All of these were included in 
the cohort survival study, but here only those meeting the additional selection criteria 























*This category includes reviews not focused on a specific class of drug, device or 
procedure, as well as ones focused on educational or behavioral interventions, or 
complementary therapies.  
†This category includes updates of systematic reviews already in cohort, topics similar 
to that of a systematic review already included, or the journal version of an included 
Cochrane review 
‡ This category includes meta-analysis using individual patient data without regular 















Cochrane reviews for which the most recent update had the same studies as the 
original review were updated through test searches and are included in the cohort of 
77. 
6.1.2 Updated Cochrane Cohort 
Twenty-six Cochrane reviews were assessed through an existing updated 
systematic review. These were screened against further eligibility criteria to assemble a 
cohort in which to study SVM. Six met all eligibility criteria and SVM searching was 
done. Exclusions reasons are shown in Figure 18. 
 
Clinical areas of the individual reviews, year of publication of the original and 
updated reviews, number of newer studies included in the update, and final classification 
are shown in Table 10. These six systematic reviews included a median of 17 studies 
(inter-quartile range, 14 to 20) and 8679 participants (inter-quartile range, 4085 to 
50,109) making them much larger than was typical for the main cohort. Again, most 
reviews evaluated drug therapies; the most common clinical content areas differed from 
the main cohort, with a clustering in infectious diseases (Table 11). All had at least one 
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new eligible trial, indeed this was an inclusion criteria for this cohort. There was a median 
of five new trials (inter-quartile range, 2 to 6) and a median of 2469 participants (inter-
quartile range, 730 to 8731) per review. These are larger studies than were typical of the 
new studies in the main cohort. 
Table 10. Characteristics of the Cochrane Reviews Updated by the Authors 
Characteristic 
6 Updated By Authors 
 
N 
100 Studied For Main 
Survival Analysis 
N 
Publication type   
Peer-reviewed journal article  - 72 
Cochrane review  6 27 
Health technology assessment  - 1 
Therapy evaluated   
Medications  5 85 
Medical devices 1 8 
Procedures - 7 
Clinical topic area   
Cardiovascular - 20 
Gastroenterology - 13 
Neurology - 11 
Infectious Disease 3 9 
Critical Care 1 8 
Respiratory Systems 1 9 
Urology and Nephrology 1 5 
Other 6 categories  - <10 each 
Publication period   
January 1995–February 1997 - 16 
March 1997–April 1999 3 22 
May 1999–June 2001 1 25 
July 2001–August 2003 2 20 
September 2003–December 2005 - 16 












Table 11. Characteristics of the Cochrane Update Cohort Outcomes 















Critical care 2001 2005 2.75 2 Potentially 
invalidated 
A1 
Respiratory 1999 2005 7.73 1 Minor - 
Urology & 
Nephrology 
2001 2005 3.04 1 Major A4 
Infectious diseases 1997 2004 4.39 6 Minor - 
Infectious diseases 2001 2004 5.96 5 Minor - 
Infectious diseases 1999 2004 6.34 5 Minor - 
6.1.3 AHRQ Evidence Reviews Cohort 
One hundred and twenty four AHRQ Evidence Reports were identified from the 
AHRQ web site253 and screened against the inclusion criteria of the main cohort, except 
that they there was no requirement that they have been reviewed by ACP Journal Club.  
Fourteen were assessed for signals for updating and ten of these met the additional 
inclusion criteria for the SVM study cohort. Exclusion reasons are shown in Figure 19. 
Clinical area of the individual reviews, year of publication of the original and final 
classification are shown in Table 12. 
These ten Evidence Reports included a median of 96 studies (inter-quartile range, 
31.75 to 121.5) and 22,830 participants (inter-quartile range, 14172 to 49687) making 
them much larger than was typical for the main cohort (Table 12) or the updated 
Cochrane reviews (Table 10). Again, most reviews evaluated drug therapies, however in 
this cohort there were reviews that examined multiple treatment modalities, such as 
medication or surgery. The most common clinical content areas differed from the main 
cohort, with the specialties of obstetrics/gynecology and psychiatry having greater 
representation. These Evidence Reports were somewhat newer than the range of ages 
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seen in the Cochrane and Main cohorts. The Evidence Practice Center program was 
established in 1997, and the first reports appeared in 1998 and 1999.253 At least one new 
eligible study was identified for each Evidence Report. There was a median of 20 new 
trials (inter-quartile range, 6 to 41) per evidence report, and these new trials involving a 
median of 18,471 participants each (inter-quartile range, 1283 to 26,853). These are the 





Table 12. Characteristics of the AHRQ Evidence Reports Updated by Searching 
Characteristic 10 Evidence Reports 100 Studied for 
Main Survival 
Analysis 
 N N 
Publication type   
Peer-reviewed journal article  - 72 
Cochrane review  - 27 
Health technology assessment  10 1 
Therapy evaluated   
Medications  9* 85 
Medical devices 1 8 
Procedures 3 7 
Clinical topic area   
Cardiovascular 2 20 
Gastroenterology - 13 
Neurology 1 11 
Obstetrics and Gynecology 3 5 
Psychiatry 2 5 
Other 8 categories  1 each <10 each 
Publication period   
January 1995–February 1997 - 16 
March 1997–April 1999 - 22 
May 1999–June 2001 3 25 
July 2001–August 2003 3 20 
September 2003–December 2005 4 16 








IQR is inter-quartile range 
*One Evidence Report included both drugs and devices, another Evidence Report 




Table 13. Characteristics of the AHRQ Cohort Outcomes 
Classification Year of 
Original 
Final Classification Specific 
Criteria Met 
Neurology 2004 Major A4 
Cardiac & Cardiovascular Systems  2003 Major A4 And B2 
Obstetrics and Gynecology  2000 Potentially invalidating A2 
Psychiatry 2004 Minor - 
Psychiatry 2003 Major A6 
Obstetrics and Gynecology  2003 Potentially invalidating A1 
Cardiac & Cardiovascular Systems  2000 Major A4 and A6 
Oncology 2003 Major A4 
Endocrinology 2004 Major A5 
Obstetrics and Gynecology  2000 Potentially invalidating A1       
6.2 NEW EVIDENCE 
Across the three cohorts (Main77, Cochane6, AHRQ10) and all methods of 
identification (searches, reviewer nomination and updates) 18,960 new records were 
identified. Of these, 11,586 new records were evaluated and 860 eligible new records, 
representing 601 different studies, were identified. Median publication date of new 
eligible studies was a decade newer than the median date of studies in the original 
reviews. Median sample size increased 78% from 100 participants in studies included in 
the original reviews to 178 participants in the newer studies identified in updating (Table 
14).  
Table 14. Quantity, Sample Size and Age of New Evidence 
 Original Evidence New Evidence 
 N or Median 1st and 3rd 
Quartiles 
N or Median 1st and 3rd 
Quartiles 
Eligible Records 3117  860  
Eligible Studies 2758  601  
Publication Date 1993 1988, 1998 2003 2000, 2004 
Sample size 100 40, 313 178 71.25, 538.25 
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Most eligible new evidence was identified through the test searches (Table 15), 
with important exceptions. In the main cohort, 8% of new studies were identified by 
reviewer nomination – these were mostly newer primary studies identified by examining 
the included studies of newer meta-analyses on a similar topic, but could also be studies 
known to our review team but not identified by the test searches. These reviewer 
nominated studies represented incomplete identification of new evidence by the test 
searches and were included in the demoninator for calculations of recall.  
In the main cohort, some new evidence was identified from updates. Nine 
systematic reviews were assessed exclusively on the basis of newer systematic reviews on 
the same topic. When two systematic reviews on the same topic passed screening and 
were eligible for inclusion, the older was kept in the cohort and the newer was excluded 
but retained as a source of new studies – three such journal-published reviews were 
updated exclusively on the basis of these newer reviews on the same topic, and six 
Cochrane reviews had updates sufficient to determine their survival, but were not eligible 
for the updating cohort. These updates identified 95 new studies across the nine 
systematic reviews. Three systematic reviews had updates, but required additional 
searching to extend the period of coverage, although the updates identified 13 new 
studies. Two of these were Cochrane reviews and one was a journal-published systematic 
review. 
The Cochrane Update cohort only included studies found in updates, by 
definition. For the AHRQ cohort, all candidate studies were screened, and new meta-
analyses were not provided as a short cut to identifying signals for update, and as a result, 


















Main Cohort 416 (90.6) 43 (9.4) 0 (0.0) 459 (100) 
Cochrane Updates 0 (0) 0 (0) 20 (100.0) 20 (100) 
AHRQ Evidence Reviews 270 (100.0) 0 (0) 0 (0)  270 (100) 
Total 686 (91.6) 43 (5.7) 20 (2.7)  
 
Distribution of the new evidence across the three cohorts is shown in Table 16. 
Although the Main Cohort includes 83% of the reviews, only 61% of the new eligible 
studies and 69% of new N are associated with that cohort. The Cochrane cohort of 
systematic reviews updated by the original review teams represents 7% of reviews 
examined, yielded only 3% of the eligible new studies (targets for retrieval), but 6% of 
new participants – suggesting fewer studies but with larger sample sizes were included. 
The AHRQ10 cohort, in which all new candidate studies were screened, made up 11% of 
the reviews, but 37% of the new evidence and 25% of the new participants. The 
disproportionate amount of new evidence in the AHRQ cohort relative to the main cohort 
likely reflect the complete screening of the candidate list in the AHRQ cohort – 
identification of new evidence for the main cohort is likely incomplete as it relied 
somewhat on rapid identification of newer evidence through newer systematic reviews 
(see Section 4.5.1).  
Table 16. Distribution of New Evidence Amongst the Cohorts Studied 
Cohort % of Cohort % of Targets % of New N 
Main Cohort (N=77) 82.8% 60.5% 68.7% 
Cochrane Updates (N=6) 6.5% 2.5% 6.3% 
AHRQ Evidence Reports (N=10) 10.8% 37.0% 25.0% 




6.3 SEARCH PERFORMANCE 
6.3.1 Characteristics of the Subject Searches 
 Characteristics of the 77 subject searches for main cohort have been previously 
reported.18 The mean number of terms used was 3.6 (standard deviation 1.59). Thirty-six 
of the 77 searches (46%) used free text terms, 58 (74%) used exploded MeSH terms, 21 
(27%) used starring, and 2 (3%) used subheadings. The mean (standard deviation) of 
features used was 1.51 (0.58). The specificity clinical query was used for 13 (17%) of the 
searches (Table 17). Examples of subject searches are available electronically as 
Appendix C of the technical report,16 
For the AHRQ cohort, the mean (standard deviation) number of terms used in the 
Boolean test searches was 12 (7.5). All of the searches (100%) used both free text terms 
and exploded MeSH terms, none (0%) used starring or subheadings. The mean (standard 
deviation) of features used was 2 (0.0). The specificity clinical query was used for 6 
(60%) of the searches. These searches were quite different from those used in the main 
cohort, relying on devices that increase recall (such as explosion and free text terms), and 
then using a hedge designed for higher precision. This may reflect the increased number 
of interventions examined in the AHRQ reports, or it could reflect a shift in style over the 
course of the project, as the searches were done over eight months and the AHRQ 
searches were done last. The correlation between number of terms and numeric sequence 
in the main cohort is -0.04, suggesting that complexity of the Evidence Reports is the 
more likely explanation.  
6.3.2 Characteristics of the Authors’ Original Boolean Searches 
Original searches were replicated for the Cochrane and AHRQ cohorts. More 
terms were used in the author searches than in our test searches – in the case of the 
AHRQ Evidence Reports, the only direct comparison possible, the authors of the original 
reviews used more than twice as many terms as were used in our searches. Similar 
numbers of search features were used in the author searches as in our test searches. Free 
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text search strings were used in all of the AHRQ and half of the Cochrane searches. 
Exploded MeSH terms were employed universally. Limiting to major MeSH terms was 
never used and subheadings were used sparingly – in one (10%) AHRQ search and two 
(33%) of the Cochrane updating searches prepared by the review authors.  
Table 17. Comparison of Boolean Search Features 
 Test Searches Author Searches 




Mean N of Terms (SD) 3.6 (1.59) 12 (7.5) 27.4 (15.7) 18.3 (22.1) 
Mean N of Features (SD) 1.51 (0.58) 2 (0.0) 2.1 (0.32) 1.7 (0.52) 
Methodological Filter Used 100% 100% 70% 100% 
Language Limit Applied 0% 0% 50% 0% 
Human Limit Applied 0% 0% 90% 66.6% 
 
6.4 PERFORMANCE OF THE TEST SEARCHES 
Several aspects of performance were considered. Recall of new On Topic and 
Eligible studies, recall of new participants, and overall retrieval size all inform slightly 
different aspect of search performance (see Section 4.4.1.1). Somewhat different 
information is available for the different cohorts, for example, the search strategies of the 
original reviews could not be replicated for many of the systematic reviews in the main 
cohort, so, while it gives us a good overall picture of the performance of the various 
strategies, the test strategies cannot be compared directly to the performance of the 
authors’ original search. Therefore, the performance of the various searches is first 
presented cohort by cohort, and finally, all are consolidated in large tables for the main 
outcome measures of recall of new studies (Table 31) and recall of new study participants 
(Table 32).  
Precision cannot be calculated for all cohorts, as not all records were assessed. 
Retrieval size will be examined for comparative purposes. As will be seen later, there is a 
positive association between retrieval size and recall, which is to be expected if precision 
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and recall are inversely related. Recall can be calculated for all cohorts and both recall of 
new studies and recall of new participants can be considered. Results of the main cohort 
will be shown first, followed by the two cohorts with included SVM tests. Finally, the 
results from the three cohorts will be presented together (Table 31). 
6.5 SEARCH PERFORMANCE IN THE MAIN COHORT 
The searches tested in the cohort of 77 systematic reviews updated by searching 
are Clinical Queries, AIM RCTs, Citing RCTs, and Related Articles RCTs. New studies 
were assessed until a stopping point was reached, but not all candidates up to the stopping 
point were assessed, as reviewers focused on newer meta-analyses to identify relevant 
studies. Indexing status of relevant articles was tested retroactively in CENTRAL only for 
those systematic reviews in the main cohort that had a potentially invalidating or major 
signal for updating.  
6.5.1 Retrieval Size in the Main Cohort 
Size of the retrievals for the test searches are shown in Table 18. There are great 
discrepancies between retrieval size across the search methods, for example, the 
maximum retrieval size for Clinical Queries is more than ten times that of the Citing RCT 
search. On the other hand, the number of null retrievals, systematic reviews in which the 
search method found no new articles at all, was ten-fold higher for Citing RCT searches 
than for Clinical Queries. Number of records retrieved is not reported for CENTRAL, as 
only relevant items were looked up, no subject searching was done. 
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Table 18. Number of Records Retrieved Per Systematic Review by Test Searches in 
the Main Cohort 
Retrieval Method Median 1st Quartile 3rd Quartile Maximum Null 
Retrievals       
N         (%) 
Clinical Queries 53 17 155 861 1 (1.3) 
AIM RCTs 11 2 40 250 10 (13.0) 
Citing RCTs 4 0 11 124 23 (29.9) 
Related Articles RCTs 100 62 142 376 1 (1.3) 
6.5.2 Recall in the Main Cohort 
Recall of the searches was taken as the proportion of all Eligible new evidence 
identified by each search. Recall of new N was taken as the proportion of new 
participants from the Eligible new studies that were identified by each search. For the 
main cohort of 77 systematic reviews, recall of On Topic studies, Eligible studies, and 
recall of new participants from eligible studies are shown in Table 19 through Table 21. 
 
Table 19. On Topic Recall in the Main Cohort  




Clinical Query 1133 .68 
Abridged Index Medicus RCT 288 .17 
Citing RCT 119 .07 
Related Article RCT 1075 .64 
Total N 1673   
Recall of On Topic records varied greatly between the searches. Only 7% of the 
On Topic records were randomized controlled trials that cited the original review – this 
was the lowest recall of any of the search approaches, while 68% of the On Topic 
material was identified by our standardized subject search limited by the Clinical Query. 
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Table 20. Recall of Eligible Studies in the Main Cohort 




Clinical Query 233 .51 
Abridged Index Medicus RCT 95 .21 
Citing RCT 61 .13 
Related Article RCT 354 .78 
Total N 456   
Search performance in recall of new Eligible studies followed a similar pattern as 
recall of On Topic evidence but two strategies, Abridged Index Medics RCTs and Citing 
RCT, made gains in recall while Clinical Queries dropped back both in level of recall and 
rank, falling to second place behind Related Article RCTs. 
Recall of new N is shown in Table 21. A total of 578,126 participants were 
enrolled in the eligible new studies identified for the systematic reviews in the main 
cohort. Eighty-three percent of this total was enrolled in the studies detected by the 
Related Article RCT search, for example.  
Table 21. Recall of Participants from Eligible Studies in the Main Cohort 
Retrieval method Retrieved N from 
Eligible Studies 
Recall 
Clinical Query 285,491 0.49 
Abridged Index Medicus RCT 249,627 0.43 
Citing RCT 159,525 0.28 
Related Article RCT 480,245 0.83 
Total 578,126  
 
Comparing across these three measures, we find that for three of the searches, recall 
improved as the criteria tightened. For example, the AIM RCT search identified only 288 
of the 1673 records judged to be On Topic (recall = 0.17). When only Eligible records 
were considered, the AIM RCT search showed slightly better performance, finding 95 of 
459 Eligible records (recall = 0.21), however, those 95 records represented studies that 
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contained 249,627 of the 578,126 new participants from these studies. Recall of new 
participants is thus 0.43, approaching the performance of the Clinical Queries that had 
identified four times as many On Topic records.  
6.6 SEARCH PERFORMANCE IN THE UPDATED COCHRANE COHORT 
The six reviews in this cohort were Cochrane reviews that were updated by the 
authors of the reviews. As we did not do any screening, there is no assessment of the 
search performances for On Topic studies. Eligible new studies were those included in the 
updated review and which were newer than the search date of the original review. All 
new included studies were tested to see if they were indexed in CENTRAL, and the 
performance of the author’s search was tested in CENTRAL, as was the performance of 
our subject search used in the Clinical Query and Abridged Index Medicus RCT test 
searches, with the modifications described in Section 4.2.4.2. 
Support Vector Machine was tested in the cohort using four different standards – 
one using all records with a relevance score of  0.5 or more, up to a maximum of 200 
retrievals (SVM200point5) and sets consisting of all records with relevance scores of 0.95 
or more (SVM95), 0.90 or more (SVM90) and 0.80 or more (SVM80).  
6.6.1 Retrieval Size in the Updated Cochrane Cohort 
As with the main cohort, not all candidates retrieved by the searches were 
assessed, and so precision cannot be established, but the retrieval sizes of the various 
searches can be compared (Table 22). 
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Table 22. Retrieval Size per Systematic Review for Search Methods in the Updated 
Cochrane Cohort 






 N     % 
Clinical Queries 70 24 96 145 0 0 
Abridged Index Medicus RCTs 17 6 20 22 1 16.7 
Citing RCTs 2 1 2 3 0 0 
Related Articles RCTs 67 56 88 174 0 0 
SVM* 32 27 32 39 0 0 
*Total number ranked by SVM 
6.6.2 Recall in the Updated Cochrane Cohort 
Recall of included new studies is shown in Table 22 and recall of new participants is 
shown in Table 24.  
Table 23. Recall of Eligible Studies in the Cochrane Updates  
Retrieval Method  N of Studies 
Identified 
Recall 
Clinical Query 16 .80 
Abridged Index Medicus RCT 9 .45 
Citing RCT 1 .05 
Related Article RCT 20 1.00 
SVM200point5 19 .95 
SVM80 20 1.00 
SVM90 20 1.00 
SVM95 18 .90 




Table 24. Recall of N from Eligible Studies in the Cochrane Updates 
Retrieval method Retrieved N from 
Eligible Studies 
Recall 
Clinical Query 33,638 0.95 
Abridged Index Medicus RCT 25,395 0.72 
Citing RCT 561 0.02 
Related Article RCT 35,504 1.00 
SVM200point5 34,287 0.97 
SVM95 35,504 1.00 
SVM90 35,504 1.00 
SVM95 34,167 0.96 
Total N 35,504  
 
This picture differs from the picture in the main cohort in that recall of studies and 
new participants is much higher, with the exception of Citing RCTs, where only one 
small study was identified. It should be noted that there is one very large trial of 17, 966 
which accounted for a third of the total N. All search methods but Citing RCTs identified 
this study, and this accounts for the extremely low recall of Citing RCTs relative to the 
other test searches. 
6.7 SEARCH PERFORMANCE IN THE AHRQ EVIDENCE REVIEWS 
Ten AHRQ Evidence Reports comprise the final cohort. What differs about this 
set is that all retrieved candidates were assessed, at least up to the stopping point, which 
was the point where major or potentially invalidating new evidence was detected. This 
complete screening enables calculation of precision for the various searches and provides 
a better assessment of the SVM, as all SVM retrievals were assessed. In comparison, in 
the Cochrane Cohort, SVM assessment was limited to determining which of the studies 
found by the authors through conventional search methods were also detected by SVM, 
there was not opportunity to assess the yield of material uniquely identified by SVM or 
by another the other test searches. As well, in this cohort, recall of both On Topic and 
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Eligible studies can be determined. The results for this cohort are therefore the most 
comprehensive of the three. 
6.7.1 Retrieval Size in the AHRQ Evidence Reviews 
Table 25. Retrieval Size Per Systematic Review for Search Methods in the AHRQ 
Evidence Reports 





Retrievals   
N    % 
Clinical Queries 147 78 212 418 0  0.0  
Abridged Index Medicus RCTs 31 23 44 128 0  0.0  
Citing RCTs 0 0 0 28 8  80.0  
Related Articles RCTs 79 45 106 172 0  0.0  
SVM200point5 60 37 85 104 0  0.0  
Comparing these results to the retrieval sizes in the main cohort, we see a reversal 
in position between Clinical Queries and Related Articles RCT – while Related Article 
RCTs were the largest result sets in the main cohort, Clinical Queries are the largest here. 
Support Vector Machine returned small retrievals than either clinical Queries or Related 
Article RCTs in both this cohort and in the Cochrane updates, and in both cases, returned 
larger sets than the strategy limited to RCTs from Abridged Index Medicus journals. 
While all search methods yielded some null retrievals in the main cohort, here, as in the 
Cochrane Updates, the only null retrievals were for Citing RCTs.  
6.7.2 Recall in the AHRQ Evidence Reviews 
Table 26. On Topic Recall in the AHRQ Evidence Reports  
Retrieval Method N of Studies 
Identified 
Recall 
Clinical Query 640 0.74 
Abridged Index Medicus RCT 208 0.24 
Citing RCT 17 0.02 
Related Article RCT 373 0.43 
SVM200point5 242 0.28 
Total N 862  
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Table 27. Recall of Eligible Studies in the AHRQ Evidence Reports  
Retrieval Method   N of Studies 
Identified 
Recall 
Clinical Query 181 0.67 
Abridged Index Medicus RCT 66 0.24 
Citing RCT 0 0.00 
Related Article RCT 154 0.57 
SVM200point5 125 0.46 
Total N 270  
Table 28. Recall of Eligible New Participants in the AHRQ Evidence Reports 
Retrieval Method Retrieved N from 
Eligible Studies 
Recall 
Clinical Query 163,352 0.79 
Abridged Index Medicus RCT 151,065 0.73 
Citing RCT 0 0.00 
Related Article RCT 150,585 0.73 
SVM200point5 89,347 0.43 
Total N 205,844  
 
Comparing the three measures of recall (Figure 21), we see a familiar decline in 
the retrieval performance of Clinical Queries between On Topic and Eligible records, but 
unlike the pattern in the other two cohorts, there is a rebound when recall of new 
participants is considered. AIM RCT remains strong in recall of new participants 
probably driving the strong performance of the Clinical Queries here, as Clinical Queries 
would have little unique contribution of new participants beyond those contributed by the 
Abriged Index Medicus subset. Citing RCTs was not a useful approach in this cohort. It 
did not identify a single relevant piece of evidence. Related Article RCT repeated the 
pattern seen in the main cohort of gains with each tightening of the relevance criteria, 
although only matching AIM RCTs for recall of new N. This method identified all new 




Support Vector Machine, despite strong performance in detecting the new 
evidence in the Cochrane reviews, did not show as strongly here, with recall below that of 
the other viable methods.  
In this cohort, there were four eligible new studies that had more than 10,000 
participants. Two of these four were included in two AHRQ Evidence Reports in this 
cohort, and so carry considerable weight in the recall of new N. Those reviews examined 
antioxidants for the prevention and treatment of cardiovascular disease201 and for the 
prevention and treatment of cancer.254 The first of these two trials was the Women’s 
Health Study.255 It was eligible for one systematic review in the main cohort as well, and 
was the second largest eligible new trial in any of the cohorts, with 39,876 participants. 
The other, the fourth largest in the AHRQ cohort, with 13,017 participants, was the 
SU.VI.MAX study,256 which was also eligible for one review in the main cohort. The 
related article RCT and Clinical Query searches retrieved the main report for both these 
studies for both AHRQ Evidence Report for which they were eligible, while SVM 
retrieved the main report of Women’s Health Study only for the cardiovascular Evidence 
Report, and did not retrieve the SU.VI.MAX study for either review. These misses 
accounted for most of the deficit in recall of new participants seen with SVM. 
As might be expected with such large and complex trials, both of these studies had 
had multiple reports, with N attributed to a single publication. How did SVM do at 
retrieving other relevant reports of the same study? The Reference Manager databases and 
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reviewer spreadsheets for these two Evidence Reports were examined for other reports of 
these studies that would be eligible or where the title or abstract would clearly indicate 
the existence of one of the eligible reports (Table 29).  
Table 29. SVM Retrieval of Multiple Publications of Large Trials Eligible for 
AHRQ Evidence Reports 
 Antioxidants for 
Cardiovascular Disease201 
Antioxidants for Cancer254 
 Relevant? Retrieved by 
SVM? 
Relevant? Retrieved by 
SVM? 
Womens Health Study    
*Lee, 2005257 Yes Yes Yes No 
Buring, 2006258 Yes No Yes No 
Liu, 2006259 Yes Yes … .. 
Song, 2004a260 No No No No 
Schaumberg, 2003261 No No No No 
Christen, 2004262 … … Yes No 
Cook, 2005263 … … No No 
Song, 2004b264 … … No No 
     
SU.VI.MAX     
*Hercberg, 2004256 Yes No Yes No 
Galan, 2005265 Yes Yes Yes No 
Hercberg, 2002266 Yes No Yes No 
Galan, 2003 267 No No No No 
Czernichow, 2005268 Yes No … … 
Zureik, 2004 269 Yes No … … 
Meyer, 2005 270 … … Yes No 
Malvy, 2001271 … … Yes No 
Hercberg, 2005 272 … … No No  
*Indicates primary report for that review.  
… indicates that the report was not retrieved for that Evidence Report by any search, and 
so was not assessed. 
For Women’s Health Study, there were seven additional reports other than the 
report to which N had been attributed that were in the candidate list for one or the other of 
these reviews. SVM found the main report and one additional report for the 
cardiovascular Evidence Review but none of the reports assessed as Eligible for the 
cancer Evidence report. For the SU.VI.MAX study, there were eight reports in addition to 
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the report to which N had been attributed. For cardiovascular Evidence Review, SVM 
identified one of these four additional reports assessed as Eligible. For the cancer 
Evidence Review, four reports in addition to the index report were assessed as Eligible 
and SVM retrieved one of these.  
If SVM was credited with identifying the SU.VI.MAX trial for the cardiovascular 
Evidence Report, recall of new participants would increase from 0.43 to 0.49 (total new n 
retrieved would go from 89,347 to 102,364). This is still low relative to the Clinical 
Queries and Related Article searches (Table 28). As well, it is possible, had this method 
of determining if any reports of a large trials, not just the first eligible, be computed for 
all trials, the other search methods might also have shown higher recall of new N.  
6.8 COMPARISON OF RECALL OF ELIGIBLE STUDIES PRE AND POST SIGNAL 
Although the intention was to completely assess all candidates, in two of the ten 
Evidence Reports the reviewers stopped assessments at the signal. To assess the potential 
for bias based on this early stopping, recall was considered for studies up to the point of 
the signal, and studies appearing after the signal, performance was very similar for the 
two periods, thus the incomplete data for two Evidence Reports would not appear to 
complicate interpretation of the results. 
 
Table 30. Comparison of Recall of Eligible Studies Pre and Post Signal  












Pre-signal  N=151 0.61 0.46 0.66 0.23 0.00 
Post-signal N=135 0.52 0.47 0.68 0.26 0.00 
Total N=286 0.57 0.46 0.67 0.24 0.00 
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6.8.1 Summary of Recall of the Test Searches 
Results have been presented for three recall measures in up to eight test searches 
in three cohorts. Table 31 and Table 32 compile these for two of the recall measure, recall 
of Eligible studies, which is the most conventional measure, and recall or identification 
relevant new participants, which has not commonly been reported but may be of greater 
interest in the updating context.  
Table 31. Summary: Recall of New Studies, All Cohorts  







Clinical Query 0.51 0.81 0.67 0.56 0.65 
Abridged Index Medicus 
RCT 
0.21 0.45 0.24 0.22 0.25 
Citing RCTs 0.13 0.05 0.00 0.08 0.00 
Related Article RCTs 0.78 1.00 0.55 0.69 0.57 
SVM .5 or 200 NA 0.95 0.46 NA 0.48 
SVM .8 NA 1.00 NA NA NA 
SVM .9 NA 1.00 NA NA NA 
SVM .95 NA 0.90 NA NA NA 
NA indicates not available for this cohort. 
 











Clinical Query 0.49 0.95 0.77 0.59 0.80 
Abridged Index Medicus RCT 0.43 0.72 0.73 0.52 0.72 
Citing RCTs 0.28 0.02 0.00 0.20 0.002 
Related Article RCTs 0.83 1.00 0.73 0.81 0.76 
SVM .5 or 200 NA 0.97 0.46 NA 0.50 
SVM 8 NA 1.00 NA NA NA 
SVM .9 NA 1.00 NA NA NA 
SVM .95 NA 0.96 NA NA NA 




Table 33. Recall of New Participant by Clinical Area, All Cohorts Combined 














Cardiac & Cardiovascular 
System 
21 0.707 0.682 0.382 0.400 0.650 
Clinical Neurology 11 0.299 0.251 0.009 0.642 0.494 
Critical Care Medicine 11 0.144 0.119 0.333 0.943 1.000 
Endocrinology & Metabolism 6 0.976 0.783 0.000 0.766 0.446 
Gastroenterology & 
Hepatology 
8 0.406 0.107 0.066 0.949 NA 
Infectious Diseases  8 0.938 0.790 0.033 0.905 0.977 
Obstetrics and Gynecology   7 0.244 0.030 0.149 1.000 0.988 
Oncology 5 0.992 0.965 0.013 0.493 0.009 
Peripheral Vascular Diseases 5 0.435 0.396 0.050 0.126 0.199 
Psychiatry 4 0.515 0.196 0.000 0.990 0.492 
Respiratory System 3 0.200 0.000 0.053 1.000 1.000 
Rheumatology 3 1.000 1.000 0.000 0.793 NA 
Urology & Nephrology 1 0.922 0.216 0.055 1.000 1.000 
Total 97 0.587 0.488 0.155 0.744 0.520 
NA – recall could not be computed as there were no instances of Gastroenterology & 
Hepatology  or Rheumatology in the AHRQ or Cochrane update sets 
 
6.9 SEARCH PERFORMANCE BY INTERVENTION TYPE 
All systematic reviews focused on interventions, either treatment or prevention. 
Considering search performance according to the type of intervention, drug, device or 
procedure, we see that almost all reviews focused primarily on drugs (Table 34) and most 
new evidence was for these reviews (Table 35).  While the number of eligible articles for 
the few systematic reviews of devices and procedures are small, there do not seem to be 
great differences in search performance across intervention type. 
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Table 34. Number of Reviews of Drugs, Devices and Procedures 
 







Drug 67 5 9 81 87.1% 
Device 3 1 0 4 4.3% 
Procedure 7 0 1 8 8.6% 
 









Clinical Query 0.56 0.50 0.65 0.56 
Abridged Index Medicus RCT 0.22 0.20 0.35 0.22 
Citing RCT 0.08 0.00 0.20 0.08 
Related Article RCT 0.68 1.00 0.73 0.69 
SVM200point5 0.46 1.00 0.67 0.48 
 
6.10 PRECISION OF THE TEST SEARCHES 
Precision can only be assessed with complete confidence in the cohort of AHRQ 
Evidence Reviews, as it was only in this cohort that all candidates were screened.  
Table 36. Overall Precision 
 N Eligible N of Candidates Retrieved Precision Rank 
Clinical Query 181 1637 0.1106 5 
Abridged Index Medicus RCT 66 441 0.1497 4 
Citing RCT 17 33 0.5152 1 
Related Article RCT 156 814 0.1916 2 
SVM200point5 125 659 0.1897 3 
Precision ranged from 0.515 to a low of 0.111. There is a clear associated with 
retrieval size – rank of precision (high to low) is almost the same as rank of N of 
candidate retrieved (low to high) with the exception of Abridged Index Medicus RCT, 
which has lower precision than would be expected based on it fairly small retrieval size. It 
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should be noted that for SVM, fixing the retrieval size may results in good precision with 
large numbers of relevant records and poor precision with few records – in either case the 
denominator is fixed.  
6.11 BALANCE OF RECALL AND PRECISION 
Similarity search methods had some advantage over Boolean searches in terms of 
improved precision, but at some cost to recall. The correlation between overall precision 
and recall precision and recall of new studies (r= -0.823) (Figure 22) and between of new 




Turning to the cohort of updated Cochrane reviews, precision can be considered if 
it is assumed that the authors of the updated Cochrane searches successfully identified all 
relevant new evidence shows the performance of all searches tested against this cohort, 
including several that will be discussed below; the authors’ actual update search (see 
Section 6.26 for complete results) and the update search and the subject search used for 
Clinical Queries and AIM RCT searches when run in the CENTRAL registry of 
controlled trials, part of the Cochrane Library (see Section 6.14 for complete results). 
When the recall of new eligible studies is considered, with the exception of the authors’ 
actual update search (Actual) and the Related Article RCT search, there is a negative and 
near- perfect linear association between recall and precision. The correlation between 
overall precision and recall of new studies for the test searches – that is, excluding the 
author searches, is r= -0.876 (Figure 23, left panel). The picture changes somewhat when 
recall of new participants is balanced against precision (Figure 23, right panel). Boolean 
searches, at a disadvantage in the recall of new studies, now approach the similarity-based 
searches in terms of recall, and precision becomes the more salient distinguishing factor. 
The authors’ own searches (Actual) had inferior precision compared to the more 
formulaic Boolean searches. The correlation between overall precision and recall of new 
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participants remains negative for the test searches – that is, excluding the author searches 
(r= -0.808).  
6.12 RANKING 
6.12.1 Ranking in the Updated Cochrane Cohort 
In the Cochrane set, both the SVM and Related Article RCT searches placed more 
than half of the targets (the studies added in the updates that were newer than the original 
review) in the top twency when the retrievals were ranked by relevance scores (Table 37). 
Thirteen of twenty targets were ranked in the top ten by either SVM or the Related Article 
RCT search (Table 38 and Table 39). While both ranking systems placed a high 
proportion of targets in the top ten, only two of the included new studies were ranked in 
the top ten by both methods (15.4%). For all systematic reviews in this cohort, any target 
that was retrieved by the search method would have been identified by the time the first 
fifty records were examined, if records were screened in order by relevance. This is the 
case for both search methods. 
Table 37. Precision and Recall of Ranked Retrieval at Various Cut Points in the 
Updated Cochrane Cohort 
 SVM Related Article RCT 
  Recall Precision Recall Precision 
Top 10 0.35 0.117 0.40 0.133 
Top 20 0.55 0.092 0.70 0.117 
Top 30 0.75 0.078 0.95 0.094 
Top 40 0.80 0.063 1.00 0.079 
Top 50 0.95 0.053 1.00 0.067 
Top 100 0.95 0.032 … … 
 
The SVM runs for the six Cochrane reviews examined here identified 546,014 
MEDLINE records with a relevance score greater than zero. However, for the binomial 
test, the retrieval size was taken as the count of all retrievals with a relevance score of 0.8 
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or greater (the SVM.8 search), making the test more conservative. Seven of twenty targets 
were ranked within the top ten. A binomial test revealed that this significantly exceeded 
chance (p < 0.001). All targets were ranked within the top 250, also exceeding chance, 
(p<.001). Complete results are shown in Table 38.  


































10 60 3207 7 20 0.019 0.35 <0.000 
20 120 3207 11 20 0.037 0.55 <0.000 
30 180 3207 14 20 0.056 0.70 <0.000 
40 240 3207 15 20 0.075 0.75 <0.000 
50 300 3207 16 20 0.094 0.80 <0.000 
100 600 3207 19 20 0.187 0.95 <0.000 
150 900 3207 19 20 0.281 0.95 <0.000 
200 1200 3207 19 20 0.374 0.95 <0.000 
250 1500 3207 20 20 0.468 1.00 <0.000 
Suppose there are b records in the initial retrieval. Suppose that a records (here we 
consider a range of values for a from 10 to 250) are considered, yielding a proportion p = 
a/b. Note that a is reported for each systematic review while b is reported for the entire 
sample – this is accounted for in the calculation of p (p=6a/b). Suppose further that this 
subset includes c of the d relevant records from the initial retrieval, i.e. a proportion q = 
c/d. If the ranking performs no better than would be expected by chance, then we would 
expect q = p. The single sided binomial test returns the exact probability of getting the 
value observed or any larger value, considering the valued expected by chance. [adapted 
from Sampson et al 2006178] 
 
*The cut point exceeds the retrieval size in many cases, so a is less than 6 times the cut 
point. 
Related Article RCT rankings put slightly more targets above each cut point, 
relative to SVM, however, results were similar overall and all targets were ranked in the 
top fifty. Testing within the set, ranking performed better than chance through the top 
twenty only, due to small set sizes. Eight of twenty targets were ranked within the top ten. 
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A binomial test revealed that this significantly exceeded chance, p < 0.040. Complete 
results are shown in Table 39. 
Table 39. Recall of the Ranked Related Article Retrieval at Various Cut Points in 
































10 60 265 8 20 0.226 0.40 0.040 
20 120 265 14 20 0.453 0.70 0.016 
30 180 265 17 20 0.679 0.85 0.052 
40 240 265 19 20 0.906 0.95 0.287 
50 300 265 20 20 1.000 1.00  - 
6.12.2 Ranking in the AHRQ Evidence Reports 
Of 286 Eligible new records for the Evidence Reports in the cohort, 125 were 
retrieved by SVM (43.7%) and 154 by Related Article RCT searches (53.8%). Looking at 
the retrieved portion, both the SVM and Related Article RCT ranking placed half of the 
Eligible retrieved records in the top thirty in terms of relevance scores (Table 40).  
Sixty-one of 286 (20.3%) Eligible new studies were placed in the top ten by either 
SVM or Related Article RCT. Of those, ten (16.4%) were in the top ten by both the SVM 
and Related Article RCT rankings. This is similar to the overlap found in the updated 
Cochrane reviews where two of the 13 targets (15.4%) placed in the top ten were placed 
there by both ranking systems. All relevant records identified by the search method were 
within the first 150 records for SVM (Table 41) and within the first 200 records for 
Related Article RCT, and all but one were in the top 150 (Table 42). 
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Table 40. Precision and Recall of Ranked Retrieval at Various Cut Points – AHRQ 
Cohort  
 SVM Related Article RCT 
Cut point  Relative 
Recall* 
Recall† Precision Relative 
Recall* 
Recall † Precision 
10 0.10 0.22 0.270 0.12 0.22 0.340 
20 0.17 0.39 0.245 0.21 0.39 0.316 
30 0.23 0.52 0.226 0.28 0.51 0.272 
40 0.28 0.62 0.216 0.32 0.59 0.260 
50 0.31 0.70 0.204 0.36 0.66 0.240 
100 0.49 0.94 0.186 0.50 0.92 0.204 
*Recall into that rank, using all Eligible studies as the denominator. The denominator is 
286 for both SVM and Related Article RCT. 
†Of those recalled by that search method, proportion placed at or above that rank. The 
denominator is 125 for SVM and 154 for Related Article RCT. 
Testing the obtained versus expected proportion above each threshold with the 
binomial test, both rankings performed significantly better than chance, and provided 
similar performance (Table 41 and Table 42). In the cohort of updated Cochrane reviews 
ranking performed better than chance through the top twenty only, due to small set 
retrieval sizes. With this larger set, ranking was significantly better than chance 
throughout the range and up until the point where all eligible studies had been retrieved, 
and this is the case for both SVM and Related Article RCT.  

































10 100 612 27 125 0.016 0.22 <0.000 
20 200 612 49 125 0.033 0.39 <0.000 
30 287 612 65 125 0.049 0.52 <0.000 
40 359 612 78 125 0.065 0.62 <0.000 
50 429 612 88 125 0.082 0.70 <0.000 
100 608 612 118 125 0.163 0.94 <0.000 
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150 612 612 125 125 0.245 1.00 <0.000 
200 612 612 125 125 0.327 1.00 <0.000 
250 612 612 125 125 0.409 1.00 <0.000 
*The cut point exceeds the retrieval size in many cases, so a is less than 10 times the cut 
point.  



































10 100 814 34 154 0.123 0.22 <0.000 
20 190 814 60 154 0.233 0.39 <0.000 
30 270 814 79 154 0.332 0.51 <0.000 
40 350 814 91 154 0.430 0.59 <0.000 
50 421 814 101 154 0.517 0.66 <0.000 
100 675 814 141 154 0.829 0.92 <0.000 
150 787 814 153 154 0.967 0.99 <0.000 
200 814 814 154 154 1.000 1.00 <0.000 
250 814 814 154 154 1.000 1.00 <0.000 
*The cut point exceeds the retrieval size in many cases, so a is less than 10 times the cut 
point.  
 
Comparing the ranking performance in SVM and Related Article RCT (Table 40), 
the Related Article RCT search put a slightly higher proportion of all Eligible records into 
the top portion of the retrieval at cut points 10 through 50, but by the top 100, where 
almost all relevant retrieved records were ranked by both searches, the difference in 
relative recall was negligible. When only Eligible records retrieved by that search method 
were considered, recall above a certain cut point was very similar thorough out the range 
for both SVM and Related Article RCT, thus the two ranking systems are equally 
effective. Precision declines steadily for both searches as the cut points increase, but the 
drop off is more marked for Related Article RCT than for SVM. The correlation between 
relative recall and precision and recall and precision at the different cut points is -0.99 for 
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SVM and -0.97 for Related Article RCT. Differences in ranked performance are due to 
differences in retrieval effectiveness rather than ranking effectiveness. 
6.12.3 Receiver Operating Characteristics (ROC) Analysis 
Receiver Operating Characteristics can be calculated for the search methods that 
rank results, SVM and Related Article RCT.  
 
 
Table 43. Test of Significance of Area Under the Curve 
    Asymptotic 95% 
Confidence Interval 




SVM Rank 0.945 0.019 0.000 0.907 0.982 
Related Article RCT Rank 0.684 0.057 0.006 0.573 0.795 
* Under the nonparametric assumption 
† Null hypothesis: true area = 0.5 
The area under the curve is tested against the null hypothesis that the true area = 
0.5, the value that would be obtained if the true shape of the curve were a diagonal. That 
occurs when, for all values of sensitivity, sensitivity=1-specificity, and the variable tested 
offers no improvement over chance. Here, although ranking was useful in determining 
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relevance, the gain was much greater for SVM, with area under the curve was 0.945, than 
for Related Article RCT, where the area under the curve was 0.684. The more impressive 
receiver operating characteristics curve for SVM is due to effectively distinguishing a 
small number of targets from a large set of irrelevant records (Figure 24).  
Turning to the AHRQ cohort, the receiver operating characteristics curves are less 
impressive (Figure 25) being much closer to the diagonal and here the area under the 
curve is not different from chance for SVM (Table 44).  
Table 44. Test of Significance of Area Under the Curve, AHRQ Cohort 
    Asymptotic 95% 
Confidence Interval 




SVM Rank 0.553 0.031 0.067 0.493 0.613 
Related Article RCT Rank 0.660 0.024 0.000 0.613 0.708 
* Under the nonparametric assumption 




6.13 SUMMARY OF THE RESULTS OF THE MAIN EXPERIMENT 
The main experiment examined the performance of searches in three cohorts. Two 
Boolean searches were based on a subject search. The subject searches were simple, using 
a mean of 3.6 terms and 1.5 search features. The subject search was paired with a filter 
selecting only RCTs from Abridged Index Medicus journals and with the Clinical Query.  
Clinical Query provided good recall but with large retrievals. Abridged Index 
Medicus RCT had smaller retrieval sizes and identified fewer new Eligible studies, but 
did detect many large studies, so performed well when recall of new participants was 
considered. The two similarity searches were SVM, where various cut points were tested 
in the Cochrane and AHRQ cohorts, and an algorithm based on related article searching 
in PubMed. The similarity searches were similar to the Clinical Query approach, but the 
Related Article search showed the highest recall of new Eligible studies overall, with 
SVM lower, and trailing the Clinical Query. SVM’s advantage was smaller retrieval 
sizes. A high proportion of Citing RCTs were Eligible for inclusion in updated reviews, 
but this method identified only a small proportion of all relevant new studies.  
Relative performance of the test searches was fairly stable across the three 
cohorts, although there was a ceiling effect in the updated Cochrane reviews, where most 
searches performed strongly. Relative performance was also fairly stable regardless 
whether the intervention was a drug, device or procedure, and whether the evidence 
appeared before or after the signal that an update was necessary.  
Precision, tested in the AHQQ cohort and updated Cochrane Cohort, ranged from 
0.111 to 0.192 for the more productive test searches but reached 0.515 for the Citing RCT 
method. Similarity methods showed higher precision than did the two Boolean 
approaches. Precision and recall showed a strong negative correlation whether recall of 
new studies or recall of new participants was considered.  
Ranking was examined for the similarity searches. Placement of Eligible studies 
near the top exceeded chance for both the SVM and Related Article RCT searches. When 
receiver operating characteristic curves were examined for these searches, SVM 
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outperformed Related Article RCT in the Cochrane set, although the area under the curve 
was significantly greater than chance for both. Area under the curve was less impressive 
in the AHRQ Evidence Report searches, with only the Related Article RCT search 
improving over chance. 
6.14 CENTRAL 
6.15 Central Indexing of New Material for the Main Cohort 
CENTRAL was not one of the methods used to build the candidate study list 
screened by the reviewers, it was added in after the fact to allow us to determine how 
complete the coverage of relevant new evidence is in CENTRAL. It is possible that 
additional relevant studies would have been found had we searched it to build the 
candidate lists. We tested CENTRAL coverage of Eligible new studies for those 
systematic reviews in the main cohort that had a signal for updating (N=48). Several 
systematic reviews were reclassified after the CENTRAL searching was done, thus data is 
missing for five systematic reviews subsequently assessed as having major or potentially 
invalidating new evidence.  
Recall of each test search for this subset is presented in Table 45 so CENTRAL 
coverage can be compared with the recall of the other searches. The performance of the 
test searches in this subset is, however, very similar to the performance for the entire 
main cohort for all three measures of recall (Table 20 - Table 22). This subset contained 
27 reviewer nominated record - records identified because they were included in another 
systematic review, were known to our team, or were found through ad hoc searching. 
CENTRAL indexed only one (0.04%) of these. 
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Table 45. Recall in the CENTRAL Subset  

















Clinical Query 699 0.65 143 0.45 244,612 0.51 
Abridged Index 
Medicus RCT 
168 0.16 64 0.20 227,281 0.47 
Citing RCT 76 0.07 38 0.12 154,472 0.32 
Related Article RCT 671 0.62 246 0.77 390,383 0.81 
CENTRAL 469 0.44 121 0.38 246,055 0.51 
Total N 1077  320  481,770  
 
6.16 CENTRAL in the Updated Cochrane Cohort 
The twenty targets, representing newer studies added to the six Cochrane reviews 
in the update were examined to determine if they were indexed in CENTRAL, and if the 
subject search developed by our team would have retrieved them, and if the search used 
by the authors of the updated review would have retrieved them. Recall of included 
studies and recall of new participants are presented in Table 46.  










Eligible studies indexed in CENTRAL 20 1.00 35,504 1.00 
Update search in CENTRAL 14 0.70 26,125 0.78 
Subject Search in CENTRAL 14 0.70 32,825 0.98 
Total 20  35,504  
*19 of the new included records had N attributes 
 
Although the authors’ search used for the update and our subject search recalled 
the same number of the included studies, the structured subject search had the advantage 
of retrieving all but the smallest studies.  
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6.17 SEARCHES FOR NEWER META-ANALYSES 
The retrospective nature of the AHRQ Updating project made it practical to 
identify newer meta-analyses which would aid in identifying new primary studies. Two 
searches were used to do this – the subject search limited by the MEDLINE publication 
type Meta-analysis, and the result of the Related Articles algorithm limited to the 
MEDLINE publication type Meta-analysis. As efficient identification of newer meta-
analyses is potentially useful in a variety of contexts, the performance of these searches is 
examined here. These searches are for the main cohort of 77 systematic reviews. 1193 
purported new meta-analyses identified, 793 by the subject search and 539 by the related 
articles approach (139 were identified by both). 
 
Table 47. Retrieval Size for Search Methods to Detect New Meta-analyses 






No.    (%) 
Subject Search – MA 6 3 13 63 4 5.2 
Related Articles – MA 5 2 9 68 8 10.4 
 
Median retrieval size was approximately equal across the two searches, with the 
main distinguishing feature being a slightly higher number of null retrievals – searches 
yielding no new material – with the related article algorithm (Table 47). Null retrievals 
are more common here than with the searches for primary studies for two reasons. First, 
there are fewer meta-analyses conducted than there are primary studies.§§ Second, the 
observation period is shorter for meta-analyses. Primary studies were searched starting 
from the end date of the search of the original review, while the searches for newer meta-
                                                
§§ There are examples where the ratio of meta-analyses to primary studies is high. Biondi-Zoccai et al 
studies 10 meta-analyses of the role of acetylcysteine in the prevention of contrast associated nephropathy, 
for which there were 28 trials273 In the case of tissue plasminogen activator for stroke, a PubMed search of 
those MeSH headings finds 63 records with the publication type of randomized controlled trial and 68 
systematic reviews, using the systematic review topic limit. Ten of these 68 are classified as meta-analyses. 
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analyses commenced one year after the search of the original review to allow some time 
for new primary studies to accumulate (see Methods 3.16). 
Table 48. Precision of Meta-analyses 
   N Retrieved N assessed N Eligible Precision 
Subject Search – Meta-analyses 793 171 74 0.433 
Related Articles – Meta-analyses 539 119 49 0.412 
 
Of 230 assessed records from the meta-analyses search, 171 were retrieved by the 
subject search and 119 were retrieved by Related Article search (Table 48). These 
retreivals are the denominator for calculation of precision of the search methods. Seventy-
four of meta-analyses identified through the subject search were Eligible 
(precision=0.433) while 49 of the 119 assessed records found through related article 
searching were Eligible (precision =0.421). Sixty-six purported meta-analyses were 
retrieved by both searches and 33 (50%) of these were Eligible. 
6.18 STRUCTURAL RELATIONSHIP BETWEEN SEARCHES 
6.18.1 Unique Contribution and Overlap in the Cochrane Cohort 
The overlap and unique component of the material retrieved by the test searches 
for the updated Cochrane cohort was examined (see Methods 4.2.1) and is shown in 
Figure 26. The size the of the circle is proportional to the size of the retrieval. In this 
figure, the overlap and unique portions are approximations. Exact figures for the unique 
components are presented in Table 49. Accurate figures for overlap are presented in Table 
50. This figure is simplified to show only test searches (not the actual searches used in the 
review) and only one SVM search is shown.  
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Table 49. Unique Component of Each Search from the Cochrane Cohort  
 Records Retrieved 
Uniquely by that 




% of Retrieval 
Unique to that 
Search Method 
Clinical Query 66 258 23.2 
Abridged Index Medicus RCT 0 57 Nil 
Citing RCT 0 1 Nil 
Related Article RCT 81 259 31.3 
SVM200point5* 984 1200 82.0 
SVM95*† 591 771 76.7 
SSCENTRAL† 15 184 7.9 
Actual† 507 985 51.5 
* SVM95 and SVM200point5unique were unique relative to the other search types, but 
not necessarily unique relative to any SVM variant, including SVM95 vs. 
SVM200point5. Other searches are unique relative to SVM if the records were not found 
by any of the SVM methods.  
†Not shown in Figure 26. Actual is tested as unique against all others. Others as tested as 
unique against the other searches listed, but not against Actual. 



























Clinical Query 258     
Abridged Index Medicus RCT 57 57    
Citing RCT 1 1 1   
Related Article RCT 99 38 1 259  
SVM200point5 146 52 1 149 1200 
SVM95 125 44 1 124 1031 
Subject Search in CENTRAL 158 52 1 78 129 




6.18.2 Unique Contribution and Overlap in the AHRQ Evidence Reports Cohort 
Clinical Queries, Related Articles RCT, Citing RCT and Support Vector Machine 
searches all identified some material not retrieved by any other search method. The AIM 
RCT search is narrower than the Clinical Query, thus that search had no unique 
component. This cohort provides the only opportunity, in these experiments, to assess the 
unique contribution of Vector Machine. In addition, unlike the Cochrane cohort, data is 
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available on whether the unique material was On Topic, Eligible, and whether it identified 
novel material (reports with new n attributed). Overlap of retrievals is shown in Figure 
27, - this is based on the entire search retrieval, regardless of relevance status of the 
records retrieved. Exact figures for unique material, unique On Topic records, Eligible 
records and records with new N attributed are given in Table 50.   
Table 51. Unique Component of Each Search for AHRQ Evidence Reports 





















Clinical Query 1060 272 40 26 40.77 
Abridged Index Medicus 
RCT 
0 0 0 0 - 
Citing RCT 31 14 0 0  - 
Related Article RCT 466 103 35 12 38.83 
SVM200point5 388 63 26 17 22.82 
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In total, there were 928 On Topic new records and 283 Eligible new records, and 
35.69% of these Eligible new records (n=101) were detected by only one of the search 
methods. The proportion of unique material that was eligible ranged from a high of 
0.0751 for the Related Article RCT to 0.0377 for Clinical Queries.  
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In terms of impact on updating, the identification of previously unidentified 
studies is arguably more important - of the Eligible new retrievals, 45.54% had no new N 
attributed as the study had previously been identified through another report.  
It is notable that while SVM methods provided the largest unique retrievals for the 
Cochrane cohort, Clinical Query is the more significant contributor in the AHRQ cohort. 
6.19 CONVERGENCE OF MULTIPLE RETRIEVAL METHODS 
In the main cohort of 77 the mean number of methods retrieving any one relevant 
record was 1.88 (standard deviation 1.23), the mean number of methods retrieving any 
one irrelevant record was 1.10 (standard deviation 0.40). Association between number of 
retrieving searches and relevance was examined (Methods 4.2.2). Convergence measured 
either by the number of search methods retrieving a candidate or the number of search 
types (where two methods based on subject searching, Clinical Query and Abridged 
Index Medicus RCTs, are considered a single type of search) retrieving a candidate was 
associated with eligibility (For searches 26 = 1283.5 P2 sided <.001, for search types 
24=754.8, P2 sided <.001). Thus the more times an item was retrieved, the more likely it 
was that it was relevant. Table 52 through Table 54 show the distributions of off topic, On 
Topic and Eligible retrievals by number of times the record was retrieved. The 
distributions are also presented graphically in Figure 28, which shows complete details, 
and Figure 29 which focuses on On Topic (labeled as Not Relevant) and Eligible records 
(labeled as Relevant) using a larger scale.  
When the four searches are considered (Table 52), we see the very high proportion 
of relevant records among those nominated by the review team and not found by any of 
the test searches, but otherwise there is a steady and large gain in proportion of retrieved 
records that are eligible as the number of searches finding the item increases. Although 
overall, only 0.05 of the records considered in this analysis were Eligible, over a third of 
those retrieved by all search methods were relevant (precision=0.37). The pattern is 
similar for the cases in which the number of types of searches, where types are similarity 
search, Boolean search and citing reference search (Table 53). 
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Recall declines as precision increases. Because so few relevant records are Citing 
RCTs, this limits the recall that can be achieved by this convergence approach. When 
three of the four searches find the record, recall is 0.19 and precision is 0.149. When two 
of the three search approaches find the record, recall is 0.42 and precision is 0.115. When 





Table 52. Relevance by Number of Searches Retrieving a Candidate in the Main 
Cohort 
Found by 
x of 4 
searches*  
Off topic On topic Eligible Total Recall† Precision 
4 25 13 22 60 0.05 0.367 
3 251 120 65 436 0.19 0.149 
2 1090 376 124 1590 0.46 0.078 
1 5827 708 212 6747 0.93 0.031 
0 5 0 33 38 1.00 0.868 
Total 7198 1217 456 8871  0.051 
*Searches are Related Article RCT, Clinical Query, Abridged Index Medicus RCT, and 
Citing RCT 
†Recall is cumulative – that is, while only 5% of records were retrieved by 4 searches, 
19% were retrieved by at least 3 of the searches, 46% were retrieved by at least 2 of the 
searches, and so on. 
Table 53. Relevance by Number of Types of Searches Retrieving a Candidate in the 
Main Cohort 
Found by x 
of 3 search 
types*  
Off Topic On Topic Eligible Total Recall† Precision 
0 5 0 33 38 1.00 0.868 
1 6337 777 231 7345 0.93 0.031 
2 809 415 159 1383 0.42 0.115 
3 47 25 33 105 0.07 0.314 
Total 7198 1217 456 8871  0.051 
*Search types are similarity search, Boolean search and citing reference search. 
†Recall is cumulative – that is, while only 7% of records were retrieved by all 3 search 




Table 54. Relevance by Number of Related Article RCT and Clinical Query 
Searches Retrieving a Candidate in the Main Cohort 
Found by x of Related 
Article RCT and 
Clinical Query 
Off Topic On Topic Eligible Total Recall* Precision 
2 721 427 169 1317 0.37 0.128 
1 6233 767 249 7249 0.92 0.034 
0 244 23 38 305 1.00 0.125 
Total 7198 1217 456 8871  0.051 
*Recall is cumulative – that is, while 37% of records were retrieved by both searches, 
92% were retrieved by one or the other or both. 
 
The figure shows that, across the five search types considered here (Clinical 
Query, Abridged Index Medicus RCT, Citing Reference, Related Article RCT and 
CENTRAL) 
6.20 POPULATION ESTIMATION THROUGH CAPTURE – RECAPTURE 
Capture-Recapture analysis was undertaken to estimate whether the search 
methods were likely to have missed relevant studies and to explore the dependencies 
between searches (See Methods 4.2.5). 
Applying this method to the current data, the best estimate should be obtained by 
the two methods with highest recall and most likely to be independent. These are Related 
Article RCT and Clinical Query. Eligible records retrieved by either Related Article RCT 
or Clinical Query were selected from all sets, and a cross tabulation was performed 
(Table 55). 
Table 55. Cross-tabulation of Retrieval Status for Clinical Query and Related 
Article RCT.  
  Clinical Query  
  Retrieved Not Retrieved Total 
Retrieved 282 246 528 Related 
Article RCT Not Retrieved 148 0 148 




The number of Eligible studies missed by both is nil in this table, as only records 
found by one or the other are considered, but the expected number missed is calculated 
using Bailey’s estimator and Jensen’s confidence intervals: 
M = 430 
n = 528 
m = 282 
 N = M(n+1) 
  m+1 
  = ((430 * 529)/283) 
The total population size is estimated to be 804 (95% confidence interval: 768, 
843). The number of relevant records that appear to be missing after these two searches 
have been conducted is 128. Recall after two methods, Related Article RCT and Clinical 
Query, would therefore be 0.84. The predicted total population size can be compared to 
the number of Eligible records identified by any method, including reviewer nomination. 
Across the three cohorts, 752 Eligible records were found, below the lower level of the 
confidence interval of the population estimate, so approximately 52 Eligible records were 
still unidentified (confidence interval; 16, 90). Thus true recall could range from 0.89 – 
0.98. 
In the sample, the true number of relevant articles is likely most closely 
approximated in the AHRQ Evidence Report. All records retrieved by the searches were 
assessed directly, with no reliance on identification through author searches in updated 
systematic reviews (this reliance occurs in the large set as the first approach was to look 
at newer systematic reviews on the same or similar topics). In the other samples, it is 
possible or even likely that there were additional records in the retrievals that were 
relevant.  
6.20.1 Positive Dependence 
Capture-recapture should underestimate the true population size (here, the actual 
number of relevant records) when the samples are not independent. This allows us to 
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explore the dependence between searches in these cohorts. Positive dependence occurs 
when the probability of overlap is equal to the average probabilities of appearing in A and 
of appearing in B, and positive dependence of sources will tend to produce an 
underestimate of the true population size.218 If the probability of ascertainment (of being 
retrieved by a search method) is taken to equal recall, than if the product of recall of 
method 1 and recall of method 2 is equal to the overlap between the two methods, there is 
a potential for underestimation. When one search result is a subset of another, dependence 
is complete. This can be demonstrated by examining estimates derived from Abridged 
Index Medicus RCT and Clinical Query, as the Abridged Index Medicus RCT retrieval is 
a subset of Clinical Query retrieval.  
Relative recall of Abridged Index Medicus RCT is estimated at 0.22 across the 
three cohorts, and the recall of Clinical Query is estimated at 0.56 (Table 31). The product 
of these is 0.22 x 0.56 or 0.12. The overlap is =2936/13539 records or 0.22, much greater 
than the product. Calculating the capture-recapture statistics, the estimated number of 
targets is 430 (95% confidence interval; 430, 430) while the actual number of Eligible 
records identified by all searches was 752. Therefore, capture-recapture in this case where 
one search is a subset of the other, underestimates the true population size considerably.  
6.20.2 Negative Dependence 
Hook continues by demonstrating that if, the probability of being in both samples 
is less than the product of the probability of being in any one of them, as is the case when 
there is no overlap between methods, than there is negative dependence and capture-
recapture methods will tend to overestimate the true population size. When the upper 
boundary of the confidence interval for a population estimate is less than the actual 
number of eligible records, we can attribute the result to underestimation, and infer 
positive dependence between methods. When the actual eligible records found was 
outside the lower limit of the estimate, this could be due to missed records, or due to 
negative dependence between sets. While the existence of missed records was the more 
plausible explanation, negative dependence cannot be ruled out. 
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6.20.3 Capture – Recapture Population Estimates when Recall of the Ascertainment 
Methods is Low 
What happens when searches can be expected to be independent, but recall is low? 
This would be the case when Abridged Index Medicus RCT and Citing RCTs searches 
are used to estimate population size. Based on the capture-recapture calculations for all 
three cohorts combined, the estimate of total Eligible records is only 412 (confidence 
interval; 325, 562), while there are 752 known Eligible records across these three cohorts. 
Therefore, capture-recapture underestimates the true population size in this case. 
Substituting Clinical Query for Abridged Index Medicus RCT, the estimated population 
becomes 713 (confidence interval; 599, 880), and the number of known Eligible records 
falls within the estimate. Although it would seem that low recall of both searches impairs 
estimation, one is still faced with a competing hypothesis that there is a positive 
dependence between the Abridged Index Medicus RCTs and Citing RCTs. This could 
occur if the journals in the Abridged Index Medicus journal set are more likely to insist 
on a complete literature review, with relevant prior evidence cited, than other MEDLINE-
indexed journals. This is easily explored. Across all three cohorts there were 838 citing 
RCTs, of which 835 were indexed in MEDLINE. Of these 835 records, 321 were from 
Core Clinical Journals (38.4%). Compare this to the 13364 records retrieved by the 
Clinical Query searches, of which only 2936 (22%) were in Core Clinical Journals.  
Comparing the estimate based on Abridged Index Medicus and a similarity search 
with the estimate of Clinical Query and a similarity search, we see that using the lower 
recall Boolean search method does lower the overall estimate, although the number is 
plausible – the estimate of 770 records (confidence interval; 716, 834) is very similar to 
the 752 Eligible records actually found whereas the estimate with Clinical Query was 826 
(confidence interval; 792, 863). 
In a less extreme example, a capture-recapture population estimate based on 
Abridged Index Medicus RCT and Related Article RCT can be compared with estimates 
obtained using Clinical Query and Related Article RCT as the ascertainment methods. 
 
201 
The contrast is between lower and higher recall is less marked when only one of the 
searches is low recall; the lower recall pairing results in a population estimate of 719 
(confidence interval; 667, 781) while substituting the higher recall Boolean search yields 
an estimate of 804 (confidence interval; 768, 843). The known population falls within the 
range of the first estimate, but is lower than the second.  
Thus, it seems that the capture – recapture method is somewhat sensitive to the 
recall of the searches used to make the estimates. Use of capture-recapture method to 
estimate completeness of retrieval seems not to be warranted unless dependencies 
between methods are understood and recall of the methods used is expected to be high. 
6.20.4 Capture-Recapture Estimates from Various Ascertainment Methods 
The population estimates derived from other pairs of ascertainment methods are 
shown in Table 56 and Figure 30. 
Diamonds represent the estimated number of eligible records, whiskers show the 
confidence intervals. Squares represent the eligible studies found by all methods 
including searches, studies included in updates, and nominations.  
Search pairings are; a - Clinical Query and RI_RCTorSVM200point5, b - Clinical Query 
and Related Article RCT, c - Clinical Query and SVM200point5, d - Related Article RCT 
and SVM200Point5, e - Clinical Query and AIM RCT, f - AIM RCT and Citing RCT, g - 
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Author’s actual search for the original review and authors’ update search in CENTRAL, h 
- Author’s actual search for the original review and our subject search in CENTRAL, i - 
Clinical Query and update search in CENTRAL. 
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Table 56. Comparison of Eligible Records and Capture-Recapture Population 
Estimates in the Three Cohorts 























   
AHRQ Evidence Reports 
a CQ, RI 
RCTorSVM200point5  
273 319 (298,  343) 49 46 
b CQ, RI RCT  273 286 (265,  312) 16 13 
c CQ, SVM200point5 273 317 (284, 359) 82 44 
d RI RCT, SVM200point5  273 258 (234,  288) 53 - 
e CQ, AIM RCT 273 181 (181, 181) † -  
f AIM RCT, CR 273 66 ‡  † - 
   
Updated Cochrane  
a CQ, RI 
RCT&SVM200point5 
20 20 (20,  20) 0 0 
b CQ, RI RCT 20 20 (20, 20) 0 0 
c CQ, SVM200point5 20 20 (19, 21) 0 0 
d RI RCT, SVM200point5 20 20 (20, 20) 0 0 
e CQ, AIM RCT 20 16 (16, 16) † - 
f AIM RCT, CR 20 9 ( 9, 9) † - 
g ACTUAL, UCENTRAL  20 13 (13,  13) † - 
h ACTUAL, SSCENTRAL  20 18 (17,  20) † - 
i CQ, UCENTRAL  20 19 (17,  21) 1 1 
   
Main Cohort 
b CQ, RI RCT ** 459 487 (461,  516) 69 28 
e CQ, AIM RCT 459 233 (233, 233) † - 
f AIM RCT, CR 459 236 (188, 317) † - 
Abbreviations: CQ is Clinical Query, AIM RCT is Abridged Index Medicus RCT, RI 
RCT is Related Article RCTs, SVM200point5 is the support vector machine retrieval 
limited to the first 200 records or those with relevance of .5 or greater, CR is Citing RCT, 
RI RCT&SVM200point5 is the joint retrieval of the RI RCT and SVM200point5 
searches, ACTUAL is the actual subject search of the original review, UCENTRAL is the 
update search used in CENTRAL by the original reviewers, SSCENTRAL is the test 
subject search run in CENTRAL 
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*This may indicate that there are missed relevant records, or may be an overestimate due 
to source independence. 
†  Underestimates  
‡ The confidence interval can’t be calculated as the second source (citing RCTs) did not 
identify any eligible records. 
**CQ & RI RCT and CQ & RI RCTorSVM200point5 would yield identical estimates in 
this cohort as SVM200pint5 was not run. 
 
The ascertainment pairings a, b, c, and d, involving combinations of Clinical 
Query, Related Article RCT, and SVM200point5 all yielded population estimates 
relatively consistent with observed values. There is indication of some missed records in 
the AHRQ Evidence Reports and in the main cohort. Only in the two combinations 
involving SVM200point5 did the actual number of Eligible records fall below the 
confidence interval of the population estimate from capture-recapture. The first case is the 
pairing of Clinical Query with “RIRCTorSVM200point5”, where  “RI 
RCTorSVM200point5” represents records retreived by either similarity search method, 
and Clinical Query with SVM200point5. This could indicate negative dependence 
between Clinical Query and SVM200point5 or it could be that there is positive 
dependence between Clinical Query and Related Article RCT, which is lower the other 
estimates. 
Searches pairings e (Clinical Query and AIM RCT) and f (AIM RCT and Citing 
RCT) underestimate the actual number of Eligible records in all cohorts, indicating 
positive dependence between those pairs, possibly with the relatively low recall of 
Abridged Index Medicus and Citing RCTs contributing.  
Looking at the Updated Cochrane reviews, the three ascertainment pairings 
involving CENTRAL - g (Author’s actual MEDLINE search for the original review and 
authors’ update search in CENTRAL), h (Author’s actual search for the original review 
and our subject search in CENTRAL) and i (Clinical Query and update search in 
CENTRAL) - all underestimate the actual number of Eligible records to some degree. In 
the case of pairing g, the number of Eligible studies is well above the confidence interval 
for the capture- recapture estimate. 
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6.21 MULTIDIMENSIONAL SCALING 
Modeling the similarities between search results (see Methods 4.3.1), the derived 
stimulus configurations for the combined AHRQ and Cochrane Cohorts are shown in 
Figure 31 and for the main cohort in Figure 32. These are two dimensional 
multidimensional scaling analyses, with the number of dimensions was decided a priori 
due to the limited number of input variables (called stimuli in these analyses). Stress (a 
measure of goodness of fit) with this number of dimensions was very low at .00092 for 
the AHRQ and Cochrane cohort and 0.00381 for the analysis of the main cohort, 
considered excellent. Examination of distance in the model compared to the original 
similarity scores did not identify outliers for either analysis, again suggesting that the data 





Examining the plots, the two subject searches are alone on the negative scale of 
the first dimension. Related articles RCT is alone in a quadrant for the main cohort, and 




Citing RCT is in its own quadrant except in the main cohort when it is joined by 
the searches for newer meta-analyses. Although one meta-analysis search approach 
(labeled MA) is the subject search with the MEDLINE meta-analysis publication type 
limit applied, and the other (labeled RI_MA) is the Related Article search with the meta-
analysis publication type instead of the randomized controlled publication type limit, 
these to not group with their search types. Of 818 distinct citing RCTs, only 12 have the 
publication type Meta-analysis, and only four were retrieved by the subject search with 
the MA publication type limit, and four by the related article search with the publication 
type limit, so overlap between the sets is not an explanatory factor in the close grouping 
of these searches. One aspect that could explain the proximity is recency (we enforced a 
one year lag from the search date of the original review for the MA searches, and citing 
RCTs would be offset from the publication of the original reviews by a publication lag). 
Another aspect is that both the MAs and the citing RCTs would both be expected to cite 
prior RCTs. Finally, both the searches for newer meta-analyses and the searches for citing 
RCTs had smaller retrievals than the other search methods.  
The capture-recapture analysis suggested a positive dependency between Citing 
RCT and Abridged Index Medicus RCT search methods. In both these multidimensional 
scaling analyses, the test search closest to Citing RCTs is Abridged Index Medicus RCT 
(although the distance from Citing RCTs to SVM is only slightly greater than the distance 
from Citing RCTs is Abridged Index Medicus in the AHRQ-Cochrane analysis). 
The most parsimonious interpretation of Dimension 1 in both analyses is type of 
search, with subject searches at one end of the scale, and similarity methods on the other. 
Searches for publications that cite RCTs are in the middle. The second dimension is less 
clear-cut, but is likely influence heavily by retrieval size and precision (which are 
correlated) but not recall. These results are congruent with the dependencies implied by 
the capture-recapture analysis. 
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6.22 CORRELATIONS OF ACTUAL AND TEST SEARCHES  
The poor performance of the MEDLINE searches used by the authors in updating 
these systematic reviews makes it difficult to assess the hypothesis arising from Cohen’s 
work15 that searches where the librarian is able to achieve precision are also where the 
classifiers are able to obtain good precision, however, this was examined briefly (see 
Methods 4.3.2). The authors’ Actual searches only identified relevant included studies in 
two of the six updated systematic reviews. As precision is calculated with relevant 
retrievals as the numerator, precision is zero when no relevant studies are found.  
The precision of the various test searches is shown in Figure 33. It does seem that 
precision of both the Boolean searches (shown with solid lines) tends to rise and fall as 
the precision of the SVM searches (shown with dashed lines) and Related Article RCT 




6.23 RELATED ARTICLE SEED REFINEMENT 
6.23.1 Optimizing the Selection Criteria for Seeds 
Characteristics of related article seed articles were studied in the Cochrane cohort 
for indications of how the search algorithm could be refined (see Methods 4.2.3). Seeds 
were classified based on qualifications as seeds (independent variable) and performance 
(dependent variable). Seeds could qualify by being one of the three largest or one of the 
three newest studies included in the original review, and some met both criteria. Their 
performance could be productive, when one or more new included studies were related to 
that seed, or unproductive, when none of the related articles were new included studies. 
Super seeds were productive seeds that were related to all new included studies in the 
updated reviews. In some cases, an included study was eligible as a seed, but was not 
indexed in MEDLINE and so could not be searched for related articles.  
Each systematic review could have a maximum of six related article seed articles. 
In this cohort, there were only 26 distinct MEDLINE-indexed seeds (Table 57). Seven 
seeds qualified by being both among both the newest and largest, two were super seeds, 
two were otherwise productive seeds and thee were unproductive seeds. Three articles 
that qualified as seeds were not indexed in MEDLINE and so could not be used in the 
Related Article RCT search.  
Table 57. Productivity of the Related Article Seeds in the Cochrane Cohort 
 Frequency Percent 
Super seeds 5 17.2 
Other productive seeds 9 31.0 
Unproductive productive seed 12 41.4 
Non-MEDLINE  3 10.3 
Total 29 100.0 
 
Mean number of related RCTs for each seed was 262.2 (Standard deviation 
163.1), median number of related RCTS for each seed was 222.5 (1st and 3rd quartile 
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130.3, 307.5). It was previously seen that none of the related article RCT searches for this 
cohort resulted in null retrievals (Table 22). In fact, all MEDLINE-indexed seeds yielded 
related RCTs newer than the search date of the original review, with a minimum retrieval 
of 103 related RCTs and a maximum of 666 related RCTs. There was overlap between 
the retrievals for each systematic review, the mean retrieval size was 952.5 (standard 
deviation; 220.7). There was no difference in retrieval size between seeds that included 
one or more new studies added in the update and those that did not retrieve any of the 
relevant new studies. (Table 58, t24 = -0.378, P 2 sided =0.709). 
Table 58. Number of Newer Related Randomized Controlled Trials for Seeds that 
Did or Did not Retrieve New Studies Added in the Cochrane Updates 




N of Related Unproductive 12 248.92 146.030 42.155 
 Productive 14 273.57 181.212 48.431 
 
Turning to the qualifications of the seeds as determinants of productivity (Table 
59), it is notable that all five super seeds were new studies (two were also large studies) 
but qualifications were not significantly associated with productivity when the 
MEDLINE-indexed seeds were considered (22=1.5, P2 sided =0.462).  
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Table 59. Productivity of Largest and Newest Related Article Seeds for the 
Cochrane Cohort 
  Qualification   
 Large New Total* 
Super Seed 2 5 7 
Other Productive Seed 6 6 12 
Unproductive Seed 8 6 14 
Non-MEDLINE  2 1 3 
Total 18 18 36 
*Seeds qualifying by being among both the newest and biggest are counted in each 
category. 
Position within newest or largest was assessed to see if the number of seeds of 
each type could be trimmed (Table 60). Non-MEDLINE seeds where excluded from the 
analysis. MEDLINE-indexed records that were qualified both as one of the newest and as 
one of the largest studies were included in the analysis one for each qualification. Again, 
there was no association between position and productivity (24=4.1, P2 sided =0.397). 
Overall, analysis of variance with qualification and position as independent variables and 
productivity as the dependent variable was not significant.  
Seven seeds qualified by being both amongst the newest and amongst the largest 
studies included in the original Cochrane reviews. Five of the six Cochrane reviews in 
this cohort have at least one doubly-qualified seed. To examine whether these seeds were 
more productive than others that met only one criterion, seeds were classified 
dichotomously as Productive (with Super and Other productive seeds combined) vs. 
Unproductive (unproductive or non-MEDLINE seeds combined) and also as Super vs. 
Other. The association between these variables and whether seeds were doubly qualified 
was assessed through 2, which did not approach significance in either case 
(Productive/Unproductive 21=2.0, P2 sided =0.159, Super/Other 21=0.8, P2 sided =0.362). 
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Table 60. Productivity of Related Article Seeds by Position for the Cochrane Cohort 
Position Super Other 
Productive 
Unproductive  Total 
1 3 2 7 12 
2 2 5 5 12 
3 2 5 2 9 
Total 7 12 14 33 
 
6.23.2 MEDLINE Misses as Seed Articles 
Twelve of the articles that qualified as seeds for the related article search were 
indexed in MEDLINE but missed by the MEDLINE search used by the authors in the 
original systematic review (Table 61). These MEDLINE misses were productive in 
almost equal proportion to those seeds found by the authors’ search in the original review 
21=0.1, P2 sided =0.716.  
Table 61. Productivity of Seeds by Retrieval Status in the Original Cochrane Review 
Productivity Found  Missed Total 
Unproductive 6 6 12 
Productive 8 6 14 
Total 14 12 26 
 
6.23.3 Performance of Related Article Searching when Retrieval Size is Limited 
Retrieval sizes for the three cohorts are shown in Table 62 and these numbers 
have been drawn from  Table 18, Table 22 and Table 25 where it can be seen that the 
related article search method yield larger retrievals, similar overall to Clinical Queries, 
but larger than the other search methods.   
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Table 62. Retrieval Sizes for Related Article RCT Searches in the Three Cohorts  
 Median 1st Quartile 3rd Quartile Maximum 
Main Cohort 100 62 142 376 
Updated Cochrane Reviews 67 56 88 174 
AHRQ Evidence Reports 79 45 106 172 
 
The feasibility of improving precision of the Related Article searches by limiting 
the retrieval size was explored in the updated Cochrane reviews and the AHRQ Evidence 
Reports. Position in the ranking of related article retrieval was recorded for each Eligible 
study, and the number of Eligible new studies that would have been missed had the 
retrieval been truncated at various sizes was determined. Recall and precision of the 
truncated searches was computed.  
 
Complete recall of new studies added in the updates was achieved in the updated 
Cochrane reviews by the time the Related Article RCT set size reached 50, as the lowest 
ranking new study in the updates was in position 43 (Figure 34). In the AHRQ Cohort, 
where the Related Article RCT search has relative recall of 0.57, that maximum would 
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have been obtained had set size been limited to 150 records, as the lowest ranking new 
eligible study was in position 146 (Figure 34).  
Precision increased considerably when the retrieval size was restricted (Figure 
35). In the Cochrane cohort, full recall was obtained within the top 50 records, and 
precision would have been above 0.200 at that point. At a retrieval size of 100, precision 
would have been 0.033, which is a typical value for systematic reviews (see Section 
6.25). At an arbitrary retrieval size of 200, precision would have dropped to 0.017, but 
this is artificial, as the Related Article RCT search returned a maximum of 174 records. In 
the AHRQ cohort, gains in precision are even greater, with precision exceeding 0.100 at 
rank 180, by which point all relevant records had be identified.  
Looking at the position of the lowest ranked relevant record in the Cochrane and 
AHRQ sets, it does not seem feasible to set a cut point as a proportion of the retrieval size 





Table 63. Lowest Related Article RCT Rank of Eligible and Ineligible Records 
Systematic Review Lowest Ranked 
Eligible Record 
Lowest Ranked  
Ineligible Record 
Cochrane   
Alejandria, 2001274 9 56 
Arroll,1999275 43 60 
Cody, 2001276 2 20 
Fisher 1994277 36 50 
Demicheli, 2001278 28 53 
Lengeler, 1999279 26 38 
AHRQ   
Santaguida,2004280 116 117 
Shekelle, 2003201 155 154 
Berkman, 2000281 37 75 
Duscemi, 2004282 96 116 
Grady, 2003283 145 172 
Guise, 2003284 -- 15 
McNamara, 2000285 50 58 
Shekelle, 2003254 69 88 
Shekelle, 2004286 24 41 
Velmahos, 2000202 12 15  
While there is the problem with larger set sizes in the Main cohort (the largest 
retrieval was 376 records), the set size exceeded 200 records in only 12 systematic 
reviews (15.6%) and exceeded 150 records in 21 systematic reviews (27.2%). The 
precision and recall seen at various limits of retrieval size are shown in Table 64. 
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Table 64. Search Performance of Related Article RCT at Various Limits to Set Size 
in the AHRQ Evidence Reports 




Unlimited 853 154 0.57 0.181 
200 853 154 0.56 0.183 
150 826 151 0.56 0.183 
100 692 143 0.53 0.207 
50 421 102 0.38 0.242 
6.24 SUFFICIENT STRATEGIES  
Seventy-two systematic reviews in the main cohort (those for which new Eligible 
studies were identified) were examined to determine which combinations of searches 
would have been sufficient to identify all of the Eligible studies found through any of the 
searches (see Methods 4.2.4). 
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Table 65. Search Strategies Sufficient to Retrieve All Eligible New Studies 
 N* % 
One Strategy (N=59, 81.9%)   
Related Article RCT 46 63.9% 
Clinical Query 34 47.2% 
CENTRAL 14 19.4% 
Abridged Index Medicus RCT 8 11.1% 
Citing RCT 3 4.2% 
Two Strategies Needed (N=12, 16.6%)   
Related Article RCT with Clinical Query  10 13.9% 
Related Article RCT with CENTRAL 4 5.6% 
Related Article RCT with Abridged Index Medicus RCT 1 1.4% 
Related Article RCT with Citing RCT  1 1.4% 
Three Strategies needed (N=1, 1.4%)   
Related Article RCT with Citing RCT with (Clinical 
Query or CENTRAL) 1 1.4% 
* Some systematic reviews had more than one sufficient search, therefore figures sum to 
more than the number of cases (n=72). 
In 59 of the systematic reviews, a single search strategy would have been 
sufficient to retrieve all Eligible new report found by any method. Related Article RCT 
was sufficient in 46 cases, Clinical Query in 34, Abridged Index Medicus RCT in 8, 
CENTRAL in 14 and Citing RCT in 3. Systematic reviews with few studies seem to be 
more likely to have multiple sufficient strategies.  
In 12 cases, a combination of two search strategies was needed to find all Eligible 
new reports found by any method. Related Article RCT with Clinical Query was 
sufficient in ten cases, Related Article RCT with CENTRAL in four, Related Article RCT 
with Abridged Index Medicus RCT in one and Related Article with Citing RCT in one.  
In only one case was it necessary to use three methods to find all found by any 
method. In that case, Related Article RCT with Citing RCT and either Clinical Query or 
CENTRAL would have been sufficient. 
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In 69 of the 72 systematic reviews examined (96%), searching Related Article 
RCT and Clinical Query would have retrieved all studies either because one strategy or 
the other was sufficient or because the two together was sufficient. For the three reviews 
that needed additional searches to retrieve all relevant new studies identified through any 
strategy, the combination needed was different in each case.  
6.25 PRECISION OF SEARCHES IN A CROSS-SECTIONAL SAMPLE 
Ninety-four of 300 (31%) systematic reviews in the cross-section sample of 
December 2006 reported their search results in enough detail that precision could be 
calculated3 (see Methods 4.4). As a quality measure, the search was replicated for ten 
systematic reviews, mostly in cases where precision seemed very high.  
In the cohort of 300, 43% of the systematic reviews studies were Cochrane 
reviews, while in the 94 cases where precision could be calculated, 45 (47%) were 
Cochrane reviews (21 = 0.984 P2 sided =.321). Although reporting is generally more 
complete in Cochrane reviews relative to journal published reviews, the greater use of 
QUOROM flow diagrams in journal-published reviews results in more complete 
reporting of the number of retrieved, screened and included records and studies.3 
QUOROM is “Quality of Reporting of Meta-analyses”, a reporting standard published in 
1999.42 The flow diagram documents the number of possibly relevant reports identified, 
the number included, and the number excluded and the reasons for exclusion. Figures 17-
19 at the beginning of chapter are examples of QUOROM flow diagrams. 
Overall, there were 5,734 relevant included studies across the 94 systematic 
reviews and a total of 189,334 retrieved records were screened. The overall precision is 
therefore 0.030. The median precision, calculated by taking the median of the precision 
scores for the individual systematic reviews,  is 0.029 (1st and 3rd quartiles; 0.013, 0.081). 
The maximum precision achieved by any search was 0.368 while the minimum was 
0.0007. Median number of records screened was 634 (1st and 3rd quartiles; 169, 1612). 
Median number of included studies was 15.5 (1st and 3rd quartiles; 5, 30). 
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Six of the 94 for which precision could be calculated were described as updated 
systematic reviews. Here, the number of studies added in the update was used as the 
numerator and the number of records retrieved by the update search was used as the 
denominator. Median search precision for these was 0.023 (1st and 3rd quartiles; 0.016, 
0.045).  
The number of records screened is compared to the number of included studies in 
Figure 37 and the distribution of  precision by retrieval size is shown in Figure 36. 
In these figures, two outliers are excluded, one case with 10,578 records screened 
and 254 included studies and precision of 0.038,287 and another with 64,586 records 
retrieved and 2443 included studies for precision of 0.024.288 The Gulmezoglu review had 
the largest retrieval of any review of which I am personally aware. Not surprisingly, they 
published an article on the experience.289 
All systematic reviews included in our cohorts and searched with the test searches 
were systematic reviews of interventions (See Methods 3.3). Intervention studies may 
benefit from the existence of search aids for identifying clinical trials, such as the 
Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Highly 
Sensitive Search Strategies for MEDLINE, and the MEDLINE Randomized Controlled 
Trial publication type tag, and so may achieve higher precision than is possible in 
searches for other types of systematic reviews where such tools still need to be developed. 
Precision was calculated for each type of systematic review represented in the 
Epidemiology of Systematic Reviews cohort (Table 66, Error! Reference source not 
found.). Searches for systematic reviews of interventions show no better precision than 









Table 66. Precision for Different Types of Systematic Reviews 
Focus of the Review N Median 1st Quartile 3rd Quartile 
Intervention (Treatment or Prevention) 71 0.027 0.011 0.076 
Diagnosis 10 0.028 0.016 0.251 
Epidemiology 4 0.040 0.029 0.103 
Other*  9 0.065 0.014 0.103 
* Other includes harms, education, associational studies, instrumentation and research 
methods. 
 
Sixty-eight of the 94 (72.3%) were described as restricted to randomized 
controlled trials. Median precision for these searches was 0.024 (1st and 3rd quartile; 
0.013, 0.068) while median precision for the 25 systematic reviews not restricted to 
randomized controlled trials was 0.034 (1st and 3rd quartile; 0.015, 0.107). 
6.26 RECALL OF THE AUTHORS’ SEARCHES FROM THE ORIGINAL REVIEWS FOR 
UPDATING 
In the Cochrane updates, all studies added in the updates were indexed in 
MEDLINE. Performance of the author search was assessed and found to be variable, 
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achieving perfect recall of new relevant studies in two Cochrane updates while failing to 
recall any of the new relevant studies in the other four. Overall recall of new evidence 
was 0.60.  
AHRQ author searches showed a similar pattern of results compared to the new 
evidence found by the test searches. Four achieved perfect recall but the remaining six 
searches had recall below 0.30, and in two cases failed to recall any of the new evidence. 
Overall recall of new evidence was 0.52 for the AHRQ Evidence Report author searches.  
The author search strategy used for the original review was modified for update in 
two Cochrane reviews (33.3%), and unchanged from the original in the other four reviews 
(66.6%). One modification improved recall of the MEDLINE-indexed studies included in 
the original review from 0.50 to 0.67, the other reduced it from 0.42 to nil.  
Table 67. Recall of New Evidence by the Actual MEDLINE Search Used in the 
Original Review 
 Recall of New Records Recall of New N 
Cochrane Updated Systematic Reviews (n=6) 0.60 0.15 
AHRQ Evidence Reports (n=10) 0.52 0.77 
Our practice of allocating all N to a single report, in those cases where multiple 
reports of the same study had been identified, could have lowered recall of new N. 
Therefore, the relevant new evidence was re-examined and, if any report of a relevant 
study was found, the N was credited. All studies added in the Cochrane updates had N 
attributed, so the allocation practice had no impact on those results. For the ten AHRQ 
reports, three had to be reexamined. In the other seven reports either all of the new studies 
were found by the authors’ ACTUAL search (n=4), none of the new studies were found 
(n=2) or all relevant new studies had new N attributed (n=1). For the three systematic 
reviews that were re-examined, there no cases where re-attribution of N would change the 
result. In all cases, either the main report of the study had been found, or none of the 
reports of the same study had been found.  
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6.27 RECALL OF ORIGINAL EVIDENCE BY SEARCHES USED IN THE ORIGINAL 
REVIEWS 
The performance of the authors’ MEDLINE searches in the original reviews was 
examined when the true positive and true negative training sets were being developed for 
SVM testing. First, known-item searches of included studies for each systematic review 
showed that the number of MEDLINE-indexed records was 97 for the Cochrane cohort 
and 972 for the AHRQ cohort. Of these, 396 (37%) were not found by MEDLINE 
searches used in the review – these are false negatives. Conversely, the 673 that were 
found represent recall of 0.63. AHRQ Evidence Reports had many more included studies 
than did Cochrane reviews (Table 68). Although the median number of included studies 
not retrieved by the MEDLINE search was higher for the AHRQ Evidence Reports, this 
was offset by the larger size of the reviews. Median recall of MEDLINE-indexed studies 
was 0.60 for AHRQ Evidence Reports and 0.49 for Cochrane reviews. Overall recall of 
the authors’ search in AHRQ Evidence Reports was 0.64 and for Cochrane Reviews, 
0.50. 
Table 68. Number of Included Reports from the Original Reviews Indexed in 
Medline and not Retrieved by the Authors’ Search for the Cochrane and AHRQ 
Cohorts 
 MEDLINE indexed   Not retrieved by the MEDLINE search 
 Median  1st, 3rd Quartile Median 1st, 3rd Quartile 
Cochrane 17 13.75, 19.5 6.5 3.5 , 11 
AHRQ 96 32.0, 121.7 23.5 15.25, 28.5 
Overall 30 18.75, 111 15.5 7.25, 24.75 
 
6.28 RELATED ARTICLE SEARCHING AS AN ADJUNCT SEARCH IN THE ORIGINAL 
REVIEW 
In the cohort of updated Cochrane reviews, the reviewers’ MEDLINE searches 
missed included studies that were indexed in MEDLINE in all six of the original 
systematic reviews. The search used by the authors in the update did not improve upon 
this performance (Table 67). The related article search was run to see how many of the 
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MEDLINE-indexed included studies could be detected, and how many of the studies 
missed by the authors’ search would be detected (see Methods 4.6).  Performance of the 
Related Article RCT search was good in five of the six Cochrane reviews (Table 69). 
Retrieval of MEDLINE misses by the Related Article RCT searches was 0.81 overall (43 
of 53 retrieved), and recall was 0.95-1.00 in five of the six systematic reviews. Precision, 
estimated based on trimming the Related Article RCT set to those records entering 
MEDLINE prior to 2005, was adequate, ranging from 0.028 to 0.282 in the individual 
reviews, and was 0.068 overall.  
Thus, related article searching appears to be a useful adjunct to the MEDLINE 
search undertaken by these review authors. 
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Table 69. Related Article RCT Performance in Retrieving Studies in the Original 

















































N of MEDLINE indexed 
studies included in the 
original review 23 6 12 15 20 21 97 
Retrieved by Related 
Article RCT search 19 6 10 8 14 20 77 
Recall of Related Article 
RCT search 
0.83 1.00 0.83 0.53 0.70 0.95 0.79 
Missed by Original Search  12 3 8 5-10† 1 19 53 
Miss by Original Search but 
Retrieved by Related 
Article RCT  12 3 8 1 1 18 43 
Recall of MEDLINE misses 
by Related Article RCT 1.00 1.00 1.00 0.10 1.00 0.95 0.81 
Size of Related Article RCT 
retrieval* 362 213 162 152 169 71 1121 
Precision of RI search 0.052 0.028 0.062 0.053 0.083 0.282 0.068 
*All were date limited to 2005 or earlier 
†High and low estimates under various interpretations of the authors’ search 
 
6.29 PERFORMANCE OF THE HSSS REVISED 
The performance of the revised Highly Sensitive Search Strategy (HSSS2006) was 
tested in the updating dataset (see Methods 4.7). Three sources of “relevant evidence” 
were used; the signaling evidence, targets from the six updated Cochrane reviews used to 
test SVM, and all Eligible evidence from the screened material, including candidate 
studies from the test searches and reviewer nominations. Removing overlap, there are 695 
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pieces of relevant evidence with PMIDs. The HSSS2006 retrieved 689 of these (recall = 
0.991).  
Of six PMIDs not retrieved, five were from the candidate and reviewer 
nomination lists (n=687), none were from the new included studies in the updated 
Cochrane reviews (n=27), and two were from the final signaling evidence set (n=58).  
In comparison, the original HSSS missed 23 records from the set of 687 On Topic, 
Eligible candidates and reviewer nominations (3.3%), two of the 27 added studies from 
the updated Cochrane reviews (7.4%) and one record from the final evidence set of 58 
new studies (1.7%). Overall recall was 0.965. 
The total retrieval size of the HSSS2006 was 2,060,797 records and of the original 
HSSS was 784,592 records when tested in Ovid MEDLINE as of January 26, 2009. 
6.30 CHARACTERISTICS OF THE EVIDENCE IN UPDATED SYSTEMATIC REVIEWS  
6.30.1 Where Does The New Evidence Come From? 
There were 421 unique new MEDLINE-indexed records found eligible for the 
systematic reviews in main cohort. These were examined to determine some bibliographic 
characteristics (see Method 4.8.1). There were 270 different Eligible PubMed records for 
the AHRQ Evidence reports, and 20 new Eligible records for the cohort of updated 
Cochrane reviews. There was overlap between sets, and when duplicate records were 
removed, the number of records dropped from 711 to 690. The broad bibliographic 
characteristics of the new evidence are shown in Table 70. 
Table 70. Bibliographic Characteristics of New Evidence 
Characteristic N 
Number of references 690 
Authors 4045 
MeSH terms 1528 
Periodicals 245 




6.30.2 Journals Contributing New Evidence 
The Abridged Index Medicus list includes 119 journal titles. Forty-five of those 
journals (37.8%) yielded new Eligible evidence, and Abridged Index Medicus Journals 
account for 43.3% of the new eligible records but make up only 18.3% of the journals 
represented.  
Examining the distribution of journals by productivity, 11 journals each with 10 or 
more Eligible articles account for a third of the new MEDLINE-indexed evidence. This is 
the first zone of a three zone Bradford distribution, and in this case includes 241 articles, 
34.9% of the total. The next rough third encompasses 51 journals each with between 3 
and 9 articles. This second zone accounts for 226 articles, 32.7% of the total. The final 
third encompasses 183 journals each with 1 or 2 articles. This final zone has 223 articles, 
32.2% of the total. 
The distribution, shown in Figure 39, is convex through all three zones. The 
classic distribution describing a field, at least part of zone one (shown at the bottom of the 
graph) rises above the diagonal, and this represents the core or nucleus. The middle zone 
would be linear, while the third zone or part of it, (here at the top of the graph) droop 
below the line plotted on the linear part of the semi log distribution.290 In this distribution, 
we see a large core rising above the diagonal. All of the first zone is in the core, and even 
part of the second zone, when a diagonal is plotted along the most linear part of the semi-
log curve (Figure 39). The third zone rises above the diagonal, due to the large number of 
journals contributing the same number of articles. All journals in the third zone 
contributed either 1 or 2 pieces of new evidence.  
Taking the nucleus as those journals in zone 1 and the part of zone 2 rising above 
the diagonal, the first 13 data points are included. These represent 13 journals all 
contributing 9 or more pieces of new evidence. These journals, along with the number of 




Table 71. Journals Publishing the Most Eligible New Evidence  
Zone Title AIM* Impact 
Factor 
Articles Cumulative 
% of New 
Evidence 
1 JAMA Yes 23.175 38 5.5 
 New England Journal of 
Medicine 
Yes 51.296 37 10.9 
 Circulation Yes 10.940 34 15.8 
 Lancet Yes 25.800 33 20.6 
 American Heart Journal Yes 3.514 23 23.9 
 American Journal of Cardiology Yes 3.015 20 26.8 
 Journal of the American College 
of Cardiology 
 9.701 14 28.8 
 American Journal of Geriatric 
Psychiatry 
 2.894 12 30.6 
 Alimentary Pharmacology & 
Therapeutics  
 3.287 10 32.0 
 Diabetes Care  7.912 10 33.5 
 European Heart Journal  7.286 10 34.9 
2 American Journal of 
Gastroenterology 
 5.608 9 36.2 
 International Journal of Geriatric 
Psychiatry 
 2.197 9 37.5 
*AIM is Abridged Index Medicus 
Bradford’s explanation of the concentration in zone 1 and scattering in zone 2 
related to the organization of the literature – the core are journals devoted to a subject.291 
In this case, we probably have many topics, defined by population and intervention, 
which we have classified into 12 medical specialties (see Methods 3.35), several of which 
are reflected by specialty journal in Zone 1. i.e. cardiology and psychiatry. As well as 
subject concentration, we are seeing a concentration of certain types of evidence,  
randomized controlled trials in important topics, concentrating in a few journals. The 
correspondence between Abridged Index Medicus membership and Bradford zones is 
quite good, 54% of titles in zone 1 are Abridged Index Medicus journals, as are 35% of 
zone 2 and 11% of zone 3.  
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 Of the 245 journals represented, 204 had journal impact factors in the 2007 
Journal Citation Reports.241 Journal impact factors ranged from 51.296 for the New 
England Journal of Medicine to 0.329 for the Saudi Medical Journal, with a median of 
2.864 (first and third quartiles; 1.769, 4.644). Looking at the journal impact factors across 
the zones (Table 72 and Figure 39) it is apparent that the higher impact journals 
concentrate in zones 1 and 2, but that lower impact journals are well represented in all 
zones. Journal Citation Reports does not assign an impact factor to all journals. Most 
journals without impact factors were found in the third zone, contributing either one or 
two pieces of new evidence. Fifty-five studies (8% of new evidence) came from journals 















Drop lines indicate the limits of the zones. The diagonal represents the segment 
with linear growth on a semi-log scale. 
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Table 72. Journal Impact Factors of New Evidence by Zone 
 
Median 1st Quartile 3rd Quartile N of Journals without 
Impact Factors 
Zone 1 7.912 3.401 17.058 0 
Zone 2 4.021 2.529 5.981 4 
Zone 3 2.523 1.487 3.801 37 
Overall 2.864 1.769 4.664 41 
 
In summary, the journals publishing new evidence for this cohort followed a 
Bradford distribution, with a few journals contributing a disproportionate amount of 
evidence and a long tail of journals contributing one or two new studies. Journals 
included in Abridged Index Medicus and journals with high journal impact factors were 
strong contributors, although evidence came from journals not in Abridged Index 
Medicus and with no journal impact factor. It would be interesting to examine the 
scattering of evidence from systematic reviews such as those undertaken for management 
and policy making and described by Greenhalgh as being based on “complex and 
heterogeneous evidence”292 rather than studies of intervention effectiveness examined 
here. 
6.31 DOES OLD EVIDENCE PERSIST?  
Eighteen systematic reviews,177,177,274-276,278,279,279,293-304 all of which were 
Cochrane reviews, had explicit updates and these were examined to determine the 
persistence of evidence (see Methods 4.8.2). Six of the reviews (33.3%) had references to 
included studies that were present in the original but not in the update.275,296,297,299-301  
Such references ranged from one to eight in number and made up between 4.5% and 
87.5% of the total trials in the original review. Overall, in this subset of 18 updated 
reviews, 25 of the 329 (7.6%) references in the original reviews were excluded from the 
updates. 
Looking at the distribution of these “Original Only” references across the 
quintiles, the proportion of the updated systematic reviews in the age quintile where the 
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update excluded references that were in the original review increased as the age of the 
oldest trials increased (Figure 40). 
 
 
6.31.1 Characteristics of References to Studies Excluded on Update 
The excluded references were neither the oldest nor newest of the studies included 
in the original. They tended to have somewhat smaller N than studies retained in update. 
One exception was a single study excluded from CohortID28275 – the excluded study was 
the second newest and the largest in the trial. It was excluded from the update as it was 
not placebo controlled. Overall, the most notable characteristic of these excluded trials is 
that only 11 of 25 (44%) of them were indexed in MEDLINE. 
6.31.2 Reasons for Exclusion 
All exclusions were acknowledged and explained by the investigators, with the 
exception of one systematic review that excluded a single study on update.296 This 
accounting occurred either in the “Reasons for Exclusions” list or the “What’s New” 
section of these Cochrane reports. 
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The most common reason for exclusion was that the original study had been 
reported as an abstract, but was replaced by a report in a full publication – that is, only the 
report was excluded, not the study (n=4 reports representing three studies). Cochrane 
reviews use study-based reporting, where references to studies are grouped by study, 
rather than being presented in a standard reference list in order of appearance in the text 
or by date. An asterisk is used to designate the major publication of the study. Thus, these 
excluded references could still have been reported although the “major” report would 
presumably become the full publication. An additional two reports of a pilot study, one of 
which was an abstract, the other a journal publication, were replaced by another 
publication released the following year by the same author. It is not clear if this was the 
same or a different study. Treating these six cases as partial results being subsequently 
published more fully, the mean lag in publication between versions was 2.3 years. The 
median difference was 2.5 years with a minimum of one and maximum of four years. 
Scherer et al.247 show that approximately 45% of reports of randomized controlled trials 
initially published as abstracts are published as peer-reviewed journal articles within this 
time frame, with just over 60% ever being fully published (Figure 2). Positive results 
favour publication.  
Four (16%) studies in two systematic reviews were excluded from the updates for 
design reasons.  One was not placebo controlled and three were open label. One (4%) 
study was excluded based on intervention. It used a higher dose of the intervention than 
was eventually licensed. Six studies (24%) were excluded based on population. These 
came from one systematic review of TENS in the treatment of chronic low back pain.301 
The definition of “chronic” had been changed from pain persisting eight or more weeks to 
pain persisting 12 or more weeks. These six studies became ineligible as they included a 
mix of patients with chronic pain and some with duration of symptoms less than 12 
weeks. Only one trial from the original review met the revised criteria and was retained. 
One additional trial was added in the update. The update found the intervention less 
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effective than had the original, and one commentator (in the feedback section of the 
review) argued that the redefinition and exclusion biased the review against the treatment. 
In one case, the systematic review was split into two separate reviews on 
update.305 The topic was pressure sores, and studies of treatment and prevention were 
treated separately. The eight studies not appearing in the update (which was the 
prevention study) appeared to deal with treatment. As of The Cochrane Library Issue 4, 
2007, the treatment review had not been published so inclusion of those eight reports in 
that systematic review could not be verified. 
In summary, few papers included in original reviews are excluded from explicit 
updates. Such exclusions occur for various reasons including replacement by a more 
complete report of the study and changes in the eligibility criteria for the systematic 
review. Study-based reporting of references is helpful, and it seems preferable to retain 
references to abstracts even when a more complete version of the study has available at 
the time of update, unless those preliminary results are discordant with the final results. 
Similarly, a section detailing changes in inclusion criteria for the review is helpful when 
such changes occur between versions of reviews. This group of Cochrane reports 
demonstrates that such exclusions can be accounted for. Full accounting is helpful to the 
reader who can assess the influence of these changes on the results of the review. 
Although reviews with older evidence were more likely to have reports included in the 
original review but excluded on update, this does not seem informative. 
6.32 IS MATURITY OF THE LITERATURE A PREDICTOR OF SURVIVAL? 
The final avenue of exploration is the age of the literature reviewed, using the 
oldest included study to represent the maturity of the evidence base (see Methods 4.9). 
The cohort of 100 reviews considered in the survival analysis were divided into five 




Table 73. Distribution of Systematic Reviews by Age of First Evidence 
  Maximum Age of First 
Evidence at Search 
Reviews with Major or 
Potentially Invalidating New 
Evidence (n=59) 
 Quintile  Years N in 
Quintile 
 N % of Quintile 
Youngest 1 6 25 20 80.0 
  2 10 17 13 76.5 
  3 16.4 18 9 50.0 
  4 22 23 10 43.5 
 Oldest 5 47 17 7 41.2 
 
In keeping with the more limited time since the first trial, systematic reviews in 
the lower quintiles tended to have fewer included studies, and fewer included study 
participants – with the exception of the average included N in the systematic reviews of 
the fourth quintile (Table 74 ). 
Table 74. Size of Systematic Reviews by Age of First Evidence 
 Quintile  Mean Number of Included 
Trials in Original Review 
Mean Total N of All Trials 
Included in Original Review 
Youngest 1 12.6 9247 
  2 13.5 10068 
  3 17.7 12212 
  4 16.7 3780 
 Oldest 5 39.6 24757 
 
One indicator of the stability of reviews relative to the age of the included 
evidence is the number of systematic reviews in each quartile with potentially 
invalidating or major new evidence. There are 100 reviews in the cohort, 58 of these had 
potentially invalidating or major new evidence that would have altered the clinical 
application of the evidence. The array of these reviews, by quintile, is shown in Figure 41 
and Table 73. 
The criteria of potentially invalidating new evidence could be met through one of 
three qualitative signal; opposing findings; substantial harm; or a superior new treatment. 
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Four qualitative signals for major changes in evidence were; important changes in 
effectiveness short of ‘opposing findings’; clinically important expansion of treatment; 
clinically important caveat and finally; opposing findings from discordant meta-analysis 
or non-pivotal trial. These are fully defined in the on-line Appendix A of the AHRQ 
technical report.16 Fifty-six of the 59 reviews with signals for updating had qualitative 
signals. The final three reviews306-308 met statistical criteria only. 
 
Only three of the qualitative criteria occurred with any frequency; potentially 
invalidating opposing findings (n=8, 14.3% of qualitative signals) major changes in 
effectiveness (n=27, 48.2% of qualitative signals) and major caveats (n=16, 28.6% of 
qualitative signals). The other four qualitative signals occurred only five times in this 
cohort, and accounted for only 8.9% of qualitative signals. They are not considered 
further. Distribution of the three common qualitative signals are shown in Figure 42.   
Caveats and changes in effectiveness, both considered major not necessarily 
invalidating new evidence, occurred more frequently in reviews with a more recent 
evidence base. Opposing findings, considered by us as potentially invalidating evidence, 
occurred sporadically – that is, infrequently, and with no discernable pattern. This can be 
characterized as a trend in the evidence (Table 75). 
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 In 12 of the 54 (22.2%) systematic reviews with signals for updating, the signal 
involved harm. These signals were distributed evenly through the quintiles of age of 
oldest evidence (28= 5.71, P2 sided =.680).  
Table 75. Quintile of Age of First Evidence by Specific Qualitative Criteria  






Movement of One 
Point Toward More or 
Less Effective than 
Thought 
Total 
Youngest 1 2 7 7 16 
  2 1 8 3 12 
  3 1 5 3 9 
  4 3 5 1 9 
 Oldest 5 1 2 2 5 
Total 8 27 16 51 
Eta not significant (p with quintile as dependent measure = 0.180). When only caveats and small 




Heterogeneity, publication bias and ongoing trials refer to issues of the evidence 
arising in the original review. These may be influenced by the maturity of the oldest 
evidence.  
Table 76. Attribute of the Evidence by Quintile of Age of First Evidence  




 Heterogeneity  
(Known or Suspected) 
in Original Review 
Publication Bias 
(Known or Suspected) 
in Original Review 
Ongoing Trials 
Identified by Original 
Reviewers 
   
Youngest 1 0.76 0.24 0.28 
  2 0.47 0.06 0.34 
  3 0.39 0.17 0.22 
  4 0.65 0.26 0.17 
 Oldest 5 0.71 0.06 0.29 
 Overall 0.61 0.17 0.26 
For these indicators, the total number of systematic reviews in the quintile forms 
the denominator. Observed publication bias is low and fluctuates. This may be more a 
factor of incomplete assessment for the presence of publication bias by the original 
reviews. It was assessed in only 40% of these systematic reviews.17 The percent of 
systematic reviews reporting awareness of ongoing trials is likewise low, but quite stable, 
as would be expected under linear growth of trials. Still, if later trials involved longer-
term follow-up of participants, one might expect to see an increase in this measure.  
The presence or suspicion of heterogeneity was a significant predictor of survival 
in the multivariate analysis.17 Heterogeneity was common in all quintiles, but less so in 
the second and third quintile. This could be a chance observation, but could also be based 
on changes in the application of the intervention in the context of trials – possibly early 
work lacks refinement in terms of selection of the population most apt to benefit from the 
intervention, or variation in dosing strategy until optimal doses are established. Later 
trials, in part as a function of their larger size, could explicitly study subgroups or 
particular populations as the application of the intervention becomes more refined. Such 
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trends should be reflected in two of the categories of qualitative evidence, caveats and 
expansions of treatment.  
 
Caveat (A4): Pivotal trial, new meta-analysis, “discordant” meta-analysis, trial 
indexed in ACP Journal Club, more recent practice guideline, or recent textbook does 
not contradict the previous review, but adds an important caveat about the patient 
populations who benefit.  
Such caveats emerged for 27 of the 100 systematic reviews in the cohort. They were 
common in the reviews with the newest evidence and declined by cohort. 
 
Expansion of treatment (A5): Instead of a caveat, there has been expansion of the role 
of the treatment (e.g., the treatment has now been shown to be of benefit in primary 
prevention, not just secondary; or now shown to be of benefit in children or aged 
population etc).  
In fact, the expansion of the role of treatment was observed only three times in the 
cohort of 100, once in each of the first, second and fifth quintile. Thus, these two signals 
potentially arising from heterogeneity in the evidence do not show the same bimodal 
pattern as the heterogeneity variable.  
6.32.1 Survival by Age of Oldest Included Evidence 
When the 100 systematic reviews included in the original survival analysis were 
divided into quintiles based on the age of the oldest included evidence, signals were more 




 Table 77. Quintile for Age of Oldest Evidence by Signal  
  Signal    
 











 Youngest     1 8 32.0 17 68.0 25 
 2 4 23.5 13 76.5 17 
 3 10 55.6 8 44.4 18 
 4 13 56.5  10 43.5 23 
 Oldest       5 11 64.7 6 35.3 17 
 Total 46 46.0 54 54.0 100 
 
Figure 43 shows the survival curve of the complete sample. Figure 44 shows the 
survival curve for each quintile based on age of oldest included evidence. In these figures, 
each step in the line indicated the point in time where one or more system reviews went 
out of date based on a signal from new evidence. Each tick on the horizontal line 
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represents the point where one systematic review was censored, that is, survived to the 
end of the follow period before going out of date.  
 
The first quintile, those systematic reviews where the age of the oldest included 
evidence was six years or less at the time of the search, showed the shortest survival. All 
were out of date or censored by eight years. While the second quintile (maximum age of 
included studies of ten years) generally showed the next shortest survival, some reviews 
survived until 12.5 years. The fourth quintile actually tends towards shorter survival - any 
systematic reviews in the fourth quintile that survived eight years survived until censored 
at the end of our follow-up period. The oldest evidence in the systematic reviews in the 
fourth quintile ranged between 16.5 and 22 years. The third and fifth quintiles both show 
a pattern with most reviews surviving to the five year mark and a few surviving for the 
duration of follow-up, to September 2006.  
The median search date of all cohorts was 1998, except for the youngest cohort, 
with a median search date of 2000, so this cohort was at risk for slightly less time than the 
others. The protocol stipulated that no systematic review with a search date later than 
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2004 was eligible (see Section 4.1.2.1), and all quintiles but the oldest has one systematic 
review with a 2004 search date – the latest search date in the oldest quintile was 2003. 
 
6.32.2 Nature of the original and subsequent findings: youngest and most mature 
cohorts 
Titles and major conclusions of reviews signals for updating are presented in 
Table 79. This is followed by the classification of the qualitative signal, and the major 
supporting evidence for that classification. 
Table 78. Reviews Including the Oldest Evidence with Major or Invalidating New 
Evidence 





Collaborative meta-analysis of randomised trials of antiplatelet 
therapy for prevention of death, myocardial infarction, and stroke 
in high risk patients 
“In patients at high risk for occlusive vascular events because of 
preexisting disease, antiplatelet therapy reduces the risk for 
nonfatal myocardial infarction, nonfatal stroke, or death from 
vascular or unknown causes.”309 
Movement of one point toward more or less effective than thought: 
Promising results from the original systematic review are now 
confirmed. For a select high risk population with previous 
ischaemic cereberovascular event, the combination regimen of 
aspirin plus dipyridamole over aspirin alone as antithrombotic 
therapy reduces incidence of vascular death, stroke, or myocardial 
infarction.310 
Bucher, 1998311 Effect of HMGcoA reductase inhibitors on stroke: A meta-analysis 
of randomized, controlled trials 
“HMGcoA reductase inhibitors reduce risk for fatal and nonfatal 
stroke, coronary heart disease mortality, and all-cause mortality. 
Resins decrease risk for fatal coronary heart disease, but this effect 
has not been shown for fibrates or diet.”311 
Expansion of the role of treatment: “In patients with recent stroke 
or TIA and without known coronary heart disease, 80 mg of 
atorvastatin per day reduced the overall incidence of strokes and of 
cardiovascular events, despite a small increase in the incidence of 
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hemorrhagic stroke”.312 Thus a population that could not be 
examined in the original cohort is now examined in this major new 
trial and new information of treatment efficacy in this population is 
available. 
Cullum, 2000297 Beds, mattresses and cushions for pressure sore prevention and 
treatment 
“In patients at high risk for pressure ulcers, foam-based, constant 
low-pressure (CLP) mattresses are better than standard hospital 
mattresses for reducing pressure ulcers. High-technology, CLP, 
alternating pressure, and other surfaces have varied success in 
reducing pressure ulcers.”297 
Movement of one point toward more or less effective than thought: 
The alternating pressure devices appeared less effective than 
originally thought in the 2004 update to this review313 and a 
subsequent large trial.314 
Freemantle, 1999315 Beta Blockade after myocardial infarction: systematic review and 
meta regression analysis 
The original review concluded that beta blockers were underused 
following myocardial infarction, leading to avoidable mortality and 
morbidity.315 
Important Caveat: The new evidence, from a large trial published 
in the Lancet, found that while beta-blockers increase the risk of 
cardiogenic shock, at least initially. "Consequently, it might 
generally be prudent to consider starting beta-blocker therapy in 
hospital only when the haemodynamic condition after MI has 
stabilised."316  
Jefferson, 2001302 Amantadine and rimantadine for preventing and treating influenza 
A in adults 
“Amantadine and rimantadine are similarly effective in the 
prevention and treatment of influenza in healthy adults, but 
rimantadine is associated with fewer adverse effects.”302 
Important Caveat: The author of the original review subsequently 
recommended that use of these drugs for prophylaxis and treatment 




Lefering, 1995303 Steroid controversy in sepsis and septic shock: a meta-analysis 
“Corticosteroids do not reduce mortality in patients with sepsis, 
septic shock, or severe infections.”303 
Opposite characterization of effect: a subsequent definitive trial 
demonstrated important gains in patients with inadequate adrenal 
reserves.318 
These systematic reviews involve serious conditions, high risk populations, and 
often mortality as an outcome. While several of the changes involve effectiveness, the 
signals also involve harms or caveats regarding the application of the intervention. 
Two of the six had potentially invalidating new evidence. In one,315 the emergence 
of a harm added an important caveat to the original treatment recommendations. The 
original review concluded that beta blockers were underused following myocardial 
infarction, leading to avoidable mortality and morbidity. The new evidence, concluded “it 
might generally be prudent to consider starting beta-blocker therapy in hospital only when 
the haemodynamic condition after MI has stabilised."316 In the other review with new 
evidence potentially invalidating the original findings,303 the new evidence resulted in an 
opposite characterization of the effect. Rather than being ineffective in treating septic 
shock, a subsequent definitive trial of corticosteroids demonstrated important gains in 
some patients.318 
The other four had major new evidence, although new findings did not appear to 
invalidate the original review. In two cases, antiplatelet therapy in seriously ill patients,309 
and beds, mattresses and cushions for the prevention at treatment of bed sores297 the 
intervention appeared less effective than originally thought. In one, HMGcoA reductase 
inhibitors on stroke,311 the new evidence supported an expansion of treatment, to include 
those with prior stroke - a group excluded from the original review due to the amount of 
heterogeneity in the evidence. In the final case,302, the author of the original review 
subsequently recommended that use of these drugs for prophylaxis and treatment should 
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be limited to pandemics due to marked increase in drug resistance.317 This 
recommendation is not without controversy.319-321 
Four of the systematic reviews demonstrated a change in effect size with the 
addition of new evidence. One showed a change from non-significant to significant (but it 
became clear the intervention was less effective than originally thought), while another 
showed a gain with a decrease in the confidence interval of at least 50%. Four met one or 
more criteria involving the amount of new evidence. The four all had an increase in the 
number of patients at least 50% while one has a new study emerge that was at least three 
times larger than the previous largest trial. Three also had an increase in the number of 
trials by at least 50%. 
Titles and major conclusions of reviews without signals for updating are presented 
in Table 79. Where there was new evidence not fully consistent with the findings of the 
original review it is noted in the table. 
Table 79. Titles and Conclusions of Reviews Including the Oldest Evidence but 
Without Major or Invalidating New Evidence 
Review Title  
Adams, 2001293  Inhaled beclomethasone versus placebo for chronic asthma 
 “In adults and children with chronic asthma, inhaled beclomethasone 
diproprionate reduces airflow limitation, need for rescue bronchodilators, 
and symptoms. In patients dependent on oral corticosteroids, 
beclomethasone reduces use of oral prednisolone.”293 
 
Anand, 1999306 Oral anticoagulant therapy in patients with coronary artery disease: a meta-
analysis 
“In the presence of aspirin, low intensity OA does not appear to be superior 
to aspirin alone, while moderate to high intensity OA and aspirin vs. aspirin 
alone appears promising and the bleeding risk is modest, but this requires 
confirmation from ongoing trials”.306  
This systematic review is guarded about the benefit of this combination of 
intervention as it acknowledges that the analysis is based on smaller number 
of patients and the confidence interval is wide. Our review team concluded 
that, after adding newer eligible trials, the estimate of benefit on composite 
outcome is now more precise, albeit a bit less strong, and the risk of major 
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bleed is confirmed as significant. This was not considered a major change as 
it confirmed the conclusions of the original review.  
 
Arroll, 1999275 Antibiotics versus placebo in the common cold 
“In patients with acute upper respiratory tract infection, antibiotics are no 
more beneficial in terms of general improvement than placebo and are 
associated with a nonsignificant increase in adverse effects.”275  
With the addition of new evidence, a previously non-significant harm – 
gastrointestinal side effects, became significant, but this was not considered 
to have major implications as the original reviews had not recommended the 
treatment. 
 
Chronicle,2004322 Anticonvulsant drugs for migraine prophylaxis 
“In patients with migraine, anticonvulsants as a class are more effective than 
placebo for reducing the frequency of migraine attacks. The most common 
adverse events were nausea, asthenia or fatigue, tremor, weight gain, and 
dizziness or vertigo.”322  
Colman, 2004323 Parenteral metoclopramide for acute migraine: meta-analysis of randomised 
controlled trials 
“In patients with acute migraine, metoclopramide reduces headache pain 
more than placebo. Compared with other single agents, metoclopramide 




Are amoxycillin and folate inhibitors as effective as other antibiotics for 
acute sinusitis? A meta-analysis 
“In patients with acute sinusitis, any antibiotic reduces clinical failure. 
Newer, more expensive antibiotics are not superior to amoxycillin or folate 
inhibitors.”324 
 
del Mar, 1997a177 Antibiotics for the symptoms and complications of sore throat 
“Antibiotics (oral or intramuscular) modestly reduce the complications and 




Are antibiotics indicated as initial treatment for children with acute otitis 
media? A meta-analysis 
“In children with acute otitis media, the use of antibiotics decreases pain at 2 
to 7 days after presentation and reduces contralateral acute otitis media and 
deafness at 3 months. Antibiotics do not reduce pain within 24 hours or 






Vaccines for preventing influenza in healthy adults 
“In healthy persons 14 to 60 years of age, vaccines reduce the incidence of 
serologically confirmed influenza.”278 
 
Furkawa, 2002326 Meta-analysis of effects and side effects of low dosage tricyclic 
antidepressants in depression: systematic review 
“In adults, low-dose (75 to 100 mg/d) tricyclic antidepressants are more 
effective than placebo and as effective as standard-dose (>= 100 mg/d) 
tricyclic antidepressants and are associated with fewer dropouts from side 
effects than standard-dose regimens.”326 
Heidenreich, 
1999327 
Meta-analysis of trials comparing -blockers, calcium antagonists, and 
nitrates for stable angina 
“In patients with stable angina, -blockers and calcium antagonists have 
similar clinical outcomes. -blockers result in fewer withdrawals because of 
adverse events.”327 
 
Conditions being studied here are less serious, the interventions are mostly well 
established and in some cases the review is considering whether a new drug in a class is 
more effective than existing therapies. Although quite a bit of new evidence emerged, it 
was in accordance with the finding of the original review and mainly functioned to 
narrow the confidence interval around the point estimate. 
In eight of 11 (73%) the number of new trials increased by at least 50% and in 
seven of 11 systematic reviews (64%), the number of new patients increased by 50% or 
more, but in only one case was there a new trial at least three times larger than the largest 
trial in the original review. The accumulated new evidence reduced the width of 95% 
confidence interval by at least 50% in six cases (55%). In all but one of these six cases, 
there had been significant heterogeneity suspected or identified by the original reviews, 
while heterogeneity was a factor in one other review that did not meet any size criteria. 
Looking at reviews where the age of the oldest included trials were in the newest 
quintile, we see that more had signals for updating due to major or potentially 
invalidating new evidence. Of the 25 reviews in the quintile, 20 (80%) had major or 
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potentially invalidating new evidence signaling the need for updating. That percent 
declines with each quintile, falling to 41.2% in the quintile with the oldest included 
evidence (Table 73). Survival was also shortest in this quintile.  
Table 80. Reviews Including the Youngest Evidence with Major or Invalidating New 
Evidence 
Review Title 
Birck, 2003294 Acetylcysteine for prevention of contrast nephropathy: meta-analysis 
“In patients with chronic renal insufficiency, adding prophylactic 
acetylcysteine to hydration reduces the incidence of contrast 
nephropathy more than hydration alone.”294 
Movement of one point toward more or less effective than thought: 
Several subsequent meta-analyses found this effect non-significant after 






Effects of ACE inhibitors, calcium antagonists, and other blood-
pressure-lowering drugs: results of prospectively designed overviews of 
randomised trials 
“In patients with hypertension, diabetes mellitus, coronary artery 
disease, or renal disease, angiotensin-converting enzyme inhibitors and 
calcium antagonists are more beneficial than placebo. Calcium 
antagonists lead to a lower risk for stroke but to a slightly higher risk for 
coronary artery disease than do diuretics or -blockers.”328 
Important Caveat: A subsequent meta-analysis overturned this finding, 
concluding that “the relative risk of stroke was 16% higher for BB than 
for other drugs “.329 
Blumenauer, 
2003330 
Etanercept for the treatment of rheumatoid arthritis 
“Etanercept (25 mg subcutaneously twice weekly) reduces symptoms 
and disease activity in patients with rheumatoid arthritis.”330 
Important Caveat: The intervention appears to be more effective if 
delivered as combination therapy.331  
Boucher, 2002332 Efficacy of rosiglitazone and pioglitazone compared to other anti-
diabetic agents: systematic review and budget impact analysis 
“In patients with type 2 diabetes, little evidence exists to support 
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rosiglitazone or pioglitazone being more effective monotherapy than 
existing antidiabetic agents. When added to a nonthiazolidinedione 
agent, both drugs reduce glycosylated hemoglobin and fasting plasma 
glucose levels more than monotherapy with either agent.”332 
Important Caveat: Significant harms were identified in a new trial.333  
Brown, 2001334 Meta-analysis of effectiveness and safety of abciximab versus 
eptifibatide or tirofiban in percutaneous coronary intervention 
“The use of glycoprotein IIb/IIIa inhibitors in patients who are having 
percutaneous coronary interventions does not reduce mortality but does 
decrease the need for urgent revascularization. Abciximab, but not 
eptifibatide or tirofiban, is associated with a reduced rate of recurrent 
myocardial infarction.”334 
Movement of one point toward more or less effective than thought: A 
subsequent trial provided enough new evidence to make a trend toward 
efficacy significant. 335 
Bucher, 2000336 Percutaneous transluminal coronary angioplasty versus medical 
treatment for non-acute coronary heart disease: meta-analysis of 
randomised controlled trials 
“Percutaneous coronary angioplasty was associated with a lower rate of 
angina and a higher rate of coronary artery bypass grafting in patients 
with nonacute coronary artery disease.” 336 
Movement of one point toward more or less effective than thought: 
Where the original review concluded that the intervention was probably 
not effective, additional trials led a subsequent meta-analysis to conclude 
"In patients with chronic stable CAD, in the absence of a recent 
myocardial infarction, PCI does not offer any benefit in terms of death, 
myocardial infarction, or the need for subsequent revascularization 
compared with conservative medical treatment." 337 
Crouse, 1997338 Reductase inhibitor monotherapy and stroke prevention 
“Lowering LDL cholesterol levels by using statin monotherapy reduces 
stroke in patients with coronary heart disease.”338 
Movement of one point toward more or less effective than thought: 
Subsequent research extended the role of this intervention to primary 
prevention, even in patients without diagnosed coronary disease.339,340 
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Ducharme, 2001299 Anti-leukotriene agents compared to inhaled corticosteroids in the 
management of recurrent and/or chronic asthma in adults and children 
“In patients with chronic asthma, daily antileukotrienes are not as 
effective as inhaled corticosteroids and increase asthma exacerbations 
requiring systemic corticosteroids.”299 
Opposite characterization of effect: The review team felt that the author 
of the original review had understated his findings to some degree, 
stating "In the end the review could not clearly rule in or out anti-
leukotrienes as first line agents: “Reliable conclusions cannot yet be 
drawn regarding the efficacy of this treatment due to the paucity of trials 
published in full text”. A subsequent update, with new evidence, is 
clearer about the superiority of steroids.298 
Etminan, 2002341 Efficacy of angiotensin II receptor antagonists in preventing headache: a 
systematic overview and meta-analysis 
“Angiotensin II receptor antagonists prevent headache in patients with 
mild-to-moderate hypertension.”341 
Important Caveat: Reservations expressed in the original review due to 
lack of a clear mechanism of action are set aside by subsequent 
reviewers, although they were working with essentially the same data. 
The change is that the later review found this effect occurred with other 
hypertensive drugs.342 
Evans, 2004343 Tegaserod for the treatment of irritable bowel syndrome 
“Tegaserod is more effective than placebo for reducing some symptoms 
in women with the constipation-predominant irritable bowel 
syndrome.”343 
Important Caveat: Cases of severe diarrhea associated with dehydration 
and syncope have been described in 0.04 percent of patients, prompting 
the FDA to issue an advisory in April 2004. 
Ezekowitz, 2003344 Implantable cardioverter defibrillators in primary and secondary 
prevention: a systematic review of randomized, controlled trials 
“In patients at risk for sudden cardiac death, implantable cardioverter 
defibrillators reduce sudden cardiac death, all-cause mortality, and 
cardiac mortality.”344 
Important Caveat: The ICD malfunction replacement rate is significantly 
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higher than that for pacemakers, which must be considered when 
selecting between the new treatment (ICD) and the standard of care 
(pacemaker).345 
Gotzsche, 1995346 Somatostatin v placebo in bleeding oesophageal varices: randomised 
trial and meta-analysis 
“Compared with placebo, somatostatin did not increase survival or 
decrease the number of blood transfusions in patients with bleeding 
esophageal varices.”346 
Movement of one point toward more or less effective than thought: 
While the original review was unable to show benefit, a later systematic 
review found this to be a safe and effective adjuvant therapy.347 
Jong, 2002200 Angiotensin receptor blockers in heart failure: meta-analysis of 
randomized controlled trials 
“In patients with heart failure, angiotensin-receptor blockers do not 
reduce mortality or hospitalization rates more than do angiotensin-
converting enzyme inhibitors or placebo.”200,200 
Movement of one point toward more or less effective than thought: The 
change did not involve the main conclusion, but rather the role of 
Angiotensin receptor blockers as monotherapy, which the original 
reviewers found probably beneficial. Additional evidence makes them 
clearly beneficial.348 
Keenan, 1997349 Effect of noninvasive positive pressure ventilation on mortality in 
patients admitted with acute respiratory failure: a meta-analysis 
“Standard therapy plus NIPPV reduces mortality and the need for 
endotracheal intubation in adults in the intensive care unit with acute 
respiratory failure. The benefits are greater when only patients with 
COPD are analyzed; patients without COPD may need further study.”349 
Expansion of the role of treatment: Additional evidence supported the 
expansion of treatment to patients with acute hypoxemic respiratory 
failure not due to cardiogenic pulmonary edema and chronic obstructive 
pulmonary disease.350 
Kjaergard, 2001351 Interferon alfa with or without ribavirin for chronic hepatitis C: 
systematic review of randomised trials 
“In patients with chronic hepatitis C, interferon- plus ribavirin is more 
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effective than interferon- alone for improving the hepatitis C virologic 
response, but not for reducing liver-related morbidity and mortality.”351 
Another treatment is superior: A significantly more effective 
combination was subsequently discovered.352 
Laine, 2001353 Therapy for Helicobacter pylori in patients with nonulcer dyspepsia: A 
meta-analysis of randomized, controlled trials 
“Helicobacter pylori therapy in patients with nonulcer dyspepsia and 
Helicobacter pylori infection does not reduce symptoms.”353 
Movement of one point toward more or less effective than thought: A 
subsequent systematic review found a small, but statistically significant, 
effect.354 
Lord, 2003355 Metformin in polycystic ovary syndrome: systematic review and meta-
analysis 
“Metformin used alone or combined with clomifene is effective for 
improving ovulation rates in women with the polycystic ovary 
syndrome.”355 
Opposite characterization of effect: A subsequent much larger trial 
overturned this finding.356 




Table 81. Titles and Conclusions of Reviews Including the Youngest Evidence but 
Without Major or Invalidating New Evidence 
Review Title 
Barr, 2005357 Inhaled tiotropium for stable chronic obstructive pulmonary disease 
“In patients with stable chronic obstructive pulmonary disease, 
tiotropium reduces exacerbations and hospitalizations, and improves 
health-related quality of life.”357 
Dalby, 2003307 Transfer for primary angioplasty versus immediate thrombolysis in 
acute myocardial infarction: a meta-analysis 
“In patients with acute ST-segment elevation myocardial infarction, 
transfer to a percutaneous coronary intervention (PCI) center for 
primary PCI is more effective than immediate thrombolysis for 
reducing all-cause mortality, reinfarction, or stroke.”307 
Ducharme, 2003298 Addition of anti-leukotriene agents to inhaled corticosteroids for 
chronic asthma 
“In patients with chronic asthma who are symptomatic while receiving 
moderate-to-high doses of inhaled beclomethasone, the addition of 2 
to 4 times the licensed dose of antileukotriene (AL) agents reduces the 
rate of exacerbations that require systemic corticosteroids. Insufficient 
evidence exists that AL confers benefit over doubling the dose of 
corticosteroids or that it has an inhaled corticosteroid-sparing 
effect.”298 
Edmonds, 2001300 Inhaled steroids in acute asthma following emergency department 
discharge 
“Inhaled corticosteroids alone appear to be as effective as oral 
corticosteroids after discharge from the emergency department in 
patients with mild asthma exacerbations. Evidence is insufficient on 
the benefit of addition of inhaled corticosteroids to oral corticosteroids 
in this setting.”300 
Eikelboom, 2001358 Extended-duration prophylaxis against venous thromboembolism after 
total hip or knee replacement: a meta-analysis of the randomised trials 
“In patients who have received total hip or knee replacement, 
extended-duration prophylaxis with heparin is more effective than 
placebo or no treatment for preventing deep venous thrombosis. The 
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preventive effect is associated with increased minor bleeding.”358 
Fink, 2002359 Sildenafil for male erectile dysfunction: a systematic review and meta-
analysis 
“Sildenafil improves erectile dysfunction and is well tolerated.”359 
Kong, 1998308 Clinical outcomes of therapeutic agents that block the platelet 
glycoprotein IIb/IIIa integrin in ischemic heart disease 
“Platelet glycoprotein IIb/IIIa-receptor antagonists reduce the 
combined end points of death or MI and death, MI, or 
revascularization in patients with ischemic heart disease.”308 
Lane, 1995360 Endoscopic ligation compared with sclerotherapy for treatment of 
esophageal variceal bleeding: A meta-analysis 
“Compared with sclerotherapy, endoscopic ligation has lower rates of 
rebleeding, mortality, and complications and requires fewer treatments 
for obliteration of esophageal varices.”360 
 
These all had clear statements of efficacy, although two 298,300 claim insufficient 
evidence to draw conclusions for some comparisons. 
 
6.32.3 Summary 
Systematic reviews done closer to the date of the first included trial tend to have 
fewer trials, fewer participants were enrolled in those trials, and major and potentially 
invalidating changes in evidence were seen more often than those reviews with a longer 
record of trials. Changes such as caveats involving certain study populations and shifts in 
strength of the evidence were seen in the same proportion as in the oldest cohort, as did 
signals involving harms.  
Finding of reviews done closer to the date of the first included trial seemed more 
robust when they supported the use of the intervention under consideration than when 
findings were negative or inconclusive. Reviews that were overturned sometimes went 
from non-significant findings to significant findings, but rarely did the direction of effect 
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reverse. Thus new evidence could be largely overcoming the heterogeneity commonly 
found in these reviews and causing the meta-analysis to gain power through the addition 
of studies and participants. Still, one intervention was superseded by another more 
effective intervention, and another intervention thought to be effective was shown 
ineffective by a large trial.  
Findings of reviews done in topics with a more established evidence base tended 
to be overturned when the treatment had been considered effective in the initial review. 
These reviews had much larger evidence bases than the first quintile reviews, both in 
terms of patients and studies. These results most commonly overturned because more was 




Chapter 7: Discussion and Conclusion 
 
7.0 INTRODUCTION 
In the discussion, I will review the major findings of this research. First, I will 
review the performance of the test searches, and the patterns of the dependence between 
them. I will discuss two search methods that performed below expectations. Later I will 
discuss how the complementary nature of some of the search methods can be used in 
update searching to replace some of the more time consuming aspects of standard 
systematic review searches. Before that discussion, however, I will discuss the 
implications of the historical context in which systematic review searching developed, 
and the opportunities and challenges that history creates for update searching. Next, I will 
review the performance of the searches used in the original reviews, and in the Cochrane 
sample, their adaptation and performance in the updates.  
From there, I argue that the performance of the test searches supports replacing 
some of the multi-database, multi-modal aspects of searching used (and apparently 
needed) in original reviews with a more streamlined approach in the update. Namely, I 
will argue that Boolean searches and similarity searches represent two independent 
approaches to the literature, and that they are sufficient to achieve optimal recall from a 
single database in most cases. By examining the bibliometric characteristics of the 
original evidence base, and leveraging the original evidence base through similarity 
search methods, we will often find that we can simplify the update search, reducing the 
number of databases and eliminating the systematic non-database portion of the search. 
Finally, I will discuss barriers to implementation, including limitations of the 
generalizability of these results, and suggest areas for further research and development. 
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7.1 SUMMARY OF MAIN FINDINGS 
The main experiment examined the performance of searches in three cohorts. Two 
Boolean searches, two similarity searches and one non-database search approach were 
tested. The two Boolean searches were based on a simple subject search that used a mean 
of 3.6 terms and 1.5 search features (Section 6.3.1). The subject search was paired with a 
filter selecting only RCTs from Abridged Index Medicus journals and with the balanced 
Clinical Query.  
Clinical Query provided good recall but with large retrievals. Abridged Index 
Medicus RCT had smaller retrieval sizes and identified fewer new eligible studies, but did 
detect many large studies, so performed well when recall of new participants was 
considered. The two similarity searches were Support Vector Machine (SVM), where 
various cut points were tested in the Cochrane and AHRQ cohorts, and an algorithm 
based on related article searching in PubMed. The Related Article search showed the 
highest recall of new eligible studies overall. Recall with SVM was lower, and it trailed 
the Clinical Query. SVM’s advantage was smaller retrievals. The non-database approach 
was citing reference searches, where the citing references were randomized controlled 
trials that cited the systematic review being updated. A high proportion of Citing RCTs 
were eligible for inclusion in updated reviews, but this method identified only a small 
proportion of all relevant new studies (Section 6.8.1).  
Relative performance of the test searches was stable across the three cohorts, 
although there was a ceiling effect in the updated Cochrane reviews, where most searches 
performed strongly. Relative performance was also stable regardless of whether the 
intervention was a drug, device or procedure (Section 6.9), and whether the evidence 
appeared before or after the signal that an update was necessary (Section 6.8). All search 
approaches showed variable performance across clinical areas, but Related Articles RCT 
showed the most consistency (Section 6.8.1). 
Precision, tested in the AHRQ cohort, ranged from 0.111 to 0.192 for the more 
productive test searches but reached 0.515 for the Citing RCT method. (Section 6.10) 
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Similarity methods showed higher precision than did the two Boolean approaches. 
Precision and recall showed a strong negative correlation whether recall of new studies or 
recall of new participants was considered (Section 6.11) 
Relevance ranking was examined for the similarity searches. Placement of eligible 
studies near the top exceeded chance for both the SVM and Related Article RCT 
searches. (Section 6.12.1 and 6.12.2) When receiver operating characteristic curves were 
examined for these searches, SVM outperformed Related Article RCT in the Cochrane 
set, although the area under the curve was significantly greater than chance for both. Area 
under the curve was less impressive in the AHRQ Evidence Report searches, with only 
the Related Article RCT search improving over chance (Section 6.13). 
The structural relationship between search methods was explored using capture-
recapture and multidimensional scaling. The Boolean and similarity searches appeared to 
be independent, based on capture-recapture population estimates (Section 6.20.4) and 
appeared to operate on different dimensions (Section 6.21). The approaches 
complemented each other and the pairing of Related Article RCT and Clinical Query 
gave excellent recall of new relevant material (Section 6.24). 
7.1.1 Performance of SVM 
Support Vector Machine has an excellent record of accomplishment174,361,362 and 
was expected to perform well in this task. It was surprising that the Related Article search 
outperformed it. It could be that the PubMed Related Articles feature is more effective 
than has been recognized simply because it has been overlooked for study. Still, Cohen’s 
work with SVM, which appeared while this research was underway, found the MeSH 
terms figured prominently in successful ranking.111 We limited emphasis on MeSH due to 
technical limitations with refreshing the database to ensure the MeSH indexing was 
completely up to date. It may be that SVM performance would have been improved had 
we given more weight to MeSH terms. On the other hand, because the role of MeSH was 
restricted, these results give some indication of the sort of performance that could be 
achieved by using Support Vector Machine with databases other than MEDLINE. 
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7.1.2 Performance of Citing Reference RCT 
The Citing RCT approach was not useful in these tests. In part, this is due to the 
short update interval over which we were working. Pao and Lee noted that the most 
recent articles would not have had time to be cited.162 I tested a very simple approach to 
using citing references. I only examined citations to the systematic review itself. 
Larson363 suggests using network analysis of overlapping citations. Such a network could 
be constructed from the subsequent citations of all included studies. A more complex 
approach could broaden the scope of retrieval, and could possibly overcome the citation 
lag problem inherent in looking only at citations to the systematic review itself. 
 
7.2 EVOLUTIONARY INFLUENCES 
The original vision of The Cochrane Library was for it to be a library of living 
documents. These documents would be systematic reviews with meta-analysis, and as 
each relevant new study was added, the statistical computation and graphical presentation 
of the results would be updated in real time. The importance of regular updating was 
recognized, and the early Cochrane Collaboration Reviews were to be updated “at least 
annually”. In that vision, new material would be found through centralized and ongoing 
efforts based on hand searching of journals and electronic searches. Those studies using a 
controlled clinical trial design would be added to the Cochrane CENTRAL register of 
controlled trials, and to systematic reviews for which they were relevant (see Section 2.2). 
Two main influences prevented the realization of that vision. First, awareness of 
the complexity of managing bias in systematic reviews appears to have increased rapidly. 
It would soon have become clear that simply adding one or more new studies, updating 
the results in real time, and applying that new result to clinical practice was naïve. The 
original approach was likely based on the idea that setting the bar for eligible study 
designs at randomized controlled trials, as Archie Cochrane proposed, would provide 
adequate protection against methodological bias.22 In fact, not all randomized controlled 
trials are created equal and quality assessment of included studies is now an important 
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part of conducting a systematic review. For example, The Cochrane Collaboration has 
introduced a “Risk of Bias” table to their reviews in which each included study is 
assessed on several dimensions that could potentially introduce bias.364 This assessment 
must be completed for each existing Cochrane Collaboration Review when it is next 
updated. 
Second, although CENTRAL is still considered the single best source of new 
studies,41,79 there is no evidence that reviewers anywhere have come to consider it a 
sufficient source.365 Thus, broader searches, involving multiple databases, are used. The 
large retrievals from more comprehensive updating searches paired with the continual 
advances in methodological and reporting complexity make updating a much more 
complex task than just adding several new studies. Large volumes of new material may 
be identified and require screening and assessment. If studies with stronger research 
designs, better diagnostic criteria, less subjective outcomes or other improvements 
appear, the inclusion criteria may need to be refined and all included studies may need to 
be re-assessed and some may be excluded (see Section 3.2.5). The report structures 
become more complex and detailed over time, increasing the complexity of updating as 
all evidence may be re-evaluated and additional data may need to be extracted from 
studies included in the original review.96 These two influences, the greater attention to 
bias and the complex searches, make periodic updating more feasible than continual 
updating.  
7.3 MULTIPLE DATABASE SEARCHING AS THE NORM 
7.3.1 Actual versus Potential Contribution of Databases 
In the absence of any other proven approach, current guidance from the Cochrane 
Updating Group has the reviewers repeat the search in each database used in the original 
review.118 Any decision to search multiple databases has important implications for 
updating a systematic review, so alternatives should be considered.  
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The notion that only about half of the relevant material for reviews will be found 
from a search of MEDLINE stems from the article that introduced the original highly 
sensitive search strategy, the Randomized Controlled Trial publication type, and the 
Cochrane/National Library of Medicine re-tagging effort.64 This article is still heavily 
cited today.*** In a commentary on that paper, close to the time of its publication, Hersh 
pointed out that the introduction of the Randomized Controlled Trial tag “also invalidates 
the results of the studies reported in this paper, since the sensitivity of finding trials is no 
doubt improving with the new indexing tags.”66 Was this anticipated improvement in 
recall realized? 
Let us consider the evidence base for the multiple database imperative. The 
contribution of databases depends first on the proportion of relevant studies indexed in 
the database, and second, on the proportion retrieved by the searches used. Some studies 
examining database contributions also consider whether excluding those studies found 
only in the additional sources would bias the estimate of intervention effectiveness. 
Examples of this approach include my own work in the contribution of Embase to meta-
analyses of randomized controlled trials366 and Egger’s study of MEDLINE versus non-
MEDLINE indexed trials in meta-analyses of randomized controlled trials.75 Bias occurs 
if the studies found in the additional sources differ consistently from those found in the 
main source. If no bias is present, the loss of the additional studies will not change the 
estimate of how well the treatment works. However, adding more information that is 
consistent with previous information increases confidence in the finding. In meta-
analysis, this is reflected in a narrower confidence interval.  
MEDLINE indexing of eligible RCTs is 90% or greater in studies other than case 
reports of single systematic reviews.203,367,368 Figures of 86% indexing of diagnostic 
studies92 and 62% coverage of prevalence and incidence studies289 have been reported. 
                                                
*** According to Web of Science, this paper had been cited 780 times of April 10, 2009, and 101 of these 
citations occurred in articles published in 2008 or 2009. Of course, the paper is multifaceted and not all of 
these references would have been to the retrieval rate from MEDLINE. However, by 2008 most systematic 
reviews citing the highly sensitive search strategy in support of their search methods should have been 
citing the revised HSSS that was published in 2006, not the 1994 study.  
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The discrepancy between potential and perceived database contributions indicates that 
research into how to optimize retrieval from the most complete sources is needed.  
7.3.2 Precision Is Reduced In Multiple Database Searches 
While recall may be improved by searching multiple databases, precision will be 
reduced. We have seen that the precision in systematic reviews is quite low – slightly 
below 3% of retrieved records are eligible (see Section 6.25). Material identified from 
multiple sources is more likely to be relevant than material found from only one source 
(see Sections 5.1.5 and 6.19). Therefore, we would expect that the incremental yield from 
each additional source would come at the expense of precision, as few of the uniquely 
identified articles would be expected to be eligible.  
The most precise searches will most likely be those done in CENTRAL, as its 
included studies have been pre-selected by study design. However, as it is a secondary 
database, indexing lag is inevitable and limits recall in the short run. Further, its lack of a 
searchable entry date field limits precision for updating searches at present. The next most 
precise searches will be those that come from MEDLINE. MEDLINE has numerous 
features that enhance precision, including the highly-developed MeSH thesaurus, the 
validated Clinical Queries, the Randomized Controlled Trial publication type, the Core 
Clinical Journals subset, accurate indexing of age and gender, and for the case of 
updating, entry dates indicating when a record was added to MEDLINE.  
Given the strengths and precision enhancing tools available in MEDLINE, 
particularly for identifying controlled clinical trials, the low precision of RCT-base 
systematic reviews is most easily explained by hypothesizing that these reviews use 
searches that are more exhaustive than the searches used for other designs. Precision is 
undermined by backfilling from other databases that cannot be searched with as much 
precision as MEDLINE. As there is no evidence that I am aware of that indicates that 
these non-RCT reviews are incomplete, despite their higher precision, it may be that 
RCT-focused systematic reviews are searching more extensively than necessary, at the 
expense of precision. Still, the retrieval sizes for the cohort described in Section 6.25  are 
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larger for non-RCT systematic reviews than for systematic reviews of RCTs (data not 
shown), so screening burden is higher although precision is similar. 
The searches tested in the updates of the cohort of AHRQ reviews have much 
higher precision than was seen in full systematic reviews (see Section 6.10). While 
whole-review precision was below 0.030 for most types of reviews, the test searches 
showed precision above 0.100. Some of this increase is because the test searches were 
designed to be of higher precision (and this would account for variability between the test 
searches, which ranged from 0.111 to 0.192 for the approaches involving MEDLINE). 
However, much of the increase in precision is achieved by restricting the search to 
MEDLINE.  
 
7.4 SUPPLEMENTAL SEARCHES AS THE NORM 
Another issue to be considered is the role of non-database searches in both the 
original review and in the update. Specifically, do these efforts need to be repeated in the 
search for the update? These non-database efforts include contacting investigators to 
identify unpublished studies or published studies not otherwise found, checking reference 
lists to find additional relevant studies that may have been cited, and hand searching 
journals and conference abstracts. I refer to searches using these techniques to supplement 
database searches as multi-modal searches. Most published guidance on searches for 
systematic reviews advocates such measures.40,242,369,370 However, a systematic review of 
evaluations of the contribution of checking reference lists identified that the efficacy of 
such measures has not been either proved or disproved. In fact, the issue has not been 
studied systematically using prospective research designs. Only case reports, cross 
sectional and retrospective observational studies were identified.371 Case reports are 
susceptible to publication bias, since a paper about how much time was spent in 
unproductive efforts to find relevant articles is not likely to hold much appeal for journal 
editors. None of the studies identified for that review controlled for the quality of the 
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electronic searches. As recall of the electronic searches improves, the apparent 
contribution of alternate approaches will appear to decline.  
Unpublished trials are considered grey literature.372 Van Driel et al. examined the 
contribution of unpublished trials to Cochrane Collaboration Reviews. They called into 
question the role of unpublished trials in original reviews, which they found to be limited 
at best and possibly introduced bias.373 Unpublished trials are typically found through 
methods other than searching bibliographic databases. Van Driel et al. found that few 
Cochrane Collaboration Reviews published since 2000 included any unpublished trials, 
and when they were included, they were few in number. Those trials also tended to 
included fewer participants and be of lower methodological quality than published trials. 
Their analysis indicated that trials that were eventually published were of better 
methodological quality, and therefore less susceptible to bias, than those trials that were 
truly unpublished. Further, other researchers have found discrepancies between 
preliminary results, such as conference abstracts, and results presented in full 
publication.374 Van Driel et al. suggest that a more efficient and scientifically sound 
approach is to forego extensive searching for unpublished studies, and instead include 
those studies in updates after they have been vetted by the publication process.373 In my 
examination of studies included in original reviews but excluded from the update, the 
most common reason for exclusion was that the original study had been reported in an 
abstract, which was replaced by a full publication in the update (Section 6.31.2). 
My results from testing the performance of authors’ searches to find MEDLINE-
indexed studies included in the original review may provide the best evidence for the role 
of non-database supplemental search methods in the original reviews, although it is 
indirect evidence. In the six updated Cochrane Collaboration Reviews, recall of 
MEDLINE-indexed included studies was only 0.50 and in the ten AHRQ Evidence 
Reports it was only 0.64 (Section 6.27). This begs the question of how the remaining 36-
50% of studies was found. There are several possibilities. These studies may have already 
been known to the investigators or their advisors, they may have been found through 
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checking reference lists, hand searching or contacting experts, or they may have been 
found through the other databases searched. It is apparent that these MEDLINE misses 
were found somehow, but we do not know how.  
Importantly, these systematic reviews were selected, in part, because they used 
comprehensive searches, including supplemental search methods. This improved the 
chances that a high proportion of all relevant studies would be found and included, even if 
the MEDLINE searches were not particularly effective (Section 4.1.2.2). We do not know 
which aspects of the multi-database, multi-modal search was productive, and each review 
may have had a different combination of productive approaches. What seems clear is that 
when searches are done using methods that depend, in part, on operator skill, it is 
necessary to build in multiple opportunities to find relevant studies. Non-database 
methods, such as checking reference lists or contacting authors, provide approaches to the 
literature that do not require skill in Boolean searching. 
7.5 ROLE OF REDUNDANCY 
In summary, it would seem that in the original reviews, multi-database, multi-
modal searches serve two functions. First, they provide opportunities to identify material 
uniquely available through only one of the sources. In addition, they provide second, third 
and fourth chances to retrieve material available through several sources. We have seen 
that the number of sources identifying a study was correlated with its probability of 
relevance (Section 5.1.5 and 6.19). Therefore, it is important to find these studies. 
Lemeshow et al. give an account of multiple search modes as second chances in their 
analysis of searches for observational studies; “The publications found during the cross-
check of the reference lists of the reviews and meta-analyses were not accessible solely 
through this method of searching. The titles either originally appeared in one or more of 
the databases but were prematurely discarded because of seemingly irrelevant titles, or 
the databases had access to the publications but did not yield them because of our choice 
of search terms or the miscoding of keywords.”375 Savoie also acknowledged that many 
studies identified through supplemental methods were indexed in major databases, but 
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were missed by the searches.376 That is, redundancy appears necessary in the searches for 
the original reviews in order to identify as many relevant studies as possible.  
7.6 INDEPENDENT APPROACHES TO THE LITERATURE ARE NECESSARY 
I argue that the overriding conclusion that can be drawn from the research 
evidence and actual practice is that multiple independent approaches to the literature are 
needed. By searching different databases, for instance, MEDLINE and Embase, a 
reviewer may be able to identify a higher proportion of relevant trials than by searching 
MEDLINE alone. This need not be because there were additional trials indexed in 
Embase but not in MEDLINE – my previous work has demonstrated that the majority of 
systematic reviews that searched both did not include any Embase-unique trials.366 
Instead, it seems likely that the real contribution was that trials were found through 
Embase that were missed from MEDLINE. The gain would come because those trials 
were indexed differently (MEDLINE and Embase use different subject headings), and the 
search may have used a subject heading other than that assigned by the MEDLINE 
indexers but may have achieved a match in Embase. Title, abstract, author and journal 
information would typically be the same between databases – the gain would due to 
differences in indexing. In this scenario, it is the independent approach to the literature 
rather than the additional coverage of the second database that results in more complete 
recall.  
On the other hand, searches of MEDLINE and CENTRAL cannot really be 
considered independent approaches to the literature. Most CENTRAL records come from 
either MEDLINE or Embase. If searchers use their MEDLINE subject search in 
CENTRAL, they are unlikely to identify additional records; in particular, they will not 
have the opportunity to identify overlapping Embase records. The MEDLINE and 
CENTRAL searches would be independent is a) CENTRAL retained overlapping records 
from Embase and MEDLINE, and b) the searcher consulted the Embase thesaurus and 
added EMTREE terms to the search. In fact, Embase records that represent articles 
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already identified from MEDLINE are not added to CENTRAL.79††† My impression, after 
reviewing many CENTRAL searches for research purposes, is that it is not a common 
practice for EMTREE terms to be included in the CENTRAL search. 
The Cochrane Reviewer Handbook states that CENTRAL includes “310,000 trial 
reports are from MEDLINE, 50,000 additional trial reports are from EMBASE and the 
remaining 170,000 are from other sources such as other databases and handsearching.”79 
Thus, CENTRAL will be useful for identifying the material unique to sources not 
searched directly, but will not help reviewers compensate for a sub-optimal selection of 
terms in MEDLINE. In fact, good retrieval from these additional sources will depend on a 
well-developed free text component to the search.  
Related Article RCT and Clinical Queries do constitute two independent 
approaches to the literature. The capture-recapture results (see Section 6.20.4), and 
multidimensional scaling results (Section 6.21) both support this. In addition, the two 
searches together resulted in nearly complete retrieval of relevant new studies (Section 
6.8.1). Taken together, these findings provide strong evidence that these two searches 
represent independent approaches to the literature. These two searches of MEDLINE 
represent the most practical and efficient approach to update searches.  
7.7 STREAMLINING SOURCE SELECTION AND SEARCH LIMITS FOR THE UPDATE 
When a new review is started, the bibliometric characteristics of the relevant 
literature will not be known. This includes the language distribution, where or how the 
published literature will be indexed and the contribution grey literature will make to the 
evidence base. Since one of the functions of a comprehensive search is to guard against 
potential bias, it may be inevitable that reviewers will wish to make the initial search as 
inclusive as possible, regardless of the evidence for or against the global prospect of bias. 
A recent systematic review of the impact of language restrictions stated, “We could not 
find evidence of a systematic bias from the use of language restrictions in systematic 
                                                
††† Handbook section 6.3.2.2 
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reviews/meta-analyses of conventional medicine.” Yet they went on to conclude, “it 
seems that systematic reviewers of conventional medicine who hope to minimize the risk 
of producing a biased summary effect estimate should search for foreign language studies 
when resources and time are available.”377 By the time a systematic review with 
comprehensive search methods is updated, quite a bit will be known about where and 
how the evidence can be found. Rather, quite a bit could be known, if the productivity of 
sources and the performance of the MEDLINE search for the original review were 
evaluated post hoc.  
These data provide numerous examples where multi-database searching could be 
replaced by a search of MEDLINE, if recall from MEDLINE could be maximized. The 
original review provides a real world test of the performance of the subject search and the 
potential contribution of MEDLINE. If retrieval from MEDLINE was sub-optimal, the 
search can be revised for the update. The related article protocol complements the subject 
search - it is independent from the subject search, and does not rely on operator skill. The 
similarity search methods, such as Support Vector Machine or Related Article RCT, have 
a clear role in the update, but they may not be so practical in the original review. This is 
because these similarity searches are informed by the true positive examples from the 
original review in the case of Related Article RCT, and in the case of Support Vector 
Machine, by the true positives and true negatives from the original review. These 
complementary approaches (Boolean subject search plus similarity search) provided quite 
complete identification of evidence for the update.  
There are numerous examples of methodological research into search factors or 
bias factors in which the authors note that the results may not hold for some specialties. 
Egger, who studied several aspects of comprehensive literature searches and trial quality 
concluded “our results indicate that unpublished trials are also important in oncology, 
whereas non-English language trials are particularly prevalent in psychiatry, 
rheumatology and orthopaedics.”75 One very important result of these findings is the 
relative stability of recall of the Related Article RCT search across medical specialties – 
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greater stability than was seen with the Clinical Query, or Abridged Index Medicus RCT 
search, both of which more closely resemble standard search methods (see Section 6.8.1). 
Thus, the related articles approach tested here may help protect against variable 
retrievability of evidence between specialties. 
Bibliometric characteristics of the evidence base of the original review can inform 
other aspects of the search plan for the update. If all eligible evidence in the original 
review was published in English, even though records in any language were sought and 
were eligible, one could restrict the update search to English language studies. Similarly, 
if grey literature was sought through a comprehensive approach such the CADTH 
protocol,378 but no relevant grey literature was found, one could restrict the update search 
to the published literature. It could be that a small number of unpublished studies were 
included in the original review, but all appeared early in the life cycle of the intervention 
being studied, and a substantial body of published evidence appeared subsequent to grey 
studies. In this case, reviewers might also streamline the update search to focus on the 
published evidence, which is much less time consuming to find.  
The advantage of using the bibliometric characteristics of the original included 
studies to inform the update search is that this evidence is derived from the exact context 
under study. This may assuage reviewer concerns that their topic may be an exception to 
the global findings that language restrictions or exclusion of non-MEDLINE articles, for 
example, tends not to bias results. Returning to the evidence hierarchies (Section 2.11), 
Guyatt placed N-of-1 trials at the pinnacle of evidence for guiding treatment decisions. 
This is because the results of most randomized controlled trials represent average 
treatment effects, and any given patient may or may not experience that degree of effect. 
The N-of-1 trial provides the best and most direct evidence of how that patient individual 
will respond.379  
The execution of a full N-of-1 design in the search context might include blinding 
of searcher and reviewer, random selection of the search methods to be used, and a 
standard-search control condition (adapted from 36). This is more than the average 
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systematic reviewer will wish to undertake in their review, but observational evidence 
from their initial systematic review can help reviewers decide if research findings will be 
applicable in their case. 
Of course, if analysis of the included studies and their indexing showed that the 
evidence base was multilingual, that grey literature was important or that two or more 
databases were necessary for the complete identification of material, the update search 
can be broadened. However, results in these cohorts indicate that a more streamlined 
approach is usually possible. 
Given the evidence gaps pointed out by McAllister where “the therapeutic options 
for many diseases which cause substantial disability adjusted life years lost worldwide 
have not been systematically examined at all,”142 it does not seem like a good use of 
research resources either to do more updates than needed, or to use an exhaustive 
approach to the search for new material when analysis of that topic indicates that a more 
parsimonious approach is possible. 
7.8 WAYS FORWARD 
The information retrieval problem of updating is quite distinct from the problem 
of creating the original evidence base. Decisions around the update search can be 
informed by the results of that original search and the included studies from the original 
review can be leveraged through similarity searches. 
In the update, I recommend the following practice: 
 Validate the MEDLINE search against MEDLINE indexed articles, assuming the 
original search was comprehensive; 
 If recall is low, amend that search, structuring it after the approach used here to 
develop the clinical query searches. That is, describe the population and 
intervention under study using the appropriate MeSH subject headings, adding 
free text terms only when suitable MeSH headings are unavailable (see Section 
4.2.4.1); 
 Have the amended search peer reviewed;83 
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 Complement this with a related article search based on the three newest and three 
largest studies included in the original review, limited with the Randomized 
Controlled Trial publication type tag; 
 Date limit both searches to the material added to MEDLINE since the original 
search date; 
 Forego non-database search methods and grey literature searching unless grey 
literature has been present and influential beyond the initial stages. However, if 
unpublished trials were excluded from the original review, following van Driel’s 
recommentations373 then full published versions of the excluded trials could be 
sought for the update; and 
 Forego other databases unless they have been demonstrated to contribute material 
not also indexed in MEDLINE. 
The advantages of such an approach are simplicity, lack of variability across 
clinical area, high levels of identification of new material and that the search is tailored to 
the particular review. 
One of the most important aspects of this recommendation may be the validation 
of MEDLINE search by testing the proportion of MEDLINE-indexed material that it 
retrieves. It should be stressed that validation of the original MEDLINE search is only 
possible when multiple databases and supplemental methods not dependent of searching 
skill were use to form the original evidence base.  
If such testing were done routinely,‡‡‡ MEDLINE searching might improve. First, 
feedback, either knowledge of results or knowledge of performance, improves 
performance of skilled activity.380 Examples of this phenomenon range from the use of 
audit with feedback to influence physician behaviour381 to machine learning like Support 
Vector Machine.361 Techniques like peer review83 can provide knowledge of performance 
(or how well the skill was executed). In the case of feedback on the recall of the 
MEDLINE search, knowledge of result is the salient aspect, and this type of feedback 
may allow searchers to improve their searching skills. Second, upon finding that the 
                                                
‡‡‡ I have seen only one published systematic review in which post hoc testing of MEDLINE retrieval was 
reported, but I have not been able to locate it again to cite it. 
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results of their MEDLINE searches were poor, searchers may be inclined to have their 
future searches peer reviewed prior to use, or may seek out someone with more extensive 
training and expertise to create the searches.  
Curiously, there has been very little attention paid to validating subject searches 
other than the methodological filters. A recent review of reporting standards for the 
searches of systematic reviews382 found only one of 11 standards called for evidence of 
the effectiveness of the search strategy used.20 Patrick states, “any reporting of a retrieval 
strategy that does not also report evidence of the effectiveness of that strategy is similarly 
at odds with the basic tenets of evidence-based medicine.”39 I have demonstrated a simple 
validation procedure that should be widely used. I have proposed it as a test of the search 
before it is re-used in updating, but it could be done as soon as final inclusion decisions 
are made for an original systematic review. 
7.9 SURVEILLANCE: SETTING TARGETS 
In Chapter 3, we have seen a movement from updating at fixed intervals to 
updating based on need. Our own and other studies fail to find many predictive factors of 
survival time, and where found, they are quite general.17,124 Our major predictor, for 
example, was that the topic involved cardiovascular disease.17 However, the concept of 
optimum information size does provide some guidance on when to update (see Section 
3.6.2), although none of those working with the concept of updating based on the 
accumulation of new evidence have suggested how this accumulation can best be tracked.  
For efficient surveillance, some automation would be needed. My results shed 
some light on how effectively various searches detect new N. Automated extraction of N 
from abstracts of randomized controlled trials has been demonstrated with 97% 
accuracy.383 
Studies retrieved from ongoing searches could be sorted from largest to smallest 
N, or by some weighting of N and relevance score, and the most promising candidates 
flagged for immediate relevance assessment. Such screening would continue until a 
predetermined threshold of new N is reached. Not all candidates will be assessed under 
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such an approach; therefore, the threshold should be set below the optimum information 
size. For example, if the optimum information size for a review was 1,000 new 
participants, formal screening of all remaining candidate studies could begin when 800 
new participants had been detected through surveillance.  
The best surveillance approach for use with such a scheme may be Related Article 
RCT, which provides useful relevance scores (see Section 6.11) paired with Abridged 
Index Medicus RCT, which has better precision than Clinical Queries and preferentially 
finds larger trials. Once the threshold for updating is reached, Clinical Queries could be 
run, and material not already screened from the Abridged Index Medicus results could be 
added.  
7.10 IMPLEMENTATION CHALLENGES 
Systematic reviewers tend to be very conservative in adopting research findings 
into their own practice, as has been discussed. However, two factors may aid adoption of 
these findings. First, it is clear that updating goals have been consistently unmet. 
Reviewers must choose between leaving potentially outdated evidence in the public 
arena, finding significantly more resources to support updating, adopting efficiencies or 
implementing some combination of these strategies. The efficiencies suggested here are 
evidence-based and so worthy of consideration. Second, these results are derived from the 
same cohort as the Annals of Internal Medicine survival paper,17 which has seen good 
uptake. It has been cited 24 times in a relatively brief period, and some of these 
articles,147,384-386 may be influential as they, in turn, have already been cited two or more 
times. This encouraging initial response suggests that the systematic review community 
accepts its findings as valid.  
Still, widespread adoption may depend on groups such as the Cochrane Collaboration 
endorsing such an approach. Current recommendations from the updating working groups 
provide an exhaustive protocol for monitoring for new studies (see Section 3.2.1). As 
well, the Cochrane Handbook sets limited expectations for identification of studies 
through MEDLINE based on the 1994 article that introduced the original highly sensitive 
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search strategy, the Cochrane handsearching initiative and the National Library of 
Medicine re-tagging of randomized controlled trials.64 The handbook cites, in section 
6.1.1.2, that “only 30% - 80% of all known published randomized trials were identifiable 
using MEDLINE.”79 Changes to those expectations may be needed to pave the way for 
acceptance of a search protocol that would involve, in many cases, searching only 
MEDLINE. 
7.11 LIMITATIONS OF THIS RESEARCH 
7.11.1 Screening Method 
We screened new records up to the point where we could confidently say the 
systematic review needed to be updated. It is possible that search performance results 
would have been different had all records available during the observation period been 
reviewed. However, for the eight AHRQ Evidence Reports where all retrieved records 
were assessed, recall of eligible studies was very similar for the periods before and after 
the signal (sees Section 6.8). 
7.11.2 Precision 
One very real limitation imposed by our screening method is that precision of the 
searches could only be established in the cohort of ten AHRQ Evidence Reports (see 
Section 4.5.4). The estimates may not generalize to Cochrane Collaboration Reviews or 
journal published systematic reviews. As one objective of this research is to find more 
efficient ways to conduct update searches, more reliable precision figures would be 
helpful. Retrieval size for the searches was examined in each cohort (see Sections 6.5.1, 
6.6.1 and 6.7.1) and these give some indication of what levels of precision might be 
expected. Median retrieval size was substantially lower for Related Articles RCT than for 
the other searches in the AHRQ cohort where the precision scores were derived. This did 
not hold for the largest cohort - median retrieval size was larger there for Related Article 
RCTs than for Clinical Queries, the search approach closest to it in terms of recall. This 
suggests that the precision for Related Articles seen in the AHRQ cohort may be 
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optimistic. However, in all three samples, the third quartile was lower for Related Article 
RCT than for Clinical Queries, suggesting that un-manageably large retrievals would be 
relatively uncommon. The other search approaches with data available in all three cohorts 
were Abridged Index Medicus RCT and Citing RCTs. These had relatively higher 
precision in the AHRQ sample (see Section 6.10), and small retrievals in all three 
samples, but that is at the expense of recall (see Section 6.11).  
7.11.3 Generalizability 
The selection of the sample may have implications for generalizability. Strengths 
of the selection criteria were that they ensured the topics were clinically important and the 
quality of the reviews met certain minimum criteria. However, we excluded systematic 
reviews of complementary and alternative medicines. These findings may still be 
applicable there as the most recent evidence suggests that most randomized controlled 
trials of complementary and alternative medicines are indexed in MEDLINE.368  
I considered systematic reviews of drugs, devices or procedures, and excluded 
reviews of diagnostic measures, epidemiology, educational interventions, associational 
studies, instrumentation or research methods, for example. The searches were tested for 
their ability to retrieve randomized controlled trials, and therefore will be most applicable 
to searches of randomized controlled trials. A reasonable approach in other areas would 
be to use the appropriate clinical query – they have been developed and validated to find 
clinically important studies of causation (including harm), diagnosis or prognosis, for 
example.14 This would substitute directly for the Clinical Query tested here, which was 
balanced query for studies of treatment and prevention. The Related Article search, based 
on a similar seed selection protocol, could also be limited by the appropriate clinical 
query. Pairing it with a validated query may still provide good performance. A more 
conservative approach would be to run the Related Article protocol using the three newest 
and three largest included studies as seeds, but without any methodological or study 
design limits. This unrestricted approach may be quite feasible for topics where there are 
few studies or where precision is not a concern.  
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The finding that the major search innovation presented here, Related Article RCT, 
shows consistent recall across clinical area is a very positive sign that these results may 
be generally applicable. However, exceptions cannot be ruled out.  
7.11.4 Goals Not Achieved 
An early goal of this research was to find a search strategy that would have 
precision and recall around 0.80 to enable efficient surveillance. I have developed a 
deeper understanding of the performance measures of a search during the course of this 
research and this has helped my understanding of why this goal remains elusive.  
Using the analogy of the search as a diagnostic test for document relevance, the 
standard two-by-two epidemiology table where the marginals are the prevalence of the 
disease and prevalence of the attribute.387 This corresponds to the prevalence of relevant 
articles and prevalence of retrieved articles. Sensitivity and specificity are unaffected by 
the prevalence of the disease, or the frequency of relevant documents within the 
collection. Sensitivity is calculated in the same way as recall. Sensitivity, recall and 
specificity “condition on the test.” Precision is the positive predictive value of a test, or in 
our case, how likely it is that a record is relevant give that it is retrieved. Predictive 
values, whether positive or negative, are influenced by underlying prevalence of the 
disease. They “condition on the disease”. The disease we wish to diagnose is not a disease 
of course, but rather relevance of an article for a particular systematic review. Precision 
will be influenced by the prevalence of relevant documents in the collection. This means 
the precision of a search will be higher when the search is run in a database with a high 
concentration of relevant documents than it will be if the same search is run in a database 
with a lower concentration of relevant documents.388 This is predicted by the functional 
relationship between recall, precision and fall-out that van Rijsberen calls generality, or G 
(see Section 4.4.4.3)195 In any search of MEDLINE, it is highly probable that most of the 
records in the database will be on some topic other than the one you are searching, this 
limits precision, except in the simplest searches, like the search for a named entity.  
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I now understand that the most effective way to increase precision is not to refine 
the search strategy, but rather to restrict the search to sources with a higher concentration 
of relevant documents. Thus, better precision will be obtained in CENTRAL, which 
contains only controlled trials, than in MEDLINE. Precision will be better if the search is 
restricted to MEDLINE Core Clinical Journals, as the concentration of trials is greater 
here than in all of MEDLINE.  
7.12 FUTURE WORK 
7.12.1 Related Articles 
The most exciting finding of this research is the complementary nature of the 
Related Article and Clinical Query searches. Further exploration and refinement of 
similarity searching as an adjunct to subject searching would be very useful.  
PubMed’s Related Article feature has been widely adopted by those searching 
PubMed. Based on query logs gathered during a one-week period in June 2007 roughly a 
fifth of all non-trivial PubMed user sessions contain at least one related article search.168 
However, I found few evaluations of its performance.169,389 It has not been widely 
adopted for systematic review searches. Using an automated MEDLINE query run 
throughout this research period, I identified only five systematic reviews that reported a 
related article search in the methods section of their abstract.389-393 The PubMed Related 
Articles feature warrants further research and greater use by systematic reviewers. 
The Related Articles RCT out-performed Support Vector Machine in this sample. 
However, Related Articles is available only for PubMed. Further work to optimize SVM 
and deploy it to search other databases would be very useful for updating those systematic 
reviews where databases other than MEDLINE have a demonstrable contribution. If only 
a few included studies where indexed in those databases it would be impossible to 
establish an adequate training set of true positives and true negatives. Ideally, those would 
be studies not also indexed in MEDLINE, so that overlap might be minimized when SVM 
was used to find new relevant material. Realistically, the MEDLINE component of almost 
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all systematic reviews is too large to make such an approach practical. Other challenges 
would be publisher agreement to access the database, and costs associated with such 
access.  
Computing nearest neighbour scores for other databases using the computational 
strategy employed by National Library of Medicine for PubMed Related Articles searches 
would be another approach. Other search interfaces provide related article-like features. 
Ovid has a “find similar” feature that seems to be based solely on words in the title of an 
article, and this impression is confirmed by the Ovid Online Help.394 EBSCOhost 
provides a feature labeled "Find Similar Results using SmartText Searching”. In 
CINAHL, the system appears to use the title and subject headings as the basis for the 
search, although the EBSCOhost Help indicates that the abstract will be the basis for the 
search in some databases, and subject headings will be used in others.395 The EBSCOhost 
feature returns a prohibitive number of records – over 700,000 similar articles to a 
randomized controlled trial of antioxidants, although the results were relevance ranked 
and top-ranked articles appeared useful. 
7.12.2 Maturity of the Literature 
The search for factors that predict the survival of systematic reviews has had 
limited success to date, although it is still a new area of study. My finding that reviews of 
evidence of new drugs, devices or procedures went out-of-date more quickly than reviews 
of more established therapies may be useful (see Section 6.32.1). This makes some sense 
when one considers the “regression toward the truth”142 whereby early promise of some 
therapies is not maintained (see Section 3.2.7). Altman considers this a natural 
phenomenon as “only those treatments that appear promising in early studies are likely to 
be the subject of extensive further study. We might expect, therefore, that treatments will 
perform somewhat less well in further studies simply as a consequence of regression to 
the mean.”34 Altman used this as an argument for rigorously controlled trials. We have 
seen that early results from abstracts may not reflect final findings.374 Publication bias and 
selective reporting of the most favourable results are likely contribute to distortion in the 
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early literature.396 Finally, the number of new participants needed to overturn a result will 
be smaller in these early systematic reviews, due to the smaller number of included 
participants. 
It may be that reviews can be characterized as early exploratory reviews that 
attempt to arrive at a definitive answer as soon as possible, as Lau et al. argue should 
have happened with streptokinase as thrombolytic therapy for acute infarction.135 These 
exploratory reviews may require frequent updating. Middle stage reviews may attempt to 
address treatment complexities and resolve differences between individual studies, and 
explore sub-populations. AHRQ Evidence Reports, with their multifaceted questions and 
large numbers of included studies are examples of these. Finally, there may be 
confirmatory systematic reviews, such as those on the efficacy of bed nets for prevention 
of malaria.279 Few surprises and few new primary studies are expected in these areas, but 
the systematic review may still play an important role by providing a single source of 
synthesized information for reference purposes. Such reviews may need little updating. 
If the updating thresholds are set using optimum information size, then the 
distinction between these types of reviews becomes less important. The exploratory 
reviews will need fewer new participants to trigger updating; the middle stage reviews 
will vary in the amount of new information needed depending how conclusive their 
results are. Additional studies will be unlikely to overturn the findings of confirmatory 
reviews – the cumulative slope described by Muellerleile and Mullen will approach 
zero,146 suggesting that they will need little or no ongoing attention. 
7.12.3 Interagency Collaboration to Automate Support for Updating 
Given the current interest of major national and international groups in updating 
(see Section 3.2.9), this may be an opportune time for agencies to collaborate to develop 
infrastructure to support automating some aspects of surveillance and signaling of the 
need to update. Sutton suggests that instead of updating all systematic reviews in a 
collection annually, thresholds should be established for each review based on the amount 
of new evidence that is likely to be needed to influence the result in ways that have 
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implications for practice. Calculation of these thresholds could be paired with automated 
systems to search for new studies, rank them by priority for review, and extract new N. 
Components of such a system have been developed.102,112 Collaboration in developing 
such systems could support the goal of harmonization of updating efforts between 
agencies (see Section 3.2.9). 
Even in the absence of such automation and integration, an automated procedure 
for capturing related article would be extremely helpful. At present, if the Related 
Articles search is done through the PubMed interface, a second step is needed to apply the 
limits – including date limits – and relevance ranking is lost in that second step. Searching 
through the eLink utility allows date limiting and the addition of a single limit, but 
converting the results from the XML output to a form more amenable to systematic 
reviews is cumbersome. The programming of such a query interface is likely less 
complex than the programming involved in the SYRIAC system.112 Although the 
relevance ranking seems to successfully sort relevant material toward the beginning of the 
result list, it is not yet clear how best to include relevance ranking into the systematic 
review itself. However, for surveillance purpose, assessing the most relevant material first 
will allow efficient signal detection.  
7.13 CONCLUSION 
This research conceptualizes systematic review searches as being made up of 
multiple approaches to the literature, which need to be independent in order to achieve 
good recall. An overlooked aspect of the traditional approach of using both database and 
non-database methods is that such multimodal searches combine methods that require 
Boolean search skills with those that are independent of such skill.  
I introduce the need to test the performance of the MEDLINE subject search, both 
to provide feedback to the searcher and to determine the potential contribution of 
MEDLINE to the update of the evidence base. The biblometrics of the initial evidence 
base can guide the update search by informing the selection of databases and limits, and 
by providing seed articles for similarity searching.  
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This is the first demonstration of the structural relationship between different 
modes of information retrieval – traditional Boolean searches and similarity-based 
methods – in the context of the very high levels of recall needed for systematic reviews. 
A similarity search and a Boolean subject search, used together, were shown to provide 
comprehensive identification of relevant new evidence in several cohorts. A similarity 
search using the PubMed Related Articles feature is effective and is accessible to all 
systematic reviewers since it requires no special resources and no proficiency in Boolean 
searching.  
This thesis also introduces the idea of considering the information density of 
documents, here measured as the number of patients enrolled in studies, rather then 
number of studies retrieved, as the unit of measure in assessing the performance of 
searches in the systematic review context. For surveillance purposes, the identification of 
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